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ABSTRACT:
The biological validity of the histopathological classification of ductal carcinoma in situ 
(DCIS) of the breast was evaluated in this study by correlating the three histopathological 
grades of DCIS to  immunohistochemical expression of Ki67, p53, cerbB-2,  markers of 
poor prognosis in invasive ductal carcinoma (IDC) and also to bcl2 and ER, markers of 
good prognosis in invasive breast cancer. DCIS grades correlated positively to Ki67, p53, 
cerbB-2 and negatively to bcl2 and ER, suggesting validity of the classification.
The incidence of bax protein expression was determined immunohistochemically in DCIS 
and  IDC.  It  did  not  correlate  to  histopathological  grades  of  DCIS  or  IDC.  The 
relationships  of  bax  protein  to  the  above  mentioned  biological  markers  were  also 
determined in DCIS and IDC.
Furthermore, the expression of bax, bcl2, Ki67, ER, p53 and cerbB-2 within DCIS grades 
was compared with the expression of these markers within IDC grades. The DCIS grades 
were determined subjectively as well as objectively by means of computer assisted image 
analysis  with  significant  correlation  found  between  subjective  and  objective  measures. 
Image analysis was also used to determine percentage of positive cells per case  for the 
nuclear stains (Ki67, ER, p53).
Immunohistochemically  positive  p53  cases  were  analysed  for  p53  mutation  by 
polymerase  chain  reaction  (PCR)  and  subsequent  DNA  sequencing  to  compare  the 
incidence of p53 mutation in DCIS to that of IDC.
Biochemical changes within tissue may either initiate disease or occur as the result of the 
disease  process  and  these  changes  can  be  studied  by  both  fourier  transform  infrared 
(FTIR) and FT-Raman spectroscopic techniques. FTIR and FT-Raman were employed to 
distinguish the  DCIS  and  IDC  grades.  It has the potential to distinguish between  DCIS 
grades, between IDC grades and also between DCIS and IDC as whole groups.
The implications of the obtained data for the understanding of the molecular biology of 
DCIS of the breast and  IDC  are discussed and  future  investigations to further elucidate 
the molecular and cellular mechanisms involved are proposed.Dedication: II
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ICE interleukin- 1  p-converting enzyme
IDC invasive/infiltrating ductal carcinoma
IGF-1 insulin like growth factor- 1
IGSS immunogold staining with silver precipitation
IHC immunohistochemistry
ING intermediate nuclear grade (of DCIS)
IR infraredAbbrevimdons: XVI
IRS immuno-reactive score
JNK JUN N-terminal kinase
kb kilobase pair
LABC locally advanced breast cancer
LCIS lobular carcinoma in situ
LHRH luteinizing hormone releasing hormone
LI labelling index (of Ki67)
LN lymph node
LNG low nuclear grade (of DCIS)
LOH loss of heterozygosity
M mitotic phase of cell cycle
MAP mitogen activated protein
MAPK mitogen activated protein kinase
MAPKK mitogen activated protein kinase kinase
MBC male breast carcinoma
MDM2 murine double minute 2 gene
Mg2+ magnesium
MI mitotic index
MIC micro-invasive carcinoma
ml millilitre
pl microlitre
mm millimetre
pm micrometer
MMM mitozantrone, methotraxate, mitomycin
MMP matrix metalloproteinase
MMPI matrix metalloproteinase inhibitor
MMTV mouse mammary tumour virus
MNA mean nuclear area
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
NCAM neural cell-adhesion molecule
NCGBSP National Coordinating Group for Breast Screening Pathology
NEQAS National External Quality Assessment Scheme
NF neurofibromatosis
NGS normal goat serum
NHL non-Hodgkin’s lymphoma
NICE National Institute for Clinical Excellence
nm nanometers
NME non-metastatic cells, expressed gene
NM23 non-metastatic 23 gene
NMR nuclear magnetic resonance
NOS not otherwise specified
NPI Nottingham prognostic index
NSABP National Surgical Adjuvant Breast and Bowel Project
NSCLC non-small-cell lung cancer
NST no special type
OCP oral contraceptive pill
OS overall survival
PAP peroxidase-antiperoxidase
PAS periodic acid SchiffAbbreviations: XVII
PCNA proliferating cell nuclear antigen
PCR polymerase chain reaction
PDGF platelet derived growth factor
PFGE pulsed field gel electrophoresis
PI proliferative index
PLL Poly-L-Lysine
PR progesterone receptor
RFLP restriction fragment length polymorphism
RNA ribonucleic acid
RT-PCR reverse transcription-polymerase chain reaction
S synthesis phase of cell cycle
SAPK stress-activated protein kinase (another name for JNK)
SERM selective oestrogen receptor modulator
SLNB sentinel lymph node biopsy
SPF S-phase fraction
SSCP single-strand conformation polymorphism
STATs signal transducers and activators of transcription
TAF-I transcription activator factor I
TAF-II transcription activator factor II
TBE Tris borate EDTA buffer
TBP TATA binding protein
TBS Tris buffered saline
TDLU terminal duct lobular unit
TGFa transforming growth factor alpha
TGFP transforming growth factor beta
TGGE teperature-gradient gel electrophoresis
TIMP tissue inhibitor of matrix metalloproteinase
TNF tumour necrosis factor
TNM tumour, node, metastasis
tPA tissue plasminogen activator
UDH usual ductal hyperplasia
UICC International Union Against Cancer Criteria (Union Internationale 
Contre le Cancer)
UKCCCR United Kingdom Co-ordinating Committee on Cancer Research
uPA urokinase-type plasminogen activator
UV ultraviolet
VEGF vascular endothelial growth factor
VHL von Hippel-Lindau disease
VNTR variable number of tandem repeats
WHO World Health Organisation
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CHAPTER 1:  THE BREAST -  EMBRYOLOGY. ANATOMY AND
PHYSIOLOGY:
EMBRYOLOGICAL DEVELOPMENT:
The breasts are often described as modified sweat glands. The phylogenetic relationship 
of the  mammary  glands  to  sweat  glands  is  fully  established  (1).  However,  this  is  an 
oversimplified  view,  since  the  breasts  undergo  complex  physiological  changes  during 
reproductive life, which are not seen in sweat glands.
The  mammary  line,  also  known  as  the  primitive  milk  streak  or  galactic  streak,  is  the 
initial stage in development of the breast tissue, which appears at about the 7 mm stage of 
embryonic growth (fifth to  sixth week) and extends on each side of the body  from the 
axilla to  groin (1).  The  caudal  two thirds of each  line  disappears  by the  20  mm  stage 
(seventh  to  eighth  week)  and  eventually  only  the  mid  portion  of the  cephalic  third 
remains.  It  is  from  this  residuum  of the  mammary  line that the  mammary  primordium 
develops. By the 60-90 mm stage (12-16 weeks) mesenchymal cells differentiate into the 
smooth muscle of the nipple and areola. Then the epithelial buds develop and branch to 
form  15-25  sprouts representing the future secretory apparatus and adipose tissue forms 
around these sprouts. This is followed by hair follicle, sebaceous gland and sweat gland 
differentiation.  It  appears  that  the  developments  until  this  stage  are  independent  of 
hormonal influences.
From  about  20th-32nd  week  of  pregnancy,  placental  sex  hormones  enter  the  fetal 
circulation and induce canalisation of the epithelial sprouts to form a branching system 
composed of 15-25 major ducts.  Distinction into the two layers of epithelium, secretory 
and  myoepithelial,  can  be  recognized  ultrastructurally  at  about  2 0   weeks  (2 ),  but  the 
biochemical  phenotype  is  not yet  established (3).  Between  32  and 40 weeks,  secretory 
activity begins, with the production of colostrum.  The nipple-areolar complex develops 
further and becomes pigmented.
Apart from minor growth and branching of the duct system, no significant changes occur 
in  the  mammary  tissue  from  then  onwards  until  the  onset  of puberty.  The  changes  at 
puberty are described on page 6 .Chapter 1:  The breast -  embryology, anatomy and physiology 2
ANATOMY: 
Surface and Macroscopic Anatomy:
The adult female breasts lie on the upper chest wall, the upper edges at the level of the 
second or third rib and the lower edge at the level of the sixth rib. Medially they extend to 
the edge of the sternum and laterally to the anterior axillary line, although the tail may 
extend  further into the axilla.  The superficial  pectoral  fascia covers the breast  from the 
anterior aspect and deep pectoral  fascia from the posterior aspect.  Fibrous bands called 
Cooper’s suspensory ligaments connect these two layers providing support to the breast. 
The breasts vary greatly in size and contour from individual to individual.
Microanatomy:
The anatomy and microanatomy of the breast has been discussed in great detail by some 
authors  (4;5).  Briefly,  the  breasts  consist  of  three  major  components  -  skin,  the 
subcutaneous  adipose  tissue and the  functional  glandular tissue,  which comprises  both 
parenchyma  and  stroma.  The  nipple-areolar  complex  is  centrally  placed  and  contains 
abundant  sensory  nerves  and  sebaceous and  apocrine  glands.  Morgagni’s tubercles  are 
elevations located in the areola,  formed by the openings of the ducts of Montgomery’s 
glands, which are sebaceous glands. At the tip of the nipple are the openings of collecting 
ducts.  Immediately beneath the nipple the collecting ducts dilate to form the lactiferous 
sinuses. Deep to this the breast is divided into  15-25 lobes, each of which is based on a 
branching duct system and consists of 20-40 lobules which drain through ductules into 
subsegmental  ducts,  then  segmental  ducts  and  finally  into  the  collecting  ducts  via the 
lactiferous  sinuses.  A  lobule  itself consists  of  10-100  acini  bound  together  in  a  fine 
vascular connective tissue. A lobule, with its draining ductule, is termed a terminal duct- 
lobular unit (TDLU), which is the functional site of milk production (figure  1.1 )(6 ). The 
main bulk of each lobe is made up of adipose tissue and fibrous stroma called interlobular 
connective tissue. A low power view of normal breast lobules is shown in figure 1.2a.
The  nipple  is  covered  by  stratified  squamous  epithelium,  which  extends  for  a  short 
distance  into  the  collecting  ducts.  Then  there  is  an  abrupt  change  to  the  glandular 
epithelium, which is present throughout the duct and the lobular system. This epithelium 
is  composed  of  two  distinct  types  of  cell,  the  secretory  or  luminal  cell  and  the 
myoepithelial  cell.  In  the  collecting  ducts  the  luminal  cells  are  generally  columnarChapter 1:  The breast -  embryology, anatomy and physiology 3
whereas  in the  lobular acini  they  are  cuboidal.  Detailed  microanatomical  studies  have 
shown that there are two types of luminal secretory cell (5).  Basal cells have relatively 
clear cytoplasm and form microvilli where they are in contact with the lumen; the nucleus 
is oval and lacks a nucleolus. Superficial cells are darker with basophilic cytoplasm rich 
in  ribosomes.  The  myoepithelial  cells  form  an  often  discontinuous  layer  between  the 
luminal  secretory  cells  and  the  basement  membrane  (figures  1.1  and  1.2c).  The 
myoepithelial  cells  are  small  and  flat  with  dark  nuclei  and  clear  cytoplasm.  Their 
cytoplasm  contains  myofibrils  50-80  nm  in  diameter  which  are  inserted  by 
hemidesmosomes into the basement membrane. These myoepithelial cells may be readily 
identified by immunostaining with anti smooth muscle actin (3;7).
Figure 1.1; Ductal system of human mammary gland
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Figure 1.1a; Schematic diagram of the ductal system of human mammary glandChapter I:  The breast -  embryology, anatomy and physiology 4
Figure 1.1b; Diagram of a single terminal duct -  lobular unit showing 
the inter-relationship between the epithelial and stromal components
The TDLUs are set within interlobular stroma, which is composed of variable proportions 
of collagenous connective tissue and adipose tissue.  Both normal ducts and lobules may 
be  entirely  surrounded  by  adipose  tissue.  The  acini  within  a  lobule  are  immediately 
surrounded by connective tissue called intralobular stroma (figure  1.2b). This connective 
tissue is more cellular and vascular than the interlobular stroma and mucopolysaccharide 
ground substance is also more abundant.  It contains a delicate meshwork of fine elastic 
fibres  and  small  number  of  lymphocytes,  plasma  cells,  mast  cells  and  macrophages. 
Elastic tissue surrounds the extralobular ductal system and increases in amount with age 
and parity.
Figure 1.2; Photomicrographs of lobules from normal mature female breast tissue at 
different magnifications
Figure  1.2a;  Low  power  view  of lobules  from  normal  mature 
female breast tissue. Magnification x 50.Chapter 1:  The breast -  embryology, anatomy and physiology 5
Figure  1.2b;  Same  lobules as  in previous  photomicrograph.  The 
interlobular  and  intralobular  connective  tissues  can  be  seen. 
Magnification x 100.
Figure  1.2c;  Showing  same  lobule  as  in  1.2  a  &  b  at  higher 
magnification  with  epithelial,  myoepithelial  and  stromal  cells. 
Magnification x 400.Chapter I:  The breast -  embryology, anatomy and physiology 6
Lymphatic Drainage:
The breasts have a rich and complex network of lymphatic channels and the drainage to 
the  loco-regional  lymph  nodes  has  been  well  documented  (5;8).  Over  95%  of  the 
lymphatic  flow  is  towards  the  axillary  lymph  nodes,  although  drainage  to  the  internal 
mammary  chain  can  occur  from  any  quadrant  of the  breast  (9).  Small  intramammary 
lymph nodes may be present within the interlobular connective tissue in any quadrant of 
the  breast  (10).  Drainage  also  occurs  to  subclavicular  and  supraclavicular  nodes  and 
periareolar plexus. The first node draining the primary tumour (sentinel node) is briefly 
discussed on page 25.
PHYSIOLOGY:
During  childhood,  both  male  and  female  breasts  are  relatively  insignificant  structures 
composed  only  of  a  small  nipple-areolar  complex  and  underlying  rudimentary  duct 
system. At puberty, the female breast develops its characteristic adult structure described 
above  and  can  then  be  regarded  as  being  in  its  ‘resting’  state.  Minor variations  occur 
during the menstrual  cycle but major physiological  changes are seen during pregnancy 
and  lactation.  Thereafter  the  appearances  alternate  between  these  two  states  until  the 
menopause when there  is a major regression and atrophy associated with aging.  These 
physiological  changes can  result in quite different histological  appearances,  which  still 
fall within the range of normality.
Changes at Puberty:
At puberty, elongation and branching of the ducts occurs, mainly under the influence of 
oestrogenic  stimulation  from  the  ovaries,  as  oestrogen  levels  increase  2 0 -fold. 
Progesterone,  growth hormone, adrenal  cortical  steroids, thyroxine and  insulin are also 
thought to play a role in pubertal breast development (1 1). Oestrogens mainly cause the 
growth and branching of the ductal  system,  whereas progesterone causes the growth of 
the  lobulo-alveolar  system.  As  a result of the  epithelial  proliferation,  lobule  formation 
occurs  and  these  bud  out  from  terminal  ducts  to  form  the  normal  adult  resting  breast 
structure.  There  is  also  an  increase  in  connective  tissue  stroma,  interstitial  matrix  and 
adipose tissue and an increase in pigmentation and size of the nipple.Chapter 1:  The breast -  embryology, anatomy and physiology 1
Changes During Menstrual Cycle:
The majority of women experience cyclical changes in the breasts during the menstrual 
cycle  including  increase  in  size  and  nodularity  during the  latter  part  of the  cycle  with 
increased sensitivity. There is a feeling of engorgement 3-4 days before menstruation and 
then the breasts return to the resting state at the end of menstruation. These changes are 
related  to  the  cyclical  variation  in  the  levels  of ovarian  hormonal  secretion  and  can 
manifest  as  morphologically  recognizable  parenchymal  changes  (12).  During  the 
follicular phase of the menstrual cycle, proliferation of the breast epithelium occurs with 
an increase in mitotic index (13; 14). In the luteal phase, breast ducts and acini dilate and 
secretory  changes  occur  in  the  acinar  cells,  with  lipid  material  in  the  lumina.  The 
premenstrual engorgement has been attributed to increased intralobular oedema and the 
epithelial  proliferation.  At  the  onset  of menstruation  secretory  activity  ceases  and  the 
breast epithelium returns to the resting state. Apoptosis occurs approximately 3 days after 
the peak of mitotic activity in order to restore the balance between cell proliferation and 
cell  death.  Changes  in  the  stromal  cells  during  the  menstrual  cycle  are  not  well 
understood.
Changes During Pregnancy and Lactation:
Well  defined  changes  occur  in  the  breasts  during  pregnancy  and  lactation  under  the 
influence of oestrogen,  progesterone,  placental  lactogen and prolactin.  These hormones 
stimulate the proliferation of ductular and lobular epithelium to form new lobular units. 
Microscopically, by the 5^-6* month, a great increase in the amount of lobular tissue has 
taken  place.  Though  oestrogen  and  progesterone  are  essential  for  the  physical 
development of the breasts during pregnancy,  they inhibit the actual  secretion of milk, 
which is promoted by prolactin.  This hormone is secreted by the female pituitary gland 
and its concentration in the blood rises steadily from the 5th week of pregnancy till the 
baby’s  birth,  at  which  time  it  is  10  times  the  non-pregnant  level.  Secretory  activity 
becomes prominent within the luminal secretory cells and lipid droplets appear in acinar 
lumina.  Myoepithelial  cells become  flattened  and relatively  less prominent as does the 
intralobular  stroma.  Interlobular  connective  tissue  and  adipose  tissue  also  appear 
relatively insignificant. Further changes occur at parturition when the uninhibited action 
of prolactin and the stimulus of suckling by the infant quickly lead to the establishment of 
lactation.  There  is  sudden  loss  of both  oestrogen  and  progesterone.  Other  hormones,Chapter I:  The breast -  embryology, anatomy and physiology 8
which play an important role at this stage are growth hormone, cortisol and parathyroid 
hormone.  These  are  necessary  to  provide  the  amino  acids,  fatty  acids,  glucose  and 
calcium for milk formation. Once lactation starts, the acini become dilated. The cells may 
be tall or columnar and the cytoplasm granular or vacuolated.
Secretory activity is cyclical within the breast. Milk is expressed at the nipple following 
sensory nerve stimulation by the infant suckling, which results in release of oxytocin from 
the posterior pituitary  gland.  The  impulses travel  from  sensory  nerves of the nipple to 
spinal cord and then to the hypothalamus and finally along the neurosecretory fibres of 
the hypothalamoneurohypophyseal tract.  Oxytocin causes the myoepithelial  cells of the 
breast  acini  to  contract  and  eject  milk  into  the  duct  system  and  then  the  lactiferous 
sinuses.
Involution:
When lactation ceases, there is a gradual return to the  ‘resting’  state, which takes three 
months on average (15). The reduction in prolactin level is a major contributory factor to 
this. Involution of the epithelial tissue occurs, with regression towards the resting ratio of 
connective tissue to lobules. However, the breasts never return completely to their former 
state and there is a variation in the degree of involution from one area to another.
Postmenopausal Atrophy:
At  the  end  of  reproductive  years,  there  is  marked  reduction  in  ovarian  hormonal 
secretions, accompanied by progressive atrophy of the epithelial components of the breast 
(16; 17).  There  is  an  increase  in  the  amount  of adipose  tissue,  with  hyalinization  of 
connective  tissue  stroma.  Most  of  the  main  duct  system  is  preserved  but  there  is 
considerable loss of lobular units. Remaining lobules show a marked reduction in size due 
to  loss  of acini.  Hyalinization  of intralobular  stroma  is  also  seen.  Some  ducts  appear 
ectatic and focal microcyst formation is common in residual lobules. With advancing age 
any residual lobules become very small and indistinct and ductal structures predominate 
within a dense hypocellular stroma. Sometimes, an apparent myoepithelial hyperplasia is 
seen in the atrophic lobules (18; 19). Occasionally, some apparently normal, resting type 
lobules, may be found in post menopausal breast tissue; and some of these may exhibit 
secretory  features  (lactational  lobules).  These  have  also  been  observed  in  nulliparous 
women (2 0 ).Chapter 2: Breast cancer 9
CHAPTER 2:  BREAST CANCER:
INCIDENCE:
Breast cancer (BC)  is  increasing  worldwide  with  the  highest  rates  reported  in  affluent 
western societies, (1  in  8 to  1   in  12).  In the UK alone, it accounts for  15,000 deaths per 
year. The lifetime risk in the UK is 9% and average incidence 65 per 100,000 persons per 
year (1).  Breast cancer remains the leading cause of cancer death of adult women under 
54 years of age and the second most common cause after age 54 (1). Among women of all 
ages, breast cancer is second only to lung cancer as the leading cause of cancer deaths. 
Less than 1% of all breast cancer cases occur in men; in whom the course of disease and 
its clinical management are very similar to that in women.
RISK FACTORS:
Women  at  a  higher  risk  for  developing  breast  cancer  are  those  with  a  strong  family 
history  of  breast  cancer  (2 ),  a  personal  history  of  breast  cancer  (2 -1 1%  of  women 
diagnosed with  BC  will  develop contralateral  BC  in  their  lifetime)  (3),  past history of 
benign breast biopsy especially if this shows atypical hyperplasia (4), early menarche or 
late menopause or a  first full term pregnancy after age 30 (5), age at the last full term 
pregnancy  may  be  important  as  well  (6 ).  The  risk  of developing  breast  cancer  also 
increases with age, being most common after age 50. Long term oestrogen therapy [oral 
contraceptive pill (OCP) (7), hormone replacement therapy (HRT)(8;9)], a high fat diet, 
obesity (10) and alcohol use (11) have all been reported as risk factors. Ionizing radiation 
has  also  been associated  with  increased risk  (12; 13).  It  has  been  suggested that breast 
cancer may be associated with exposure to oestrogens and other hormones in utero. Twin 
pregnancies  have  higher  levels  of  pregnancy-associated  hormones  than  singleton 
pregnancies,  and  these  levels  may  be  higher  in  dizygotic  than  in  monozygotic  twin 
pregnancies.  Twins  seem  to  have  a higher risk  than  the  general  population,  especially 
dizygotic twins and females with twin brothers (14). However, the risk is less in mothers 
of twins (15), due to proposed inhibitory effect of human chorionic gonadotrophin (HCG) 
and alpha-feto protein (AFP) (16).Chapter 2: Breast cancer 10
CLINICAL PRESENTATION:
Most of the patients (85%) with breast cancer have a lump in the breast. Less commonly, 
nipple  discharge  (5%),  skin  deformity  or  ulceration  (1%),  an  axillary  lump  (1%)  or 
Paget’s disease of the nipple may be presenting features. Breast pain (5%) can also be a 
symptom  of early  breast  cancer  (17).  With  the  advent  of  mammographic  screening, 
asymptomatic cancers are being increasingly diagnosed. These are more likely to be node 
negative (65%), small (50% < 15mm) and more likely to be of good prognostic type, well 
differentiated or in situ cancers (18; 19).
Patients  may  present  with  metastatic  disease  and  its  complications  e.g.,  bone  pain, 
hypercalcaemia, pleural effusion, liver disease etc.
SCREENING:
With  modem  technology,  breast  cancer  can  be  detected  at  a  very  early  stage  of 
development when the chance for cure is highest (20). The key to cure is early detection 
and prompt treatment. Physical examination, mammography and breast self examination 
comprise an early detection approach.
Population screening of women over 50 with mammography has been shown to reduce 
breast  cancer  mortality  at  10  years  follow  up  by  30%  (21).  National  screening 
programmes examine women aged 50-64 years with a single oblique mammogram every 
3  years, there is increasing evidence that screening during the fifth decade (40-49 years 
age group) may also be effective (22;23).
DIAGNOSIS AND INVESTIGATIONS:
1.  Mammography:  Mammography can detect the majority of breast cancers, although 
10-14%  of clinically  diagnosable  cancers  will  not  be  detected,  therefore,  a normal 
mammogram  does  not  exclude  breast  cancer.  Radiological  signs  of  malignancy 
include spiculate masses, microcalcification, stellate lesions, parenchymal distortions 
and skin tethering.
2.  Ultrasound:  Ultrasound is not useful as a screening tool. Cancers are typically seen as 
solid,  irregular  and  vascular.  Ultrasound  is  not  as  sensitive  or  specific  as 
mammography  but  it  is  particularly  useful  in  younger  women.  Ultrasound  canChapter 2: Breast am eer 11
categorize palpable masses, which are indeterminate mammographically.  Ultrasound 
is sometimes used to improve the accuracy of fine needle aspiration.
3.  MRI:  The  role  of  magnetic  resonance  imaging  (MRI)  as  a  modality  to  detect, 
diagnose and stage  breast cancer is as  yet unclear.  It  is  costly  but very  accurate to 
detect breast implant failure (24). It is sensitive for the visualization of both DCIS and 
IDC  and  can  detect  these  when  they  are  clinically  and  mammographically  occult, 
offering the  future  potential  for more  accurate  breast cancer staging and  optimized 
treatment planning.
4.  Fine  Needle  Aspiration  Cytology  (FNAC):  This  is  a  simple  technique  with  58% 
specificity.  It can differentiate between cysts and  solid tumours,  however,  it cannot 
distinguish between in situ and invasive carcinoma.
5.  Core  Biopsy:  A  core  biopsy  performed  under  local  anaesthetic,  can  accurately 
confirm the diagnosis preoperatively. It provides a large core of tissue for histological 
study  and  allows  further  investigations  (e.g.,  hormone  receptor  staining  to  be 
performed).  It  is  a  highly  sensitive  and  specific  technique  for  the  management  of 
patients with mammographic abnormalities.
6 .  Localization  Biopsy:  This form of biopsy is  done for impalpable mammographically 
suspicious lesions.
7.  Tumour  Markers:  The  major  role  of tumour  markers  (CA  15.3,  CEA)  is  in  the 
diagnosis and monitoring of metastatic BC.
STAGING:
Staging is a method of grouping patients by the extent of disease to determine the choice 
of treatment  and  predict  prognosis.  The  more  advanced  the  stage  of the  disease,  the 
poorer  the  prognosis.  Staging  investigations  include:  full  blood  count,  serum 
biochemistry, chest X-ray in all patients and liver ultrasound and bone scan for patients 
with stage II, III and IV disease.
The staging system (TNM) recommended by the American Joint Committee on Cancer 
(AJCC) in the 5th edition is shown in table 2.1:Chapter 2: Breast cancer 12
Table 2.1; The staging system (TNM) recommended by 
the American Joint Committee on Cancer (AJCC)
Stage Tumour  m Nodes  (N) Metastasis  (M)
0 Tis NO MO
I T1 NO MO
IIA TO N1 MO
T1 N1 MO
T2 NO MO
IIB T2 N1 MO
T3 NO MO
IILA TO N2 MO
T1 N2 MO
T2 N2 MO
T3 N2 MO
T3 Nl, N2 MO
IIIB T4 Any N MO
Any T N3 MO
IV Any T Any N Ml
Explanation:
(1)  Primary tumour (TV
Tx - Primary  tumour cannot be assessed 
TO - No evidence of primary tumour
Tis - Carcinoma in situ (DCIS, LCIS, Paget’s disease of nipple)
T1 - Tumour size < 2cm
Tla - <0.5 cm
Tib - 0.5 -  1  cm
Tic - 1  -  2 cm
T2 - Tumour size  2-5 cm
T3 - Tumour size  >5 cm
T4 - Tumour of any size with direct extension to chest wall or skin 
T4a - Chest wall extensions
T4b - Oedema or ulceration of skin or satellite skin nodules
T4c - Both T4a and T4b
T4d - Inflammatory carcinomaChapter 2: Breast cancer 13
(2)  Regional  Lymph Nodes  (N):
Nx  -  Regional lymph nodes cannot be assessed 
NO  -  No nodal metastasis
N1  -  Metastasis to mobile ipsilateral axillary lymph node/s 
N2  -  Metastasis to fixed ipsilateral axillary  lymph node node/s 
N3  -  Metastasis to ipsilateral internal mammary, supraclavicular or infraclavicular 
nodes.
(3)  Distant Metastasis (M):
Mx - Presence of distant metastasis cannot be assessed.
MO - No distant metastasis 
Ml - Distant metastasis
An alternative staging system used quite often in clinical situations is shown in table 2.2.
Table 2.2; Staging of breast cancer by defining risk groups of
patients
Stage Group
Five year 
Survival
Example Treatment
0 Minimal risk >90% Screen detected <lcm 
DCIS
Local
I Low risk 70 - 90%
Node -  negative 
histological 
Grade I and II
Loco -  regional
II High risk 30 -  70% Node -  positive or 
Grade III
Loco -  regional 
and systemic
III
Locally
advanced
10-30%
Large tumour or skin 
fixation/ulceration Primary systemic
IV Metastatic <10%
Liver and lung 
metastases
Primary systemicChapter 2: Breast cancer 14
CLASSIFICATION & PATHOLOGY:
Classification of breast malignancy is based on the morphological features described by 
the World Health Organisation (WHO) (25-29) and is as follows:
Epithelial:
1- Ductal carcinoma in situ (high grade, intermediate grade, low grade and mixed).
2- Micro-invasive carcinoma (MIC).
3- Invasive carcinoma (the usual types are ductal carcinoma of no special type 45-70%, 
lobular  5-10%,  medullary  2-10%,  tubular  1-7%,  invasive  cribriform  0.8-3.5%,  tubular 
mixed  14%, mucinous  1-3%,  invasive papillary <2%,  metaplastic  , mixed, and the rare 
types  are  squamous  cell,  mucoepidermoid,  low  grade  adenosquamous,  adenocystic, 
malignant adenomyoepithelioma, malignant myoepithelioma, apocrine, primary oat cell, 
clear cell and secretory) (30).
Mesenchymal:
These  include  angiosarcoma,  lymphangiosarcoma,  fibrosarcoma,  malignant 
fibrohistiocytoma,  liposarcoma,  osteogenic  sarcoma,  leiomyosarcoma, 
rhabdomyosarcoma,  chondrosarcoma.  Primary  malignant  mesenchymal  tumours  are 
exceedingly uncommon in the breast.
Miscellaneous:
These  are  malignant  lymphoma  (Non-Hodgkin’s  and  Hodgkin’s),  plasmacytoma, 
leukaemia and metastatic tumour from cancer at other sites.
It has been shown that majority of breast carcinomas arise from the terminal duct lobular 
unit (TDLU)(31).
The commonest histological type (70%) of breast cancer is invasive or infiltrating ductal 
carcinoma (IDC)(32).  Fisher et al have added the term “not otherwise specified (NOS)” 
(33) and Page et al have used the term “no special type (NST)” (34). IDC is subdivided 
into  well  differentiated  (Grade  I),  intermediate  differentiated  (Grade  II)  and  poorly 
differentiated  (Grade  III)  on  the  basis  of histological  features.  Elston  and  Ellis  (1991)Chapter 2: Breast cancer 15
reported  16 years survival  in grade  I  tumours to be 90%,  55% in Grade II  and 48% in 
Grade  III  (35).  The  Elston  and  Ellis  grading  system  has  been  modified  from  the  one 
described  by  Bloom  and  Richardson  (36).  The  following  protocol  is  based  on  that 
described by Elston and Ellis. The method involves the assessment of three components 
of  tumour  morphology:  tubule  formation,  nuclear  pleomorphism  and  frequency  of 
mitoses. Each is scored from  1-3. Adding the scores gives the overall histological grade 
as shown below.
Tubule Formation: 
Score:
1.  majority of tumour (greater than 75%)
2.  moderate amount (10 - 75%)
3.  little or none (less than 10%)
Nuclear Pleomorphism:
Score:
1.  nuclei  small,  with  little  increase  in  size  in  comparison  with  normal  breast 
epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size.
2.  cells larger than normal with open vesicular nuclei, visible nucleoli and moderate 
variability in both size and shape.
3.  vesicular  nuclei,  often  with  prominent  nucleoli,  exhibiting  marked  variation  in 
size and shape, occasionally with very large and bizarre forms.
The evaluation of nuclear grade in the grading of invasive breast cancer is one of the most 
difficult  and  least  reproducible  category  compared  with  tubule  formation  and  mitotic 
count (37).
Mitosis:
The score depends on the number of mitoses per  10 high power fields (hpf) assessed at 
the tumour periphery. For example, for a field diameter of 0.48,
Score:
1.  0 - 6  mitoses/hpf
2.  7-12 mitoses/hpf
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A minimum of 10 fields is counted at the periphery of the tumour where the proliferative 
activity has been demonstrated to be the greatest (38;39).
Overall Grade:
The  scores  of  tubule  formation,  nuclear  pleomorphism  and  mitoses  are  then  added 
together and assigned to grades as below:
Well differentiated  (Grade  I)  =  score 3-5  (Figure 2.1 a-b)
Intermediately differentiated  (Grade  II)  =  score 6 -7   (Figure 2.2 a-b)
Poorly differentiated  (Grade III)  =  score  8 -9   (Figure 2.3 a-b)
Histological grade is a powerful independent prognostic factor like lymph node stage (35) 
(40)and  the  consistency  and  reproducibility  of  histological  grading  has  now  been 
confirmed in several studies (41-43). Both grade and type should be assessed in all cases 
of invasive breast cancer (44), although both histological grading and typing are subject 
to interobserver variability (45;46).
Invasive lobular carcinoma has a greater tendency to be multifocal (10-15% of cases) and 
bilateral than ductal tumours and is often (60%) associated with in situ lobular carcinoma 
(LCIS) (47;48). Tubular, medullary and mucinous (colloid) constitute  10% of all breast 
cancers collectively and have a notably better prognosis (49). These histological types are 
found more frequently among mammographically detected cancers (50-52).
In situ carcinoma of the breast may be ductal, lobular or mixed. Ductal carcinoma in situ 
(DCIS) is discussed in detail in chapter 6. Lobular carcinoma in situ (LCIS) is usually an 
incidental finding as it is typically impalpable and undetectable mammographically. It is 
usually diagnosed  in premenopausal  women, multicentric  foci may be present  in up to 
90% of cases  and  contralateral  LCIS  is  found  in  25%  when a mirror image  biopsy  is 
performed  (53).  It  is  generally  regarded  as  a  risk  factor  rather  than  a  premalignant 
condition (relative risk increased  10 fold) because invasive cancer, when it develops, can 
occur in either breast with equal  frequency and can be of either ductal  or lobular type. 
Approximately 25% of women with LCIS will develop invasive breast cancer within 20 
years from diagnosis giving an estimated cumulative annual risk of 1% per year.Chapter 2: Breast cancer 17
Figure 2.1; Photomicrographs of a case of invasive ductal carcinoma
(histological grade I)
Figure  2.1a;  Low  power  view  of a  grade  I  IDC  showing 
marked tubule formation (score = 1). Magnification x 50.
Figure 2.1b;  Same case as in 2.1a, showing mild degree of
nuclear  pleomorphism  and  scanty  mitosis.
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Figure 2.2; Photomicrographs of a case of invasive ductal carcinoma
(histological grade II)
Figure  2.2a;  Low  power view of a grade  II  IDC  showing 
some tubule formation (score = 2). Magnification x 50.
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Figure 2.2b; Same case as in 2.2a, showing moderate degree
of nuclear pleomorphism and mitosis. Magnification x 400.Chapter 2: Breast cancer 19
Figure 2.3; Photomicrographs of a case of invasive ductal carcinoma
(histological grade III)
Figure 2.3a;  Low  power view of a grade  III  IDC  showing 
scanty tubule formation (score = 3). Magnification x 50.
Figure 2.3b; Same case as in 2.3a, showing marked nuclear
pleomorphism and abundant mitosis. Magnification x 400.Chapter 2: Breast cancer 20
Extensive in Situ Component (EIC):
Extensive in situ component (EIC) is defined as the presence of DC IS within an invasive 
carcinoma, in which the DCIS comprises 25% or greater of the tumour mass and extends 
clearly beyond the infiltrating margins of the tumour into grossly normal adjacent breast 
tissue  (54;55).  The  presence  of EIC  is  a significant  risk  factor  for  local  recurrence  in 
patients treated with conservative surgery and radiotherapy (54-57).
Breast cancer commonly metastasizes to ipsilateral axillary nodes and nodal involvement 
is found in up to 50% of symptomatic cases at presentation (58). The more axillary nodes 
that  are  involved,  the  greater  the  risk  of micrometastasis  elsewhere  and  of relapse  or 
recurrence. The reported incidence of ‘occult’ axillary lymph node metastases in patients 
with apparently ‘node-negative’ breast cancer is between 9-33% but their significance is 
debated (59). However, one recent study has demonstrated these to be of no prognostic 
significance (60).  Common sites for distant metastasis for breast cancer are bone, liver, 
lung and brain. Lobular carcinoma may also spread to atypical sites such as the meninges 
or the serosal surfaces of pleura and peritoneum.
PROGNOSIS:
Overall survival (OS) for breast cancer at 5 years is 50%, at 10 years 35% and at 15 years 
is 30%.  The most important prognostic factor is the number of involved axillary nodes 
with 78% 5 years survival for node-negative cancer, 63% 5 years survival if 1  -3 nodes are 
involved and 32% 5 years survival for breast cancer with 4 or more involved lymph nodes 
(61 ;62).
Other prognostic factors include tumour size, histopathological grade, hormone receptor 
status and lymphovascular invasion.  Large tumour size, higher histopathological  grade, 
absence of hormone receptors and presence of lymphovascular invasion correlate to poor 
prognosis.  Some  studies  have  shown  that the  presence  of vascular  invasion  in  tumour 
specimen predicts for local recurrence (63).
Analysis  of a range  of prognostic  factors,  using the  multiple  regression  model  of Cox 
(64), showed that only tumour size, histological lymph node stage and histological grade 
give  a  significant  correlation  with  overall  survival  (65).  Based  on  these  findings,  the 
Nottingham prognostic index (NPI) has been formulated as follows:Chapter 2: Breast cancer 21
NPI = 0.2 x tumour size (in centimetres) + lymph node stage (1 -  3) +  histological grade 
(1-3)
[Lymph node stage 1   = 0 nodes involved, stage 2=1-3 nodes involved and stage 3 = >3 
nodes involved.]
Prognosis worsens as the numerical value of NPI increases and by using cut-off points of 
3.4 and 5.4, patients may be categorized into good, moderate and poor prognostic groups 
having an annual mortality of 3, 7 and 30% respectively (6 6). The predictive value of the 
NPI  has  been  confirmed  after  long-term  (15  year)  follow-up  (67)  and  also  validated 
independently by the Yorkshire Breast Group (6 8).
Increased  tumour  proliferation  as  measured  by  S-phase  fraction,  thymidine  labelling 
index, tumour ploidy and Ki67 immunostaining, has also been related to worse prognosis. 
Furthermore cerbB-2 oncoprotein and cathepsin D expression are also associated with a 
worse prognosis.  However, these molecular markers are not yet widely used in clinical 
decision making.
Recently, under the auspices of the College of American Pathologists, a multidisciplinary 
group  of clinicians,  pathologists  and  statisticians  considered  prognostic  and  predictive 
factors  in  breast  cancer  and  stratified  them  into  categories  reflecting  the  strength  of 
published evidence.  Category  I included factors proven to be of prognostic  importance 
and  useful  in  clinical  patient  management  and  these  were  TNM  staging,  histological 
grade, histological type, mitotic figure counts and hormone receptor status.  Category II 
factors were those which have been  studied extensively biologically and clinically, but 
whose  importance  remains  to  be  validated  in  statistically  robust  studies  and  these 
included  cerbB-2,  proliferation  markers,  p53  and  lymphatic  and  vascular  channel 
invasion.  Category  III  factors  were  all  other  factors  not  sufficiently  studied  to 
demonstrate  their  prognostic  value  and  included  DNA  ploidy  analysis,  microvessel 
density,  epidermal  growth  factor  receptor  (EGFR),  transforming  growth  factor-alpha 
(TGF-a), bcl2, pS2 and cathepsin D (69).
FAMILIAL BREAST CANCER:
Familial  breast  cancer  (FBC)  accounts  for  10-15%  of all  breast  cancers.  The  genes 
responsible  include  BRCA-1  on  chromosome  17q21,  BRCA2  on  13ql2-13,  p53  onChapter 2: Breast cancer 22
17pl3, ataxia telangectasia (AT) on  1  lq23, HRAS minisatellite locus on  11 pi5 and the 
androgen receptor (AR) gene on the X chromosome. These genes do not account for all 
high risk breast cancer families, therefore probably there are other genes responsible that 
remain to be identified yet.  The above mentioned genes differ markedly  in the risks of 
breast cancer they confer and the proportion of breast cancer cases which they explain. 
BRCA-1  mutations account for 5% of all breast cancer cases, that is, a high proportion of 
familial BC cases and the relative risk of developing BC is 50% by the age of 50.This is 
discussed further in chapter 3. BRCA-2 has a strong association with male breast cancer. 
Germline p53 mutations are rare and cause less than 1% of breast cancer cases, although 
the risk of developing BC is high, over 50% by age 50 (70;71). Germline mutations of the 
androgen  receptor (AR)  gene  are  an  even  rarer cause  of breast  cancer,  and  have  been 
shown to cause male breast cancer in only two families (72). Ataxia-telangiectasia (AT) 
gene is more common, probably responsible for 7% of BC cases, but confers a low risk, 
about  11% by age 50 (73). The HRAS minisatellite locus has alleles, which are mutated 
much  more  frequently,  but  confers  a  very  low  risk  (about  3%  by  age  50).  Thus  only 
BRCA-1  explains  a  substantial  proportion  of ‘familial  breast  cancer’  cases.  The  other 
genes  are  either too  rare  (p53,  AR)  or  confer  too  low  a  risk  (AT,  HRAS)  to  have  a 
measurable familial effect.
Familial Genotypes:
Familial genotypes include:  1) site-specific breast cancer which is characterized by early 
age of onset and frequent bilaterality,  2) breast cancer displaying a familial association 
with  ovarian  and  endometrial  carcinoma,  3)  breast  cancer  displaying  a  familial 
association with carcinomas of gastrointestinal tract, 4) breast cancer in Cowden’s disease 
(multiple  hamartoma  syndrome),  5)  breast  cancer  in  Klinefelter’s  syndrome,  6)  breast 
cancer showing a familial association with cutaneous malignant melanoma (74) and 7) Li 
Fraumeni  syndrome  which  is  characterized by bone/soft tissue  sarcoma,  breast cancer, 
brain  tumour,  adrenocortical  carcinoma  and  leukaemia  (75)  and  is  associated  with 
germline p53 mutation. The criteria for diagnosis include  1) a proband with bone or soft 
tissue  sarcoma diagnosed  under  the  age  of 45  years,  2)  one  first  degree  relative  with 
cancer under the age of 45 years and 3) one first or second degree relative in the same 
lineage with cancer under 45 years of age or sarcoma diagnosed at any age.Chapter 2: Breast cancer 23
MALE BREAST CANCER:
Male breast carcinoma (MBC) is uncommon, with the reported incidence in the literature 
being 1% or less (76-78). MBC affects an older population, presents late and is frequently 
fatal (78). The mean age at presentation is 60-65, which is approximately  10 years later 
than in females (77). Over 80% of patients present with a breast lump and histologically 
the  majority  of the  male  breast  carcinomas  are  ductal,  NST  (78).  Other  histological 
subtypes  occur  rarely.  Pure  DCIS  has  also  been  reported  in  males,  but  the  reported 
frequency  varies  from  2.5-14%  of total  cancers  in  males  (78;79).  The  potential  risk 
factors  include  hyperoestrogenism,  gynaecomastia,  family  history  in  either  female  or 
male  relatives  and  prior  radiation  exposure.  Klinefelter’s  syndrome  is  known  to  be  a 
definite risk factor (80). The differential diagnosis is from gynaecomastia and secondaries 
from other sites. Cancers which frequently metastasize to male breast are prostate, lung, 
kidney and malignant lymphoma. MBC was thought to have a worse prognosis than BC 
in females, the overall 5- and 10-year survival rates being 38 and 17% respectively in one 
series (81).  However,  one  new study has  shown that there  is no real  difference  in  OS 
between males and females when known prognostic factors are taken into account (82). 
Biological factors such as ER, MIB1, cerbB-2 and p53 have been studied in some MBC 
patients but there are insufficient data available on the prognostic value of these in MBC. 
The management of MBC is similar to BC in females.
BREAST CANCER IN CHILDREN:
This is exceedingly rare.  Less than 50 cases were reported by  1973. Isolated cases since 
then  have  been  reported  (83-85).  The  most  common  pattern  is  secretory  carcinoma 
(86;87).  It may  develop  local  recurrence,  and can rarely metastasize to  regional  lymph 
nodes  (88)  or  to  systemic  sites.  Usually  breast  cancer  in  children  has  an  excellent 
prognosis  (89).  Isolated  examples  of  rhabdomyosarcoma,  angiosarcoma  and  non- 
Hodgkin’s lymphoma (NHL) of the breast have been reported in patients in the second 
decade of life.
CLONALITY OF HUMAN BREAST CANCER:
Tumours  are  generally  considered  to  be  monoclonal  (90;91),  including  breast  cancer. 
Some  hyperplasias  are  also  monoclonal.  However,  Going  et  al  (92)  have  recently 
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X-chromosome inactivation in DNA extracted from microdissected  in situ and invasive 
breast  carcinoma  by  Hpa  II  restriction  and  polymerase  chain  reaction  (PCR)  of the 
androgen receptor (AR) exon I CAG polymorphism.
MANAGEMENT:
1.  Carcinoma in situ:  (la) Ductal carcinoma in situ (DCIS)  :  Management of DCIS is 
dealt  with  in  chapter  6.  (lb)  Lobular  carcinoma  in  situ  (LCIS):  Wide  local  exision 
(WLE)  is  inappropriate  as the condition  is usually multifocal.  As  LCIS  is a marker of 
increased risk of BC, patients should be observed clinically with regular mammography. 
Tamoxifen  is  currently  being  used  in  a  randomized  clinical  trial  by  the  European 
Organization for Research and Treatment (EORTC).
2.  Invasive  carcinoma of the  breast:  Management  depends  on  the  type  and  stage  of 
disease  at  the  time  of  diagnosis.  Treatment  is  generally  multidisciplinary  with  a 
combination of surgery,  radiotherapy  and chemotherapy  (93).  Stage  I  and  II  disease  is 
potentially curable by surgery and is considered early breast cancer.  Stage III is locally 
advanced breast cancer and Stage IV  is metastatic breast cancer.  Locally advanced and 
metastatic breast cancers are incurable but the natural history is very variable and ranges 
from months to many years.
(2a) Early breast cancer:  This is generally treated by breast conservation surgery (which 
is usually wide local excision and axillary dissection to either level I, II or III) followed 
by radiotherapy to the whole breast or by modified radical mastectomy with or without 
breast  reconstruction.  Simple  excision  of the tumour in the absence  of radiotherapy  is 
associated with a high incidence of local recurrence (about  15-40%) (94).  Studies have 
shown  no  survival  difference  between  breast  conservation  surgery  followed  by 
radiotherapy  and  modified  radical  mastectomy provided tumours  are  small  in  size  and 
there  is  no  evidence  of multifocal  disease  or  extensive  in  situ  carcinoma.  Criteria  for 
selecting patients for conservation include tumour size <3cm, histological grade I or II, no 
lymphatic  or  vascular  invasion  and  no  extensive  in  situ  changes.  The  indications  for 
mastectomy  include  tumour  size  >4cm,  multifocal  disease,  recurrent  disease,  centrally 
located tumour, DCIS component >40mm and the patient’s preference.
Axillary node status is the best single predictor of disease outcome in patients with early 
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status- axillary node sampling (ANS), axillary node clearance (ANC) and sentinel lymph 
node  biopsy  (SLNB).  Recent  studies  have  demonstrated  that  the  sentinel  lymph  node 
biopsy (SLNB) is a simple and reliable method for determining the status of the regional 
lymph  nodes  in  patients  with  clinically  node-negative  breast  cancer  (96).  In  this 
technique, subdermal or peritumoral injection of vital blue dye or radiolabelled colloid, or 
both  substances  together  can  be  used  to  identify  the  first  lymph  node  (sentinel  node) 
draining  the  primary  tumour.  The  sentinel  node  can  be  examined  intra-operatively  by 
frozen section. Axillary node clearance can subsequently be performed if intra-operative 
examination of the node is positive for malignancy, thus avoiding the need for a second 
surgical procedure.
Surgery  and  radiotherapy  are  local  treatments  and  will  not  affect  undetectable 
micrometastasis at the time of diagnosis. Adjuvant therapy may be given to patients with 
early stage disease who are at higher risk of developing metastatic disease based on the 
number of involved axillary nodes, menopausal status and hormonal receptor status (97).
Adjuvant Therapy:
Adjuvant therapy is considered in three different groups of patients as follows:-
(I)  Premenopausal node positive:  These patients should receive polychemotherapy. 
The  commonest  regime  used  is  FEC  (5-fluorouracil,  epirubicin  and 
cyclophosphamide)  for  6  months.  The  other  common  regime  is  CMF 
(cyclophosphamide, methotraxate, 5-fluorouracil).
(II)  Premenopausal node negative: 30% of women with node negative cancers relapse. 
Consideration for chemotherapy in this group should be given particularly to those 
with  large,  poorly  differentiated,  oestrogen  receptor  negative  tumours.  These 
patients can  also  benefit  from  tamoxifen  unless  the  tumours  are  ER  (oestrogen 
receptor) negative.
Trials are still being conducted of chemotherapy in node negative patients.
(III)  Post  menopausal:  Irrespective  of nodal  and  ER  status,  postmenopausal  patients 
benefit  most  from  tamoxifen  and  increased  benefit  may  occur  with  combined 
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mortality  by  25%  and  17%  at  5  years  respectively,  the  benefits  of  adjuvant 
tamoxifen are greater for node positive patients compared with node negative and 
also for women older than 50.
Neo-adjuvant Therapy:
Primary  medical  therapy  for  tumours  >4cm  may  allow  breast  conservation  without 
detriment to survival. Several different regimes are being evaluated. The most commonly 
used  regime  is  AC  (adriamycin  60mg/m  and  cyclophosphamide  600mg/m ). 
Follow-up is usually by three monthly reviews for first two years following treatment, six 
monthly  reviews  uptil  five  years  after treatment  and  yearly  afterwards  with  an  annual 
mammogram.
(2b) Locally advanced breast cancer:
Patients with locally advanced (stage III) breast cancers have a poorer prognosis and are 
not candidates for curative surgery.  However, good local control may be achieved with 
combination surgery, and radiotherapy,  followed by chemotherapy, to improve disease- 
free (DFS) and overall survival (OS).
(2c) Metastatic breast cancer:
The main aim of therapy for patients with metastatic breast cancer is palliation of disease 
related  symptoms and  improved  quality  of life.  Premenopausal  patients  are  treated  by 
combination  chemotherapy  and/or  hormonal  therapy  such  as  LHRH  agonists  and 
tamoxifen. Chemotherapeutic regimes include CMF, FEC (5-fluorouracil, epirubicin and 
cyclophosphamide), MMM  (mitozantrone, methotrexate and mitomycin ) and taxol.
Post  menopausal  patients  in  the  past  were  primarily  treated  by  tamoxifen  followed by 
aromatase inhibitors such as anastrozole or progestogens. At relapse, the overall objective 
response rate with tamoxifen based on 5353  patients in  86 clinical trials was 34% with 
disease stabilisation in a further 19%. The median duration of response varied between 2 
and 24 months (98). Breast cancer patients more likely to respond to tamoxifen are those 
that are ER positive, progesterone receptor positive, with a long disease-free interval (>2 
years) and predominantly soft-tissue and/or bone disease and a single site of disease. Ten 
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recent randomised trial data, aromatase inhibitors are now  1st line treatment for hormone 
positive metastatic breast cancer.
Patients with metastatic disease rarely exhibit a lasting response to standard treatments, 
therefore, researchers are finding the use of high dose chemotherapy regimes followed by 
autologous  bone  marrow  transplant  (BMT)  or  peripheral  blood  stem  cell  rescue  to  be 
promising. In early phase II studies in patients with measurable disease, there were high 
response rates with a complete remission rate of up to 60% (99).
New chemotherapy drugs in the treatment of metastatic breast cancer include navelbine 
(100), taxol (101) and Herceptin (discussed further in chapter 4).
Other  treatment  modalities  include  management  of  specific  problems,  for  example, 
radiotherapy  for  bone  metastasis,  central  nervous  system  (CNS)  metastasis  and  spinal 
cord compression, bisphosphonates for hypercalcaemia, surgical fixation of pathological 
fractures, pleurodesis for recurrent pleural effusions, Leveen shunt for recurrent ascites, 
pleuropericardial  window  for  recurrent  symptomatic  pericardial  effusion,  adequate 
analgesia, psychological support and good palliative care.
PROPHYLACTIC THERAPY (CHEMO-PREVENTION):
Trials are in progress to assess the value of tamoxifen and raloxifene in the prevention of 
breast cancer in patients  with  a strong  family  history  of BC.  The  use of tamoxifen in 
prevention is being tested in an international clinical trial (IBIS).  Striking reductions in 
breast cancer risk were observed for raloxifene in a randomised, placebo-controlled trial 
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CHAPTER 3:  MOLECULAR BIOLOGY OF BREAST CANCER:
In this chapter,  an account of the  molecular biology of cancers  in  general  is given  for 
basic understanding, followed by the description of specific genetic alterations in breast 
cancer.  The recommendations of the  International  Standing Committee  on human gene 
nomenclature have been followed. Thus human genes are written in italicised capitals and 
their  gene  products  in  non-italicized  capitals  (1).  For  genes  of  other  species,  the 
nomenclature recommended for murine genes has been followed, genes are italicised with 
an initial capital letter followed by lower case letters and the corresponding proteins are 
written in non-italicized capitals (2).
GENETIC EVENTS IN CANCER DEVELOPMENT:
Cancer develops through a succession of stages marked by the accumulation of genetic 
events within the cell (3). The progression from normal cell to cancer cell is a complex 
multistep process. Initially genetic alterations are thought to confer a growth advantage to 
individual  cells  by  either  decreasing  tumour  suppressor  gene  activity  or  increasing 
oncogene activity or both.  Further genetic  alterations result  in the development of cell 
clones that have the  ability to  invade  adjacent tissue, establish metastatic deposits  and 
evade immune surveillance. At some point in the process, these malignant cell clones also 
lose the normal ability to respond to hormonal growth regulatory signals.
Tumours result from disruption of the processes that control the normal growth and the 
mortality of cells. This loss of normal control mechanisms arises from the acquisition of 
mutations in three broad categories of genes:
1.  Proto-oncogenes,  the  normal  products  of  which  are  components  of  signalling 
pathways  that  regulate  proliferation  and  which  in  their  mutated  form,  become 
dominant oncogenes (4).
2.  Tumour suppressor  genes,  which  generally  exhibit  recessive  behaviour,  the  loss  of 
function of which leads to deregulated control of cell cycle progression and inability 
to undergo apoptosis.
3.  DNA repair genes, mutations in which promote genetic instability.Chapter 3: M olecular biology o f breast cancer 29
Cancers arise mainly from deregulated proliferation; however, modulation of the normal 
processes  that  leads  to  cell  loss  (programmed  cell  death,  apoptosis)  is  also  sufficient, 
although not necessary, for tumour development. A further consequence of the activation 
of oncogenes or the ablation of tumour suppressor genes may be that the growth arrest 
process  associated  with  ageing  (senescence)  may  be  over-ridden.  Senescence  usually 
correlates with decrease in the length of telomeres which are short, tandem repeats of the 
hexanucleotide  5’-TTAGGG-3’  at  the  ends  of  each  chromosome.  Telomeres  are 
synthesized by telomerase, a ribonucleo-protein DNA polymerase that is active in many 
tumours but is not common in normal tissues (5). In tumour cell lines telomerase activity 
reaches a maximum in the S phase and a variety of inhibitors of cell cycle progression 
(e.g. transforming growth factor pi) inhibit telomerase activity (6).
ONCOGENES:
Oncogenes were first identified in viruses capable of inducing tumours in animals and of 
transforming  cells  in  vitro.  These  viruses  have  RNA  genomes  and  are  called 
‘retroviruses’.  They  can  replicate  through  a  DNA  intermediate  in  infected  cells  (e.g. 
mouse  mammary  tumour  virus-MMTV).  The  oncogenes  carried  by  these  viruses  are 
strongly  homologous  in  sequence  to  normal  cellular  genes  (proto-oncogenes)  that  are 
highly conserved in evolution.  Despite their potent tumorigenic capacity in appropriate 
animal  hosts,  no  retrovirus  has  yet  been  shown  to  be  directly  oncogenic  in  humans. 
However,  it is quite  likely that the latent development of cancers commonly associated 
with  infection  by  human  T-lymphotropic  viruses  (HTLV-I  and  II)  and  human 
immunodeficiency  virus  (HIV)  occurs  from  subversion  of  normal  cellular  control 
mechanisms  by  the  transcription  factors  encoded  in  the  virus  genomes  (3).  The  DNA 
viruses of the  adenovirus,  herpesvirus,  poxvirus and papovavirus  families also  possess 
oncogenic  potential.  Some  DNA  tumour viruses are  oncogenic  in humans  (hepatitis  B 
virus, Epstein-Barr virus) but most are only tumorigenic in other species. The oncogenes 
of DNA viruses differ from those of retroviruses and their transforming genes have not 
yet been shown to have proto-oncogene homologues within the normal human genome, 
except  for  a  few  including  the  presence  of BCL2  sequences  in  the  Epstein-Barr  virus 
(EBV) BHRF1 gene.
There are nearly 200 known oncogenes among about 60,000 functional human genes (3). 
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(e.g.HSTFl,  INT2,  PDGFB/SIS,  WNT1,  WNT2,  WNT3  etc.),  tyrosine  kinases  (FMS, 
EGFR,  KIT,  MET,  HER2/NEU,  RET,  TRK,  SRC),  serine-threonine  kinases  (AKT1, 
AKT2),  membrane  associated  guanine  nucleotide  binding  proteins  (HRAS,  KRAS, 
NRAS), cytoplasmic regulators (CRK) cell cycle regulators (INK4A,  INK4B, CYCLIN 
Dl,  CDC25A,  CDC25B),  transcription  factors (BCL3,  E2F1,  ERBA,  ETS,  FOS,  JUN, 
MYB,  MYC,  REL,  TALI,  SKI),  intracellular  membrane  factor (BCL2),  RNA  binding 
proteins  (EWS)  and  others;  and  these  act  at  different  points  in  signalling  pathways. 
Oncogene activation mainly is the result of somatic events rather than hereditary genetic 
causes transmitted by mutation in the germline. In normal cells proto-oncogene activation 
may occur by mutation. DNA rearrangement or gene amplification. Point mutations may 
arise  from  the  action  of chemicals  or  radiation.  Mutation  of the  coding  sequence  can 
result  in  formation of hyperactive  protein  in  normal  amounts.  The  mechanism of gene 
amplification  can  result  in  overproduction  of  a  normal  protein  product.  DNA 
rearrangement  (chromosome  translocation)  can  give  rise  to  elevated  cellular 
concentrations of the normal protein product or to the expression of new proteins created 
by in-frame fusion of coding sequences from separate genes.
GROWTH FACTORS AND PROLIFERATION CONTROL PATHWAYS:
The regulation of normal cell proliferation occurs through the activation of biochemical 
pathways  by  growth  factors  (mitogens)  interacting  with  their  receptors  on  the  plasma 
membrane (figure  3.1).  There are many different growth  factors like epidermal  growth 
factor (EGF), platelet derived growth factor (PDGF), insulin, bombesin etc. and a single 
cell  often  possesses  a  variety  of  different  receptors.  Normal  and  malignant  breast 
epithelial  cells co-express a number of epidermal growth factor (EGF)  related peptides 
including EGF, transforming growth  factor a (TGFa), amphiregulin and cripto-1  (7;8). 
TGFa is  a  single  chain  polypeptide  which  can  stimulate  growth  by  binding  to  and 
activating the EGF receptor (9; 10). In normal breast epithelial cell lines and some breast 
cancer  cell  lines,  the  production  of  TGFa  is  controlled  partially  by  oestrogen.  It  is 
secreted  by  all  tumour  cell  lines  including  breast  and  studies  have  demonstrated  that 
TGFa is an important modulator of malignant progression of mammary epithelial cells in 
breast cancer (8). TGFp is a two-chain polypeptide which has a growth inhibitory effect 
on epithelial cells including mammary epithelium (11; 12).Chapter 3: Molecular biology of breast cancer 31
Go
I
Growth factor/mitogen
Receptor
Primary Signal
Phosphatidyl inositol 4, 5, biphosphate hydrolysis, 
Tyrosine kinase; CAMP: cGMP
r
METABOLIC RESPONSES
Ca^ signal 
Na+  influx 
Protein kinase C 
Ornithine decarboxylase 
Protein phosphorylation 
Glucose uptake glycolysis 
Amino acid uptake
g e n e a c tiv a x iq n
Ornithine decarboxylase 
FOS, EGR, JUN, ETS 
MYC, CDC 25A, MYB 
Interleukin 2 
Interleukin receptor
RNA and Protein Synthesis
i
DNA Synthesis
Figure  3.1;  Biochemical  events  during  proliferation  in 
eukaryotic cells (3)
The four basic signalling mechanisms that can be activated by transmembrane receptors 
are:
1. Activation of adenylate cyclase, which generates cyclic AMP
2. Activation of guanylate cyclase to generate cyclic GMP.Chapter 3: M olecular biology o f breast cancer 32
3.  Activation  of  phospholipase  enzymes,  which  increases  free  intracellular  Ca +  
concentration as a result of the action of inositol  1,4,5  triphosphate released during the 
hydrolysis of phosphatidyl inositol 4,5 bisphosphate.
4.  Activated  protein  kinases,  the  most  important  group  of which  are  tyrosine  kinases. 
These include receptors for many growth factors (e.g. EGF, PDGF, nerve growth factors).
Nine different classes of tyrosine kinase growth factor receptors have been identified. The 
type  1   family  includes  epidermal  growth  factor  receptor  (EGFR,  cerbB-1),  cerbB-2 
(HER-2/neu),  cerbB-3  (HER-3),  and  cerbB-4  (HER-4),  all  four  of  which  may  be 
expressed in breast cancer (13). Receptors with intrinsic serine / threonine kinase activity 
include  the  transforming  growth  factor  p  (TGF  P)  receptor  family  that  forms 
heterodimeric complexes following cytokine binding and generally transmits signals that 
inhibit growth. The interaction of growth factors with their receptors on the cell surface 
causes quiescent somatic cells to leave Go, traverse Gj and enter S phase, where cells are 
normally committed to one round of the cell cycle.  Following the generation of one or 
more primary signals, a sequence of metabolic events occurs that includes ionic changes, 
increased  ornithine  decarboxylase  activity,  protein  phosphorylation  and  enhanced 
glycolytic  flux  (figure  3.1).  In  parallel  with  and  independent  of  these  events  the 
coordinated transcription of nearly  100  genes is activated within  6 hours  (14; 15).  This 
large number of genes includes JUN,  FOS,  ETSl,  ETS2,  MYC, MYB and many more.  In 
normal  cells,  these proto-oncogenes  function as  essential  mediators of the biochemical 
pathways that regulate proliferation and their corresponding oncogenic forms give rise to 
cancers by sustained proliferation.
Oncoproteins function at most of the known steps in signalling pathways associated with 
cell proliferation (figure 3.2). As mentioned above, they may arise as extracellular growth 
factors  (SIS),  ligand-independent  transmembrane  proteins  (FMS,  ERBB,  RET), 
membrane associated proteins (SRC, YES, RAS, RAF1), cytosolic factors (ABL, MOS), 
nuclear  transcription  factors  (ERBA,  ETS,  FOS,  JUN,  MYB,  MYC)  or  DNA  repair 
enzymes  (MSH2).  A  major  signal  transduction  pathway  in  which  growth  factors  or 
oncoproteins  cause  the  activation of mitogen-activated  protein  serine/threonine  kinases 
(MAPKs or extracellular signal-regulated kinases ERKs) is shown in figure 3.2.  In this 
pathway,  growth  factor-activated  receptors  or  oncoproteins  (SRC,  BCR/ABL)  interact 
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form. Activated RAS then causes the initiation of a cascade of protein phosphorylation by 
serine/threonine kinases including RAF, MAPKK (MEK MAP kinase) and MAPKs (16).
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Figure 3.2: Schematic diagram showing cellular location of some oncoproteins
Thus RAS functions as a relay switch, the activity of which is dependent on the enzyme 
famesyl  transferase.  Some  cancers  contain  RAS  mutations  encoding  a protein  product 
that is permanently activated in the ‘on’ position resulting in enhanced cell proliferation. 
In  germ  cells,  MOS  activates  MAPKK  by  serine  phosphorylation.  MAPKs  target 
transcription factors like ETS, FOS, JUN. A variety of cytokines (including interleukins,Chapter 3: M olecular biology o f breast cancer 34
interferons,  erythropoietin,  growth  hormone,  prolactin  and  granulocyte  colony- 
stimulating factor) and growth factors signal by activating members of the Janus family 
of  protein  kinases  (JAK1,  JAK2,  JAK3  and  TYK3)  that  phosphorylate  on  tyrosine 
residues various STAT proteins (signal transducers and activators of transcription) which 
then dimerize and are translocated to the nucleus to direct gene transcription (17). STATs 
may  form  stable  homodimers  or  heterodimers  that  are  active  as  transcription  factors. 
Several  tyrosine  kinase  inhibitors  and  famesyl  transferase  inhibitors  are  now  entering 
phase  1   and  II  clinical  trials  for  the  treatment  of various  cancers.  Some  of the  better 
understood oncogenes/oncoproteins are described below:
Growth Factor-related Proteins:
PDGF: This is SIS gene product and appears to function as an autocrine growth factor. Its 
role in human cancers is not clear yet.
Receptor Tyrosine Kinases:
EGFR Family: EGFR, HER-2, HERS and HERS are discussed in chapter 4.
SRC: Data from published studies indicate that SRC may play a role in both progression 
through Gi phase and in mitosis. However, no mutations have yet been identified in SRC 
although increased SRC kinase activity has been reported in some colon carcinomas, skin 
tumours and breast carcinomas.
Membrane -  associated G Proteins:
RAS: The RAS family (HRAS1, KRAS2, NRAS) is involved in a wide range of cancers. In 
all  cancers  the  average  incidence  of RAS mutations  is approximately  15%  (18)  but  in 
pancreatic  carcinomas  KRAS2  mutations  occur  in  95%  of tumours  and  in  colorectal 
carcinoma,  the  reported  range  is  from  20-50%.  NRAS  mutations  occur  in  acute 
mylogenous  leukaemia.  Mutations  in  RAS reduce  its  GTP-ase  activity,  the  oncogenic 
protein thus remaining in an active, GTP-bound state. This results in sustained activation 
of RAS-MAPK pathways. RAS mRNA is overexpressed in a variety of tumours including 
breast  (19).  The  minisatellite  region  of HRAS1  also  appears  to  be  mutated  in  some 
cancers. Minisatellites are tandem arrays of between 14 and  100 bp in length of a locus- 
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repeats and hence called  “variable number of tandem repeats” (VNTRs).  Minisatellites 
are dispersed throughout the genome and many VNTR loci display dozens of alleles.  In 
the HRAS1  minisatellite locus, there are 4 common and 25  rare alleles, the  latter being 
more than twice as common in the genotypes of cancer patients than they are in normal 
individuals (20).  Mutant alleles of the HRAS1  minisatellite locus represent a major risk 
factor  for  10%  of breast,  colorectal  and  bladder  carcinomas  (21).  HRASp21  protein 
expression has been  studied  in human breast tumours by immunohistochemistry.  There 
are conflicting results, some groups finding increased p2 1  expression in carcinomas and 
pre-malignant  lesions  (22-25)  and  others  finding  similar  expression  in  benign  and 
malignant lesions (26;27).
RAF: RAF1 is amplified in some non-small cell lung cancers and there is over-expression 
in many small cell lung cancers.
Nuclear Oncoproteins:
ETS: ETS proteins may be involved in tumour-associated angiogenesis and invasiveness. 
However, most epithelial tumours do not express ETS.
FOS:  There are few reports of involvement of FOS in human cancers,  although in one 
study its overexpression  was detected in 60% of osteosarcomas (28).
JUN: JUN overexpression has been detected in small cell and non-small cell lung cancers 
(29;30).
MYB:  Amplification  of MYB  has  been  detected  in  a  small  proportion  of leukaemias, 
colon carcinomas, melanomas and breast carcinomas.  In breast cancer, MYB expression 
may correlate inversely with that of HER-2 and constitutes a good prognostic factor (31). 
Abnormally  high  levels  of MYB  transcripts  have  been  detected  in  some  ovarian  and 
cervical carcinomas (32;33).
MYC:  MYC proteins (MYC,  MYCN and MYCL)  induce proliferation,  inhibit terminal 
differentiation in adipocytes and myeloid cells and in the absence of appropriate growth 
factors, induce apoptosis. MYC has long been known to activate ornithine decarboxylase, 
which is necessary for cell proliferation. Also, it can trans-activate cyclin D1  and cyclin 
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complex  trans-activates  CDC25A,  which  itself  has  oncogenic  capacity.  Furthermore, 
MYC is repressed as a component of p53-mediated growth arrest.
Amplification  and/or  overexpression  of  MYC  commonly  occurs  in  a  wide  range  of 
tumours.  MYCN  is  amplified  in  neuroblastomas  and  also  in  retinoblastomas, 
astrocytomas, gliomas and small cell lung carcinomas. A high level of MYCN expression 
is associated with the advanced stages of cervical intraepithelial carcinoma. Amplification 
of MYCL1  has  been  detected  in  small  cell  lung  carcinoma  (34).  Deregulated  MYC 
expression occurs also in breast carcinomas (35-37). This is further discussed later in the 
chapter.  The  most common genetic  rearrangements in  B  cell  lymphomas  involve MYC 
(8q24) or BCL2 (18q21.3).
REL:  Amplification  of  REL  occurs  in  some  lymphomas  and  rearrangement  of  its 
chromosomal region (2pl2-15) is associated with some non-Hodgkin’s lymphomas.
THR/ERBA:  This  encodes  thyroid  hormone  receptor  a.  Loss  of heterozygosity  at  the 
THRA1  locus has been detected in sporadic breast carcinomas and in a breast carcinoma 
cell line (38).
Other  oncogenes  include  BCL1,  which  is  also  known  as  CCND1  (cyclin  D1  gene)  or 
PRAD1,  and is  located on chromosome  1  Iql 3  along with the I  NT2 and HSTF1  genes. 
BCL1, 1NT2 and HSTF1 are co-amplified in 22% of breast carcinomas (36;39). Cyclin D1 
together  with  cyclin  D2&3  is  a  rate-limiting  controller  of  Gi  phase  progression  in 
mammalian cells and is discussed in a later section on cell cycle control. The expression 
of cyclin D1  in breast cancer is considered later on in the chapter. BCL2 is discussed in 
the  section  of  apoptosis.  BCL3,  located  on  chromosome  19q 13.1,  encodes  for  a 
transcription  factor.  It  is  involved  in  chromosomal  translocations  in  some  B-cell 
leukaemias.
TUMOUR SUPPRESSOR GENES:
The existence of tumour suppressor genes was first suggested in studies of rare inherited 
cancer  syndromes.  In  familial  retinoblastoma,  for  example,  a  genetic  change  was 
inherited  through  the  germline,  but  mutation  or  ablation  of  the  other  allele  on  the 
homologous  chromosome  was  required  for  tumour  development  (Knudson’s  two  hit 
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genes are required; as a result, sporadic retinoblastoma is less common than the familial 
form (42).
In  normal  organisms,  cell  proliferation  is  balanced  by  regulated  cell  loss  through 
apoptosis.  Many  tumour  suppressor  genes  are  involved  in  cell  proliferation,  genetic 
stability and cell death, and they often show mutation in cancer. Such mutations in these 
genes generally ablate the ability to cause apoptosis and result in increased cell numbers.
There  are  approximately  50  known  tumour  suppressor  genes,  the  normal  function  of 
which is to control cell proliferation. The two best understood tumour suppressor genes 
are retinoblastoma (RBI) gene and  TP53 (also called P53).  Retinoblastoma provides the 
classical model for a recessive tumour suppressor gene in that both paternal and maternal 
copies of RBI must be inactivated for the tumour to develop.  For TP53 and some other 
tumour  suppressor  genes,  mutation  at  one  allele  may  be  sufficient  to  give  rise  to  the 
altered  cell  phenotype.  Some  of the  better  understood  tumour  suppressor  genes  are 
described below.
RBI: Retinoblastoma protein (pRb) is a signal transducer, connects the cell cycle clock 
with transcriptional control mechanisms and mediates progression through the first phase 
of the  cell  cycle  (figure  3.3).  It  inhibits  transcription  factors  that  are  required  for the 
expression of genes  involved  in  DNA replication.  Its  loss releases a brake at the  Gi/S 
phase  transition  and  drives  proliferation  and  hence  the  accumulation  of  mutations. 
Retinoblastoma protein  binds  to  and  inhibits  the  E2F  family  of cellular proteins.  The 
phosphorylation of pRb appears to be essential for progression through the cell cycle and 
inhibition of pRb phosphorylation causes cell cycle arrest. The RBI  gene is defective in 
all retinoblastomas, whether familial or sporadic, and there is loss of both copies of the 
gene by inactivating mutations.  Inactive RBI  alleles also occur commonly in small cell 
lung carcinomas, non-small cell lung carcinomas, bladder, pancreatic and  2 0% of breast 
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Figure 3.3; Cyclin dependent kinases in the control of the cell cycle
Cyclin dependent kinases (CDKs) regulate progression through the cell cycle. They are activated by 
specific association  with cyclins and the  rate-limiting controllers of G! phase are  D and  E cyclins 
(also called G! cyclins). D cyclins associate with CDK2, CDK4, CDK5 and CDK6, of which CDK4 
is the most abundant. The activation of CDK4/cyclin D in the cell cycle precedes that of other CDKs 
in the order:
D/CDK4 — ►  D/CDK6 — ►  E/CDK2 —► A/CDK2—► A/CDC2—► B/CDC2.
A  critical  substrate  of D/CDK4  is  pRb,  the  phosphorylation  of which  causes  its  inactivation  and 
permits entry  from G|  to  S-phase.  CDKs are  inhibited by  WAF1  (also called cipland p21),  INK4 
(also called pi 6), KIP1 and KIP2. See list of abbreviations for the abbreviations listed in the figure.
P53:  The  P53  gene  is  located  on  chromosome  17pl 3.1  and consists  of 11  exons.  The 
protein product p53, is located in the nucleus and functions as a transcription factor that 
regulates  normal  cell  growth  cycle  by  activating  transcription  of genes  which  control 
progression through the cycle. It also controls other genes that cause arrest in Gi when the 
genome is damaged and in some cell types, promotes apoptosis (47). Hypoxia, occurring 
in areas of tumours with poor blood  supply,  promotes p53  dependent  apoptosis,  while 
cells with mutated P53 are resistant to killing by hypoxia (48). Genes activated by P53 
include  WAF1,  MDM 2,  GADD45,  BAX and cyclin G, whilst P53 represses MYC,  BCL2,Chapter 3: Molecular biology of breast cancer 39
FOS,  JUN,  MYB,  PCNA,  RBI  and  others.  In  addition  to  these  activities,  which  are 
mediated  by  transcriptional  control,  wild-type  p53  also  possesses  3’  to  5’  DNA 
exonuclease  capacity.  This  Mg++  dependent  activity  may  be  involved  in  replication 
associated DNA repair, p53 acting as a proof-reading enzyme for DNA polymerases.  In 
most transformed and tumour cells, the concentration of p53 is increased 5- to 100-fold as 
compared to the concentration in normal cells (49), principally due to the half-life of the 
mutant forms (4 hours) compared to that of the wild-type (20 min). A schematic diagram 
of the structure of P53 gene and p53 protein is given in figure 3.4.
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Figure: 3.4; Schematic diagram of the structure of P53 gene and protein.
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Normal  function  of p53  is  regulated  post-translationally  and  could  be  influenced  by 
phosphorylation  state,  sub-cellular localization and interaction with many other cellular 
proteins. Wild type p53 is a negative regulator of cell growth, thought to act by forming 
homodimers around DNA, allowing DNA repair to occur before cell division, or if repair 
does  not occur then  inducing  cell  death through apoptosis.  Mutations  of P53  result  in 
more stable forms of protein,  which  form ineffective dimers around wild type p53  and 
lead to a failure of growth regulation. Other effects of mutation include nuclear exclusion 
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single  amino  acid  substitution  with  50%  of mutations  occurring  between  exons  5-8, 
which are highly conserved during evolution (50).
Mutations in the single copy P53 gene are the most frequent genetic changes yet shown to 
be associated with human cancers (51;52), over 6000 of which have been detected (53). 
Point  mutations,  deletions  or  insertions  in  P53  occur  in  approximately  70%  of  all 
tumours.  The  most  frequently  mutated  residues  lie  in  the  regions  that  directly  bind  to 
DNA but other mutations modulate  function by affecting the overall  three-dimensional 
structure of the protein (54). Functionally, mutations in P53 may (i) be of the dominant 
negative  type  when  the  protein  overrides  the  action  of the  suppressor  wild-type  p53 
(/raws-dominant mutations), or (ii) result in the loss of suppressor function, or (iii) result 
in a protein that functions as a tumour promoter (55;56).  Mutations in breast cancer (30- 
86% of cases) occur mainly within exons 5-8 (80%) and none have been detected in exon 
1   or  in  the  putative  promoter  region  (57;58).  They  include  missense,  frame-shift  and 
splice site mutations (59;60). Two germline mutations, one in intron 5 and one in exon 7 
that create truncated proteins have been detected in families with early onset breast and 
ovarian  cancer  (61;62).  The  percentage  of  mutations  in  P53  in  different  malignant 
tumours is summarized in table 3.1.
The rare, autosomal dominant Li-Fraumeni syndrome arises from P53 mutations inherited 
through the germline, usually in exon 7 (63). Fifty percent of the carriers develop diverse 
cancers by 30 years of age, compared with 1% in the normal population. The role of p53 
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Table 3.1; Percentages of P53 mutations in different tumours.
TUMOUR TYPE % CASES
Breast carcinomas 30-86
Ovarian carcinomas 44-61
Lung carcinomas 60
Colorectal carcinomas 30-60
Acute mylogenous leukaemias 6
Brain tumours 10
Malignant astrocytomas 30
Oesophageal adenocarcinomas 80
Gastric carcinomas 57
HBV-positive hepatomas 18
Head and neck cancers 69
Primary melanomas 97
Multiple myelomas 20
Osteosarcomas 41
Pancreatic carcinomas 40
Papillary thyroid carcinomas 50
Renal cell carcinomas 79
Rhabdomyosarcomas 45
Squamous cell laryngeal carcinomas 60
Wilm’s tumours 73
BRCA1 and 2: BRCA-1 (breast cancer susceptibility gene 1) was located on chromosome 
1 7 q 2 1 (1 7 q 21) 12-21  b y   genetic linkage analysis in  1990 by King et al (64). It encodes a 
220 kDa protein expressed predominantly in the nucleus and involved in DNA repair. The 
protein has  1863 amino acids with an amino terminal domain that exhibits similarity to a 
zinc  finger domain found  in  several  regulatory and transcription  factors (65).  Germline 
mutations in BRCA-1 confer a high risk of developing early onset breast cancer (66) and 
ovarian  cancer (67),  which  is  inherited  in  an  autosomal  dominant  manner.  Germline 
mutations  in  the  BRCA1  gene  appear to  be  responsible  for  approximately  50%  of the 
families that have a dominant predisposition to breast cancer and between 80 and 90% of 
those in which multiple cases of both breast and ovarian cancer occur. There is significant 
correlation between the location  of mutations and the relative risk  of breast or ovarian 
cancer within a family.  Mutation in the N- terminal  of the protein carries a significant 
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with breast cancer.  Several studies of sporadic breast tumours have suggested that BRCA- 
1 mutations also play an important role in the development of non-inherited breast cancer. 
Studies  by  the  International  Breast  Cancer  Linkage  Consortium  have  indicated  that 
approximately half of all cases of inherited breast cancer are attributed to germline BRCA- 
1  mutations  (6 8).  Prostate  (69;70)  and  colon  (71)  cancer  risks  are  also  increased  in 
individuals  harbouring  germline  BRCA-1  mutations.  Carriers  of BRCA2  (breast  cancer 
susceptibility gene  2 located on chromosome  13ql2-13) mutations also have a high risk 
of developing breast cancer (72).
Other tumour suppressor genes not discussed in this thesis include:  APC (adenomatous 
polyposis  coli)  gene  which  gives  rise  to  familial  adenomatosis  polyposis,  NF1 
(neurofibromatosis  type  1)  gene,  VHL  (Von-Hippel  Lindau)  gene,  WT1  (Wilm’s 
tumour 1) gene and others.
CELL CYCLE CONTROL:
If the cell cycle is considered to be like an automobile in motion under normal conditions, 
proto-oncogenes are like the accelerator and tumour suppressor genes are like the brakes. 
The cell cycle comprises of 4 phases: Gi (gapl), S (synthesis), G2 (gap2) and M (mitosis). 
Progression through the cell cycle is governed by a family of cyclin-dependent kinases 
(CDKs) and their regulatory subunits, the cyclins (73). As cells enter the cell cycle from 
Go, D- and E-cyclins are synthesized sequentially and both are rate limiting for S-phase 
entry  (figure  3.3).  CDKs  inactivate  pRB  and  its  relatives  pi07  and  p i30  by 
phosphorylation, these proteins being negative regulators of progression, so that exit from 
Gi occurs with entry into S-phase.
D-cyclins  bind  pRb  directly  and  pRb  is  the  critical  substrate  of  CDK4  and  CDK6 
although cyclin E/CDK2 may also phosphorylate pRb.  Phosphorylation of pRb relieves 
its  inhibitory  effect  on  the  trans-activation  function  of both  E2F  family  transcription 
factors and UBF (which regulates  RNA polymerase I) that are required for S-phase. The 
activities of the CDK family are regulated by CDK inhibitors. These include WAF  1, the 
INK4 family, KIP  1   and KIP 2.  WAF1  mediates T\5J-dependent Gi  arrest by inhibiting 
cyclin  D/CDK4,  cyclin  E/CDK2  and  cyclin  A/CDK2,  therefore  preventing  Gj/S 
transition. WAF1 exists as a quaternary complex with a cyclin/CDK and proliferating cell 
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replication and repair. WAF1 inhibits PCNA and its capacity to activate DNA polymerase 
delta  and  also  prevents  interaction  of  PCNA  with  GADD45,  which  is  involved  in 
stimulating DNA excision repair.  Thus the induction of WAF1  by p53  causes both cell 
cycle  arrest and  inhibition of DNA  synthesis.  WAF1  also  inhibits the JUN  N-terminal 
kinases (JNKs), also called stress-activated protein kinases (SAPKs), and MAP kinases 
that  are  activated  by  a  variety  of  oncoproteins,  cytokines,  heat  or  ultraviolet  (UV) 
radiation.  Therefore  WAF1  plays  a  central  role  in  mediating  the  transition  from  a 
proliferative  to  a  differentiated  phenotype  through  its  capacity  to  inhibit  cyclin  D1 
activity and to prevent the Gi/S transition. Maintenance of the differentiated state requires 
the abrogation of signals that normally drive proliferation, as this, in combination with a 
block to cell cycle progression, often promotes apoptosis.
MYC  expression  causes  activation  of  both  cyclin  D1  and  cyclin  E  and 
hyperphosphosylation  of pRb,  thus  increasing  proliferation.  This  is  a  result  of direct 
activation  of CDC25  transcription.  However,  in  the  absence  of growth  factors  or  in 
combination with p53, the expression of MYC will result in apoptosis (figure 3.5).
Similar to components of growth factor signalling pathways, any cell cycle regulator is a 
potential oncogene or tumour suppressor gene.  In addition to loss of RBI  and the high 
frequency of mutations in P53, mutation and deletion of INK4A is also very common in 
primary tumours. Mutations in WAF1 and KIP  I are much less common.
Abnormal  expression  of  cyclin  D1  occurs  in  a  considerable  variety  of  cancers, 
amplification of cyclin D2 has been detected in colorectal carcinoma and abnormally high 
expression of both cyclins  D1  and  D3  occurs  in some primary breast carcinomas.  The 
cyclin-dependent kinase  activator CDC25B  is over-expressed  in approximately 30% of 
primary human breast carcinomas  and  this  correlates  with  a  less  favourable  prognosis 
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Figure 3.5; Myc up-regulation can lead to proliferation or apoptosis 
PROLIFERATIVE ACTIVITY AND PROLIFERATION MARKERS:
It has been shown by many groups that estimation of proliferative activity of a tumour, no 
matter what  method  is  employed,  can  give  prognostic  (75;76) and  therapeutic  (77;78) 
information. It is important to note that true assessment of the growth rate of a tumour can 
only  be  determined  by  combining  measurements  of the  proliferative  fraction  and  the 
length of the cell cycle (79). A single measurement in time of the growth fraction of a 
tumour  is  regarded  as  an  index  of proliferation  only  (79;80),  which  is  a  measure  of 
proliferation state, not rate. The growth fraction can be assessed by counting the number 
of cells  in mitosis  called  mitotic  index  (MI)  (81),  but  this requires  high quality  tissue 
sections and is time-consuming. An alternative is to employ a technique by which cells in 
cycle can  be  labelled.  Cells  in the  synthesis  phase  of the cell  cycle  (S-phase)  take  up 
thymidine which may be tritiated or its analogues such as 5-bromodeoxyuridine (BRDU) 
and incorporated  molecules  can be  identified by  prior radiolabelling,  or in  the  case of 
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proportion of labelled cells gives an estimate of the  S-phase fraction (SPF).  Thymidine 
labelling  requires  fresh  tissue  and  cumbersome  autoradiography  which  again  is  time- 
consuming, hence rarely used nowadays.
There are also proliferation markers which label intranuclear proteins. Ki67 is a cell cycle 
associated  nuclear  antigen,  expressed  in  all  phases  of the  cell  cycle  (Gi,S,G2,M)  and 
absent in  Go. The gene encoding Ki67 appears to be located on chromosome 10q25 (82). 
The monoclonal antibody to Ki67 antigen was first described by Johannes Gerdes et al. in 
1983,  who  suggested  that  it  might  be  used  as  a  marker  for  proliferating  cells  (83). 
Development of the Ki67 equivalent monoclonal antibody MIB1, described by Key et al 
in 1993, allows retrospective studies based on immunohistochemical staining of routinely 
processed, paraffin-wax embedded tissue.  In general, there is good correlation between 
the Ki67 labelling index and other measures of cell proliferation such as thymidine and 
BRDU uptake, DNA flow cytometric analysis and interphase nucleolar organizer region 
scores. Ki67 is useful in the identification of hormone insensitivity in breast cancer and in 
the prediction of tumour growth rates and patient survival (84;85).  Therefore it is used 
prognostically (86).  It has been shown that elevated levels of this antigen are associated 
with earlier breast cancer recurrence (85),  shorter survived time and shorter disease free 
interval (87), as well as a poorer response to therapy.
KiSl  antibody  recognises  another  cell  cycle  associated  antigen,  which  is  expressed  at 
increasing levels during DNA synthesis and reaches a peak in mitosis and has been shown 
to be prognostically useful.
Proliferating cell nuclear antigen (PCNA) has received a lot of attention, particularly as 
one  of the  first  antibodies  which  could  be  used  on  paraffin-wax  embedded  material. 
However studies  have  shown that  PCNA  has  a dual  role  in cell  replication  and  DNA 
repair. These two functions contribute to the conflicting data about the value of measuring 
proliferation with PCNA antibodies.  Whilst some authors have shown it to be useful in 
lymphoid tissue, others have found it unreliable in solid tumours.
Both  the  proteins  recognised  by  KiSl  and  PCNA  have  relatively  long  half  lives. 
Expression of PCNA can also be induced by growth factors in normal and benign cells, 
which are in the vicinity of a malignant lesion.  Hence more cells are labelled than are 
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APOPTOSIS:
Apoptosis (programmed cell death) is an actively regulated cellular process that leads to 
the  destruction  of individual  cells  (88-91).  It  is  a  mechanism  by  which  cells  commit 
suicide and  is thought to play a key  role  in the development and  growth regulation of 
normal  and  neoplastic  tissues.  It  is  distinct  from  necrosis  where  a  cell  loses  its 
homeostatic  control  and  becomes  distended  with  fluid,  leading  to  lysis  and  release  of 
intracellular contents with stimulation of inflammation. Apoptosis, by contrast, involves 
shrinkage and fragmentation of cells with intact membranes and their subsequent removal 
by  phagocytosis  before  release  of harmful  intracellular  contents  can  occur.  It  can  be 
triggered  by  several  stimuli,  such  as  radiation,  drugs  and  toxins  or  by  deprivation  of 
hormones  or  growth  factors  (92;93).  As  with  proliferation,  apoptosis  appears  to  show 
cyclic variations in normal breast tissue with a peak at the end of luteal phase (94). The 
apoptotic process is controlled by several genes, including inducers (P53,  BCLXS ,  BAX, 
BAD,  BAK,  BIK) and repressors (BCL2,  BCLXl  MCL-1,  BRAG-1,  BFL-1). The balance 
between expression of these genes regulates the cell cycle and apoptosis.  The balance 
between these proteins is also regulated by other stimuli such as p53 protein or oestrogen 
receptors in breast carcinomas.
Apoptosis is characterised morphologically by chromatin condensation, intemucleosomal 
fragmentation of DNA by a Mg2+ dependent endonuclease, blebbing of the cell membrane 
and  vesicularisation  of the  cell  contents.  Apoptosis  plays  an  important  role  in  normal 
development and as a defence against viral infection. Inhibition of apoptosis can lead to 
cancer (95).
The  BCL2 (B-cell leukaemia/lymphoma 2) gene, which is located on chromosome 18q21 
and encodes a 26KDa protein, is an important regulator of apoptosis. The cellular location 
of bcl2a is on intracellular membranes including nuclear membranes and that of bcl2p is 
cytoplasmic.  Abnormalities of the BCL2 gene were first discovered in human follicular 
lymphoma in which the gene is translocated to the immunoglobulin heavy chain locus of 
chromosome  14 (96).  As a result, the BCL2 oncogene is activated which enhances cell 
survival, rather than promoting proliferation. Bcl2 is now recognized as a survival factor 
for many types of cells. In T cells, BCL2 confers resistance to apoptosis normally induced 
by  glucocorticoids,  radiation  and  other  agents.  The  expression  of Bcl2  is  widespread 
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bcl2 regulated apoptosis is interleukin-1   p-con  verting enzyme (ICE), a cysteine protease 
that  processes  IL-lp  during  the  inflammatory  response.  Over-expression  of  ICE  in 
mammalian cells causes apoptosis that is inhibited by bcl2.  In general, the activity of a 
family of ICE-related genes appears critical in driving apoptosis. A schematic diagram of 
the bcl2 protein structure is shown in figure 3.6.
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Figure 3.6; Schematic diagram of the bc!2 protein structure
BCL2 is a member of a multigene family, highly conserved in evolution. Other proteins of 
the family, bclXs, bax, bad, bak and bik antagonize inhibition of apoptosis by binding to 
bcl2. Hence the balance of expression of various members of the bcl2 family determine 
the extent to which cell death is promoted or prevented. Heterodimerization of bcl2 and 
bax proteins plays a pivotal  role in regulating the fate of individual cells co-expressing 
these  proteins (97;98).  Excess  of bcl2  promotes  cell  survival  by  inhibiting  apoptosis, 
whereas excess of bax accelerates cell death.
Expression of the bcl2 protein product has been documented in a variety of normal human 
tissues including breast epithelium (99; 100). Bcl2 protein is also expressed in a variety of 
haematological  and  solid  tumours  including  prostate,  colorectal,  squamous  cell  lung, 
bladder,  breast  and  nasopharyngeal  carcinomas.  In  invasive  breast  carcinoma,  bcl2 
protein expression is associated with well-differentiated tumours and positive oestrogen 
receptor  (ER)  status  (101-104).  Among  breast  cancer  patients  treated  with  adjuvant 
chemotherapy or tamoxifen, those with bcl2  protein positive tumours, had  significantly 
better survival rates (105). In bladder carcinomas, however, a high level of bax expression 
relative to  that of bcl2  is a good  prognostic  indicator (106).  One  consequence  of bcl2 
expression is that cells expressing MYC in the absence of appropriate growth factors that 
would normally undergo apoptosis, are prevented from doing so.
Bax is a 21KDa protein with extensive amino acid homology with bcl2 protein (107; 108). 
The protein is encoded by six exons and has been shown to undergo alternative splicing 
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heterodimers with bcl2 and the ratio of bcl2 to bax determines the survival or death of 
cells  following  an  apoptotic  stimulus  such  as  removal  of  growth  factor  (107; 110). 
Stimulation of bax synthesis also appears to be a result of wild-type but not mutant p53 
activity (111).  It has been suggested that deregulation of apoptosis due to imbalances in 
bax/bcl2 levels may contribute to the pathogenesis of breast cancer (109). Bax is normally 
expressed in several  epithelia including those in breast,  small  intestine, colon, prostate, 
respiratory tract and  skin.  Reduced expression has  been detected  in  34% of metastatic 
breast carcinomas and is associated with poor response rates to chemotherapy and shorter 
survival (112).
There  is  little  information  available  on  the  significance  of bax  expression  in  ductal 
carcinoma in situ of the breast (DCIS) and its various histological grades or in invasive 
ductal carcinoma (1DC) and its histological grades.
Growth arrest and apoptosis can be induced by a variety of cytokines including the TGFp 
family.  P53  and  TGFp  both can downregulate BCL2 expression,  but only p53  has the 
capacity to activate BAX.
Expression  of the  tumour  suppressor  gene  P53  that  can  arrest  proliferation,  may  also 
promote apoptosis. Thus p53 levels increase in response to a variety of DNA-damaging 
treatments,  and  in  addition  to  transactivating  BAX,  wild  type  p53  can  repress  BCL2 
expression.  P53  also  appears  to  be  able  to  induce  apoptosis  by  transcription  and 
translation-independent mechanisms.  Wild-type  p53  can induce cell  cycle  arrest  in Gi 
and  apoptosis  within  the  same  cell  but  susceptibility  to  these  processes  is  cell-type 
specific  and  apoptosis  may  occur  without  detectable  arrest  or,  cells  may  arrest  in  Gi 
without undergoing apoptosis. P53-independent apoptosis also occurs and is particularly 
important during normal development.
DNA REPAIR AND MICROSATELLITE INSTABILITY:
Errors  that  arise  during  DNA  replication  and  are  not  corrected  by  the  proof-reading 
activity of DNA polymerase may be rectified by a process called mismatch repair.  Six 
human DNA mismatch repair genes have been identified, MSH2,  MSH3,  MSH6,  MLH1, 
PMS1  and  PMS2.  Mutations  in  these  genes  were  first  detected  in  hereditary  non­
polyposis colon cancer (HNPCC). Mutations in mismatch repair genes lead to an overall 
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phenotype of length instability of microsatellite loci. Microsatellites are short sequences 
of DNA (up to  6bp), repeated between  10 and  50 times, that are  stably  inherited, vary 
from  individual  to  individual  and  have  a  relatively  low  inherent  mutation  rate. 
Microsatellite  instability  was  first  identified  in  colorectal  tumours  (113),  showing  that 
genomic  instability  is  a  very  early  event  in  the  development  of these  tumours.  It  was 
shown that colorectal tumour DNA in some cases showed a substantial change in repeat 
length,  often  heterogeneous  in  nature,  or  a  minor  change  (typically  two  base  pairs), 
compared to normal  DNA  from the  same patient (113).  It  is known that microsatellite 
instability  is caused by mutations  in mismatch repair genes.  Germline mutations in the 
mismatch  repair  genes  are  causative  of HNPCC.  Initially,  some  reports  indicated  the 
presence  of  microsatellite  instability  in  breast  cancer  (114)  as  well.  However, 
Anbazhagan  et  al  analysed  267  breast  carcinomas  with  a  total  of  104  primers  for 
microsatellite repeats (115). In this study, which included more than 10,000 reactions, not 
one  single  case  of  microsatellite  instability  was  detected.  Therefore  microsatellite 
instability does not appear to play a significant role in the development of breast cancer. 
The only exception may be the development of breast cancer in patients from HNPCC 
families,  in which case,  microsatellite  instability  could arise  as  a late  event in tumour 
progression.
ANGIOGENESIS AND METASTASIS: 
Angiogenesis:
Angiogenesis (neovascularization) is the sprouting of capillaries from pre-existing vessels 
and occurs during embryonic development but is almost absent in normal adult tissues. 
However,  transient  regulated  angiogenesis  occurs  in  adult  tissues  during  the  female 
reproductive cycle and during wound healing. Pathological angiogenesis is characterised 
by the persistent proliferation of endothelial cells and is a prominent feature of a number 
of different  types  of disease  including  rheumatoid  arthritis,  psoriasis  and  proliferative 
retinopathy.  In  addition,  many  tumours  are  able  to  attract  blood  vessels  from 
neighbouring tissues and the induction of new blood vessel growth is necessary if solid
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tumours  are  to  grow  beyond  2mm  size  (116; 117).  It  appears  that  angiogenesis  is 
important for the development of metastasis (118). Many studies using semi-quantitative 
histological  techniques,  have  found  a  significant  association  between  high  tumour 
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breast  cancer  (121-124).  However,  other  groups  have  failed  to  demonstrate  such  a 
prognostic  effect  (125-128).  Neovascularization  has  also  been  described  around  ductal 
carcinoma in situ (DCIS) of the breast (121).  As DCIS  is not capable of metastasising, 
this finding suggests that neovascularization may be an early event in tumour progression. 
Despite the controversies regarding the prognostic value of angiogenesis in breast cancer, 
there is increasing evidence demonstrating a predictive value of angiogenesis for response 
to  anti-cancer  therapies  and  the  development  of  anti-angiogenic  drugs  as  novel 
therapeutic strategies is underway (116; 129).
A variety of factors stimulate angiogenesis including angiogenin, fibroblast growth factor 
(FGF),  vascular  endothelial  growth  factor  (VEGF),  epidermal  growth  factor  (EGF), 
transforming growth factor alpha and beta (TGF a and P), tumour necrosis factor alpha 
(TNFa),  hepatocyte  growth  factor  (HGF),  platelet-derived  growth  factor  (PDGF), 
placental  growth  factor,  prostaglandins  Ei  and  E2,  heparinase,  integrins,  macrophage 
derived  factor,  fibrin,  nicotinamide,  oncogenes  like  INT2  and  HST1  and  others. 
Angiogenesis  inhibitors  include  angiostatin,  endostatin,  wild  type  P53,  chondrocyte- 
derived  inhibitor, heparinases,  interferons  a  and  p,  protamine,  thrombospondin,  matrix 
metalloproteinases and others. In animal studies, administration of anti-angiogenic factors 
resulted in reduced growth rate of fast growing tumours. An anti-angiogenic drug called 
TNP-470  has  been  tested  in  phase  II  trials  in  breast,  pancreatic,  renal  and  cervical 
carcinoma and Kaposi’s  sarcoma,  with evidence of tumour regression (130).  There are 
other drugs in clinical trials such as thalidomide, combrestatin A-4, endostatin and vitaxin 
that target endothelial cells. Vascular endothelial growth factor (VEGF) antagonists have 
also shown promising results in clinical trials.
Metastasis:
Metastasis is the spread of malignant cells through the body that have detached from a 
primary tumour to give rise to secondary tumours and it is the major cause of death from 
cancers.  The  transition  from  pre-invasive  tumour  to  invasion  occurs  in  parallel  with 
tumour  induced  neovascularisation  (angiogensis)  which  facilitates  dissemination  of 
tumour cells into the vascular system. The molecular events that determine whether a cell 
becomes metastatic may be divided into two categories, namely, intracellular signalling 
pathways  that  regulate  proliferation,  apoptosis  and  the  synthesis  of  cytokines;  and 
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cell regulation and proteolysis. The first category may be regarded as those events which 
determine  whether  an  individual  cell  evolves  into  a  tumour clone.  The  second  group 
refers to cellular properties that may directly determine whether tumour cells metastasise. 
Metastasis  is  a  multistep  process  that  requires  many  different  tumour-host  cell 
interactions. Crucial among these are the events associated with invasion of the basement 
membrane by the tumour cells.  The development of a metastasis requires expression of 
cell  surface  adhesion  molecules  by  the  tumour  cells  and  the  expression  of proteolytic 
enzymes involved in tissue degradation. The major families of such proteins are  (a) the 
cadherins (b) the immunoglobulin superfamily (c) the integrins (d) CD44  (e) the matrix 
metalloproteinases (MMPs) (f) the tissue inhibitors of metalloproteinases (TIMPs) (g) the 
serine, cysteine and aspartic proteinases and heparanase and (h) the metastasis suppressor 
genes, NME1 and NME2 (also called NM23).
The  cadherins  are  transmembrane  glycoproteins  that  mediate  calcium-dependent 
intercellular adhesion, cytoskeletal anchoring and signalling. E-cadherin and some other 
members  of the  family  act  as  invasion  suppressors.  The  role  of E-cadherin  in  breast 
cancer is described later in the chapter.
The immunoglobulin superfamily, also called neural cell-adhesion molecules (NCAMs),
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mediate  homophilic  or  heterophilic  Ca  independent  intercellular  adhesion.  NCAM 
expression modulates the adhesive phenotype of glioma cells.
The integrins are a family of cell surface proteins that mediate cell-substrate and cell-cell 
adhesion.  They are heterodimers of non-covalently linked a and  p  subunits.  Sixteen a 
and  8 p subunits have been identified that give rise to at least 22 distinct integrins. Loss 
and  aberrant  expression  of  various  integrins  has  been  detected  in  colon  and  breast 
carcinomas (131).
CD44  is  a  90  KDa  cell  surface  glycoprotein  implicated  in  cell-cell  and  cell-matrix 
adhesion,  lymphocyte  activation  and  metastasis.  Multiple  isoforms  are  generated  by 
alternative  splicing  of  10  ‘variant’  exons  that are differentially  expressed  in  a specific 
manner in normal tissues in response to a variety of cytokines. Gross overproduction of 
alternatively spliced forms occurs in breast and colon carcinomas and is associated with a 
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The MMPs are a big family of at least 14 members. They are synthesized by connective 
tissue  cells  and  act  synergistically  to  digest  the  major  macromolecules  of connective 
tissue matrices. They are activated by plasmin, which itself is generated by plasminogen 
activators, tissue plasminogen activator (tPA) and urokinase-type plasminogen activator 
(uPA), both of which are serine proteinases. High expression of uPA has been detected in 
a  variety  of  malignant  tissues,  including  breast  carcinomas,  brain  tumours  and 
melanomas.  uPA expression  is a powerful  prognostic  indicator for breast cancer (133). 
Specific  inhibitors  to  matrix  metalloproteinases  (MMPIs)  have  been  developed  and 
several are in advanced stages of clinical development.
The urokinase plasminogen activator (uPA) system consists of the serine protease uPA, 
its glycolipid-anchored receptor, uPAR and its 2 serpin inhibitors, plasminogen activator 
inhibitor-1   (PAI-1)  and  plasminogen  activator  inhibitor-2  (PAI-2).  These  are  present 
primarily in stromal cells in invasive breast carcinoma. Recent findings suggest that the 
uPA system is involved at multiple steps in cancer progression (134). In particular, uPA 
has  been  implicated  in  remodelling  of the  extracellular  matrix,  enhancing  both  cell 
proliferation and migration and modulating cell adhesion. Many groups have shown that 
high levels of uPA in primary breast cancers are independently associated with adverse 
outcome.  Paradoxically,  high  levels  of  PAI-1  also  correlate  with  poor  prognosis  in 
patients with breast cancer. The prognostic value of uPA/PAI-1  in axillary node-negative 
breast cancer patients was recently validated using both a prospective randomised trial 
and a pooled analysis which are 2 different level 1   evidence studies (134). Assay of uPA 
and  PAI-1  may thus  help  identify  low risk  node-negative  patients  for whom  adjuvant 
chemotherapy  is unnecessary.  Finally,  preclinical  studies  show that either inhibition of 
uPA catalytic activity or prevention of uPA binding to its receptor reduces tumor growth, 
angiogenesis and metastasis.
The  TIMPs  regulate  the  activities  of MMPs.  TIMPs  are  present  in  normal  bone  and 
cartilage cells and are secreted by a variety of cells in culture. TIMPs are potent inhibitors 
of several  steps in invasion and metastasis,  including the proteolytic degradation of the 
extracellular  matrix,  invasion  of  surrounding  connective  tissue,  extravasation  and 
subsequent tumour growth (135).  In vitro studies suggest that TIMPs may have tumour 
suppressor activity. However, their role is slightly more complex than this, since there is 
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TIMP-1  expression  is  increased  in  some  non-Hodgkin’s  lymphomas  and  metastatic 
prostate  cancer,  and  increased  expression  of  TIMP-3  has  been  detected  in  breast 
carcinomas (136). The significance of these findings is unclear.
Cathepsin D is an acidic lysosomal aspartic proteinase, involved in intracellular protein 
turnover.  It  is  over-expressed  in  most  primary  breast  cancers,  and  shown  to  have  an 
association  with  indicators  of  tumour  aggression  such  as  large  tumour  size,  high 
histological grade and lymph node positivity (137; 138). Immunohistological studies have 
demonstrated that cathepsin D can be identified not only in breast cancer cells, but also in 
accompanying  stromal  tissue.  Some  studies  have  shown  it  to  be  an  indicator  of poor 
prognosis in breast cancer (139).
NME1 (non-metastatic cells 1, expressed) and NME2 (formerly NM23-non-metastatic 23) 
encode nucleoside diphosphate kinases expressed on the cell surface. NME2 expression is 
increased in some neoplastic tissues, although in ductal breast carcinomas, this increase 
does not appear to correlate with tumour size, oestrogen receptor or progesterone receptor 
expression, lymph node metastases or other prognostic factors (140).
SPECIFIC GENETIC ALTERATIONS IN BREAST CANCER:
In  breast  cancer,  the  main  genetic  alterations  are  amplification  of approximately  10 
oncogenes  and  inactivation of an unknown number of tumour suppressor genes  (141). 
Translocations and point mutations are very rare and therefore do not seem to play an 
important role in the development of breast cancer (142). In addition, germline mutations 
in the BRCA-1  and BRCA-2 genes account for genetic predisposition to develop breast 
and ovarian cancer, and the breast cancer in these patients is often poorly differentiated 
ductal  carcinoma.  Some  other  histological  tumour  types  have  also  been  shown  to  be 
associated with the presence of specific genetic alterations, for example,  inactivation of 
E-cadherin is specific for lobular breast cancer and HER-2 (cerB-2) gene amplification is 
associated with poorly differentiated ductal carcinoma (141).
There are a number of studies examining the various genetic alterations in breast cancer 
and their association with various clinical and pathological factors, especially prognosis. 
Some of the data presented in these studies indicate conflicting results. For almost every 
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others stressed the lack of such correlation. The reasons for such conflicting results can be 
summarized as follows:
1.  There are differences in the methods used to detect the genetic alterations.
2.  Many  studies  contain  relatively  small  numbers  of  patients,  who  are  often 
heterogeneous with respect to clinical stage and treatment.
3.  Almost  all  the  genetic  alterations  are  present  in  only  a  small  percentage  of 
tumours, resulting in low statistical power.
It is hoped that as analytical  methods improve and larger series of patients are studied 
with more scientific rigour, the way in which the profile of genetic alterations in breast 
cancer affects clinical behaviour will become clearer. Most treatment decisions for breast 
carcinoma  and  other  malignancies  are  currently  based  on  clinical  and  pathological 
features  of the  tumours.  It  is  likely  that  in  future,  treatment  decisions  will  also  be 
influenced by the genetic profiles of tumours.
Gene Amplifications in Breast Cancer:
Most initial studies of breast carcinomas were carried out using Southern blot analysis. 
Employing comparative genomic hybridisation (CGH) on large series of tumours has also 
resulted  in the  identification  of regions  of several  chromosomes,  which  are  frequently 
amplified in breast cancer.  The structure of many of the amplicons in breast cancer has 
proven  to  be  relatively  complex  and  many  of them  appear  to  contain  more  than  one 
region of amplified DNA. For many of these amplified regions, it is not clear which genes 
are the actual oncogenes, for which over-expression is selected.
As many studies include relatively small number of tumours, it is difficult to estimate the 
exact frequency of amplification of each region. A very large study by Couijal et al  is 
helpful for providing estimates; these investigators analysed amplification of 26 different 
loci in  1875 breast carcinomas using Southern blot analysis (143). The main loci which 
were found to be amplified in breast cancer are as follows:
1)  Amplification of a region on chromosome 1  q31  -32 is frequent and occurs in up to 50% 
of all breast carcinomas (144). The oncogene driving this amplification event has not yet 
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2)  Amplification  of  a  region  on  the  chromosome  lp  is  less  frequent.  The  recently 
identified DA Ml gene has been found to be amplified in breast cancer, but it is not certain 
whether this gene is driving the amplification (145).
3) The EGFR gene on chromosome 7pl3 encodes a growth factor receptor located on the 
cell membrane. Amplification of this gene is found in less than 3% of breast carcinomas. 
Elevated expression of the EGF receptor protein,  in the absence of gene amplification, 
has been associated with oestrogen receptor negativity (146). EGFR expression correlates 
with that of p53 but is inversely correlated with MYB amplification, thus EGFR and MYB 
expression provide indicators of a poor or good prognosis respectively.
4)  The  FGF-receptor  l(FLG)  gene  on  chromosome  8pl2  encodes  a  fibroblast  growth 
factor receptor located on the cell membrane and is amplified in approximately  10% of 
breast  carcinomas  (147).  Amplification  has  been  correlated  with  reduced  disease-free 
survival, especially if the gene is amplified together with the CYCLIN D1 gene (144).
5) The c-myc gene on chromosome 8q24 encodes a nuclear protein which is 62 KDa and 
found in the nucleus during the Go to Gi  phase of the cell cycle (148).  It is involved in 
regulation of growth and apoptosis. A c-myc gene amplification is found in approximately 
20% of breast carcinomas (149; 150) and is associated with oestrogen receptor negativity 
(145),  locally  advanced  disease,  high  histological  grade  of the tumour (151)  and  poor 
prognosis (152). The c-myc protein has a very short half-life, precluding the analysis of c- 
myc protein overexpression as a substitute for analysis of gene amplification.
6)  Studies  using  CGH  indicate  that  in  addition  to  the  c-myc  gene,  other  portions  of 
chromosome arm 8q from 8ql2 to 8qter are present at an increased relative copy number 
in a broad range of solid tumours, including breast cancer. There appears to be at least 
one  additional  oncogene  mapping  to  chromosome  8q 12-2 2,  which  has  not  yet  been 
identified (153).
7)  The  FGF-receptor  2  (BEK)  gene  on  chromosome  10q26  encodes  a  receptor  for 
fibroblast  growth  factor  located  on  the  cell  membrane.  This  gene  is  amplified  in 
approximately 12% of breast carcinomas (147).
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family. These two, together with BCLJ, are amplified in 22% of human breast carcinomas 
(36;39).  However,  there  is  no  evidence  that  the  protein  products  of HSTF1  and  I  NT2 
genes are expressed in breast cancer.
9) CYCLIN Dl  gene on chromosome  11 ql3  encodes a nuclear protein,  involved  in cell 
cycle regulation.  Amplification occurs in  15% of breast  carcinomas.  It has been  found 
that  CYCLIN Dl  can  bind  to  the  ER,  resulting in  ligand-independent  activation  of the 
receptor (154).  CYCLIN Dl  gene amplification is associated with ER positivity.  In  ER 
positive  tumours,  CYCLIN Dl  gene  amplification  is  associated  with  a  relatively  poor 
prognosis (144; 155). Generally, however, enhanced cyclin Dl  expression correlates with 
increased  overall  survival,  whereas  the  worst  prognosis  correlates  with  reduced  levels 
(156). CYCLIN Dl  gene amplification is more frequent in lobular carcinomas compared 
with  ductal  carcinomas.  Cyclin  Dl  overexpression  can  be  detected  using 
immunohistochemistry  and  has been  identified  in  80% of invasive  lobular carcinomas, 
but it is not always accompanied by CYCLIN Dl gene amplification (157).
10)  A  region  on  chromosome  16p 11-12  has  been  found  to  be  amplified  by  CGH  in 
approximately 20% of breast carcinomas (158). More detailed analyses of this region are 
not presently available.
11)  The  cerbB-2  (HER-2/neu)  gene  on  chromosome  17ql2  encodes  a  transmembrane 
glycoprotein and is amplified  in 20-30% of breast carcinomas.  It  is discussed  in more 
detail in chapter 4.
12) PS6K gene on 17q23 is a frequent site of amplification in breast cancer as revealed by 
CGH (159;160).This gene encodes a serine-threonine kinase whose activation is believed 
to  regulate  a  wide  range  of  cellular  processes  involved  in  the  mitogenic  response 
including  protein  synthesis,  translation  of specific  mRNA  and  cell  cycle  progression 
from Gi to S phase.
13) Amplification of the CAS (cellular apoptosis susceptibility) and AIB1  (amplified in 
breast 1) genes on chromosome 20ql3. The CAS gene encodes a protein, which may have 
a function in apoptosis and cell proliferation (161). The AIB1 gene encodes a coactivator 
of the ER (162). These genes are both located in a region on chromosome 20 that is found 
amplified in approximately  15% of breast cancers.  It is currently unknown whether the 
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at chromosome  2 0q  is quite  complex;  three  independent regions  of amplification  have 
been identified and their co-amplification is common (163). Amplification of AIB1  has 
been found to be associated with ER positivity (164), but not with clinical outcome (144). 
Amplification of this region detected by FISH with a cosmid probe has been found to be 
associated with high histological grade and poor prognosis (165).
14)  Using CGH, other regions have been observed to be amplified (166). However, it is 
not known which oncogenes are driving these amplifications.
Tumour Suppressor Genes in Breast Cancer:
In  breast  cancer,  like  other cancers,  inactivation  of tumour  suppressor  genes  plays  an 
important role. The classical mechanism of inactivation is functional loss of both alleles 
of the  tumour  suppressor  gene.  In  many  cases,  one  tumour  suppressor  gene  allele  is 
mutated by a relatively subtle mutation (point mutation, small insertion, small deletion), 
while the other allele is completely lost. The presence of these subtle mutations has made 
it possible to identify the tumour suppressor genes that are presently known. In addition 
to the known tumour suppressor genes, a relatively large number of regions have been 
identified where frequent loss of heterozygosity (LOH) is observed including lp,  lq, 3p, 
5p,  6q, 7q,  8p, 9q,  lOq, lip,  13q,  14q,  15q,  16q,  17p,  17q,  18p,  18q,  19p, 21q, 22q, Xp
(167). Large efforts are being dedicated to identify the tumour suppressor genes in these 
regions. The tumour suppressor genes in breast cancer known to date are:
1) The IGF-II-receptor gene on chromosome 6q26-27, which encodes a receptor for IGF- 
II  located on the  cell  membrane.  In addition,  this receptor functions as  the mannose-6 
phosphate receptor.  Mutations in this gene have been identified in some breast cancers
(168) but no larger studies are available to find out the frequency of this mutation; most 
probably it is low (<10%).
2)  The pl6INK4a  (pi 6)  tumour  suppressor  gene  on  chromosome  9p21  is  frequently 
inactivated  in  several  tumour  types  by  homozygous  deletion,  point  mutation  or 
methylation of the 5’CpG island. The mechanism of action of pi 6 involves binding to and 
inactivating the cyclin D-dependent kinase 4 or 6 complex and making the retinoblastoma 
protein  inactive.  This effect blocks  the transcription of important cell  cycle  regulatory 
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inactivating  mutations,  the  emerging  evidence  suggesting  that  inactivating  alterations 
affecting the pi6 are rare at this site (169; 170).
3) PTEN is a tumour suppressor gene located on chromosomal band  10q23.3.This region 
displays  frequent  LOH  in  a  variety  of human  neoplasms  including  breast  carcinomas. 
Germline mutations in the PTEN gene are causative of Cowden disease (see glossary) and 
sporadic mutations in breast cancer have been reported.  However, PTEN mutations are 
not thought to play a major role in breast cancer formation (171).
4) The P53 gene on chromosome  17pl 3 encodes a nuclear protein, which binds to DNA 
as  a  tetramer  and  is  involved  in  regulation  of  transcription,  DNA  replication  and 
apoptosis.  Mutations  of P53  are  the  most  common  molecular  abnormalities  found  in 
human  solid  tumours  (11; 172)  and  are  present  in  a  high  proportion  of breast  cancers 
(173; 174). Inactivating P53 mutations are found in approximately 20% of malignancies at 
this site. The presence of P53 mutations has been associated with poor prognosis (175) 
and resistance to chemotherapy and radiotherapy. In DCIS, P53 mutations are associated 
with high grade. Missense mutations in the P53 gene result in increased stability of p53 
protein, which can then be detected using immunohistochemistry. The level of wild-type 
p53 protein is too low to be detected in breast cancer. The majority of the studies to look 
at the prognostic value of p53 alterations have been done using immunohistochemistry. A 
much  smaller  number  of studies  have  looked  at  P53  gene  mutations.  In  interpreting 
immunohistochemistry,  it  is  important  to  bear  in  mind  that  nearly  20%  of the  P53 
mutations (especially non-sense and frame-shift) lead to a truncated protein, resulting in 
negative  staining.  As  P53  is  involved  in  the  apoptotic  response  to  genomic  damage, 
inactivation of this gene can be hypothesised to be involved in resistance to chemotherapy 
and  radiotherapy  (176).  Only  a  few  studies  have  shown  this  to  be  true  in  clinical 
situations. A recent meta-analysis has confirmed the association of P53 gene mutations 
with  poor  disease-free  and  overall  survival  (42).  Some  studies  have  demonstrated  an 
inverse relationship between p53 and BCL2 protein expression in breast cancer and other 
solid tumours  (177-179).  Some  studies of P53  mutations  in  exons  5-9 have  shown  an 
association  with  low  oestrogen  receptor  (ER)  content,  high  S-phase  fraction,  positive 
nodal status and HER2/neu amplification. Mucinous and papillary tumours, which have a 
good  prognosis,  have  a  lower  frequency  of  P53  mutations.  However,  medullary 
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mutations  along  with  inactivation  of  BRCA1  gene  (180).  Currently,  there  is  some 
controversy whether medullary carcinomas really have a better prognosis. Therefore, the 
occurrence of P53 mutations in medullary carcinomas could explain these findings.
5)  The  E-cadherin  gene  on  chromosome  16q22.1  encodes  a  cell  adhesion  protein 
involved  in  adhesion  between  epithelial  cells.  In  the  majority  of  invasive  lobular 
carcinomas,  there  is  complete  loss  of plasma  membrane-associated  expression  of  E- 
cadherin.  In  most  cases  of loss  of E-cadherin,  mutations  in  the  E-cadherin  gene  are 
identified (181). In ductal carcinomas, E-cadherin expression is usually normal or slightly 
reduced and hence, E-cadherin inactivation appears to be specific for lobular carcinoma. 
Inactivating  mutations  in the E-cadherin gene  have  also  been  demonstrated  in  lobular 
carcinoma in situ (182).
Well  differentiated  DCIS  also  frequently  shows  LOH  on  chromosome  16q,  which  is 
probably  attributable  to  another  tumour  suppressor  gene  that  may  play  a  role  in  its 
development (183; 184).
6)  BRCA1  and  2.  In  approximately  5-10%  of  breast  cancer  patients,  a  genetic 
predisposition to develop breast cancer is present. It has been demonstrated that mutations 
in the BRCA1  and 2 genes are associated with a dominantly inherited breast cancer risk 
(72).  The  expression  of  BRCA1  in  tissue  sections  from  breast  carcinomas  can  be 
demonstrated using immunohistochemistry (185).  In future, detection of the absence of 
BRCA1  and/or BRCA2 expression may assist in identifying patients with BRCA1  or 2 
germline  mutations.  The  histopathological  features  of  tumours  from  BRCA1  and  2 
germline mutation carriers differ from sporadic carcinomas and from each other. Both are 
of higher  grade  as  compared  to  sporadic  cases  and  an  excess  of medullary/atypical 
medullary  carcinomas  has  been  reported  in  patients  with  BRCA1  mutations  (186). 
Multifactorial analysis shows that the only features independently associated with BRCA1 
mutations are a high mitotic count, pushing margins and the presence of a lymphocytic 
infiltrate  (187).  It  is  interesting  to  note  that  breast  carcinomas  in  BRCA1  and  2  gene 
mutation carriers show an increased frequency of mutations in the p53 gene (188).  The 
chromosomal regions of BRCA1 and BRCA2 display LOH in 25-56% of sporadic breast 
carcinomas,  whereas  somatic  mutation  of  BRCA1  and  BRCA2  in  sporadic  breast 
carcinomas is an infrequent event with a frequency of 0-9% (189-191).Chapter 3: M olecular biology o f breast cancer 60
THE MULTISTEP MODEL OF BREAST CARCINOGENESIS:
It is not known how many mutations are required for genesis of a specific cancer but it is 
supposed that approximately  12 may be involved and in most cases, these are acquired 
somatically. Animal studies have shown that the genesis of tumours requires at least two 
main steps,  ‘initiation’  and ‘promotion’.  ‘Initiation’  is irreversible whereas ‘promotion,’ 
which follows it, is reversible. These model systems also indicate that the initiating event 
in  tumorigenesis  is  mutation  and  subsequent tumour progression  may  be  mediated  by 
either genetic or epigenetic mechanisms.  In vitro studies generally support the idea that 
transformation  is  at  least  a  two  stage  process,  one  oncogene  being  needed  for 
immortalization  and  another  for transformation.  In  addition  to  the  initiating of growth 
promoting events, the loss of growth inhibitory activity of TGFp is thought to contribute 
to the development of many types of tumours.
The  multistep  model  of  breast  carcinogenesis  suggests  a  transition  from  normal 
epithelium to  invasive carcinoma via in-situ carcinoma.  It is debatable  whether typical 
and atypical hyperplasias are intermediates in this multistep model. Typical hyperplasia is 
found  in  over  50%  of women  without  breast  cancer.  A  multistep  model  for  breast 
carcinoma  development,  similar  to  that  for  colon  carcinoma,  has  not  yet  been  fully 
elucidated. The hypothetical model reported by Schnitt is mentioned on page 331.  It is 
probable that there are different types of breast cancer, each of which may be genetically 
different as suggested in (figure 3.7)(142):
IDC Grade I DCIS ( well differentiated)  1 -----------
f"—
DOS (moderately differentiated^  l -----------^
r~—
IDC Grade II
IDC Grade III
Invasive lobular carcinoma.
DCIS (poorlv differentiated)  1 -----------u --^
1 — — LCIS  I ------------
1--- BRCAl/2 germline mutation  i ----------- IDC Grade III
Figure 3.7; A hypothetical model describing the various grades of invasive carcinoma
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As DCIS and LCIS can co-exist in some cases and similarly invasive ductal and lobular 
carcinomas can show mixed patterns, this figure may be an oversimplification.
Members  of the  epidermal  growth  factor  (EGF)  family  are  widely  expressed  and  are 
thought  to  play  important  roles  in  both  mammary  gland  development  and  in 
tumorigenesis. Over-expression of at least two members of the family, amphiregulin and 
cripto-1, has been detected in breast tumours. Either can transform immortalized human 
and mouse mammary epithelial cells (192).  Other members of the EGF receptor family 
(EGFR,  HER2,  HER3  and  HER4) also  frequently  show abnormal  expression  in  breast 
and other human cancers.
A few reports on LOH in DCIS have been published, regions with frequent LOH were 
found mainly on chromosomes  16 and  17, indicating that these are early events in breast 
cancer development that precede the tumour cells becoming invasive (183; 193-195).It is 
interesting  that  normal  epithelial  cells  adjacent  to  invasive  carcinoma  show  LOH  for 
chromosome 3p (196).  Lakhani et al have described the dissection of ‘normal'  luminal 
and myoepithelial cell clones (197). Overall, LOH was found in normal cells in 50% of 
10 breast cancer cases and in one of 3 reduction mammoplasty specimens. In one case, all 
luminal and myoepithelial samples exhibited loss of the same allele on chromosome 13q, 
suggesting the presence of a common stem cell for the two epithelial cell types. LOH has 
been demonstrated in normal tissues near and away from the carcinoma, suggesting that 
genetic alterations are likely to be more heterogeneous and widespread than previously 
thought,  and probably  occur very  early  in  breast  carcinogenesis.  More  oncogenes  and 
tumour suppressor genes in breast cancer will be identified in the future and a complete 
catalogue of these genetic alterations is expected to be assembled in the next 5-10 years 
(108). Nearly,  all  the  genetic  alterations described  in  invasive breast cancer have been 
identified in carcinoma in situ, hence most of them are considered to be early events in 
breast carcinogenesis (167). One of the few changes that could be a late event in breast 
tumourigenesis is the amplification of c-myc gene, which has not been described in DCIS 
and is associated with locally advanced breast cancer.
It is a great challenge to complete this genetic modelling, to identify subgroups of breast 
cancers with distinct genetic alterations correlating with clinical behaviour and to utilize 
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TECHNIQUES  AVAILABLE  FOR  THE  DETECTION  OF  GENETIC 
ALTERATIONS:
The following techniques are currently used to detect genetic alterations in breast cancer: 
Karyotyping:  Metaphase  chromosomes  can  be  isolated  from  cultured  cells.  These  are 
subsequently  stained  and  analysed  under  the  microscope.  In  this  way  cytogenetic 
alterations have been detected in many tumour types,  which have guided the positional 
cloning of several  genes  involved  in  cancer,  especially  in  leukaemias and  lymphomas. 
Unfortunately,  the  karyotypes  of breast  cancers  and  other  solid  tumours  often  are  so 
abnormal  that  identification  of  recurrent  abnormalities  pointing  to  the  locations  of 
important genes has been difficult.  It is also difficult to take breast carcinoma cells into 
tissue culture, which further hampers cytogenetic analysis.
Southern blot analysis:
For  this  technique,  freshly  frozen  tumour  material  is  required.  DNA  is  isolated  and 
digested with an appropriate restriction enzyme. The DNA is then size fractionated on an 
agarose gel, transferred to a filter and hybridized to a labelled gene probe. The technique 
is  very  labour-intensive  and  therefore  not  very  well  suited  for  use  in  daily  clinical 
practice. The amplification of oncogenes in breast cancer has mainly been studied by this 
technique. Before the polymerase chain reaction became available, deletions of regions of 
DNA were also studied using this technique.
Comparative genomic hybridization (CGH):
Comparative  genomic  hybridization  can  be  performed  with  DNA  isolated  from  frozen 
material  and  from  paraffin  blocks  (198),  unless  tumours  have  been  fixed  in  acid- 
containing fixatives, such as Bourn’s fixative.  Differentially labelled tumour DNA and 
normal  reference  DNA  are  hybridized  simultaneously  to  normal  chromosome  spreads. 
The hybridization is detected with two different fluorochromes. Regions of gain or loss of 
DNA sequences, such as deletions, duplications or amplifications, are seen as changes in 
the  ratio  of the  intensities  of the  two  fluorochromes  along  the  target  chromosomes. 
Comparative genomic hybridization of breast carcinomas has resulted in the identification 
of a number of chromosomal regions containing amplified sequences. CGH is technically 
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over most  other techniques  is  that  the  whole  tumour  genome  can  be  analysed  in  one 
experiment.
However,  the  resolution  of  CGH  on  metaphase  chromosomes  is  limited.  Amplitude 
regions have to be 1  -2 Mb in size before they can be detected. Recently, arrays of mapped 
sequences have been developed for CGH (199). Using these arrays, the copy number of 
smaller regions of DNA can be measured with high precision.
There  is  not always  a correlation  between  loss  of heterozygosity (LOH) picked  up  by 
PCR (see below) and deletions detected by CGH. This is due to the fact that LOH is often 
the result of loss of one allele in combination with duplication of the other allele.
Polymerase chain reaction (PCR):
This technique has revolutionized the analysis of genetic alterations in tumours. The basic 
principle  is that oligonucleotide  primers  are  used to  amplify  specific  regions  of DNA. 
These amplified regions can subsequently be further studied using additional techniques, 
including sequencing and single strand conformation polymorphism (SSCP) (see below). 
In  breast  cancer,  PCR,  using  primers  for  repeated  sequences  of known  chromosomal 
localization,  has  been  used  to  study  LOH.  For  many  of  these  repeats  there  is 
heterogeneity  within  the  population,  resulting  in  polymorphisms.  The  paternal  and 
maternal  alleles  can  be  distinguished  if  the  patient  is  heterozygotic  for  such  a 
polymorphism.  By comparing DNA from normal cells with tumour DNA, LOH can be 
detected.
Fluorescent in-situ hybridization (FISH) and Bright field in-situ hybridization (BRISHL
The basis for this method is the hybridization of labelled DNA probes to cells. To obtain 
a  detectable  signal,  the  use  of relatively  large  probes  is  required.  Using  FISH,  it  is 
possible  to  identify  numerical  chromosomal  alterations  in  isolated  nuclei  or  in  tissue 
sections,  usually  using  centromere  probes.  For this  purpose,  both  frozen and  paraffin- 
embedded material may be used.  In addition,  it is possible to detect gene amplification 
using this technique. A fluorescence microscope is required in order to perform FISH. It 
is also possible to visualise the binding of label using chromogens, which can be  seen 
under  a  bright  field  microscope  (bright-field  in-situ  hybridisation,  BRISH)  but  this 
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Single  strand  conformation  polymorphism  (SSCP)  and  denaturing  gradient  gel 
electrophoresis (DGGE):
SSCP and DGGE are rapid, simple and sensitive techniques for the detection of various 
mutations,  including  single  nucleotide  substitutions,  insertions  and  deletions,  in  PCR- 
amplified DNA fragments. In breast cancer, these techniques have mainly been used for 
the detection of mutations in the P53 gene, BRCA1 and BRCA2 genes.
Sequence analysis:
To confirm the presence of mutations detected by SSCP or DGGE, sequence analysis can 
be performed.  It is also possible to look for genetic alterations in breast carcinomas by 
sequence  analysis  without  pre-screening  with  the  above-mentioned  techniques.  This  is 
relatively labour-intensive, although further automation can make sequence analysis more 
feasible for the detection of genetic alterations in large sets of tumours.
Microarrav analysis:
The technique of microarray analysis was developed at Stanford University and allows 
the study of the level of expression of up to 10,000 mRNAs in a single experiment (200- 
202). Basically, cDNAs are microspotted onto glass slides. The mRNA from the cells to 
be analyzed is isolated and reverse transcribed to cDNA in the presence of red-fluorescent 
nucleotides. Fluorescent cDNA is then mixed with a green fluorescent-labelled standard 
and the mixture is hybridised to the microarray. Using a fluorescent scanner, the level of 
fluorescence  is  computerised  and  for each  cDNA  on the microarray the  level  of gene 
expression,  relative  to  the  standard  is  determined  and  transferred to  a database.  Using 
software specifically developed for microarray analysis, the level of expression for many 
thousands of genes can be compared between different tumour samples. The power of this 
approach  for  clinical  research  was  recently  illustrated  by  Alizadeh  et  al  (203),  who 
analysed RNA from 40 large B cell lymphomas for the expression of 17,856 genes using 
microarray  analysis.  Based  on  the  pattern  of gene  expression,  two  distinct  groups  of 
tumours could be recognised within these otherwise indistinguishable B-cell lymphomas. 
One type expressed genes characteristic of germinal centre B-cells and the second type 
expressed genes normally induced during in-vitro activation of peripheral blood B-cells. 
Furthermore,  it  was  shown  that  the  germinal  centre  type  B-cell  lymphomas  had  a 
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As a result of the Human Genome Project and the contributions of individual researchers, 
partial  or complete  nucleotide  sequence  is available  for 60,000  genes  of the  estimated 
80,000-100,000  genes  that  are  expressed  in human  cells.  Technically,  with  microarray 
analysis,  it  is  possible  to  analyze  all  estimated  80,000-100,000  genes  in  the  human 
genome for their expression. With the current density of 10,000 genes per array, it would 
only take 8-10 experiments to determine the level of expression of all genes within one 
tumour  sample.  At  the  moment,  the  availability  of sequence  confirmed  cDNAs  is  the 
main  limiting  factor.  With the  rapid  progression  in gene  cloning  and  sequencing,  it  is 
expected  that  larger  microarrays  will  become  available  in  the  coming  years  and  the 
expression of all  genes expressed  in humans will  be assayed.  Also the  function of the 
proteins encoded by many of these genes will be elucidated in the coming years. Finally, 
the software required to analyse such large and complex datasets is also rapidly evolving. 
These developments make the application of microarray analysis in clinical research of 
great importance.
Immunohistochemistry:
Alterations in protein expression, resulting from genetic alterations, can often be detected 
using  immunohistochemistry.  It  is  a  very  accessible  technique  for  most  pathology 
laboratories.  For  many  proteins,  immunohistochemistry  can  be  used  on  paraffin-wax 
sections.  An  important  advance  for  the  study  of  large  series  of  tumours  is  the 
development of tissue arrays (204;205). As many as 1000 cylindrical tissue biopsies from 
individual tumours can be distributed in a single tumour tissue microarray. Sections of the 
microarray provide targets for immunohistochemistry and for parallel in situ detection of 
DNA and RNA. Consecutive sections allow the rapid analysis of hundreds of molecular 
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CHAPTER 4:  CerbB-2 IN BREAST CANCER:
INTRODUCTION:
The  proto-oncogene  cerbB-2  has been  localized  on chromosome  17ql2  and  encodes a 
185  kDa transmembrane glycoprotein which is a tyrosine kinase growth factor receptor 
(1-3). Figure 4.1  illustrates a schematic representation of the protein structure of cerbB-2.
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Figure 4.1; Schematic diagram of the cerbB-2 protein structure
The  different  groups  who  independently  identified  this  gene  have  used  differing 
terminology to describe the proto-oncogene (4;5). The name HER-2 is derived from the 
term “human epidermal growth factor receptor” because HER-2 has substantial homology 
with the epidermal  growth factor receptor (6), but cerbB-2 and HER-2 both refer to an 
identical human homologue of the Neu oncogene in the rat.
The cerbB-2  protein belongs to  a  four-member  family of closely  related  growth  factor 
receptors  that  include  HER-1  (erbB-1),  HER-2  (erbB-2),  HER-3  (erbB-3)  and  HER-4 
(erbB-4). Direct ligands have been identified for HER-1, HER-3 and HER-4, but not for 
HER-2. The cerbB-2 receptor is known to mediate lateral signal transduction in all HER 
receptor family members (6;7). After ligand binding, EGFR, HER-3, and HER-4 can all 
heterodimerize with HER-2 leading to tyrosine phosphorylation of all the receptors (8;9). 
Though the function and regulation of the normal cerbB-2 gene are not well understood, 
cerbB-2 overexpressed  in cancer cells is thought  to  function as a growth  factor and to 
play  roles  in  cell  differentiation,  motility,  and  adhesion  (10; 11).  The  gene  is  widely 
expressed  in  epithelial  cells  of human  fetal  and  adult  tissues  including  breast  tissue. 
Amplification of the cerbB-2 gene and overexpression of the protein was first discovered 
in  a  human  breast  carcinoma  cell  line  (12).  Subsequently,  cerbB-2  amplification  was 
reported in 30% of primary human breast cancers (13). To date, numerous studies have 
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15%  to  30%  of breast  carcinomas  are  positive  for  cerbB-2  (14).  Generally,  cerbB-2 
protein overexpression correlates with gene amplification (15).
ROLE OF cerbB-2 IN PATHOGENESIS OF BREAST CANCER:
Data from experiments  using in vitro cell  lines  and  in vivo with transgenic  mice  have 
suggested that cerbB-2 amplification is an early event in breast carcinogenesis (14; 16; 17). 
A number of studies have also reported a higher incidence of cerbB-2 overexpression in 
intraductal carcinomas than in invasive carcinomas (18-20). However, cerbB-2 does not 
appear to be correlated with the invasive potential of intraductal carcinoma (20;21).
The role of cerbB-2 in a multistep breast carcinogenesis model of hyperplasia, atypical 
hyperplasia,  intraductal  carcinoma,  and  invasive  carcinoma  has  been  evaluated  in  the 
literature (20-23). No gene amplification or protein overexpression has been reported in 
benign  neoplasms  or  hyperplasias,  and  most  of  the  reported  cases  of  atypical  duct 
hyperplasia have been negative for cerbB-2 overexpression (20;22;24). However, a “weak 
focal  immunopositivity”  has  been  reported  in  occasional  cases  of atypical  hyperplasia 
(25).
In 1988, van de Vijver et al. (19) first reported a significant association between cerbB-2 
positivity and a comedocarcinomatous pattern. Since then a number of other studies have 
all confirmed a significant correlation between cerbB-2 overexpression and biomarkers of 
poor  differentiation  such  as  high  nuclear  grade,  lack  of  steroid  receptors,  high 
proliferative activity,  and  DNA aneuploidy  (26-33).  Moreover,  cerbB-2  overexpression 
occurs in 70% to 90% of cases of mammary Paget’s disease (34;35), a finding that has led 
some authors to suggest that cerbB-2 may function to promote the intraepithelial spread 
of carcinoma cells.
PROGNOSTIC SIGNIFICANCE OF cerbB-2 IN INVASIVE BREAST CANCER:
More  than  a  decade  ago,  the  first  study  reporting  cerbB-2  expression  as  a  prognostic 
marker in breast carcinoma was published (13). In that initial study of 189 patients with 
both  axillary  lymph  node-negative  and  axillary  lymph  node-positive  breast  cancer, 
Slamon  et  al,  reported  that  cerbB-2  gene  amplification  was  strongly  associated  with 
shortened disease-free (DFS) and overall survival (OS) only in the lymph node-positive 
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population  (36).  Since  then,  numerous  retrospective  studies  involving  thousands  of 
patients have been published on this topic (36-74).
In general, most studies evaluating survival in patients with axillary lymph node-positive 
tumour conclude that cerbB-2 abnormalities determined by gene amplification or protein 
overexpression  are  associated  with  a  worse  clinical  outcome 
(36;43;45;48;52;55;62;63;75).  A  number  of  studies  have  also  demonstrated  that  the 
degree of amplification is important, i.e., the highest levels are associated with the poorest 
prognosis  (13;54).  However,  the  initial  studies  on  patients  with  node-negative  breast 
carcinoma reached different conclusions on the prognostic significance of cerbB-2. Some 
studies  showed a similar trend towards poor prognosis  in either all  or some  subsets of 
axillary node-negative patients whose tumours overexpressed cerbB-2 (36;42;50;52;54), 
while other studies found no significant correlation between cerbB-2 status of the tumour 
and  clinical  outcome  (40;41;47;51;53).  Some  authors  have  explained  the  discrepant 
findings in node-negative breast cancer by citing poor study design, small study size, and 
lack of a standardized test for evaluation of cerbB-2 (76;77).  Recently, however,  it has 
been suggested that cerbB-2 is an independent prognostic factor in node-negative breast 
cancer also (78).
PREDICTIVE ROLE OF cerbB-2 IN RELATION TO THERAPY IN INVASIVE 
BREAST CANCER:
It  has  been  speculated  that  cerbB-2  overexpression  might  be  a  predictive  marker  of 
response to therapy (77;79) due to the  fact that in most of the studies of cerbB-2  as a 
prognostic  marker in node-positive  breast cancer,  the patients had  adjuvant therapy.  A 
number  of  studies  have  evaluated  the  relationship  between  cerbB-2  expression  and 
response to therapy (chemotherapy, hormonal therapy, and radiation therapy).
Response to Chemotherapy:
Initial studies of the possible relationship between cerbB-2 overexpression and response 
to  chemotherapy  included  patients  treated  with  cyclophosphamide/methotrexate/5- 
fluorourcil  (CMF), one of the most common chemotherapy regimens for breast cancer. 
Results  of these  studies  suggested  that  CMF  shows  less benefit  in those  patients  with 
cerbB-2  overexpressing  tumours  (50;52;58;80).  The  association  between  cerbB-2 
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(81-83).  These  studies  suggested  that  cerbB-2  overexpression  may  determine  which 
tumours  may  be  particularly  sensitive  to  doxorubicin-containing  regimens  (82;83). 
Preclinical  and  clinical  data  suggest  that  cerbB-2  plays  an  important  role  in  the 
chemotherapeutic response to paclitaxel (Taxol) and that antitumour activity of paclitaxel 
can be influenced by modulation of cerbB-2 in vitro and in vivo (84-86).
Response to Hormonal Therapy:
The relationship between cerbB-2 overexpression and resistance to antioestrogen therapy 
with tamoxifen has been evaluated  in a number of studies  (86-91).  In  several  of these 
initial  studies, cerbB-2  overexpressing tumours were  resistant to antioestrogen therapy, 
which is expected since cerbB-2 overexpression has been reported to be associated with a 
lack of ER in breast carcinoma (86-90). However, in a recent study, Elledge et al found 
that cerbB-2 expression in ER-positive metastatic breast cancer was not associated with a 
poorer response to tamoxifen or a more aggressive course of disease (91).  Leitzel et al 
reported  that  elevated  serum  levels  of the  extracellular  domain  of cerbB-2  have  been 
associated with resistance to second line hormonal therapy (92). Another study reported a 
significant association between elevated circulating  levels of cerbB-2  and resistance to 
antioestrogen therapy with doloxifine (93).
Response to Radiation Therapy:
The  relationship  between  cerbB-2  overexpression  and  radiation therapy  has  also  been 
studied.  The  results  are  not  conclusive,  but  clinical  studies  suggest  that  cerbB-2 
overexpression may confer radio-resistance on the breast cancer (94;95).
CerbB-2 AS A THERAPEUTIC TARGET:
The cerbB-2 receptor protein is an ideal therapeutic target because it is homogeneously 
expressed  in  both  primary  and  metastatic  tumours  and  its  expression  is  quite  low  in 
normal tissues. Encouraging initial results obtained from in vitro studies using cell lines 
and xenografts have opened a new era in the treatment of breast cancer (96;97). The 4D5 
anti-cerbB-2 antibody, which is directed against the extracellular region of cerbB-2, was 
humanized by inserting its murine antigen binding regions into the framework of a human 
immunoglobulin molecule (98;99). This recombinant humanized monoclonal anticerbB-2 
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significant tumour growth-inhibitory activity in breast cancer cell lines that overexpress 
cerbB-2. Clinical phase I and II trials demonstrated encouraging results when Herceptin 
was used as a single agent or in combination with chemotherapeutic agents (100; 101). 
The  efficacy  of Herceptin  plus  chemotherapy  was  evaluated  in  phase  III  randomised 
clinical trials in which patients with stage IV metastatic breast cancers were randomised 
to receive Herceptin plus chemotherapy or chemotherapy alone. Patients who received the 
combination  had  a  statistically  significant  longer  median  duration  of  response  than 
patients who received chemotherapy alone (100-102). Herceptin was also evaluated as a 
single  agent  first-line  therapy  in  patients  with  metastatic  breast  cancer  (103; 104). 
Therefore, National Institute for Clinical Excellence (NICE) has issued guidelines for the 
recommendations on the use of herceptin in metastatic breast cancer, both in combination 
with chemotherapy and as monotherapy (105). In trial setting, herceptin is being used in 
adjuvant treatment of breast cancer.
In addition to the use of anticerbB-2 antibodies, the use of cerbB-2 as a target for gene 
therapy  via the  use  of antisense  probes  and  anti-cerbB-2  protein  vaccination  is  under 
investigation (106; 107).
METHODS OF EVALUATING cerbB-2 STATUS:
Until recently, the greatest problem limiting the routine clinical use of cerbB-2 has been 
the lack of well-standardized assays and quality control programmes (108; 109).
Methods  that  can  be  used  to  determine  tumour  cerbB-2  status  include  assays  of gene 
amplification (Southern blot hybridization, PCR, FISH), assays of protein overexpression 
(immunohistochemistry,  ELISA,  Western  blot)  and  mRNA  level  evaluation  (Northern 
blot).
There is no consensus about the reliability, reproducibility, and predictive value of each 
method  and  each  has  its  advantages  and  disadvantages.  The  main  limitation  of using 
blotting  techniques  to  assay  cerbB-2  gene  amplification  is  the  dilutional  effect  of 
nontumoural elements present in tissue samples. Furthermore, these techniques are quite 
expensive  and  require  specialized  molecular  laboratories.  The  fluorescence  in  situ 
hybridization  (FISH) technique allows simultaneous evaluation of gene amplification and 
morphology.  This  technique  is  more  sensitive  than  Southern  blot  analysis  for  the 
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small amounts of tissue and on cytological specimens (110;111). It is generally accepted 
to  be  a  more  discriminant  test  at  the  positive  negative  borderline,  has  greater ease  of 
methodological standardisation and less observer variation.
Although  FISH  assays  have  been  widely  advertised  in  the  literature  as  expensive 
techniques  requiring  special  equipment  and  reagents,  the  recent  development  of 
commercially available sensitive probes now make the cost only slightly more expensive 
than immunohistochemical methods.  The only special equipment required for FISH that 
may not be found in a routine laboratory is the fluorescence microscope.
In less than 5% of breast carcinomas, overexpression of cerbB-2 oncoprotein may be due 
to enhanced transcription without gene amplification (111).  The majority of the studies 
evaluating cerbB-2 as a predictive factor for response to either conventional therapies or 
herceptin  have  used  immunohistochemical  methods.  Immunohistochemistry  (IHC)  has 
been the predominant method used in clinical studies to determine overexpression of the 
cerbB-2  oncoprotein.  In  fact,  immunohistochemical  staining  of  frozen  tissue  is 
consistently found to be the most reliable technique in this regard (71). However, in order 
to  be  useful  in  routine  laboratories  the  technique  must  be  reliable  in  paraffin  wax- 
embedded tissues. Generally, there is good concordance between FISH assay for cerbB-2 
and its detection by IHC (112).
The  main  technical  issue  for  consideration  in  the  case  of IHC  is  the  sensitivity  and 
specificity of the antibodies used for immunohistochemistry.  Busmanis et al reported a 
wide range of detection rates and staining patterns when they used a panel of six different 
antibodies (113). A similar result was obtained by Press et al, who used 21  monoclonal 
and  7  polyclonal  antibodies  to  assay  cerbB-2  protein  overexpression  on  paraffin-wax 
embedded  tissue  sections  of breast  cancer  (77).  They  found  that  the  sensitivity  and 
specificity  of the  antibodies  varied  from  6-80%.  Another  issue  is  the  use  of antigen 
retrieval  techniques  and  resulting  false  positivity.  A  third  issue  is  the  tissue  fixation 
methods used, especially in the case of paraffin wax-embedded tissue sections. The type 
of tissue  fixation,  the  length  of fixation  and  the  method  of tissue  preparation  can  all 
influence  the  immunohistochemical  staining  results.  Prolonged  storage  can  cause  a 
decrease  or  loss  of immunopositivity  (114).  Finally,  the  fourth  important  issue  is  the 
interpretation of the staining.  A membranous staining pattern is generally considered to 
be  specific  for  cerbB-2  overexpression  and  has  been  shown  to  correlate  with  geneChapter 4: cerbB-2 in breast cancer 72
amplification. In contrast, the clinical and biological significance of cytoplasmic staining 
is  controversial.  Tetu  et  al  specifically  evaluated  the  pattern  of staining  in  relation  to 
prognosis  in  patients  with  node-positive  breast  cancer,  they  found  that  cytoplasmic 
staining  did  not  correlate  with  clinical  outcome,  but  that  membranous  staining  was  a 
significant  predictor  of  a  shorter  disease-free  survival  (58).  Another  study  using  a 
different  monoclonal  antibody,  however,  showed  that  strong  cytoplasmic  staining  did 
correlate with bad prognosis (115).
Like many other cell surface receptors, a soluble form of the extracellular domain of the 
cerbB-2  protein  can  be  detected  and  quantitated  in  the  serum  by  enzyme-linked 
immunosorbent  assay  (ELISA)  (116; 117).  Not  all  cerbB-2  positive  tumours  shed  the 
protein. Furthermore the clinical significance of circulating cerbB-2 is uncertain. Janiska 
et al found that circulating cerbB-2 protein may be a non-specific phenomenon and may 
not  necessary  correlate  with  the  presence  of a  tumour  (118).  Recently,  a  systematic 
literature review on the clinical value of measuring elevated serum levels of HER-2/neu 
oncoprotein was published in clinical chemistry (119). This review summarised data from 
55  peer-reviewed journals  and  included  over  6500  patients.  It concluded  that  elevated 
levels of serum cerbB-2 are indicative of a particularly aggressive form of breast cancer 
and therefore is a valuable clinical tool  for assessing prognosis, predicting response to 
therapy  and  detecting  early  recurrence  of breast  cancer.  In  primary  breast  cancer,  the 
prevalence of elevated serum cerbB-2 levels varied between 0-28%, whereas in metastatic 
disease elevated values were found in 23-80% of all cases. This review also showed that 
cerbB-2 positive tumours are more prevalent than generally known by tissue testing and 
that elevated  serum  levels of cerbB-2  predict a poor response to hormone therapy and 
some  chemotherapy  regimens  but  can  predict  improved  response  to  combination  of 
chemotherapy and herceptin.
In summary, although cerbB-2 expression in breast cancer has been widely studied, there 
are  still  a  number  of  unanswered  questions  regarding  its  biological  and  clinical 
significance (120). There is adequate preclinical and clinical evidence that cerbB-2 may 
be a clinically useful prognostic and predictive marker and can be used as a therapeutic 
target,  but  the  lack  of a  reliable  and  reproducible  method  of evaluation  hampers  the 
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the development of standard methodologies for evaluating cerbB-2 expression in tumour 
tissues.
Recently,  there  has  been  interest  in  using  the  FDA  (food  and  drug  agency)-approved 
HercepTest as a predictor of response to Herceptin therapy (121). The Hercep Test is a 
semiquantitative  immunohistochemical  assay  to  determine  HER-2  overexpression  in 
breast cancer tissues routinely processed  for histological  evaluation.  Currently,  it is the 
most expensive assay kit used in diagnostic histopathology laboratories (121). Therefore, 
Grady et al (121) have applied tissue microarray technology to analyse HER-2 status in 
20 samples in one experiment using the HercepTest. Similar work has also been done by 
Rampaul  et  al  (122).  Both  groups  concluded  that  HercepTest  combined  with  tissue 
microarray method is accurate, economical and easily integrated into a routine laboratory. 
However,  heterogeneity  of tumours  can  be  a  problem.  Nevertheless,  developing  this 
technique further could be the way forward for the future.
In the UK, there are now published guidelines which have been formulated to give advice 
on  methodology  and  quality  assurance  for  local  testing  to  ensure  that  HER-2  testing 
results are accurate and reliable, regardless of the test used (123) and also see appendix II. 
These guidelines have been updated further. All laboratories utilising assays for cerbB-2 
as predictive or prognostic marker are required to participate in an appropriate external 
quality assurance (EQA) programme such as the one run by the UK National  External 
Quality Assessment Scheme (NEQAS) for Immunocytochemistry.
EGFR/erbB-l/HER-1:
EGFR  encodes  the  receptor  for  epidermal  growth  factor  (124; 125).  It  is  located  on 
chromosome 7pl3  and the cellular location of the receptor is at the plasma membrane. 
There  are  at  least  15  EGFR  ligands  (126; 127)  including  EGF,  TGFa,  amphiregulin, 
cripto-1, betacellulin, heparin-binding EGF-like growth factor a, heregulin, glial growth 
factor and others. EGFR can heterodimerize with each of the other members of the EGFR 
family  (HER-2,  HER-3  and  HER-4)  and  individual  ligands  for this  family give rise to 
distinct patterns of /raws-phosphorylation (128).  EGFR  is amplified in 20% of primary 
breast carcinomas and  some  studies (129-132) have  shown it to be  strongly associated 
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found  no  prognostic  significance  for  EGFR  expression  in  invasive  breast  cancer  even 
after long-term follow-up (133).
ErbBS/HER-3:
HERS is located on chromosome  12ql 3 and the cellular location of the protein is at the 
plasma  membrane  where  it  functions  as  a  receptor  tyrosine  kinase.  HER-3  can  form 
heterodimers  with  EGFR,  HER-2  or  HER-4.  Overexpression  of  HER-3  occurs  in 
mammary tumour-derived cell  lines (134), but the role in invasive breast cancer is not 
clear.  One  study  found  no  significant  associations  with  overall  survival,  disease-free 
interval, regional recurrence, the presence of distant metastases, age, menopausal status, 
oestrogen receptor status, histological grade, lymph node stage, vascular invasion and c- 
erbB-2 protein expression (135).
ErbB-4/HER-4:
HERS is located on chromosome 2q33  and the cellular location of the protein is at the 
plasma membrane. HER-4 can form heterodimers with EGFR, HER-2 or HER-3. HER-4 
is expressed  in a variety  of mammary adenocarcinoma cell  lines  (136),  but again  like 
HER-3, the role in invasive breast cancer is not clearly defined.Chapter 5: Oestrogen receptors (ER) in breast cancer 75
CHAPTER  5:  OESTROGEN RECEPTORS IN BREAST CANCER:
INTRODUCTION:
Hormonal therapy is important in the management of breast and prostate cancer. This is 
based on the  fact that  some cancers  express  receptors  for  sex  hormones  and  that their 
growth  is  partly  dependent  on  hormonal  stimulation.  Female  sex  hormones  include 
oestrogens and progestogens. Naturally occurring oestrogens are oestradiol, oestrone and 
oestriol  whereas  synthetic  oestrogens  include  ethinyloestradiol.  mestranol  and 
diethvlstilboestrol.  There  are  two  main  groups  of progestogens, progesterone  and  its 
analogues,  which  include  dvdrogesterone.  hydroxyprogesterone  and
medroxyprogesterone;  and  testosterone  analogues  which  include  norethisterone  and 
norgestrel.  The  newer  progestogens,  desogestrel.  norgestimate  and  gestodene.  are  all 
derivatives of norgestrel. Steroid hormones are mainly produced in the ovaries and testis, 
and to some extent in the adrenal glands. Under physiological conditions, oestradiol acts 
as  a  proliferative  hormone  on  breast  epithelial  cells,  whereas  progesterone  has  no 
proliferative effects (1).  The proliferative effects of oestradiol on breast epithelial cells 
appear  to  be  mediated  by  the  cyclin  Dl-CDK2/4-pRB  pathway  as  a  result  of which 
hyperphosphorylation  of pRB  occurs  (2).  On the  other  hand,  oestradiol  also  increases 
wild-type p53 levels indirectly via increased c-myc transcription. P53 in turn, induces p21 
and  inhibits  proliferation.  Therefore,  the  effect  of oestradiol  on  breast  epithelial  cell 
proliferation is two-sided;  firstly,  increased proliferation via pRB hyperphosphorylation 
and secondly, decreased proliferation via p53 upregulation (figure 5.1).
The sex hormones bind with high specificity and affinity to intracellular receptors which 
belong to a “superfamily” of proteins whose function is to control the transcription of a 
repertoire of other cellular genes  (3).  Steroid receptors  for oestrogen and progesterone 
(ER and PR) are located in the cell nucleus. Hormone is believed to be transported to the 
nucleus  where  a  steroid-receptor  complex  is  formed  with  receptor  dimerization.  This 
dimer binds to specific DNA response element sequences usually located in the promoter 
regions of regulated genes. Some of the genes regulated by steroid receptors are involved 
in controlling cell growth.Chapter 5: Oestrogen receptors (ER) in breast cancer 76
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Figure 5.1; A hypothetical model describing relationship between oestrogen and the two 
tumour suppressors, p53 and pRB, where E = oestradiol
Since  the  end  of  nineteenth  century  it  has  been  known  that  a  proportion  of breast 
carcinomas  are  hormone  sensitive.  It  was  Beatson  (4)  who  showed  that  following 
oophorectomy, there was a regression of metastatic lesions in premenopausal women with 
breast cancer.  More than  50 years  later Huggins and  Burgenstal  (5) demonstrated that 
ablation of the adrenal glands could be similarly beneficial in post menopausal women. 
Shortly afterwards,  it was shown by Luft and Olivecrona (6) and Pearson et al (7) that 
there  was  similar  effect  following  hypophysectomy.  Approximately  30%  of  women 
treated  with  endocrine  ablation  showed  a  dramatic  improvement.  Unfortunately,  there 
was  no  way  of distinguishing  those  who  would  benefit  from  those  who  would  not. 
Therefore, there was considerable interest in finding ways of selecting women who would 
benefit  from  surgical  endocrine  ablation  so that  the  others could  be  spared  ineffective 
surgery. An early attempt to do this was made by Bulbrook and his colleagues in 1968 (8) 
when  they  measured  urinary  androgen  and  corticoid  metabolites  in  women  about  to 
undergo  adrenalectomy  or hypophysectomy,  but,  although  there  was  some  correlation 
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This approach did, however, show that it might be possible to find means of identifying 
responsive and non-responsive tumours.
Work  with  laboratory  animals  indicated  that  oestrogen-responsive  tissues  contain 
oestrogen binding proteins or ‘receptors’. This was demonstrated by the uptake of either a 
tritiated synthetic oestrogen,  hexoestrol  (9), or tritiated oestradiol  (10).  Folca et al  (11) 
administered  labelled  hexoestrol  to  1 0  women  undergoing  adrenalectomy  or  bilateral 
oophorectomy and they observed an increase in radioactivity in the tumour tissue in the 
four women who responded to the treatment. There was a major breakthrough in the early 
1970s  when  an oestrogen  binding  protein  was  found  in  primary  and  metastatic  breast 
tumours.  In  1971  Elwood Jensen and his colleagues (12) published a classic paper in a 
National  Cancer  Institute  monograph  entitled  ‘Oestrogen  Receptors  and  Breast  Cancer 
Response  to  Adrenalectomy’.  They  correlated  the  clinical  response  of breast  cancer 
patients to  endocrine  ablation  with  the  specific  binding  of oestradiol  in tumour tissue 
slices. They found that the women in whom there was an accumulation of oestradiol  in 
the tissues were more likely to respond to the treatment.
Afterwards,  simple  assays  were  developed using tumour tissue  cytosols.  Owing to  the 
introduction of tamoxifen as an effective treatment for metastatic breast cancer (13) it was 
no  longer  necessary  to  identify  the  hormone-responsive  women  in  order  to  spare  the 
unnecessary  surgery.  Unless  patients  had  rapidly  progressing  disease  many  clinicians 
were happy to use this relatively non-toxic drug in a therapeutic trial and assess response 
in vivo. Nevertheless, there has been continued interest in receptor measurement in order 
to refine treatment modalities for breast cancer,  particularly in clinical trials relating to 
both treatments for advanced disease (14) and more recently as an adjuvant treatment in 
early disease (15; 15; 16).
ER -  STRUCTURE AND FUNCTION:
The ER is subdivided into six functional domains A -  F (figure 5.2). A/B domains are 
located at the N-terminal end of the receptor and contain transcription activator factor-I 
(TAF-I).  The  C-domain  is  highly  conserved  among  members  of the  steroid  receptor 
superfamily and mediates DNA-binding. The D-domain is the hinge region. E/F domains 
are at the C-terminus of the receptor and are responsible for high affinity ligand binding; 
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specific  manner (17-20).  ER is a transcription  factor and can be a target  for signalling 
pathways.  It  can  be  modified  post-transcriptionally  at  specific  sites.  The  signalling 
pathways it can affect include the one with the “early response gene” AP-1. Reciprocally, 
these pathways can interfere, either positively or negatively, with the activity of ERs and 
can either directly modify the receptor or alter its ability to transactivate without apparent 
modification (17) (21-23)
Once  bound  by  oestrogens,  the  ER  undergoes  a  conformational  change,  allowing  the 
receptor to bind with high affinity to chromatin and to modulate transcription via specific 
DNA elements called the ERE (oestrogen response elements) of target genes. ER exists as 
a non-transformed, non-DNA bound oligomeric complex in association with heat shock 
protein hsp 70 and hsp 90 in cells (18).  Hsps function to help hold ER protein properly 
and to protect the hydrophobic hormone binding domain from inappropriate interactions. 
In one recent study (24), hsp 27 correlated positively with ER and predicted  improved 
survival in breast carcinoma.
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ER VARIANTS-ERa AND ER0:
ER exists as two subtypes-ERa and ERP (20;25). Until recently, only a single type of ER 
was thought to exist and mediate the genomic effects of oestrogen in mammalian tissues. 
However, the cloning of a gene encoding a second type of ER (ERp) from mouse, rat and 
human  has  prompted  a  re-evaluation  of the  oestrogen  signalling  system  (26;27).  The 
classical ER is now referred to as ERa. The overall homology between the ligand binding 
domains  of  ERa  and  ERp proteins  is  55%  and  homology  between  N-terminal 
hypervariable domains is 22%.  The DNA  binding domain is virtually identical (19;28). 
ERp binds  oestradiol  with  an  affinity  similar  to  that  of  classical  ERa but  tissue 
distribution and relative levels of these variants are different.  A recent study has looked 
at the cellular distribution of ERa and ERp in normal human mammary gland employing 
immunocytochemistry (29). ERa was found to be restricted to the cell nuclei of epithelial 
cells lining ducts and lobules, whereas ERp, in addition to epithelial cell nuclei was also 
detected in the cell nuclei of myoepithelial cells and some stromal and endothelial cell 
nuclei and  some  lymphocytes.  Another study has looked at ERa and ERp  mRNA and 
protein in malignant and non-malignant breast tissue (30). Sixty six percent of tumours 
expressed wild type  ERp  mRNA  in comparison to  90% for wild type  ERa.  The  ERa 
protein was detected in 70% and ERp protein in 25% of breast carcinomas. ERp showed 
a weaker association with the histopathological grades of breast carcinoma as compared 
to ERa. ERa and ERp signal differently to modulate through AP-1  sites in response to 
synthetic oestrogens (17).
The  ER  possesses  two  transactivation  factors,  TAF-I  in  the  N-  terminal  region 
(hypervariable domain) and the ligand dependent TAF-II in the ligand binding domain. 
TAF-I and TAF-II map to the A/B and E/F domains respectively (figure 5.2). The DNA- 
binding domain and ligand binding domain consist of C and E/F respectively.
H222 and  1D5  are anti-ERa specific monoclonal  antibodies whereas  14C8 is anti-ERp 
monoclonal antibody.
STEROID HORMONE RECEPTOR ASSAYS:
There  has  been  a  continuous  development  of the  methods  used  to  measure  steroid 
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slices but these were difficult to handle, therefore an alternative was sought by Gorski et 
al (31), who demonstrated the presence of ER in cytosols prepared from rat uterus. This 
led  to  the  development  of ligand  binding  assays  using  cytosols  prepared  from  breast 
tumour  tissue.  Initially  sucrose  density  ultracentrifugation  was  used  to  provide  data 
relating the sedimentation velocity  of the  receptor protein to  its molecular weight  and 
density  (32),  however  it  was  a  cumbersome  method  of  measuring  steroid  hormone 
receptor  binding.  An  alternative  was  introduced  involving  the  separation  of unbound 
oestradiol  from that bound to  the  receptors using dextran-coated charcoal  (DCC) (33). 
Tritiated  oestradiol  was  added,  usually  at  several  different  concentrations  and  after 
allowing sufficient time for specific binding to the receptor to occur, DCC was added and 
centrifugation used to separate the unbound from the bound oestradiol. Scatchard analysis 
was used to calculate the amount of specific receptor binding and results expressed as 
femtomoles (fmol) of oestradiol bound per milligram of the cytosol protein or per gram of 
tissue. These assays had several disadvantages: ER is a thermolabile, unstable protein and 
particular care has to be taken when handling the tissue from the time it is removed from 
the  patient,  throughout  storage  and  during  the  preparation  of  the  cytosol  and  all 
subsequent  stages  of the  assay.  Furthermore,  ligand  binding  assays  do  not  take  in  to 
account the receptors which are already occupied by ligand -  an important consideration 
particularly in prememopausal women (34). Other disadvantages are that these assays are 
time consuming, requiring an overnight incubation and they need approximately 500 mg 
of tissue, which is not always available.  Furthermore, the cellularity of carcinomas and 
contamination with non-malignant tissue can affect the results.
It took a long time before specific oestrogen receptor antibodies could be developed (35). 
In 1986, Jensen et al (36) first described the use of both an Enzyme Immunoassay (EIA) 
for measuring ER in tumour cytosols and an immunohistochemical assay measuring ER 
in  frozen  sections  (37).  The  antibodies  used  in  these  studies  were  H222  and  H226, 
marketed  by  Abbott  laboratories.  The  results  of  immunohistochemical  assays  were 
compared against EIA in a study reported in Supplement of Cancer Research (38). The 
ER immunohistochemical assays were discussed in detail by Pertschuk in  1990 (39). In 
another study, Pertschuk et al also showed (40) that there was a better correlation between 
ER  content  and  response  when  measured  by the  immunohistochemical  assay  than the 
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The search continued for alternative antibodies, particularly those which could be used on 
formalin fixed paraffin-wax embedded tissues. In the late 1980s, studies started to appear 
in the literature describing ER immunohistochemical assays on formalin fixed paraffm- 
wax  embedded  sections  using  various  enzyme  digestion  techniques  including  trypsin 
(41), pronase (42) and D-nase (43) with the Abbott H222 antibody.  Initially the D-nase 
technique was quite popular but later the use of pronase in conjunction  with overnight 
incubation with H222 antibody was found to give more consistent and satisfactory results 
(44). Improvements continued (45) and a new ER antibody ID5 (46) entered the market 
available in the UK from Dako Ltd. This produces good results (47). The success of these 
newer  antibodies  has  been  considerably  helped  by  the  coincidental  development  of 
antigen  retrieval  methods  using  heat,  produced  either  by  microwave  (48)  or  pressure 
cooker (49). The use of H222 has declined following the development of antibodies such 
as  ID5,  which  is  more  successful  on  fixed  tissues.  Combined  with  the  microwave 
technique, it does not require overnight incubation.  It gives an evaluation of ER status, 
which correlates well with the assessment made using Abbott H222 on both frozen and 
formalin fixed paraffin-wax embedded tissue (50).
EVALUATION OF ER STAINING IN IMMUNOHISTOCHEMICAL ASSAYS:
Immunohistochemistry revealed that the ER was located in the nucleus of breast cancer 
cells (51) although early research workers thought the protein to be in the cytoplasm. It is 
now known that the majority of receptor is only loosely bound in the nucleus and is easily 
extracted.  Only  a very  small  amount  is  so  tightly  bound to  DNA  that  even the  most 
rigorous methods fail to extract it. ER can shuttle between the nucleus and the cytoplasm, 
but  is mainly  found  in  the  nucleus  and  immunohistochemistry  fails  to  detect  it  in  the 
cytoplasm (52).
Despite  the  increasing  popularity  of immunohistochemical  methods,  there  is  still  no 
general  agreement  about  the  best  way  of scoring  ER  staining  in  tissue  sections.  The 
nuclear staining varies in both intensity and extent and the major problem is to determine 
how it should be evaluated. Kinsel et al described a method called histo-score (53). In this 
method, the staining intensity of each part of the section is assessed and allocated a value 
of 0 (nil), 1   (weak), 2 (distinct) and 3 (strong). The percentage of positive cells in each of 
the staining categories is multiplied by the intensity value and sum of these products in 
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more is considered positive. This method is time consuming and gives a numerical value 
to something which is a subjective assessment.
An alternative immuno-reactive score (IRS) suggested by Remmele and Stegner (54) is 
widely used in Germany. In this method, the average percentage of stained cells over the 
entire section is assessed and allocated a value of 0 (no staining),  1   (<10%), 2 (11-50%), 
3 (51 -80%) and 4 (>80%). The average staining is assessed as 0 (no staining), 1  (weak), 2 
(moderate) or 3 (strong) and the values are then multiplied, giving a score ranging from 1  
to  1 2.
A variation of IRS method is the quick score (55) in which the value for intensity is added 
to that for the proportion of stained cells, giving a maximum number of 7. A modification 
of this  (modified  quick  score)  has  been  recommended  by  the  National  Co-ordinating 
Committee on Breast Screening Pathology in UK, see appendix II (56).
Another easy and quick alternative scoring method is to assess the overall appearance of 
the staining and to classify it as negative, weak, moderate or strong.  The moderate and 
strong stains can be seen under the low power (xlO) objective of the microscope. Weak 
staining is only evident at higher magnifications. This is called the ‘category score’. It is 
purely  descriptive  and  does  not  attempt  to  give  a  numerical  value  thus  avoiding  the 
danger of giving the result undue significance. Some researchers use only the percentage 
of positively stained tumour cells.
The validity of any assessment of the strength of staining, even, when great care is taken 
over monitoring consistency between batches of staining, is sometimes questioned. In the 
case of cerbB-2, however, Slamon et al (57;58) have shown that using diaminobenzidine 
(DAB) as the chromogen, a pale golden colour corresponds to both a low copy number of 
cerbB-2  gene  and  a  low  level  of protein  expression  as  assessed  by  Western  blotting. 
Whereas, tumours in which the staining is a very dark brown colour, have a high level of 
gene amplification and high levels of protein. While similar direct comparisons have not 
been made for ER, there is a suggestion that tumours with very dark staining nuclei on 
immunohistochemsitry  may  have  higher  DCC  and  EIA  values.  However,  there  is 
emerging evidence that there is a closer association between oestrogen receptor status and 
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binding  and  enzyme  immunoassays  (59;60),  probably  because  of lack  of influence  of 
tumour cellularity  and type.
In one study, researchers have examined (61) the relationship between scoring methods 
and response to endocrine treatment in a series of patients with metastatic breast cancer. 
The immunohistochemical ER status was determined retrospectively on primary tumours 
from  134 patients who were treated at Guy’s hospital between  1975  and  1990.  All the 
patients subsequently received first line tamoxifen treatment for metastatic disease. The 
diagnosis and date of recurrence were determined in a standard manner according to the 
criteria of Hayward et al (62) and the response to treatment was assessed by UICC criteria 
(63). Four different methods of evaluating the staining were undertaken and comparisons 
were made to  find which method produced a result most closely related to the clinical 
course of the disease.  The methods used were;  1) the histo-score, 2) the consistency of 
staining i.e., whether negative, heterogenous or homogenous, with no attention being paid 
to the intensity of staining 3) the category score with negative, weak, moderate or strong 
and  4)  the  simplified  category  score  with  negative  and  weak  staining  combined  and 
classified as negative and moderate and strong staining classified as positive.
The relationship between various methods of evaluation and the duration of response to 
tamoxifen (i.e., from start of treatment to time of progression) was calculated using log 
rank analysis and secondly the relationship between various methods of evaluation and 
type of response, complete or partial (responders) vs static and progressive disease (non 
responders) was calculated using the x  test.  Results showed that when used to predict 
duration of response, all four methods of evaluation gave significant results but the most 
statistically  significant  result  was  for  the  simplified  category  score.  As  regard  to 
comparison  between  the  different  methods  of evaluation  and  the  type  of response  to 
tamoxifen,  all  four  methods  were  again  highly  significantly  associated  with  response, 
however  the  subjective  category  score  gave  the  most  significant  information.  These 
results  suggest that  the  information  obtained  by  the  category  score  is  superior to  that 
gained by the more time consuming histo-score.
EVALUATION OF ER STAINING AND IMAGE ANALYSIS:
Some groups have attempted to use image analysis in order to improve the consistency of 
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CAS  (Cell  Analysis  System)  specifically  for measuring the  ER but the  system has not 
been  widely  adopted  in  the  UK.  The  lack  of general  acceptance  of image  analysis  is 
because there is no really  good system at a reasonable price, which can accurately and 
reproducibly  recognise  the  stained  tumour nuclei  and  express them  as  a percentage of 
non-stained tumour nuclei. Their use is usually as time consuming as counting the nuclei 
by human eye using a graticule. Esteban et al (65) described the use of SAMBA 4000 cell 
image analysis system to evaluate staining of ER using the ID5 antibody. They found that 
the choice of cut off point was critical, but even when a point was chosen which showed a 
correlation between positive staining  for ER and  survival, the correlation was not very 
strong. At present, general consensus is that image analysis has not yet reached the stage 
of development where  it can be  used reliably  and efficiently.  However,  a recent  study 
(6 6 ) has found significant correlation between semiquantitative hormone receptor scoring 
using immunoreactive score (IRS) and quantitative computer-assisted image analysis.
INCIDENCE OF ER IN BREAST CANCER AND PREDICTION OF RESPONSE 
TO TREATMENT:
When oestrogen receptors were first measured in primary breast cancers, about 65% of 
the tumours were  found to be ER positive by the ligand binding assay using a cut off 
point  of  more  than  5  finol  of  oestradiol  bound  per  milligram  of  protein  to  define 
positivity. Approximately, 33% of patients with metastatic disease respond to endocrine 
therapy,  and  50%  of patients  with  ER-positive  tumours  are  hormone  responsive  in 
contrast to <10% of patients with ER-negative tumours. In general, patients with higher 
levels of ER are more likely to respond to endocrine therapy (67). Oestrogen receptors are 
essential for oestrogen action. Prediction of response can be further refined by combining 
oestrogen receptor assay with progesterone receptor (PR) assay (6 8 ).  ER+PR+ tumours 
have a 78% response, ER+PR- a 55% response, ER-PR+ a 45%  response and ER-PR- a 
10% response (6 8 ). These results relate to ligand binding assay systems.
ER IN RELATION TO CLINICOPATHOLOGIC PARAMETERS AND TUMOUR 
BIOLOGY: 
ER and Patient Age:
There is a steady increase in the ER content of mammary tumours with increasing patient 
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also confirmed in a large study of over 5000 patients by Romain et al  (70) using EIA. 
However, a similar effect is not seen with progesterone receptors (69).
ER in Relation to Histological Grade and Tumour Type:
ER is always present in normal breast tissue although in normal pre-menopausal breast, 
ER+  cells are distributed singly (71). Well differentiated tumours are more likely to be ER 
positive  than  poorly  differentiated  tumours  and  they  are  more  likely  to  be  hormone 
responsive (72). This association was clearly shown by Millis et al (73) in a study of 369 
cases of infiltrating ductal carcinoma, 85% of the 47 well differentiated grade I, 82% of 
193  moderately differentiated  grade  II  and  57%  of 129  poorly  differentiated  grade  III 
carcinomas  were  ER  positive.  Other  studies  (74;75)  confirmed  this  relationship. 
Infiltrating  lobular  carcinomas  are  very  frequently  ER  positive  while  medullary 
carcinomas with lymphoid stroma are usually negative (74).
ER and Tumour Stage:
There is no relationship between ER status and tumour stage, which is time related and 
reflects the stage of the disease at diagnosis (73;76). The likelihood of early recurrence is 
much more dependent on tumour burden at the time of initial treatment than it is on ER 
status.  This  is  reflected  in  the  conflicting  data  relating  ER  positivity  to  disease  free 
interval,  some  studies  (77)  showing  ER  to  be  an  independent  prognostic  marker  for 
recurrence, while others not (78;79).
ER and Ductal Carcinoma In Situ (DCIS) of the Breast:
There is no agreement in the literature about the proportion of ER positive DCIS. Using a 
variety of methods it has been reported as being as low as 32% by Poller et al (80) and as 
high as 81% by Zaffani  et al  (81).  Burr et al (82) found ER expression in 91% of non 
comedo DCIS and 57% of comedo DCIS. In contrast lobular carcinoma in situ is nearly 
always  ER  positive  (83).  ER  positivity  is  associated  with  small  nuclear  size,  higher 
proliferation fraction (S phase fraction) and lack of cerbB-2 staining (80;84).
ER of Primary Tumour and Metastasis:
Initially the ER assays were performed on recurrent skin nodules or metastatic lesions, 
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women whose metastases were in bone, lung or liver. Early studies showed that the ER 
content of metastases generally resembled that of the primary tumour (85). Therefore, it 
became common practice to measure ER in primary lesions. The results were recorded for 
use in the event of systemic recurrence.
ER status can give an indication of the likely site of metastases. ER positive tumours are 
most likely to spread to bone and ER negative tumours to lung and liver (8 6 ). There is 
generally  good  concordance  between  the  receptor  status  of the  primary  tumour  and 
metastases found in lymph nodes at the time of primary diagnosis (8 6 ).
ER and Tumour Proliferation:
Direct  comparisons  between  ER  status  and  proliferative  activity  have  been  made  in 
various studies employing different methods to measure the rate of proliferation including 
thymidine labelling (87), bromodeoxyuridine (BRDU) labelling (8 8 ), and flow cytometry 
(89).  The development of monoclonal antibodies raised against proliferation associated 
antigens,  such  as  Ki67  (90),  KiSI  (91)  and  MIB1  (92)  has  made  available 
immunohistochemical methods. Meyer et al (87) found that ER positive tumours have a 
low rate of proliferation. However, there is a small number of ER positive tumours with a 
high rate of proliferation and it is suggested that these are the ones which fail to respond 
to hormone treatment (93;94).
ER and Other Biological Markers:
Int-2 gene: Int-2 gene is amplified in approximately  15 to 2 0 % of mammary carcinomas 
and  a  very  close  association  between  ER  positivity  and  int-2  amplification  has  been 
reported (95).
CerbB-2: An inverse relationship exists between cerbB-2 and ER (96).
p53:  There  is  a significant  inverse relationship between p53  protein and  ER positivity 
(97).
BCL2: There is a significant positive correlation between bcl2 and ER (98).Chapter 5: Oestrogen receptors (ER) in breast cancer 87
ER and Prognosis:
The availability of ER assays led to studies of the relationship between hormone receptor 
status in primary breast cancer and prognosis. A highly significant association was found 
between prolonged overall survival and the presence of ER in the primary tumour (99). 
The association between receptor status and disease free interval, first shown by Knight et 
al (1 0 0),  is less strong, while the most profound effect of receptor positivity is seen in 
survival after relapse, when women with ER positive tumours live considerably longer 
than their ER negative counterparts (101).
ER and Male Breast Cancer (MBC):
Both  ER  and  PR  have  been  identified  in  a  high  proportion  of MBC  using  the  DCC 
method, ELISA and ICC (102-104). Most studies have reported that ER is expressed in at 
least 80% of MBC and PR in up to 75% of cases, which is in excess of the figures for 
female breast carcinoma. The reason for this is not entirely clear.
OESTROGEN -  INDUCED PROTEINS: 
Progesterone Receptors (PR):
Progesterone receptor (PR) is directly modulated by ER transcription protein and the level 
of PR expression therefore closely mirrors that of ER. Not all ER positive tumours are 
hormone responsive, and it has been suggested that other hormone induced proteins are 
possible markers of response. Horwitz et al (105) suggested progesterone receptor as one 
of them. They hypothesized that in unresponsive tumours ER, although present, was not 
functional. When studies of both ER and PR proteins were carried out (106; 107), it was 
found that approximately  50% of tumours are positive for both, 25% are  negative  for 
both, 20% are ER + PR- and 5% are ER -  PR+. Tumours co-expressing ER and PR have 
an 80% likelihood of response (107). However, there are still 20% of tumours positive for 
both receptors, which do not respond. Also, double negative tumours are highly unlikely 
to respond. At present, there seems to be little additional clinical benefit in determining 
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Cathepsin D:
Westley  and  Rochefort  (109) described  a  52  kDa protein  induced by  oestradiol  in the 
oestrogen  dependent,  hormone  responsive  MCF7  cell  line.  It  was  later  identified  as  a 
precursor  of  cathepsin  D  which  is  a  lysosomal  protease  (110).  Tandon  et  al  (111) 
suggested that cathepsin  D  measured  in tumour  cytosols might be  a predictor  of poor 
prognosis.  However,  immunohistochemical  studies  have  shown  it  to  be  present  in 
macrophages, in the stroma as well as in tumour epithelial cells and this may reduce the 
validity of the cytosol  assay.  Therefore,  immunohistochemical  studies generally do not 
consider cathepsin D an independent prognostic marker (112).
pS2:
Chambon  et  al  (113)  discovered  pS2  protein  produced  by  MCF7  cells  following 
oestrogen  stimulation.  An  immunohistochemical  study  on  178  breast  carcinomas  by 
Dookeran et al (114) found both cytoplasmic and membrane positivity in the majority of 
cases  but  no  relationship  was  found  between  pS2  expression  and  other  established 
prognostic markers including ER, or overall survival.
HORMONAL TREATMENT OF BREAST CANCER:
Hormonal therapeutic agents fall into three broad categories. The first includes drugs such 
as Zoladex, which is a potent gonadotrophin releasing hormone agonist and acts centrally 
to inhibit the release of gonadotrophins from the pituitary by a process of desensitization. 
The  second  category  includes  inhibitors  of  steroid  synthesis,  such  as  the  aromatase 
inhibitor aminoglutethamide, which reduces oestrogen synthesis. The new generation of 
aromatase  inhibitors  include  anastrozole  and  letrozole,  which  are  non-steroidal  and 
exemestane  which  is  a  steroidal  aromatase  inhibitor.  The third  category  includes  anti- 
oestrogens or SERMs (selective oestrogen receptor modulators). SERMs are compounds 
used as therapeutic agents which bind with high affinity to ER and mimic the effects of 
oestrogens in some tissues but act as oestrogen antagonists in others depending on the 
tissue (115). There are two types of SERMs, pure ER antagonist ICI  182,780 (Faslodex) 
and partial ER (ant)agonist tamoxifen. Tamoxifen is the most widely used agent currently 
and acts predominantly by inhibiting the action of oestrogen hormone in its target tissues 
by binding to ER. There is evidence that it stimulates the production of tumour suppressor 
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beta (TGF (3) (116;117), therefore, its mechanism of action is not just via the oestrogen 
receptor.
SUMMARY:
In general, the measurement of ER status and the part it plays in patient management have 
evolved and changed considerably over the years. ER and PR status can now be readily 
assessed on histological  material  and the assay  is therefore available to  any  laboratory 
skilled in immunohistochemistry.  Patients with an ER negative tumour have a less than 
10%  chance  of  responding  to  hormone  treatment  for  advanced  disease.  Thus, 
measurement  of receptors  is  important  in  young  women  who  may  be  considered  for 
treatment by oophorectomy and for women of all ages with rapidly progressing disease 
when  rapid  response  to  treatment  is  essential  and  therefore,  a  trial  of  treatment  is 
inappropriate. Some laboratories have already combined the use of ER with other markers 
such  as  cerbB-2  and  p53  with  the  aim of refining prediction  of response to particular 
treatment  regimes  for metastatic  disease and  in  selecting  suitable  adjuvant therapy  for 
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CHAPTER 6:  DUCTAL CARCINOMA IN SITU OF THE BREAST:
INTRODUCTION:
Ductal carcinoma in situ (DCIS) of the breast is defined as the proliferation of epithelial 
cells with cytological  features of malignancy within ductal  structures of the breast and 
distinguished  from  invasive  carcinoma  by  the  absence  of stromal  invasion  across  the 
basement membrane.
Until recently, DCIS was a relatively uncommon disease, representing only about  1% of 
all newly diagnosed cases of breast cancer (1).  It was usually regarded as a single disease 
entity with a single treatment, namely, mastectomy. With wide use of mammography, the 
number of cases has increased dramatically. DCIS now accounts for 20-25% of detected 
cancers  (2).  Most  patients  with  DCIS  (95%)  now  present  with  clinically  occult,  non- 
palpable  lesions  (3).  Furthermore,  DCIS  is  no  longer  considered  a  single  disease  but 
recognised as a heterogeneous group of lesions with a diverse malignant potential (4-6). 
As  understanding  of the  disease  has  evolved  and  the  range  of treatment  options  has 
widened, the process of making decisions about management has become more complex 
and controversial.  DCIS  has become  so common and  confusing that the  first textbook 
devoted solely to the disorder was not published until 1997 (7).
DCIS  is  frequently  associated  with  invasive  carcinoma  (45%  of  cases)  (8),  is 
conventionally regarded as the principal precursor of invasive breast cancer and is distinct 
from the other putative precursor, lobular carcinoma in situ (LCIS). LCIS is regarded as a 
high risk  factor for development of invasive breast cancer but because it is frequently 
multifocal,  pure  LCIS  without  coexistent  DCIS  is  generally  managed  differently  from 
DCIS.  At  the  2nd  European  Organisation  for  the  Research  and  Treatment  of Cancer 
(EORTC) DCIS consensus meeting in September 1991, it was agreed by the participants 
on the basis of existing evidence that:-
1   DCIS is nearly always unicentric.
2  Detection of DCIS has increased with mammographic screening.
3  Recurrences of DCIS occur almost invariably at the site of previous excision.
4  The incidence of axillary lymph node involvement by metastatic carcinoma in 
DCIS  is  negligible  (<1%),  thus  obviating  the  need  for  axillary  lymph  node 
dissection in cases of pure DCIS.Chapter 6: Ductal carcinoma in situ 91
5  DCIS  was  felt  to  be  heterogeneous,  both  histologically,  radiologically  and 
biologically (3).
The increased use of mammography as a tool for the detection of early breast cancer and 
population  mammographic  breast  screening  has  led  to  an  increase  in  the  detection  of 
ductal carcinoma in situ, particularly small localised lesions (9). This changing pattern of 
disease incidence (in reality disease detection) has highlighted many deficiencies in the 
understanding of DCIS and has produced a new range of problems.  Difficulties arise in 
determining the criteria for diagnosis of DCIS as compared to atypical ductal hyperplasia 
(ADH), LCIS or micro-invasive breast carcinoma (MIC).
Some  subtypes  of DCIS  are  difficult  to  classify  and  rarer  subtypes  of DCIS  can  be 
difficult to recognise and diagnose. Other currently debated topics include the validity of 
pathological  subclassification  systems  for  DCIS,  the  question  of  what  constitutes 
adequate pathological excision margins and the use of molecular markers in DCIS. The 
question of whether DCIS  is a real  ‘cancer’  or better regarded as a marker for patients 
with a high risk of subsequent invasive breast cancer is open (10).  The use of adjuvant 
therapies  (e.g.,  radiotherapy  or  endocrine  therapy)  is  also  an  area  of  considerable 
disagreement  among  experts  and  some  trials  trying  to  answer  these  questions  are 
mentioned later in this chapter (page 114).
HISTORICAL BACKGROUND:
The history of DCIS has been well reviewed by Fechner (10). DCIS was first described 
by Bloodgood in 1893 (11). Subsequently Lewis and Geschickter (12) described comedo 
carcinoma although they did not distinguish invasive carcinoma from in-situ carcinoma. 
Later, lobular cancerisation in DCIS was highlighted by Azzopardi (13). Page et al (14) 
identified cribriform, micropapillary and other types of non-comedo DCIS  as high risk 
factors  for  the  development  of ipsilateral  invasive  breast  cancer.  They  deduced  that 
approximately 28% of women with DCIS could be expected to develop invasive breast 
carcinoma over a period of 15 years if left untreated.
CLINICAL PRESENTATION AND DIAGNOSIS:
DCIS may be categorised on clinical (symptomatic, screening detected, associated with 
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pattern of calcification, parenchymal deformity) or on pathological grounds (microscopic 
size of lesion, margin status, nuclear grade, architecture, cell size, presence or absence of 
necrosis, cerbB-2 expression, oestrogen (ER) or progesterone receptor (PR) expression, 
P53  gene  mutation  or  p53  protein  expression,  the  presence  of associated  lesions).  In 
practice, the optimum combination of these various criteria for patient management is not 
entirely clear.  DCIS  is  not  usually  visible  to  the  pathologist  by naked  eye  inspection, 
unless comedo-type necrosis is present or there is marked periductal fibrosis associated 
with the lesion.
During  1997, more than 36,000 new cases of ductal carcinoma in situ, representing  17% 
of all new breast cancers were diagnosed in the United States (15). Most of these cases 
were diagnosed by mammography.  High quality mammography is capable of finding a 
range  of asymptomatic  non-invasive  lesions  that  cannot  be  palpated.  These  are  often 
smaller,  of low  nuclear  grade,  and  show  much  more  subtle  changes  than  the  lesions 
detected with less advanced mammographic  equipment  in the past.  The most common 
mammographic finding is microcalcification  (80% of cases) (16; 17),  but some lesions 
may  present  as  ill-defined  and  spiculate  or  architectural  distortions  with  or  without 
microcalcifications.  Approximately  25%  of  symptomatic  lesions  are  not  apparent 
radiologically  and  present  with  nipple  discharge,  Paget’s  disease  of the  nipple  or  a 
palpable mass.
Pre-operative  diagnosis  of  malignancy  can  be  achieved  using  fine  needle  aspiration 
(FNA)  cytology  but this  should  be used  as  part  of a  ‘triple  approach’  to  diagnosis  in 
combination with radiological and clinical findings (18). The cytological heterogeneity of 
DCIS  suggests  that  a  definitive  diagnosis  of DCIS  should  not  be  attempted  on  FNA 
cytology alone as it is impossible to discriminate DCIS reliably from ADH and invasive 
carcinomas (19). FNA cytology can be used for assessment of ER, PR and cerbB-2 status.
Some groups have promoted the use of multiple image guided needle core biopsies for 
diagnosis  (20).  Radiographs  of such  biopsies  can  be  taken to  confirm the presence  of 
representative foci of calcification allowing radiological and histological correlation and a 
greater ability to distinguish DCIS from invasive cancer.
Prior to the  advent of FNA  and triple assessment,  intra-operative frozen sections were 
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case immediate mastectomy could be carried out, obviating the need for a second surgical 
procedure.  However, the use of frozen sections is no longer considered necessary in the 
diagnosis  of  breast  lesions  detected  by  screening,  as  margins  cannot  be  adequately 
assessed, thorough sampling of lesions cannot be performed properly to exclude foci of 
invasion,  and  the  pathological  grade  of DCIS  or  invasive  breast  carcinoma  cannot  be 
assessed.
CLASSIFICATION AND PATHOLOGY:
Until recently there was no generally accepted method of classifying DCIS. Traditionally, 
histopathologists  have  classified  DCIS  on  the  basis  of the  intraduct  architecture  and 
cytological features (21) without any evidence of the clinical relevance of this method. 
Most pathologists recognise two major subtypes of DCIS  according to the presence or 
absence of comedo necrosis but there are variable degrees and types of necrosis and their 
significance is debatable.  These two subtypes differ not only in pathologic  features but 
also in clinical presentation, appearance on mammography and malignant potential. The 
comedo  type  of DCIS  is  diagnosed  when  at  least  one  duct  in the  breast  is  filled  and 
expanded by  large,  markedly  atypical  cells  and has abundant central  luminal  necrosis. 
This  necrotic  material  is  usually  partially  calcified  and  may  be  recognised  on 
mammography  as  linear  and  branching  calcifications.  Prominent  periductal  fibrosis  is 
common and may render the lesion clinically palpable. All other forms of DCIS are of the 
non-comedo type and include cribriform, micropapillary and solid types although focal 
necrosis can be seen in these patterns too and different histologic patterns may co-exist. 
This morphologic classification does not account for the marked heterogeneity of DCIS in 
its clinical  behaviour.  Furthermore,  the  reproducibility of this method  of assessment is 
poor.
In April  1997, a consensus conference on the pathology of ductal carcinoma in situ was 
convened in Philadelphia under the auspices of the Breast Health Institute. Although there 
was agreement on a number of basic issues, such as the need to achieve sufficiently wide 
excision  margins,  measure  tumour  extent,  and  note  nuclear  grade,  histological 
architecture,  and  polarization,  consensus  on  a  single  unified  classification  for  ductal 
carcinoma in situ was not achieved (22).Chapter 6: Ductal carcinoma in situ 94
At present, there are several classifications based on histological structure, nuclear grade, 
comedo  type  necrosis,  cytonuclear  differentiation  or  various  combinations  of  these 
factors. Nuclear grade, comedo type necrosis, tumour size and the width of the surgical 
margins  are  all  important  predictors  of the  probability  of local  recurrence  after  breast 
conservation treatment for ductal carcinoma in situ (2;21;23-29).
Many  grading  systems  have  utilized  nuclear  grade  as  the  basis  for  the  histological 
classification of DCIS.  Patchefsky  et al  (4) reported that high nuclear grade  in DCIS 
correlated  with  the  presence  of micro-invasion  and  Lagios  et  al  (26)  found  that  high 
nuclear grade DCIS was significantly associated with the  likelihood of recurrence.  The 
median nuclear area in DCIS is slightly higher than that in invasive breast cancer. Using 
current criteria for diagnosis of DCIS, MOP Kontron image analysis of nuclear area was 
performed on an unselected series of cases of DCIS and invasive breast cancer. Nuclear 
area equated morphometrically to the nuclear grade in DCIS. The mean nuclear area of 65 
cases of DCIS was 47.9pm2 (range 22.5 -  92.9pm2) as compared to 44.4 pm2 (range 22.3 
-  80.3 pm  ) for invasive ductal carcinoma (30).
The prototype system based on nuclear grading was that of Lagios and co-workers (6), 
which sub-classifies DCIS into three grades, namely high, intermediate and low nuclear 
grade. A four point nuclear grading system for DCIS, which also considers the presence 
or absence of comedo type  necrosis,  has been advocated by  Page  and  co-workers  (5). 
Another system utilizing nuclear grade has been proposed by the European Pathologists 
Working Group (EPWG) at the instigation of EORTC  following the 2nd EORTC DCIS 
Consensus meeting (3). This system is based on criteria of Holland et al (31) who have 
subdivided DCIS into poor, intermediate and well differentiated based on cytonuclear and 
architectural differentiation.
The National Co-ordinating Group for Breast Screening Pathology (NCGBSP) UK. (32), 
have  employed  Holland’s  criteria  to  divide  DCIS  into  three  categories  namely  high, 
intermediate and low nuclear grades which are described below. Other systems have been 
advocated by the Edinburgh Group (21), Nottingham Group (33) and Ottensen et al (34). 
The Nottingham system has been further refined (Van Nuys System) (24). The Van Nuys 
classification  (24)  takes  into  account  nuclear  grade  and  necrosis.  The  only  system 
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However, no matter which system is used, histological classification alone is inadequate 
for determining  proper  treatment.  If DCIS  is  truly  a  localized  lesion,  then  meticulous 
margin assessment is far more important than histological sub-classification in predicting 
disease recurrence (35).  In one study, nuclear grades of DCIS correlated  well  with the 
Nottingham prognostic index (NPI) and grades of invasive breast cancer (36).
The following is the classification system recommended by NCGBSP (33) and has been 
utilized in this study:
Low Nuclear Grade (LNG) DCIS:
This is composed of monomorphic, evenly spaced cells with roughly spherical, centrally 
placed  nuclei  and  inconspicuous  nucleoli.  The  nuclei  are  usually,  but  not  invariably, 
small. Mitoses are few and there is rarely individual cell necrosis.
The cells are generally arranged in micropapillary and/or cribriform patterns (figure 6.1) 
the latter is more common and tends to predominate. There is usually polarization of cells 
covering the micropapillae or lining the intercellular lumina. Less frequently, low grade 
DCIS  has  a  solid  growth  pattern.  When  terminal  duct  lobular  units  are  involved,  the 
process can be very difficult to distinguish from lobular carcinoma in situ.  Features  in 
favour  of  DCIS  are  greater  cellular  cohesion,  slightly  larger  cell  size,  cytoplasmic 
basophilia and  lack of intracytoplasmic  lumina.  Occasionally, however, there may be a 
combination of both processes.
Figure 6.1; Photomicrographs of a case of LNG DCIS at different magnifications
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Figure  6.1a;  LNG  DCIS  showing  predominantly  solid  and
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Figure  6.1b;  Same  case  as  in  6.1a,  cells  lining the  intercellular 
lumina show polarization. Magnification x 100
Figure 6.1c;  Same case as in 6.1a, exhibiting monomorphic cells
with  small,  rounded  nuclei  and  inconspicuous  nucleoli.
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Intermediate Nuclear Grade (ING) DCIS:
This group comprises those cases of DCIS, which cannot be assigned easily to the high or 
low  nuclear  grade  categories  (figure  6.2).  The  nuclei  show  mild  to  moderate 
pleomorphism,  which  is  less  than  that  seen  in  high  grade  DCIS  but  they  lack  the 
monotony of the small cell type.  The nucleo-cytoplasmic ratio is often high and one or 
two nucleoli may be identified.
The  growth  pattern  may  be  solid,  cribriform  or  micropapillary  and  the  cells  usually 
exhibit  some  degree  of  polarization  covering  the  papillary  processes  or  lining  the 
intercellular lumina although this is not as marked as in low nuclear grade DCIS.
Figure 6.2; Photomicrographs of a case of ING DCIS at different magnifications
Figure  6.2a;  ING  DCIS  showing  cribriform  and  micropapillary
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Figure  6.2b;  Same  case  as  in  6.1a,  showing  some  degree  of 
polarization covering the papillary processes. Magnification x 100
Figure  6.2c;  Same  case  as  in  6.2a,  the  nuclei  show  mild  to
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High Nuclear Grade (HNG) DCIS:
This is composed of cells with pleomorphic, irregularly spaced and usually large nuclei 
exhibiting marked variation in size, irregular nuclear contours, coarse clumped chromatin 
and prominent, sometimes multiple nucleoli. Mitoses are frequently present and abnormal 
forms  may  be  seen.  A  characteristic  feature  of this  type  of DCIS  is  the  presence  of 
individual necrotic cells and evidence of autophagocytosis.
High nuclear grade DCIS may exhibit several different growth patterns. It is often solid 
with  central  comedo-type  necrosis  (figure  6.3),  which  frequently  contains  deposits  of 
amorphous calcification. Sometimes a solid proliferation of malignant cells fills the duct 
without necrosis but this is relatively rare. High nuclear grade DCIS may also exhibit a 
micropapillary  or  a  cribriform  pattern  frequently  associated  with  central  comedo-like 
necrosis. Unlike low nuclear grade DCIS, there is rarely any polarization of cells covering 
the  micropapillae  or  lining  the  intercellular  spaces.  Calcification  is  frequently  present 
within  the  necrotic  material  and  is  amorphous  in  appearance.  The  involved  ducts  are 
frequently  very  distended  with  extensive  periductal  fibrosis  and  lymphocytic  reaction. 
Cancerization of lobules  is  frequently  present.  Paget’s  disease  of the  nipple  is  almost 
exclusively associated with this type of DCIS.
One of the advantages of classifying DCIS according to nuclear grade is that although 
variations of growth pattern are frequent, there is usually a dominant cell type and the 
lesion  is  fairly easily  classified  into  one  of the  main  groups.  Rarely  cells  of different 
nuclear grades may be seen within a single lesion and the case is then classified according 
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Figure 6.3; Photomicrographs of a case of HNG DCIS
Figure 6.3a; HNG DCIS showing a comedo pattern with necrosis 
at a magnification x 50
Figure  6.3b;  Same  case  as  in  figure  6.3a,  showing  marked
pleomorphism and frequent mitosis at a magnification x 400Chapter 6: Ductal carcinoma in situ 101
Micro -  invasive Carcinoma (MIC):
This is defined as a tumour in which the dominant lesion is non invasive but in which 
there are one or more clearly separate foci of infiltration, none of which measures more 
than 1mm in diameter. Tumours fulfilling these criteria are not common. If there is doubt 
about the presence of invasion, the case should be classified as DCIS as these lesions tend 
to  behave  like  DCIS  rather  than  invasive  carcinoma  (32).  In  one  series  of  115  DCIS 
specimens  (26),  the  overall  rate  of micro-invasion  was  14.7%,  with  an  incidence  of 
micro-invasion of 1.6% in lesions less than 25 mm and 29% in those larger than 26 mm.
Rare Subtypes of DCIS:
A  variety  of  rare  but  morphologically  distinct  subtypes  of  DCIS  is  recognised.  A 
complete account of these is given by Tavassoli (37).
Apocrine DCIS: The tumour cells show abundant granular cytoplasm, moderate to severe 
cytological atypia and central necrosis. Apical snouting (cytoplasmic protrusions) are not 
always seen. The cells may sometimes be highly atypical and no necrosis may be evident
(38).
Encysted papillary carcinoma in situ:  This type is more common in older women and 
carries an excellent prognosis if confined within the capsule without surrounding DCIS
(39). It is usually circumscribed and accompanied by a fibrous wall, giving an encysted 
appearance. It has a papillary structure with fibrovascular cores, which are usually fine.  It 
may  be  accompanied  by  micropapillary  or  cribriform  DCIS.  There  is  also  frequently 
haemosiderin (or haematoidin) pigment in the adjacent fibrous tissue.
Clear cell DCIS: This is a proliferation of cells with optically clear cytoplasm and distinct 
cell  margins  forming  cribriform  structures.  Central  necrosis  may  be  present.  A  solid 
pattern may also be present.
Signet ring DCIS: This is a very rare variant characterised by the proliferation of signet 
ring  cells  in  solid  or  papillary  growth  patterns.  The  cytoplasm  stains  positively  for 
diastase  resistant-PAS  or  alcian  blue  (40)  suggesting  the  presence  of intracytoplasmic 
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Neuroendocrine  DCIS:  This  lesion  has  an  organoid  appearance  with  prominent 
argyrophilia,  resembling  a  carcinoid  tumour.  The  neoplastic  cells  may  be  in  a  solid 
configuration  or  papillary,  forming tubules,  pseudorosettes,  palisades  or  ribbons  (41). 
These  tumours  may  be  truly  neurosecretory  and  produce  neuropeptide  hormones 
including ACTH and adrenaline or noradrenaline.
Cystic hypersecretory DCIS: This is a variant of micropapillary DCIS (42;43). The cells 
produce  mucinous  secretions  which  distend  the  involved  duct  spaces  giving  a  cystic 
appearance.
Male breast DCIS: This is a rare entity with only 90 or so cases reported in the World 
literature and accounting for slightly more than 7% of all male breast cancers in published 
series (44). It typically presents with a retroareolar mass and may require mastectomy.
Atypical ductal hyperplasia (ADH) and DCIS: The current guidelines for the UK Breast 
screening  programme  (32)  define  atypical  ductal  hyperplasia  (ADH)  as  a  rare  lesion, 
often co-existing with fibrocystic change, a sclerosing lesion or a papilloma. The current 
definition rests on identification of some but not all of the features of ductal carcinoma in 
situ.  It  is  commented  in  the  UK  guidelines  that  most  difficulties  are  encountered  in 
distinguishing ADH from low-grade variants of DCIS.  These two  lesions can co-exist. 
The guidelines are in keeping with Page’s view that if cellular changes typical of DCIS 
occupy two separate duct spaces this should be regarded as DCIS, if only one duct space 
is involved, then the lesion should be considered as ADH (14). Others disagree with this 
interpretation.  Tavassoli and Norris (37;45) argue that the overall geometric size of the 
DCIS lesion is more important than the number of duct spaces involved, with a lesion less 
than 2mm in overall size indicating ADH. Staining for alpha-smooth muscle actin, SI00 
protein and cytokeratin (especially CK  5/6 positive cells as they are lost in DCIS) has 
been  suggested  to  be  helpful  in  distinguishing  ADH  from  DCIS  (46).  Similarly, 
antibodies directed against basal and luminal cell cytokeratins can be used to differentiate 
usual type epithelial hyperplasia from DCIS  (47).  Stains for alpha-smooth muscle actin 
can also be useful for the assessment of the presence or absence of microinvasion.
THE NATURAL HISTORY OF DCIS:
DCIS has been shown to arise within the terminal duct lobular units (TDLU) of the breast 
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DCIS  (52).  The adult breast comprises 20 or more developmentally derived  segments, 
which extend from the nipple radially outwards to the pectoralis fascia (see Chapter  1, 
figure  1.1).  The  TDLU  connects  anatomically  via  intralobular  terminal  ducts  to 
extralobular terminal ducts, subareolar ducts and then to the nipple. The current belief is 
that  DCIS originates  in the  terminal  ducts  and  acini  of the  breast,  grows  and  expands 
these ducts until, at a certain stage in its natural history, it develops invasive properties 
and penetrates the basement membrane.  Autopsy based studies have demonstrated that 
15%  of young  asymptomatic  women  may  have  DCIS  (53;54).  The  lifetime  risk  of 
development of invasive breast cancer of between  1   in  8 and  1   in  12 in North America 
and Europe is consistent with these autopsy findings.
Using a three dimensional reconstruction technique, the serial sub-gross method of Egan 
and similar stereomicroscopic techniques, the distribution of DCIS has been mapped by 
Holland et al (49;50) as well as Faverly and co-workers (51;55). These studies show that 
the majority of cases of DCIS exist as a single lesion,  6 6 % of which are in one quadrant 
(49;50) and that DCIS should, therefore, be regarded as a unicentric disease process. The 
growth of DCIS  is  segmental  and not multicentric.  Poorly  differentiated DCIS  (HNG) 
grows continuously and well differentiated DCIS (LNG) has a multi-focal growth pattern.
The view that DCIS is a single clonal process is further supported by the observation that 
in 12 cases of DCIS which were apparently multi-focal, all showed loss of heterozygosity 
(LOH) at the same chromosome locus implying that the foci of DCIS were derived from 
the same clone (56). Micro-dissection studies have shown LOH on chromosome  16 and 
17  in both ADH and DCIS  (56-60)  suggesting that ADH  is also part of the neoplastic 
spectrum of breast disease. It has been suggested that some forms of atypical hyperplasia 
undergo clonal evolution to DCIS and then to invasive cancer (61). This is supported by 
cytogenetic (56-60;62;63) and oncogene abnormalities discovered in DCIS, as well as by 
microscopic  findings  (5).  A  diagnosis  of ADH  indicates  an  approximately  four  fold 
increased risk for the development of invasive breast cancer (64;65).  The incidence of 
invasive breast cancer after incisional biopsy showing DCIS has been reported as ranging 
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MOLECULAR BIOLOGY OF DCIS: 
Experimental Models of Breast Neoplasia:
Mice  infected  with  the  mouse  mammary  tumour  virus  (MMTV)  show  lesions 
morphologically  identical  to  those  seen  in  ADH/DCIS.  Transgenic  mice,  which 
overexpress the Gi phase associated cell cycle protein, cyclin D1  (also known as PRAD- 
1)  show  breast  abnormalities  with  epithelial  hyperplasia  and  development  of invasive 
breast tumours (71). Similar tumour models have been described for cerbB-2 (72).
Interphase Cytogenetics:
Invasive breast cancer or breast carcinoma cell lines:
Documented abnormalities identified in invasive breast carcinoma include deletions (del) 
of Chr  lp l3-36,  del  Chr  3pl4-23,  del  Chr  6q21-27  and  del  Chr  16q21-24  (73)  and 
amplification  of Chr  lq21,  8pl2,  8q24,  10q22,  llql3,  13q21,  13q31,  17qll,  17ql2, 
17q23,  17q24  and 20ql2-13.2  in breast carcinoma cell  lines (74).  Genes  implicated in 
breast cancer corresponding to these amplified chromosomal band regions include cerbB- 
2  (17ql2),  myc  (8q24),  FGFR1/FLG  (8pl2),  FGFR2/BEK  (10q26),  PRAD-1/CYCD1 
(1 lql3),  IGFR  (15q24-25).  Further  details  of  these  genes  have  been  discussed  in 
Chapter 3.
DCIS and ADH:
The  cytogenetic  abnormalities  present  in  DCIS  and  ADH  have  not  yet  been  clearly 
defined.  One  fluorescent  in  situ  hybridization  (FISH)  study  (62)  described  true  gains 
(aneuploidy) of Chr 1, Chr 17 and Chr 18 using pericentrometric probes for chromosomes 
1,16,17, 18. Loss of heterozygosity in DCIS and ADH has been shown for chromosomes 
16 and 17 (56-58). One other report also identified LOH in DCIS at Chr 3p, Chr 7q, Chr 
16q and Chr  17p.  A higher tumour proliferation  fraction in DCIS  was associated  with 
LOH  at  17pl3.3  and  3p24-26  (63).  Leal  et  al  (75)  determined  aneuploidy  by  image 
analysis and observed this in 77.5% of DCIS cases mainly in the high and intermediate 
grade subtypes.
One  study by  Page  et al  has  looked at BRCA-1  in 3  cases of DCIS,  while  in another 
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20% of informative  cases  of DCIS  studied  (76).  Munn  et  al  (77)  found  LOH  for the 
BRCA1 gene in 74% of DCIS.
Oncogenes and Other Tumour Associated Proteins in DCIS: 
Growth Factor Receptors and Growth Factors:
CerbB-2  (HER-2/neu):  The  reported  incidence  of cerbB-2  expression  of DCIS  in the 
literature is 45-60 percent. CerbB-2 gene amplification and cerbB-2 protein expression is 
more frequent in high and intermediate nuclear grades of DCIS and those with comedo- 
type necrosis than in low nuclear grade and non-comedo DCIS. This observation was first 
reported in 1988 (78) and has subsequently been identified by others (30;79-89). CerbB-2 
gene  amplification  in  DCIS  has  been  confirmed  by  the  differential  polymerase  chain 
reaction (PCR) technique in  13  (48%) of 27 cases of pure DCIS  included in a study of 
both in situ and invasive breast carcinoma (8 8). CerbB-2 expression is very common in 
Paget’s disease of the breast (90-93), reported incidence being 91  percent. At least some 
cases of invasive ductal  carcinoma that express cerbB-2  seem to  be derived from pre­
existing DCIS (94).
EFGR (cerbB-lL cerbB-3. cerbB-4:  Only limited studies are available on these growth 
factor  receptors  and  there  is  at  present  insufficient  evidence  for  them  having  any 
significant role in DCIS. In one study, cerbB-3 was shown to have an inverse correlation 
with cerbB-2, whereas no correlation was demonstrated between cerbB-3 positivity and 
type of DCIS, p53 and PR expression and proliferative activity (95).
TGF-pi:  In  a  study  reported  in  the  literature,  12  of 27  cases  of DCIS  showed  some 
expression of TGF-pi, with prominent immunohistochemical expression in 3 cases (96).
Cell Cycle Associated Genes and Proteins:
P53: The p53 protein is preferentially expressed in high nuclear grade DCIS and in cases 
of DCIS with comedo-type necrosis (80;87;97-103). The mechanism of this may be gene 
mutation,  although  one  study  (99)  was  unable  to  demonstrate  P53  gene  mutations  at 
exons 5 and 6 , and only one case out of 39 (3%) showed mutation in exon 8 of P53 gene 
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analysis (SSCP). Stabilisation of non-mutant p53 protein causing p53 protein expression 
or mutations in other exons of P53 may explain this finding.
Another study of P53 by SSCP or southern Blot which included 10 cases of DCIS found 
P53  mutations  in  2  of  17  (12%)  intraductal  carcinomas  or  carcinomas  with  a 
predominantly  intraductal  component  (103).  Conservation  of P53  mutations  has  been 
demonstrated in the progression of DCIS to invasive disease (98).
Rbl: Deletions of Rbl  in tumours with a 90% DCIS component have been described in 
one study (104).
Bcl2: Expression of bcl2 occurs at a higher frequency in in-situ than invasive carcinomas 
(105). Furthermore, bcl2 expression correlates inversely to worsening nuclear grades of 
DCIS that is from low to high nuclear grade (106).
Bax:  Bax  expression  has  been  detected  in  37/56  (6 6%)  of  DCIS  after  employing 
immunohistochemistry for its detection. It did not correlate to histological grades of DCIS 
or other molecular markers including Ki67, ER, p53 or cerbB-2. Positive correlation was 
seen with bcl2 (107).
Cvclin Dl:  Overexpression of cyclin D1  is present in 90% of malignant breast lesions, 
both DCIS and IDC (108).
p21 ras: A study by Going et al described how 14 cases of non invasive breast carcinoma 
showed  a progressive  increase  in  p2 1  ras  immunostaining  at  the  transition  of normal 
epithelium to ADH and carcinoma in situ suggesting a putative role for p21  in disease 
progression (109).
Steroid Hormone Receptor and Related Proteins:
Oestrogen Receptor (ER): The literature suggests that ER expression is more common in 
lower nuclear grade and non-comedo variants of DCIS, although there is disagreement as 
to  the  exact  overall  frequency  of ER  expression  in  DCIS.  The  rate  of ER  positivity 
depends  upon  the  grade  mix  and  method  of  detection.  In  one  study  (110), 
immunohistochemically  demonstrated  ER  expression  was reported  in  32%  of cases  of 
DCIS overall and positive tumour ER staining was related to non-comedo types of DCIS, 
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staining. Other studies have found ER expression in a higher proportion of cases of DCIS 
(80;87;111-116). Burr et al (116) found ER expression in 91% of non-comedo DCIS and 
57% of comedo DCIS.
Progesterone  Receptor  (PR):  The  frequencies  of positivity  range  from  31%  to  73% 
(80;87;115). In a study by Murphy et al, PR positivity was reported in 46% of cases using 
an immunohistochemical method with microwave antigen retrieval (117).
pS2: It has been reported that pS2 expression is more frequent in the extensive intraductal 
component of invasive carcinomas, being present in 54% of cases, in contrast with 27% 
for  invasive  carcinomas.  The  frequency  of pS2  expression was  greater in non-comedo 
than comedo DCIS  (118).  Another study  showed intensive pS2  expression in comedo, 
solid, cribriform and micropapillary DCIS with significant positivity in 63-67% of cases. 
A progressive increase in pS2 expression from normal breast tissue to malignant disease 
was proposed (119).
Stromolvsin 3:  Stromolysin 3  expression has been examined in DCIS by Northern Blot 
analysis. Stromolysin 3 either was not found or only a trace level of expression was seen 
in 9 of 10 (90%) cases of DCIS compared with 62% of primary invasive or metastatic 
breast carcinomas (1 2 0).
Metallothioneins:  Expression of metallothioneins is associated with high-grade comedo 
DCIS  with necrosis. No  evidence  of p53  or metallothioneins  co-expression was  found 
using immunohistochemistry (1 2 1).
Metastasis Suppressor Proteins:
NM23:  NM23  is  a  nucleoside  diphosphate  kinase  gene  product.  Its  expression  was 
examined in two separate published studies reporting conflicting results (122; 123). One 
of these reported greater expression of NM23 gene product in comedo DCIS as compared 
to  non-comedo, the other described opposite  results.  Allelic  loss of NM23Hi  has  also 
been described in another study of invasive tumours with a 90% DCIS component (104).
Cell Adhesion Molecules:
Pi and Ba integrins: A study described by Hanby et al, looked at the pi and p4 integrins in 
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with  the  suggestion  made  that  loss  of the  pi  integrin  chain  might  be  important  in 
malignant progression (124).
Intercellular Adhesion Molecule -   1   (ICAM-1): A study by Bacus et al (125), described 
that  in  39  cases  of invasive  breast  cancer,  a  significant  association  was  found  with 
expression of the ICAM-1  in those cases of invasive carcinoma which had a prominent 
DCIS component.
Glutathione-S-transferase Pi (GST Pi): Bellamy et al (126) reported that 37 of 92 (40%) 
of DCIS cases were GST Pi positive. No correlation with histological variables, cerbB-2 
expression or clinical outcome was found. Furthermore, there was no evidence that GST 
was a useful marker of prognosis in DCIS.
Angiogenesis:
Guidi et al (127), reported on 55 cases of DCIS, in which a diffuse pattern of increased 
micro-vessel density was associated with comedo necrosis, stromal desmoplasia, positive 
cerbB-2 expression, an increased proliferation fraction as assessed by KiSl  staining and 
the presence of lobular cancerisation.  Two patterns of angiogenesis were  identified,  a 
diffuse increase of micro-vessels in the stroma surrounding lesions which correlated with 
comedo-type  necrosis  and  micro-vessels  in  immediate  apposition  to  the  basement 
membrane of involved spaces in a “cuffing pattern”, which did not correlate with any of 
the  above  factors.  Another  study  of six  cases  of pure  DCIS  and  49  cases  of DCIS 
associated with invasive breast carcinoma showed no correlation with histological type or 
nuclear grade of DCIS and angiogenesis, although there was less angiogenesis in benign 
proliferative lesions than in DCIS (128).
Proliferation Fraction:
Cases of DCIS with high nuclear grade and with comedo-type necrosis show high cellular 
proliferation  fractions  as  assessed  by  Ki67/MIB1  staining  of tumour  nuclei,  S-phase 
estimation using flow cytometric  analysis of DNA,  or by thymidine  labelling or other 
indices of cell proliferation (30;33;80;82;87; 129-131).
To conclude, although some molecular genetic data support the hypothesis that invasive 
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prove and more work needs to be done to help understand the relation between DCIS and 
IDC and the crucial progression step of one from the other.
MANAGEMENT OF DCIS: 
Mastectomy versus Conservation:
For  many  years,  the  standard  treatment  for  most  patients  with  DCIS  has  been 
mastectomy. Although mastectomy is clearly an over-treatment for many cases, it results 
in an extremely low local recurrence rate and mortality from breast cancer with nearly 
100%  cure  rates  (1;23).  During  the  last  10  to  12  years,  interest  in  breast  conserving 
surgery  for  patients  with  DCIS  has  been  considerable.  Data  from  the  SEER  Study 
(Surveillance, Epidemiology and End Results) showed that survival rates for women who 
had mastectomy and those who had lumpectomy or other breast conserving surgery, were 
the same or better than those expected for the general population (132). The size of the 
lesion  determines  whether  breast  conservation  is  technically  feasible  or  not,  the 
alternative  being  mastectomy  with  or  without  breast  reconstruction.  Lesion  size  is 
assessed by a combination of radiological and pathological factors.  Most workers agree 
that DCIS greater than 25 mm in microscopic size is less amenable to breast conservation 
(lumpectomy) than smaller lesions.
At  present  histological  subtypes  of  DCIS  alone  cannot  be  taken  into  account  for 
management  decisions  until  more  substantive  evidence  from  large  randomised  trials 
becomes available. A small, aggressive looking lesion (HNG) may be adequately treated 
by  excision  alone  if  the  margins  are  widely  clear,  whereas  a  large,  seemingly 
unaggressive (LNG) lesion with an excision margin that is not clear may be better treated 
by  mastectomy  and  immediate  reconstruction.  Clearly  other factors,  in  addition to the 
morphological appearance, must be considered when planning treatment (25;28).
Excision Alone versus Excision plus Radiotherapy -  Protocol B-17:
There is a significant amount of published literature on DCIS treated by breast excision 
without radiotherapy (14;26;133-141) or with radiotherapy (133;137-139;142-151). One 
prospective randomised trial (139) known as “Protocol B-17”, performed by the National 
Surgical Adjuvant Breast and Bowel project (NSABP) in the United States has addressed 
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study more than 800 patients with DCIS that had been excised with clear surgical margins 
were randomised to two groups, excision only and excision plus radiotherapy. After eight 
years of follow-up, a significant decrease in local recurrence of DCIS and IDC was seen 
in the patients treated with  radiotherapy.  The  overall  local  recurrence  rate  for patients 
treated with excision alone was 27% at eight years. For patients treated with excision plus 
irradiation,  it  was  12%  at  eight  years  (152).  Radiotherapy  resulted  in  a  significant 
decrease in subsequent non-invasive DCIS as well as IDC.
Protocol B-17 has been criticised on a number of counts,  including lack of analysis of 
different pathological subsets, lack of size measurements in more than 40% of cases in 
the  initial  pathological  report,  lack  of  mammographic-pathological  correlation  or 
specimen radiography, no uniform guidelines for tissue processing or size estimation; and 
the author’s definition of what constitutes a clear excision margin (153;154). However the 
trial was designed more than 15 years ago, when researchers were asking a single broad 
question ‘does radiotherapy benefit patients with DCIS treated with breast conservation?’ 
It  was  not  designed  to  answer  the  more  sophisticated  questions,  which  are  asked 
nowadays namely  ‘exactly which subgroups of patients may benefit from radiotherapy 
and  by  how  much?’  Radiotherapy  is  expensive  and  in  a  few  cases  is  followed  by 
significant side effects, such as cardiac toxicity and pulmonary fibrosis (155). It changes 
the texture of the breast making mammographic follow-up more difficult, and may result 
in delayed diagnosis if there is a recurrence. Doctors must be satisfied that the benefits of 
radiation in terms of improved survival ffee of recurrence are greater than the side effects, 
complications, inconvenience and costs.
Current Approaches:
Current  treatment  for  DCIS  ranges  from  simple  tumour  excision,  to  various  forms  of 
wider  excision  (segmental  and  quadrant  resections),  to  mastectomy  with  or  without 
reconstruction.  All  treatments  less than mastectomy  may  be  followed by  radiotherapy. 
The  patient’s  preference  is  also  taken  in  to  account  when  planning  management, 
therefore, no single approach is appropriate for all forms of the disease and treatment for 
each patient is individualised.  If untreated, low nuclear grade DCIS may never cause a 
clinical problem since only about 40% of untreated low-grade lesions become invasive 
over a time span of approximately 20 to 30 years (156). A helpful guide in management 
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Van Nuys Prognostic Index:
As already mentioned, two of the prognostic factors in DCIS, namely, nuclear grade and 
comedo-type necrosis were used to develop the Van Nuys pathological classification (24). 
However, these two factors are inadequate as the sole guidelines in the treatment selection 
process,  tumour  size  and  margin  width  also  being  important  (28).  The  Van  Nuys 
prognostic index has been developed by combining all of these factors (25; 157). Scores 
from  1  to 3 are given for each of the three different predictors of local breast recurrence 
(size of the tumour, width of the surgical margins and pathological classification).  The 
scores for each predictor in each individual patient are combined to yield a total  score 
ranging from a low of 3 (best prognosis) to a high of 9 (worst prognosis). Patients can be 
divided into three subgroups on the basis of their score (3-4, 5-7, 8-9). The probability of 
local recurrence is significantly different for each subgroup.  Patients with scores of 3-4 
can  be  considered  for  treatment  with  excision  only  as  it  has  been  shown  that  these 
patients show no difference in survival free of local recurrence at  1 2 years regardless of 
whether they have had radiotherapy (25). Patients with scores of 5-7 show a significant 
decrease in local recurrence rates with radiotherapy. Patients with scores of 8-9, if treated 
conservatively,  can  have  unacceptably  high  local  recurrence  rates,  regardless  of 
irradiation  treatment,  and  should  be  considered  for  mastectomy.  The  Van  Nuys 
prognostic index is a numerical algorithm based on tumour features and recurrence data 
from a large series of patients with DCIS.  It allows quantification of prognostic factors 
that are easily measured and the placing of patients into one of three clearly defined risk 
groups and thus can help with treatment planning.  However, the Van Nuys  Prognostic 
Index  was  developed  in  a  retrospective  study  and  ideally  should  be  validated 
prospectively before serving as the basis for treatment recommendations. Therefore, there 
remains  a  clinical  need  for  an  accurate  and  reliable  prognostication  system  for  DCIS 
(158).
Axillary Node Management:
There is now uniform agreement that for patients with DCIS, there is no need to treat the 
axilla as the incidence of axillary node metastasis in DCIS  is very low (159; 160). For 
patients with large enough lesions to require mastectomy, a sentinel lymph node biopsy 
(SLNB) can be performed using a vital blue dye, a radioactive tracer, or both at the time 
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node can then be evaluated by haematoxylin and eosin (H&E) staining and if such routine 
stains are negative it can be followed by immunohistochemical  staining for cytokeratin. 
Whether the significance of a microinvasive focus shown by immunostaining is the same 
as  a  larger  metastasis  detected  on  H&E,  is  not  clear.  However,  in  the  case  of node­
negative  IDC,  occult  axillary  LN  metastases  are  considered  to  be  of  no  prognostic 
significance (chapter 2 ).
If invasion is documented in the mastectomy specimen, and is greater than 1  mm, then the 
lesion is no longer considered as DCIS but rather an invasive cancer with an extensive 
intraductal component (EIC).  The  lesion size under the circumstances is the maximum 
diameter of the largest invasive focus and not the diameter of DCIS.
Margin Width:
The most crucial information pathologists can currently provide is the accurate evaluation 
of  the  surgical  margin  status.  An  adequate  pathologic  evaluation  requires  proper 
orientation of the specimen during handling by the pathologist. In order to ensure this, the 
surgeons  usually  mark  the  specimen.  The  entire  surface  of the  specimen  is  inked  to 
facilitate  microscopic  recognition  of the  surgical  edges.  Margin  width  is  the  distance 
between DCIS and the closest inked margin and reflects the completeness of excision. 
Since DCIS is a non-invasive unicentric lesion, complete excision should produce a cure. 
Currently, the best way to assess completeness of excision is by determining the margin 
width.  When  the  margin  width  exceeds  10  mm,  the  likelihood  of residual  disease  is 
relatively  small  (164).  There  is  little  benefit  from  radiotherapy  after  excision  of the 
carcinoma if the margins are greater than  10 mm (165), regardless of the nuclear grade 
(166) or the presence of comedo-type necrosis (167).
Researchers  from Nottingham  (168)  have  reported  a  local  recurrence  rate  of 6 %  in  a 
group of 48 patients treated with excision alone and with the margins greater than 10 mm. 
These results were updated by Blarney et al at the fourth Consensus Conference of the 
European Organization for Research and Treatment of Cancer (EORTC) held in  1998. 
They described how 20 mm or more is a ‘clear’  margin, with  10-20 mm indicating an 
‘uncertain’  margin  status  and  less  than  1 0  mm  an  ‘incomplete’  tumour  excision 
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Adjuvant Therapy:
Opinions about the relative merits of adjuvant radiotherapy or tamoxifen treatment vary. 
Organisations  such  as  the  UKCCCR  (United  Kingdom  Co-ordinating  Committee  on 
Cancer Research) under the auspices of the UK National Breast Screening Programme, 
The  European  Organisation  for  Research  and  Treatment  of  Cancer  (EORTC), 
Scandinavian  Groups  and  the  National  Surgical  Adjuvant  Breast  and  Bowel  Project 
(NSABP) have instituted randomised clinical trials.  The early results from the NSABP 
trial (139) indicate that,  with a median 3.5  years  follow-up of 818 patients, the rate of 
local recurrence of DCIS is lower in patients treated with local excision and radiotherapy 
(15.6%) as compared with local excision alone (26.2%). Approximately half the tumour 
recurrences were as invasive carcinoma in the excision alone group while only 28% of the 
tumour recurrences  were  invasive  in the  excision  and  radiotherapy  group.  The  results 
were similar to these when the patients were followed-up for a further time period, up to a 
total of eight years (152). Similarly, the EORTC DCIS study has shown (174) that post­
operative radiotherapy for DCIS reduces both invasive and non-invasive recurrences in 
the  ipsilateral  breast.  However,  unlike  NSABP-B17,  the  EORTC  study  showed  an 
increase number of contralateral breast cancers in patients randomised to receive adjuvant 
radiation.
Trials with tamoxifen as adjuvant therapy are also underway at present. Two studies have 
tried to evaluate the role of tamoxifen in the management of DCIS. The NSABP-B24 trial 
is  comparing  tamoxifen  with  placebo  after  breast  conserving  therapy  (171)  and  a 
European study  (UKCCCR-DCIS  Phase  III-90001)  is comparing tamoxifen alone with 
tamoxifen and radiotherapy (172). The UKCCCR published their results in the Lancet in 
July 2003  of a randomised controlled trial enrolling  1701  patients (171).  They showed 
that  tamoxifen  reduced  the  recurrence  of  ipsilateral  DCIS  but  not  invasive  disease 
whereas  radiotherapy  reduced  the  incidence  of ipsilateral  invasive  disease  as  well  as 
ipsilateral DCIS. There was no reduction in the incidence of contralateral disease.
OUTCOME AFTER RECURRENCE:
The local recurrence rate for DCIS is 10-15%, but it depends on the length of follow-up. 
Retrospective studies have indicated a recurrence rate of 22-30% without RT and 8-15% 
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DCIS are as invasive breast cancer (15;23;27) and nearly all of them occur in the region 
of initial biopsy in the ipsilateral breast (131 ;136). A study by Solin et al (173; 174) has 
reported  on  272  patients  with  DCIS;  42  patients  (15.4%)  developed  recurrence  after 
excision and irradiation, 45% of which were DCIS and 55% were invasive carcinoma. Six 
of these  42  patients  subsequently  developed  metastatic breast cancer.  Forty  percent of 
these recurrences occurred between 5-10 years after treatment and 12% after 10 years. In 
another study by Silverstein et al (175) of a series of 707 patients, there were 74 (10%) 
recurrences, 39 of which (53%) were non-invasive and 35 (47%) were invasive. All of the 
patients with non-invasive recurrence did well. None developed distant disease and there 
were no deaths from breast cancer.  Among the 35 patients with an invasive recurrence, 
half presented  with  stage  I  disease  and  the  other half with  stage  2A  or higher.  Seven 
patients developed distant disease and five died of breast cancer.  The median follow-up 
for the 35 patients with invasive recurrences was 9.3 years. The chances of an invasive 
recurrence at eight years were 7% and the probability of death from breast cancer was 
1.4%.
The treatment for a patient with an invasive recurrence should be based on the stage of 
the recurrence. Patients treated initially by mastectomy generally require excision of the 
recurrence  followed  by  radiotherapy  to  the  chest  wall  and  chemotherapy.  Patients 
previously treated by excision and radiotherapy generally require mastectomy, followed 
by  chemotherapy  if the  invasive  recurrence  is  high  grade,  or  greater  than  1 0  mm  in 
diameter,  or the  markers  are those  of a poor prognosis.  Patients  previously treated by 
excision  alone  can  undergo  re-excision.  If  clear  margins  are  obtained,  they  can  be 
considered  for  breast  conservation  with  radiotherapy.  The  decision  to  add  adjuvant 
chemotherapy should be based on tumour prognostic factors. Patients treated with breast 
conservation surgery should be followed-up closely, perhaps with physical examination 
every six months and a mammogram every six to twelve months.
SUMMARY:
The  incidence  of DCIS  is  increasing  and  the  disease  is  diagnosed  in  an  increasing 
proportion of asymptomatic patients. DCIS is a heterogeneous pathological process. With 
the use of more refined molecular analysis, the relation of DCIS to  IDC  can be better 
defined.Chapter 6: Ductal carcinoma in situ 115
Until recently, our approaches to DCIS have been based on its morphology rather than its 
aetiology.  The  focus  of investigation  is  now  shifting  to  the  genotype  rather  than  the 
phenotype of carcinomas.  Morphologically  normal  looking tissue  surrounding areas  of 
DCIS may show LOH similar to that in the tumour. It is highly likely that genetic changes 
precede morphological evidence of malignant transformation. Medicine must learn how 
to recognise these genetic changes, how to exploit them, and how to prevent them. DCIS 
is a lesion in which the complete malignant phenotype of unlimited growth, angiogenesis, 
invasion and  metastasis  has  not  been  fully  expressed.  With  sufficient time,  most  non- 
invasive lesions will develop the ability to invade and metastasise (6 6 ).  We must learn 
how to prevent this.
The goal in the treatment of patients with DCIS  is to control  local disease and prevent 
subsequent  development  of invasive  cancer.  Breast  conserving  therapy  is  an  effective 
option  in  the  management  of  DCIS.  The  use  of  radiotherapy  after  lumpectomy 
significantly  decreases  the  rate  of recurrence.  Axillary  lymph  node  dissection  is  not 
routinely  recommended  in  the  management  of  DCIS.  There  is  no  defined  role  for 
hormonal  therapy  at  present.  Most  patients  with  recurrent  disease  can  be  treated 
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CHAPTER 7:  MATERIALS AND METHODS:
HYPOTHESIS:
DCIS  grades  are  not  only  morphologically  different,  but  are  also  biologically  and 
chemically  distinct  entities  as  well  and  this  may  be  reflected  in  molecular  marker 
expression  and  chemical  structural  differences.  The  nuclear  grades  of  DCIS  are 
biologically  related to  grades  of IDC.  Bax  protein  may  play  a role  in pathogenesis  of 
breast cancer.
AIMS AND OBJECTIVES OF THE STUDY:
The main aims and objectives of the study were:
1-  To determine the clinical  relevance of the DCIS classification based on nuclear 
grades  and  that  recommended  by  NCGBSP  (1),  by  correlating  the  different 
nuclear grades of pure  DCIS with established  markers of prognosis in invasive 
ductal carcinoma (IDC) of the breast. These established markers of prognosis are 
bcl2, cerbB-2, p53, ER and Ki67.
2-  To compare the expression of the above mentioned molecular markers in the three 
DCIS  grades  versus  three  IDC  grades,  to  see  if any  of these  markers  would 
reliably distinguish between DCIS  grades,  IDC  grades,  and between DCIS  and 
IDC. This would help in understanding the pathogenesis of the disease. The DCIS 
grades have not been compared against IDC grades directly in terms of molecular 
marker expression in any previous study.
3-  To investigate bax protein expression in DCIS and to correlate it to DCIS grades 
and  other molecular  markers.  There  is  very  little  information  available  on bax 
protein  expression  in  DCIS.  For  the  above  three  objectives, 
immunohistochemistry was employed.
4-  To determine if dividing DCIS into three nuclear grades on the basis of nuclear 
area  measurement  by  image  analysis  correlates  with  manual  grading  by  light 
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5-  To amplify exons 5-8 of P53 gene in DCIS and IDC cases by polymerase chain 
reaction (PCR) and subsequently to analyse these cases by direct sequencing in 
order to determine the incidence of P53 mutation in DCIS  and compare  it with 
that in IDC. There is little data available on P53 mutations in DCIS.
6 -  To  find out  if structural  characterization by  Fourier Transform  Infrared  (FTIR) 
and  FT-Raman  spectroscopic techniques can  distinguish  between  DCIS  grades, 
IDC grades, and between DCIS and IDC as whole groups. Again, there is scanty 
data on FTIR in DCIS grades and IDC grades.
MATERIALS:
This  is  a  retrospective  study  performed  on  breast  carcinoma  cases  at  the  Royal  Free 
Hospital.  Suitable  cases  were  selected  by  searching  on  the  Royal  Free  Hospital 
Histopathology Department database (SNOMED Diagnostic Retrieval  System) with the 
SNOMED  T  codes  for  the  breast  and  the  appropriate  M  codes  for  DCIS,  IDC  (LN 
negative),  IDC  (LN positive) and the corresponding lymph nodes containing metastatic 
tumour.  The  data retrieved  included  the  patient’s  name,  date  of birth  (DOB),  hospital 
number and  laboratory  number.  In  order to  ensure  confidentiality,  laboratory  numbers 
rather than patients’ names have been used. A total of 3-25 blocks per case were reviewed 
and cases were selected according to availability of enough tumour tissue. Haematoxylin 
and eosin (H&E) stained histological archive slides of selected cases were reviewed by 
light  microscopy  to  confirm  the  pathological  features  and  select  a  suitable  block  for 
further study.  In case of any disparity between personal observations and the recorded 
pathological diagnosis, clarification was obtained with a specialist pathologist (JC) at a 
conference microscope.  Histological reports of the cases were used along with medical 
records  in order to  access  further clinical  details.  Thereafter,  all research records were 
kept  separate  from  clinical  records  to  safeguard  individual  subjects  under  the  Data 
Protection Act. This study was performed before the Pearson report on Alder Hey and the 
Caldicott report on patient confidentiality.
Formalin-fixed, paraffin-wax embedded blocks of the selected cases for 1985-1995 were 
retrieved  from the  archives  of the  Histopathology  department,  Royal  Free  Hospital.  A 
total of 118 samples from 103 patients was studied for bcl2, Ki67, ER, p53 and cerbB-2 
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-ive),  15  IDC  (LN +ive) and the  15  corresponding lymph nodes containing metastases 
from the same patients as in the previous group. This is shown in table 7.1  which also 
gives details of the number of cases in different subgroups within these categories.
Table 7.1; Cases studied for bcl2, Ki67, ER, p53 and cerbB-2
Group I
(DCIS)
Group 11 
(IDC, LN -ive)
Group III 
(IDC, LN -Mve, any grade)
Group A Group B Group C Group D Group E Group F Group G Group H
LNG
n=18
ING
n=!7
HNG
n=15
G I 
n=6
G 1 1  
n=20
GUI
n=12
IDC
n=I5
Lymph Node 
Metastasis 
n=15
Total = 50 patients Total = 38 patients
Total = 30 samples from 
15 patients
Total = 118 samples from 103 patients
Within  these  118  samples,  30  normal  breast  tissues  adjacent  to  IDC  and  24  DCIS 
associated with IDC were also studied, making a total of 172 samples.
Out  of the  118  samples,  94  were  studied  for bax.  These  94  specimens  were  from  81 
patients and included 32 DCIS, 36 IDC (LN-ve),  13 IDC (LN+ve) and 13 corresponding 
lymph  nodes  from  the  same  patients  as  in  the  previous  group.  This  is  shown  in 
table 7.2 which includes numbers in subgroups.
Table 7.2; Cases studied for bax
Group I
(DCIS)
Group II
(IDC, LN -ive)
Group III 
(IDC, LN -Mve, any grade)
Group A Group B Group C Group D Group E Group F Group G Group H
LNG
n=12
ING
n=10
HNG
n=10
GI
n=6
G1 1
n=19
Gill 
n=l 1
IDC
n=13
Lymph Node 
Metastasis 
n=13
Total = 32 patients Total = 36 patients Total = 26 samples from 
13 patients
Total = =  94 samples from 81 patients
DCIS  cases  (Group  I)  were  only  included  in  the  absence  of any  associated  invasive 
component (pure DCIS) in either the diagnostic biopsy material or in the tissue removed 
as part of a second stage definitive treatment procedure and also in the absence of past 
history  of breast  carcinoma  in  either  ipsilateral  or  contralateral  breast.  All  group  II 
patients  were  either  clinically  or  histologically  proven  lymph  node  negative.  ThisChapter 7: M aterials and methods 119
highlights the fact that in spite of a meticulous search for histologically negative lymph 
node cases, it was not possible to have a histological proof in all cases of group II.  As 
there can be high clinical false negative rate in the final analysis when LN negative cases 
were compared against the LN positive cases, analysis was performed twice.  Once with 
total  numbers  of LN  negative  cases  and  then  with  histologically  proven  LN  negative 
cases against LN positive.
After selection of appropriate paraffin-wax  blocks,  cutting of histological  sections was 
performed  with a microtome at 3 pm thickness,  taking an appropriate number of serial 
sections from each block to correspond with the number of markers to be stained as well 
as  including  sections  for  negative  controls,  and  one  section  from  each  block  for 
haematoxylin and eosin (H&E) staining.  Sections from appropriate positive control wax 
blocks were also cut.  Tissues used as positive controls are shown in table  7.3  on page 
125, negative controls were provided by omission of primary antibody.
All the sections were mounted on 3-aminopropyl-triethoxysilane  (APES) coated  slides, 
the  preparation  of which  is  described  in  appendix  1.  Sections  were  then  incubated 
overnight at 37°C and stored until staining could be performed in batches. Haematoxylin 
and eosin staining was done on one section from each block and staining for each marker 
was  performed  by  employing  streptavidin-biotin  immunoperoxidase  (ABC) 
immunohistochemical  technique  which  is  described  in  the  section  of 
immunocytochemistry below.
fflSTOPATHOLOGICAL ASSESSMENT:
Cases of DCIS were classified as low nuclear grade (LNG), intermediate nuclear grade 
(ING) and high nuclear grade (HNG) according to the published criteria of Holland et al
(2) as  described  in  chapter  6.  In  cases  where  more  than  one  histological  grade  was 
identified, DCIS was graded according to the highest nuclear grade present. In addition to 
grade, histological type of DCIS was also recorded, as well as the presence or absence of 
comedo-type necrosis.
IDC cases were classified according to the grading system described by Elston and Ellis
(3) described in chapter 2, as Grade I,  Grade II and Grade III.  The histological type of 
IDC was also recorded, as well as the presence or absence of lymph node metastasis.Chapter 7: M aterials and methods 120
IMMUNOCYTOCHEMISTRY (ICC): 
Introduction:
Immunocytochemistry  (ICC),  also  known  as  immunohistochemistry  (IHC),  was 
developed by Coons et al (4) and is defined as the identification of a tissue constituent in 
situ by means of a specific antigen-antibody reaction tagged by a microscopically visible 
label. Immunocytochemical techniques have given us the potential to localize antigens in 
cells and tissues with improved diversity, selectivity and specificity of staining reactions, 
as compared to classical staining methods for the demonstration of tissue components (5- 
8). Provided that a suitable antibody can be produced and the antigen preserved, there is 
no limit to the substances that may be localized immunocytochemically. The antigen can 
be whole micro-organisms (viruses, bacteria, fungi) or their parts, whole eukaryotic cells 
or  sub-fractions.  Antibodies  that  are  raised  against  these  antigens,  may  be  polyclonal 
(usually  raised  in rabbit or goat)  or monoclonal  (usually  raised  in  mouse  or rat).  The 
introduction  of monoclonal  antibodies  in  1975  (9)  has  revolutionized  much  of  ICC. 
Initial immunocytochemical methods employed fluorescent dyes as the labels. Later, the 
search  for labels  visible by  ordinary  light microscopy  resulted  in the  use  of enzymes. 
Nakane  and  Pierce  (10),  first  described the  use  of peroxidase  as  a  label  for  antibody 
localization  and  in  the  same  year  Graham  et  al  used  diaminobenzidine  (DAB)  as  a 
substrate (11).
Applications:
ICC has a wide range of applications, as it can be performed on cell and tissue cultures 
(useful  for localization of cell  surface and intracellular antigens),  cell lines, cytological 
preparations, paraffin-wax-embedded tissue  sections and frozen sections.  ICC has been 
used to study the localization of onco-proteins (src, ras, raf, myc, cerbB-2 etc.), intrinsic 
amines  (dopamine,  adrenaline,  noradrenaline,  serotinin,  histamine),  peptides  including 
neuro-peptides  (enkephalins)  and  neuro-endocrine  peptides  (substance  P,  vasoactive 
intestinal  polypeptide,  somatostatin,  bombesin,  gastrin,  insulin,  glucagon  etc.), 
intermediate  filament  proteins  (cytokeratins,  vimentin,  desmin,  glial  fibrillary  acidic 
protein  etc),  neuro-filaments,  pituitary  hormones,  tumour  markers  [carcino-embryonic 
antigen  (CEA),  human  chorionic  gonadotrophin  (HCG),  alpha-fetoprotein  (AFP), 
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and micro-organisms. ICC can be used to aid the diagnosis of organ-specific autoimmune 
disorders,  non-organ-specific  autoimmune  disorders,  transplant  rejection,  thyroid 
diseases,  lymphoreticular  tumours,  leukaemias,  glomerular  disease  and  dermatological 
disorders.  In the  case  of tumours,  immunohistochemical  staining  for a combination  of 
markers taken  together  with the  morphology  may  help  in  determination  of the  site  of 
origin of an occult primary tumour presenting with metastases, in differential diagnosis, 
functional  classification  of malignant  disease,  prognosis,  and  in  marker  prediction  for 
immunolocalization and tumour targeting with antibodies ligated to toxic agents.
Immunohistochemistry  is  a  reliable,  reproducible  and  relatively  simple  technique  to 
perform.  It allows visualization of different protein products in paraffin and as well as 
frozen sections with accurate localization. However, the immunohistochemical expression 
of protein product in carcinoma cells does not always correlate with the abnormality in 
the corresponding gene.
Methods:
The various methods that can be employed for ICC in combination with light microscopy 
include:-
1.  Direct methods. In these methods, a labelled primary antibody is applied directly to 
the tissue preparation.
2.  Indirect  methods.  In  these  methods,  the  primary  antibody  is  unlabelled  and  is 
identified  by  a  labelled  secondary  antibody  raised  to  the  immunoglobulin  of the 
species providing the primary antibody.  These methods are more sensitive than the 
direct  methods.  Indirect  methods  include  indirect  immunofluorescence,  in  which 
secondary antibody is labelled with a fluorescent marker and the reaction is examined 
with  an  ultraviolet  light;  and,  indirect  immunoperoxidase  method,  in  which  the 
secondary antibody  is  labelled/conjugated with peroxidase and a conventional  light 
microscope  is  used.  The  immunoperoxidase  technique  has  the  advantage  of  an 
insoluble permanent reaction product, so that morphological detail is retained. In the 
case  of  immunofluorescence,  with  time  and  photographic  light  exposure,  the 
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3.  Unlabelled antibodv-enzvme methods. An unconjugated bridging secondary antibody 
is  used  between the  primary  antibody  and the  labelled  detecting  reagent,  which  is 
usually  an  enzyme-anti-enzyme  complex  [peroxidase-anti-peroxidase  (PAP)  or 
alkaline phosphatase-anti-alkaline phosphatase (APAAP)] or an avidin-biotin-enzyme 
complex (ABC).
In the case of the PAP method (6; 12), the first layer is a primary antibody (e.g. rabbit) 
which  is  directed  against  the  tissue  antigen,  the  second  layer  being  the  unconjugated 
secondary  antibody  (e.g.  goat  anti-rabbit  IgG)  and  the  third  layer  is  the  rabbit  PAP 
complex. The increased amount of label allows a high dilution of the primary antibody to 
be used thereby reducing unwanted background staining. The APAAP method works on 
the same principle as the PAP method but is mainly used with mouse monoclonal primary 
antibodies (13).
Avidin-Biotin Peroxidase Complex (ABC) Method - Principle and Technique:
The ABC method was described by Hsu et al (14).  This method has gained the highest 
popularity  and  ensures  maximal  sensitivity.  The  ABC  method  requires  incubation  of 
tissue  with  primary  antibody  (1st  layer),  followed  by  incubation  with  biotinylated 
secondary  antibody  (2nd  layer)  and  finally  the  addition  of a pre-formed  avidin-biotin- 
peroxidase  complex  (3rd  layer)  (figure  7.1).  The  avidin-biotin-peroxidase  complex 
consists of many biotinylated horseradish peroxidase molecules cross-linked by avidin to 
form a three dimensional complex. In the complex, at least one of the four reacting sites 
on the surface of avidin is free to bind a biotin residue on the antibody molecule. This 
complex remains stable for several hours after formation.
Avidin is a basic glycoprotein present in large amounts in egg white. It consists of four 
subunits  which  behave  as  specific  binding  sites  for  four  biotin  residues  (15).  The 
specificity of ICC can be further increased by replacing avidin with streptavidin, which is 
a protein  extracted  from  the  culture  broth  of streptomyces  avidinii.  Biotin  is  a water- 
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Because of its reliability, the ABC technique has been employed in this study to look at 
bax, bcl2,  Ki67,  ER, p53  and cerbB-2  in breast tissue and the detailed protocol  of the 
technique is given below:
1.  Sections were cut at 3 pm thickness, mounted on APES coated slides, as described 
above and detailed in appendix 1.
2.  Sections  were  de-paraffmised  (de-waxed)  in  xylene  and  rehydrated  in  graded
s in the following way:
(i) Xylene  I 5 minutes
(ii) Xylene  II 5 minutes
(iii) Xylene  III 5 minutes
(iv) Alcohol  1(100%) 2 minutes
(v) Alcohol  11(70%) 2 minutes
(vi) Alcohol  111(50%) 2 minutes
(vii) Double distilled water 2 minutes.
3.  The  slides  were  transferred  to  a  humidity  chamber  at  room  temperature  and 
covered with freshly prepared 0.5% H2O2 in water for 10 to 15 minutes in order to 
block the endogenous peroxidase activity. The composition of hydrogen peroxide 
solution  is  described  in  appendix  1   under  the  section  ‘blocking  endogenous 
peroxidase activity’.
4.  This step was followed by washing the slides with de-ionized or distilled water for 
2 minutes each, changing the water between washes.
5.  Antigen retrieval  was performed by pressure cooking for bax and microwaving 
for  bcl2,  Ki67,  ER,  p53  and  cerbB-2.  The  time  for  heat  pre-treatment 
(microwaving or pressure cooking) for each marker is shown below:
Bax 90 sec (pressure cooking)
Bcl2 10 minutes (microwaving)
Ki67 10 minutes (microwaving)
ER 20 minutes (microwaving)
p53 10 minutes (microwaving)
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For cerbB-2, 20 cases were repeated without microwaving as it increased the sensitivity 
of the assay.
The detail of heat pre-treatment with microwave is given in appendix 1.
6.  The slides were transferred to a humidity chamber and the sections were covered 
with two changes of Tris buffered saline (TBS) (pH 7.6) for 5 minutes each. The 
composition and preparation of TBS is described in appendix 1.
7.  Slides were incubated with normal goat serum (NGS) from DAKO at a dilution of 
1/10 for 15 minutes at room temperature to block non-specific binding of protein.
8.  Sections were drained and covered with primary antibody, optimally diluted with 
TBS  for  1   hour  at  room  temperature.  The  primary  antibodies  to  the  markers 
studied, their source, clone, type, dilution and the positive control used is shown 
in table 7.3. Optimum conditions (working dilutions) were determined by titration 
of each antibody on receipt from the supplier using control tissue sections.
Table 7.3; Primary antibodies used in the study
Antibody Source Clone Type Dilution Positive
Control
Bax Novabiochem Rabbit
polyclonal 1/20 Colon
Bcl2 DAKO 124 Mouse
monoclonal 1/50 Tonsil
Ki67 Immunotech MIB1 Mouse
monoclonal
1/50 Tonsil
ER DAKO ID5 Mouse
monoclonal 1/100 Known positive 
breast cancer
P53 DAKO DO-7 Mouse
monoclonal
1/50 Known positive 
prostate cancer
CerbB-2 DAKO
Rabbit
polyclonal 1/400 Known positive 
breast cancer
9.  In the case of negative controls, primary antibody was replaced by TBS. Sections 
were rinsed in TBS twice for 3 minutes each.
10. Sections were incubated with biotinylated goat anti-rabbit/anti-mouse secondary 
antibody mixture at a dilution of 1/200 for 30 minutes. This reagent is supplied by 
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11. Sections were once again rinsed in TBS twice for 3 minutes each.
12. Sections were incubated with StreptABComplex from DAKO, prepared according 
to the manufacturer’s protocol, for 15 minutes.
13. Sections were rinsed in TBS twice for 3 minutes.
14. Staining of the sections was developed with freshly prepared 3,3diaminobenzidine 
(DAB) solution. See appendix 1  for preparation of DAB.
15. Sections were washed in distilled water for 3 to 5 minutes.
16. Counter staining was done with Mayer's haematoxylin for 2 to 5 minutes.
17. This was followed by rinsing in water and differentiating in 0.5% acid alcohol and 
"blueing" in the blueing solution for 5 minutes.
18. Finally, the slides were dehydrated, followed by cleaning and mounting in DePeX 
(BDH Limited, Poole, England) and then covered with coverslips.
Sites of immunoperoxidase activity showed as brown colour. Assessment of the staining 
is discussed below.
Staining Characteristics and Assessment of Staining in ICC:
Ki67, ER and p53 staining was nuclear and the percentage of positive tumour cells with 
these  markers  was  determined  by  counting  1000  cells  per  section  using  a  computer- 
assisted semi-automatic image analysis system (Quantimet 500, Leica, Cambridge, UK) 
further described below. Cases were considered positive for ER and p53 when more than 
10% of tumour cells were labelled as it is well established in the case of p53 that if more 
than  10%  cells  are  positive  for p53,  then these  cases  are highly  likely  to  have  a p53 
mutation (16). In the case of ER, the positivity cut-off has been determined in one study 
by correlating IHC with the biochemical assay (17).  Rudas and colleagues have used a 
cut-off of 10% for ER, PR and p53 in DCIS (18). Quinn et al (19) have also applied 10% 
as a cut-off value to define positivity with ER, cerbB-2, bcl2 and p53 in DCIS. However, 
for the purpose of statistical analysis, the actual percentages were used to avoid missing 
any information. In the case of Ki67, it is not known from previous studies whether there 
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stained Ki67 nuclei was used and this was referred to as Ki67 labelling index (LI). Also, 
the range for percentage of labelled cells as well as the median was calculated for each 
patient group and subgroups. This was done because the histograms did not show normal 
distribution of Ki67 in patient groups and parametric tests could not be applied. Bobrow 
et al (20) have arbitrarily used  a cut off value of 10% for scoring  KiSl  as positive or 
negative  and  found  that  KiSl  positivity  was  highly  correlated  to  poorly  differentiated 
(high nuclear grade) DCIS. Ringberg et al used a 10% cut-off for Ki67 positivity in DCIS 
as described in chapter 8 (21).
Elkablawy  et  al  (22)  have  used  a  weighted  score  (WS)  for  evaluating  bcl2  and  p53 
immunoreactivity in colorectal  carcinomas based on the percentage  of positive tumour 
cells  and  the  staining  intensity,  previously  described  by  Sinicrope  et  al  (23).  In  this 
method  a score of 0  -  4  is  assigned  according to the percentage of positively  stained 
tumour cells as follows: 0 = <5% positively staining cells,  1=5- 25%, 2 = 25 -  50%, 
3 = 50 -  75%, 4>75%. Another score is assigned according to the intensity of staining as: 
1   = weak, 2 = moderate and 3 = intense. Finally, the percentage and intensity scores are 
multiplied to  produce  a weighted  score  (WS).  A  WS  of 6  or more  was  considered to 
represent a positive case with these markers.
The use of H score for the assessment of ER immunostaining similarly allows detailed 
correlation between hormone receptor levels and morphology but it is time-consuming.
CerbB-2  staining was membranous while bax and bcl2  staining was  cytoplasmic  (24). 
Labelling with these markers was assessed semi-quantitatively as: negative = 0, weak = 1, 
moderate  =  2  and  strong  =  3.  Cases  were  considered  positive  when  they  were  either 
moderately  or  strongly  positive  (score  2  or  3)  as  in  the  case  of  cerbB-2  it  is  well 
established that a moderate to  strong staining corresponds to  increase  in cerbB-2 gene 
copy number (25). However, for the purpose of statistical analysis, actual score numbers 
were used in order to make use of all the available information. Furthermore, when cases 
were repeated for cerbB-2, the recommended scoring system in published UK guidelines 
(mentioned in chapter 4) was used, which assesses staining similarly as 0-3, but regards 3 
as positive and 2  as borderline.
In most of the cases, the tumour staining was homogenous (i.e.  uniform), but in some 
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immnostaining  was  done  blind  without  any  prior  knowledge  of the  histopathological 
grade.  However,  as  some  indication  of  the  grade  is  usually  apparent  from  the 
immunostained slides, therefore in most cases, assessment of immunostaining was done 
by a histopathologist as well (JC) who did it without the knowledge of the researcher’s 
assessment for the purpose of obtaining double reading.
Factors Affecting ICC:
Main factors that need to be considered during ICC  are tissue factors, antibody factors 
and  the type of label used. Tissue factors include fixation, antigen retrieval and section 
thickness.  Antibody  factors  include  the  dilutions  of antibodies  used,  storage  and  the 
specificity.
Specificity Controls in ICC:
Positive controls:  A positive  control,  known to  contain the  antigen being  investigated, 
was  included  in every  batch  of immunostaining to  confirm  that  all  the  reagents  were 
working properly.
Negative controls: A negative control in which primary antibody was omitted, was also 
used with every batch of immunostaining to exclude non-specific staining.
Quality Control in ICC:
In view of the  need  for quality control  in  ICC,  the  factors  affecting the  staining  (i.e., 
tissue and antibody factors) were kept as constant as possible.  The tissue fixation was 
done with 10% buffered formalin in all cases; antigen retrieval times and techniques were 
constant  for the  different  antigens  at all times,  section thickness  was  kept constant  at 
3 pm. The antibodies were aliqouted on arrival and stored frozen at -20°C according to 
manufacturer’s instructions.  With every new batch of all the antibodies used,  different 
dilutions were tried on positive control first to determine an optimum dilution. To reduce 
the chances of variability in the quality of staining, some sections were stained repeatedly 
on  different  occasions  and  the  quality  of staining  ascertained  to  be  the  same  before 
proceeding to the staining of all cases. Initially, for a few cases, the number of sections 
stained per block was more than one and the number of blocks per case was also more 
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in different cases.  Finally cerbB-2 analysis was repeated in 20 cases  as  initial  analysis 
suggested that some normal tissues were stained positive as well.
STATISTICAL ANALYSIS:
All statistical analyses were performed using the SPSS  10.0 statistical software package 
(SPSS Inc., Chicago, U.S.A.). The coefficient of variation (CV) was calculated to assess 
the variation between immunostaining of at least  10  sections,  randomly  selected,  done 
twice on separate occasions. The relationships between the molecular markers studied - 
bax,  bcl2,  Ki67,  ER,  p53  and  cerbB-2  were  evaluated  using  the  Spearman’s  rank 
correlation test which is a non-parametric test, as the histograms revealed distribution of 
these markers was not normal. The Kruskal-Wallis test, also a non-parametric test, was 
used to compare the distributions of the above-mentioned molecular markers among the 
different histological grades of DCIS and IDC. A p value of less than 0.05 was considered 
significant.
IMAGE ANALYSIS (IA): 
Introduction:
Image analysis (IA) is about quantification, the classification of images and of objects of 
interest  within  images.  IA  enables  quantification  of parameters  such  as  size,  number, 
shape, area, position and optical density of identifiable parts of an image. Semi-automatic 
and  automatic  computer-assisted  image  analysis  has  made  it  possible  to  carry  out  a 
quantitative  morphological  characterization  of  immunostained  cells  and  tissues. 
Computer-assisted  image  analysis  has  been  used  to  quantify  ER  content  in 
immunostained  sections  of breast  carcinoma  as  described  in  chapter  5.  Comparable 
results have been observed between the image analysis and flow cytometry to quantitate 
DNA content in breast (26) and other carcinomas.  Furthermore,  p53  immunoreactivity 
has been quantitated using a CAS-200 image analysis system in a large series of epithelial 
ovarian cancers and the results showed that larger the p53 positive nuclear area estimated 
by  IA,  poorer  the  prognosis  (27).  In  another  study  (28),  manual  and  image  analysis 
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Applications:
IA is used in a wide range of areas including autoradiography, angiography, chromosomal 
analysis, karyotyping, cytology, dental radiography, dermatology, fibre analysis, geology, 
histology, industrial  inspection and quality assurance, kinetics, marine biology, motility 
studies,  materials  testing,  muscle  cell  analysis,  neurology,  paint  and  pigment  quality, 
paper  quality,  particle  sizing,  photographic  emulsion  monitoring,  printing  quality, 
robotics, tobacco analysis and wood structure.
The  use  of image  analysis  has  the  advantage  that  it  provides  an  objective  means  of 
assessment  for  nuclear  size  (area)  and  an  accurate  means  of counting  nuclei  stained 
positively by ICC. Once a protocol for counting nuclei has been established then it is less 
time  consuming  than  conventional  light  microscopy.  Other  advantages  apart  from 
quantification and objectivity include consistency, reproducibility and speed of operation. 
The  analysis  is  not  completely  automated,  as  the  analyser  is  unable  to  identify  two 
overlapping  nuclei,  counting  them  as  one  instead  of  two  separate  units.  Therefore, 
analysis is semi-automated, being operator dependent, i.e., the operator has to identify the 
nuclei and instruct the image analyser to do the counting.
Technique:
The  principal  steps  in  IA  include  image  capture,  segmentation,  object  detection, 
measuring and analysis. A semi-automatic computer-assisted image analyser (Quantimet 
500 by Leica, Cambridge Limited) was employed for the calculation of nuclear areas in 
the  50 cases of DCIS to classify cases into low, intermediate and high nuclear grades. 
H&E stained tissue sections of the cases studied were used. System calibration was done 
with  light  and  threshold  adjustment.  The  IA  system  consists  of an  IBM  compatible 
computer,  an  image  processor  and  a  CCD  colour  video  camera  (Sony  Corporation, 
Tokyo,  Japan)  attached  to  a  standard  Olympus  BH-2  microscope  (Olympus  Optical 
Company, Hamburg, Germany), which was used to record images with a x40 objective. 
This gave a final magnification of x400. During measurement, areas of tumour containing 
stroma, blood vessels,  inflammation or necrosis were excluded by the software editing 
mode. In this way, only tumour nuclei were entered into analysis. The IA was used for 
two purposes:  (1) for nuclear area determination in all  50  cases  of DCIS  on H and E 
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immunostained sections to determine percentage positive cells with these markers.  The 
other  three  markers:  cerbB-2,  bcl2  and  bax  immunostaining  was  assessed  semi- 
quantitatively as mentioned already because the software of the image analyser used was 
not  developed  enough  at  the  time  to  allow  quantification  of  total  stained  area  for 
membranous and cytoplasmic stains.
In the case of DCIS, the mean of the nuclear areas of at least a 100 nuclei was calculated 
for each case. This was because determination of nuclear areas of 100 nuclei  gave the 
most  consistent  and  reproducible  results  as  verified  by  a  cumulative  frequency  plot 
similar to the one shown below. The criteria used for the classification of DCIS were as 
follows:
1  -  Low nuclear grade cases had a mean nuclear area of less than 40pm .
2-  Intermediate nuclear grade cases had a mean nuclear area between 40-45pm .
3-  High nuclear grade cases had a nuclear area of greater than 45pm .
The problem with classification of DCIS by image analysis is that it is rather arbitrary and 
well-differentiated  apocrine  tumours  may  be  mis-graded  as high  nuclear grade  due  to 
their  large  nuclei.  Therefore,  it  is  probably  better  used  in  adjunct  to  traditional 
morphological classification rather than replacing it.
In the case of immunostained sections, percentage of positive cells labelled with Ki67, 
p53 and ER was calculated, by counting at least a thousand cells in each section (20-30 
high power fields). The figure of 1000 was derived from a cumulative frequency plot as 
shown in figure 7.2 for Ki67.  Similar graphs, not shown here, were plotted for ER and 
p53 as well as nuclear areas.
Factors Affecting IA:
A  large  number  of  factors  can  affect  measurement  of  objects  in  IA  especially  in 
histological image processing, such as thickness of the sections, colour and uniformity of 
the  stain,  level  of  illumination,  image  noise  and  image  magnification.  Absolute 
measurements on an image are difficult to make. It is preferable to make measurements 
relative  to  a  standard.  Absolute  measurements  involving  colour  images  are  especially 
difficult  and  require  careful  choice  of camera  and  attention to  calibration  and  quality 
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Figure 7.2; Cumulative frequency plot showing optimum number of cells counted to get 
a consistent result in a case with 20% cells labelled with Ki67.
POLYMERASE CHAIN REACTION (PCR): 
Introduction:
Since its introduction in  1985, the polymerase chain reaction (PCR) has revolutionized 
molecular  biology  by  providing  a  method  for  amplifying  a  small  quantity  of  DNA 
(29;30).  PCR allows millions of copies of any  specific  DNA  sequence to be generated 
within a few hours. PCR has now become a valuable tool for the molecular biologist and 
can  be  used  in  a  variety  of contexts,  including  DNA  sequencing,  analysis  of RNA 
transcription,  mutagenesis,  development of probes  for genetic  studies  and screening of 
cDNA libraries.
Applications:
The  PCR  has a wide  range of applications  including  detection  of viruses  [e.g.  human 
papilloma virus (HPV) in cervical smear cells, HTLV-1  in T cell lymphomas], detection 
of chromosomal translocations in haematological malignancies [e.g. t( 14; 18) in follicular 
lymphomas, t(9;22) in CML and ALL], detection of point mutations (e.g. point mutations 
in  ras  oncogene,  detection  of tumour  suppressor  genes  (e.g.  p53,  Rb),  detection  of 
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(e.g. haemoglobinopathies, cystic fibrosis). PCR can be performed on DNA which is not 
highly purified, DNA from hair roots, blood, semen, smears, bone-marrow trephines, pre­
implantation  embryos,  cytological  specimens,  frozen  and  paraffin-wax  embedded 
sections.
PCR is simple, sensitive, easily automated, and has a tremendous range of applications. A 
very important benefit of PCR is the ability to sequence directly amplified DNA without 
the  need  for  cloning.  However,  the  PCR  product  can  be  subcloned  into  a  plasmid  or 
phagemid vector and then sequenced. It can be used on crude DNA samples even of low 
purity.  The  PCR  can  also  be  used  to  generate  highly  labelled  probes  for  subsequent 
hybridization to DNA or RNA either on filters or directly on cells and tissues.
The PCR technique can be easily modified to amplify RNA.  In this situation, extracted 
RNA  is  copied  into  double  stranded  cDNA  using  the  retroviral  enzyme  reverse 
transcriptase, and the PCR is then performed on the cDNA copies.
The  disadvantages  are  that  PCR  is  not  quantitative,  it  is  notoriously  sensitive  to 
contamination and artifact resulting in false positives, therefore it is imperative that an 
appropriate range of controls is present in every assay and stringent laboratory procedures 
are followed. DNA replication during PCR has a significant error rate.
Principle:
The PCR is an in vitro technique that relies on the ability of DNA polymerases, in the 
presence of a mixture of deoxynucleotide triphosphates (dNTPs are dATP, dCTP, dGTP, 
dTTP),  to  copy  a  DNA  strand  using  a  short  complementary  DNA  fragment  as  an 
initiating template. A pair of short DNA fragments called oligonucleotide primers, which 
are  complementary  to  DNA  sequences  on  opposite  strands  of the  DNA  flanking  the 
fragment to be amplified, are used in the process (figure 7.3). The PCR involves repeated 
cycles  of heat  denaturation  of the  DNA  (usually  done  at  90-94°C),  annealing  of the 
primers to their complementary sequences (usually done at 37-60°C) and extension of the 
annealed  primers  with  DNA  polymerase  (usually  done  at  72-74°C  by  a  heat-resistant 
DNA polymerase called Taq polymerase derived from Thermus aquaticus).
The extension products of one primer can serve as templates for the other primer, so that 
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This chain reaction results in the exponential  accumulation of the  specific  DNA target 
fragment to approximately 2”, where n is the number of cycles. The amplified DNA can 
then  be  detected  by  agarose  or  polyacrylamide  gel  electrophoresis  followed  by  direct 
visualization as a distinct band with ethidium bromide, which lights up the DNA when 
illuminated with ultraviolet (UV) light. The specificity and sensitivity of the PCR can be 
further  increased  by  subsequent  hybridization  or  DNA  sequencing.  The  PCR  requires 
rapid temperature changes, which can easily be achieved using commercially available 
thermal cyclers.Chapter  7:  Materials and methods 135
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Technique:
Of the 32/118 (27%) samples that were positive for p53 protein by immunostaining, 20
were  amplified  with the  polymerase  chain  reaction  (PCR)  for exons  5-8  of P53  gene.
These included 10 DCIS (1  LNG, 2 ING, 7 HNG), 8 1DC LN-ive (0 G I, 3 G II, 5 G III),
1  IDC LN+ive and 1   LN metastasis. The protocol used was as follows:
1.  Sections were prepared from the formalin-fixed, paraffin wax-embedded blocks in the 
same way as for ICC but mounted on plain slides. A new microtome blade was used 
for each of the different paraffin blocks to avoid contamination.  The  sections were 
warmed up in an incubator the evening before use.
2.  Sections  were  de-waxed  in  xylene  three  times  for  5  minutes  each,  followed  by 
rehydration in alcohol three times for 5 minutes each, followed by rinsing in sterile 
de-ionized water twice for 7 minutes each.
3.  Sections were stained with toluidine blue solution (0.1% w/v) for about 30 seconds 
followed by rinsing in sterile de-ionized water to wash off the stain.
4.  Micro-dissection of the tissue sections (31) was performed under x40 magnification 
of a dissecting microscope after the application of 2-4 times 25pi  of proteinase K 
buffer (Sigma), taking care that tissues did not get dry and that the area of interest 
(known to  be positive  for p53  protein)  was  micro-dissected.  Micro-dissection  was 
done by scraping with a scalpel blade and the micro-dissected tissue, floating in the 
proteinase K buffer, was then sucked up with sterile pipette tip and placed in a sterile
1.5  ml eppendorf tube, adding an equivalent volume of proteinase K (1  mg/ml+lOml 
of Tween 20). For each sample, one eppendorf tube was filled with tissue.
5.  The eppendorf tubes were incubated in a shaking water bath at 37°C overnight.
6.  Proteinase K was destroyed by incubating the eppendorf tubes at 95°C for 10 minutes.
7.  The eppendorf tubes were centrifuged at 3500 rpm (rate per minute) for 10 minutes.
8.  The  supernatant  was  removed  from  each  of the  centrifuged  eppendorf tubes  and 
placed in new sterile eppendorf tubes and stored at 4°C until the PCR reaction was 
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9.  For the PCR reaction, PCR master mix was prepared. The reagents utilized for one 
PCR tube (one sample) are as follows:
73 pi PCR water (Sigma)
2 pi upstream primer (5 nmol/ml) (Cruachem)
2 pi downstream primer (5 nmol/ml) (Cruachem)
2 pi dNTPs (10 mM) (Bioline)
10 pi lOx NH4 buffer, with no Mg2+ (Bioline)
6 pi Mg2+ (Bioline)
1  pi Taq polymerase (Bioline)
This 96 pi of PCR master mix was prepared for each DNA sample and 4 pi of each DNA 
sample from the eppendorf tubes was added to it. This was followed by the addition of 40 
pi of mineral oil to each sample to prevent evaporation of the  sample during the PCR 
cycles.
The sequences of the primers used are shown in table 7.4.
Table 7.4; Sequences of primers used in the PCR for exons  5 -  8 of PS3 gene.
Primers Sequences (5’-3’) Nucleotide
position Bases
E5U GGAATTCTGTTCACTTGTGCCCTGACTTTCAAC 13004-13030 33
E5D GCAACCAGCCCTGTCGTCTCTCCA 13254-13267 24
E6U CCAGGCCTCTGATTCCTCACTGATTG 13287-13312 26
E6D AGGGCCACTGACAACCACCCTTAAC 1346713491 25
E7U ACAGGTCTCCCCAAGGCGCACTGG 13947-13970 24
E7D GGGCACAGCAGGCCAGTGTGCAG 14130-14152 23
E8U AGGTAGGACCTGATTTCCTTACTGCC 14397-14422 26
E8D GGAATTCTGAGGCATAACTGCACCCTTGGTCT 14619-14645 32
Explanation: E = exon, U = upstream of exon, D = downstream of exon.
10.  The  sample  tubes  were  placed  in  PCR  machine  (Techne  PHC)  and  run  at  the 
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94° C for 3 minutes *  one cycle
94° C for 1  minute
60° C for 1  minute  > >  35 cycles
72°C for 1  minute
72°C for 10 minutes *•  one cycle
11.  The  amplified  mixture  (5  pi)  was  run  on  an agarose  gel  and  the  rest was  sent  for 
sequence analysis. For the preparation of the agarose gel (32), 200 ml of Tris Borate 
EDTA (TBE) buffer (Sigma) (pH 8.3) was taken and 0.9 grams of agarose (Sigma) 
was added to 30 mis of this buffer, microwaving for 20-30 seconds, then allowing it 
to cool. Afterwards, 1   pi of ethidium bromide (Sigma) was added to this mixture and 
it was transferred to a gel electrophoresis kit. While this mixture cooled and solidified 
in the kit, 5 pi of gel loading solution (Sigma) was taken in sterile eppendorf tubes, 
the number of tubes corresponding to the number of samples, plus a positive and a 
negative control and one for the hyperladder. To one of the tubes, 5 pi of 100 bp DNA 
ladder  (GIBCO  BRLr)  was  added  and  to  the  rest  of the  tubes,  5  pi  each  of the 
amplified DNA sample was added. When the gel solidified, 5 pi of each sample was 
loaded into each of the wells of the gel and the electrophoresis apparatus run for half 
an  hour at a voltage  of  100-200  volts.  Afterwards,  the  gel  was  removed  from the 
apparatus and visualized using an ultraviolet (UV) transilluminator, with the pictures 
taken at the same time to record the results. Positive and negative controls were used 
every time the PCR procedure was performed.
Factors Affecting PCR:
While  the  overall  specificity  of the  PCR  is  determined  by  the  two  oligonucleotide 
primers, other factors influencing PCR specificity include (i) the times and temperatures 
of the  annealing and  extension  steps,  (ii)  the magnesium  concentration  in the  reaction 
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SEQUENCE ANALYSIS:
Introduction:
DNA  sequencing  is  the  determination  of all  or  part  of the  nucleotide  sequence  of a 
specific DNA molecule.  DNA sequencing is of major importance in molecular biology 
(33;34). The rate at which new sequence information is determined has increased rapidly 
over  the  last  20  years,  to  the  extent  that  the  entire  human  genome  sequence  of 
approximately 3xl09base pairs will be determined within the next few years (35).
Applications:
The  applications  of  DNA  sequencing  include  confirmatory  sequencing  to  check  a 
particular construct or mutant (in the case of DNA whose sequence is already known), to 
sequence PCR products and strategies for sequencing large fragments of uncharacterised 
DNA.
The semi-automated sequencers do not require the use of radioisotopes as compared to 
manual sequencing and the time from running the gel to getting the sequence information 
is less than sequencing with radioactive  labels, as the  12-24 hr autoradiography step is 
eliminated.  It  requires  much  less  template  DNA,  typically  50  fmol,  as  compared  to 
conventional or manual sequencing, which requires 500-1000 fmol of DNA.
With ABI 377,  which was used  in this study, the sequencing reaction is loaded onto a 
single lane of the gel, which allows a large number of samples to be run on the same gel, 
maximizing throughput. Up to 64 sets of sequencing reactions can be run simultaneously.
The disadvantages are that the data obtained are not of such high quality as those obtained 
by  autoradiography.  Furthermore,  the  ‘hands-on’  time  is  generally  increased  by  the 
additional  manipulations  required.  Semi-automated  sequencers  are  very  sensitive  to 
contaminants of the polymerases used. Semi-automated sequencing is still generally less 
consistent and reliable than conventional sequencing.
Principle:
There are two sequencing techniques in current use. These are the ‘chain termination’ and 
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methods  respectively,  after  their  original  inventers.  The  chain  termination  method  (or 
dideoxy  chain  termination  method)  depends  on  the  enzymatic  (by  DNA  polymerase) 
synthesis  of  labelled  DNA,  using  specially  modified  nucleotides  called 
dideoxynucleotides  (ddNTP)  to  terminate  the  elongating  strand.  ddNTPs  can  be 
incorporated by DNA polymerases into a growing DNA chain through their 5’ phosphate 
groups,  just  like  dNTPs.  However,  they  lack  the  3’-OH  group  necessary  for 
phosphodiester bond formation and chain elongation so the chain terminates at the precise 
point at which the ddNTP is incorporated.  Four sets of reactions are performed on each 
template,  differing only  in which of the 4  ddNTP  is added.  The dNTP:ddNTP ratio  is 
carefully selected so that the resulting labelled strands form a nested set of molecules up 
to several thousand bases long, each terminating at a specific base. These are separated 
according to size by high-resolution denaturing gel electrophoresis. This gives a ‘ladder’ 
of bands from which the DNA sequence can be read. The chemical degradation method is 
based on the base-specific chemical cleavage of a DNA molecule labelled at one end to 
generate a nested set of labelled molecules, each terminating at a specific base. Following 
high-resolution  denaturing  gel  electrophoresis  and  detection  of the  labelled  fragments, 
typically  by  autoradiography,  the  sequence  of the original  DNA  can  be  read  from the 
resulting  sequencing  ‘ladder’, just  as  in the  chain termination  method.  The  method  in 
most common use is the dideoxy chain termination method. One of the limitations of the 
standard  chain  termination  method  is  that  only  a  single  labelled  DNA  molecule  is 
produced  from each primer-template complex.  The sensitivity of the method is  limited 
therefore by the molar quantity of DNA template that can be used in the reaction. This is 
a major problem when sequencing large DNA templates or purified DNA fragments, for 
example PCR products. This limitation can be overcome by performing the sequencing 
reactions,  denaturing  the  template  DNA  and  repeating  the  reactions.  Repeated 
denaturation  is performed easily by thermal  cycling on a PCR machine.  This  is called 
cycle sequencing. Cycle sequencing works on the same general principles as PCR, though 
the template DNA is amplified linearly rather than exponentially.
Semi-Automated Sequencers:
Semi-automated  sequencing  machines  detect  and  analyse  fluorescently  labelled  DNA 
with  sophisticated  detection  systems  and  analysis  software.  The  genome  sequencing 
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However, these are expensive, between 40,000-100,000 pounds. The ABI 377, which was 
the  sequencer  used  in  this  technique,  can  simultaneously  detect  fluorescence  at  four 
different wavelengths, set to coincide with the emission of four different fluorescent dyes. 
As each DNA fragment moves past the detector, the base-specific dye is excited by the 
laser.  The dye emits  light at  its characteristic wavelength.  This  fluorescent emission  is 
separated according to its wavelength by a diffraction grating. The signal is detected by a 
charged  couple  device  (CCD)  camera  and  recorded  and  analysed  by  computer.  The 
software separates the signal  into four channels, each corresponding to one of the dyes. 
Use of a diffraction grating allows all four channels to be monitored simultaneously. Each 
dye is used to label strands terminating in one of the four possible dideoxynucleotides. 
The  reaction  mix  is  run  in  a  single  lane  so  that  the  colour  of each  band  passing  the 
detector represents the DNA sequence. The key advantage of automated sequencing is the 
automated  data  collection.  The  real-time  data  collection  means  that  there  is  no 
opportunity to adjust for variable signal strength, therefore sequencing reactions must be 
carefully  optimized.  Furthermore,  the  extremely  sensitive  detectors  can  detect  even 
minute levels of contamination by extraneous fluorochromes. The raw data from ABI 377 
is in the form of lanes, each lane is a ladder of coloured bands, each representing a single 
nucleotide.  This raw data is processed by the  software  to  give the best known output, 
called an electropherogram. Values are assigned to each peak, so that the final output is 
the DNA sequence in text format. For a typical double-stranded DNA template, ABI 377 
can read about 450-500 nucleotides at 99.8% accuracy. Five out of 20 samples that were 
amplified  for  each  of the  4  exons  of p53  were  sent  to  MWG  Biotech  (Ebersberg, 
Germany)  for  sequence  analysis.  They  performed  cycle  sequencing  on  an  ABI  377 
machine after purification of the samples.
Factors Affecting Sequencing by Semi-Automated Sequencers:
Factors,  which diminish  sequence  quality,  are  impure  template  or primer preparations, 
inappropriate template or primer concentrations and inefficient removal of unincorporated 
labelled  ddNTPs  or primers.  The  real-time  detection  in  these  systems  implies  that the 
above mentioned factors need to be optimized prior to gel electrophoresis.
Problems  that  can  arise  in  DNA  sequencing  can  be  template-specific  or  systematic. 
Template specific problems are commonly caused by either insufficient template DNA, 
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binding  site  in the  template.  Sytematic  problems  are  commonly  caused  by  a defective 
reagent or suboptimal gel electrophoresis.
FOURIER  TRANSFORM  INFRARED  (FTIR)  MICROSPECTROSCOPY, 
CHEMICAL IMAGING AND FT-RAMAN SPECTROSCOPY: 
Introduction:
At present the biochemical basis of human disease is a central tenet of modem medicine. 
Biochemical changes within tissue may either initiate disease or occur as a result of the 
disease process. The qualitative analysis of such changes provides important clues in the 
search for a specific diagnosis, and the quantitative analysis of biochemical abnormalities 
is  important  in  measuring  the  extent  of  the  disease  process,  designing  therapy  and 
evaluating the efficacy of the treatment.  The conventional  method for tissue analysis is 
histopathological  examination of biopsy  samples,  but this method utilizes morphologic 
abnormalities  rather  than  biochemical  differences.  Furthermore,  pathological  analysis 
requires tissue to be removed, with undesirable consequences. For example, in instances 
such as the arterial disease, the removal is extremely difficult or perhaps not possible. In 
cases where the tissue removal is permitted, the accuracy of diagnosis can be limited by 
factors  related  to  random  sampling  and  handling  of tissue.  In  addition,  conventional 
histopathology has limitations to its capability for providing immediate feedback and the 
precision to quantify the extent of the disease, particularly in the early stages. For these 
reasons,  techniques that can provide real time and precise information about the tissue 
biochemistry  are  being  developed  as  adjuncts  to  histological  examination  of biopsy 
specimens.
A number of other analytical techniques used for structural and compositional analysis of 
natural  tissues  include  electron  microscopy,  X-ray  diffraction  and  chemical  analysis. 
However,  in  preparation  for  such  analyses,  the  tissues  can  be  subjected  to  processes 
which will alter their structure and/or composition.  The ideal  situation would be one in 
which minimal tissue preparation is required and physiological conditions are maintained 
as  closely  as  possible  with  the  possibility  of in  situ  tissue  analysis  being  particularly 
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Applications:
Recently, spectroscopy has emerged as one of the major tools for biomedical applications 
and has made significant progress in the field of clinical evaluation.  Research has been 
carried out on a number of natural hard and soft tissues using Fourier Transform Infrared 
(FTIR),  FT-Raman and Nuclear Magnetic  Resonance (NMR)  spectroscopic techniques. 
These vibrational spectroscopic techniques are non-destructive to the tissue and only very 
small amounts of material (micrograms to nanograms) are required. In addition, FTIR and 
FT-Raman spectroscopy also provides molecular level information allowing investigation 
of functional  groups,  bonding  types  and  molecular  conformations.  Spectral  bands  in 
vibrational  spectra  are  molecule  specific  and  provide  direct  information  about  the 
biochemical composition. These bands are relatively narrow, easy to resolve and sensitive 
to molecular structure, conformation and environment.  FTIR analysis has been reported 
on a number of biological tissues including bone (36), cornea (37), colon (38), lung (39), 
breast (40), heart (41) and liver (42).
The  clinical  management  of breast  cancer  patients  is  guided  by  several  clinical  and 
pathological  measures  of tumour  growth  (43).  These  indicators  include  tumour  size, 
histological  type,  grade  and  stage.  However,  an  increasing  proportion  of cases  now 
present at an earlier stage as axillary node negative or pre-invasive in situ disease, where 
determination  of  the  likelihood  of  local  or  distant  recurrence  becomes  even  more 
dependent on assessment of the inherent biology of the tumour (44). Improvement in the 
accuracy of this assessment may in part come from better methods for the determination 
and  integration  of known  prognostic  factors.  Amongst  these  tumour  grade  has  been 
shown by some to be an excellent indicator of biological potential (3). However, reliable 
assessment of tumour grade has been hindered in the past by difficulties in determining 
reproducible criteria and the problem of interobserver variability (45).
In order to find a method of analysis which could measure characteristics within tumour 
tissue that would allow accurate and precise assignment in to grade categories, FTIR and 
FT-Raman spectroscopy techniques were employed to analyse breast tissue.
Principle:
FTIR spectroscopy is based upon the absorption of infrared light by covalent bonds as 
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between the atoms, for example, C -C , C = C, C -H , C = 0  etc. The absorbed peaks for 
the vibrating atoms depend on their structure. Similarly FT-Raman spectroscopy depends 
upon  the  change  in  the  polarisation  of  these  molecules  and  the  technique  provides 
complimentary  information  alongside  FTIR  spectroscopy.  Therefore,  FTIR  and 
FT-Raman  spectra  of a  sample  provide  information  about  its  chemical  structure  and 
composition.  In biological systems, functional groups that strongly absorb infrared light 
and  scatter  the  Raman  source  to  initiate  change  in  polarity  of  molecules  include 
C = 0 ,N -H , C -H  and P - O groups.
Therefore,  intensity  of the  absorption  bands  in  the  infrared  spectrum  and  scattering 
radiation in the Raman spectrum of a tissue provide information concerning lipid, protein, 
and nucleic acid contents of the sample, whereas the frequency of the absorption provides 
information relating to structure / conformation and intermolecular interactions.  In other 
terms,  FTIR and FT-Raman spectra of breast tissues provide information regarding the 
biochemistry of the tissue.
If the FTIR and FT-Raman spectra of the tissue can give information that reflects tissue 
biochemistry, then the  changes in tissue biochemistry  accompanying a disease process 
should  be  reflected  in  the  changes  in  the  obtained  spectra  of  the  diseased  tissue. 
Therefore, it is reasonable to  speculate that tumours of differing grades will  also  show 
different  spectroscopic  features,  in  principle  allowing  analysis  of tumour  spectra  by 
grade.
Materials Analysed:
FTIR  micro-spectroscopy,  FTIR  chemical  imaging  and  FT-Raman  spectroscopic 
techniques were employed to analyse a selection of the breast carcinoma cases. A total of 
67 cases, which included 30 DCIS (10 LNG,  10 ING,  10 HNG), 30 IDC (10 GI,  10 GII 
and  10  GUI)  and  7  normal  cases  were  analysed.  Details  of the  cases  analysed  are 
tabulated in table no. 8.35. Less common subtypes of DCIS for instance apocrine, signet- 
ring etc were not included  in the analysis to minimize heterogeneity and the cases  for 
each grade analysed were typical of the respective grade.  Formalin-fixed paraffin wax- 
embedded  sections  from  each case  were  2 0pm thick and were dewaxed  in xylene  and 
rinsed  in  graded  alcohols  by  immersion  in  50,  70  and  100%  absolute  alcohol  for  5 
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reproducibility. These  15 spectra were obtained from 3 nuclei (5 spectra per nucleus) in 
each case to obtain a spectrum of nuclear DNA and then these  15 spectra from each case 
were superimposed to obtain one representative spectrum from each case.
Figure, 7.4; Cancerous tissue sample mounted on a glass slide
FTIR Analysis of Breast Tissue:
Infrared spectra were obtained using a Nicolet 800™ spectrometer in conjunction with a 
Nicplan™  microscope  equipped  with  a  liquid  nitrogen  cooled  MCTA  detector.  An 
Attenuated Total Reflectance (ATR) slide on an objective equipped with diamond crystal 
(Spectra-Tech™,  USA) was mounted on the microscope.  This ATR objective provides 
two modes of operation; one is for viewing of the specimen and the other for infrared (IR) 
analysis.  The view mode allows viewing of the area of interest and the  IR mode is for 
spectral data acquisition. A zoom on aperture was used to mask areas of interest. Spectra
were obtained at 4cm' 1  resolution, averaging 256 scans.
Three nuclei were analysed for each specimen as mentioned above, taking fifteen spectra 
for each tissue. FTIR spectrophotometer was calibrated by using polystyrene standard at 
4cm'1   resolution.  To  evaluate  the  accuracy  and  precision  of the  technique,  spectra  of 
cancer tissues were overlaid and evaluated for peak positioning.
FTIR Chemical Imaging:
Recently,  an  infrared  chemical  imaging  technique  has  been  developed  which  also 
provides very useful information regarding the chemical structure of the tissues.  In this 
study, a total of 67 samples were analysed using this technique.  Details of the samples 
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Spectra were obtained using a Digilab rapid-scan FTIR spectrometer Excalibur FTS 3000 
equipped with the UMA-600 infrared microscope equipped with a liquid nitrogen cooled 
MCTA  detector  and  a  MCT  focal  plane  array  detector.  The  obtained  spectra  were 
processed by using WIN-IR™ PRO software. The samples were mounted on glass slides 
and  collected  using  infrared  reflectance  techniques.  A  gold  mirror  was  used  as  a 
background. Spectra were collected at 8cm'1  resolution, averaging 256 scans. A variety of 
techniques such as imaging and mosaic  images were  employed for samples with areas 
varying from 350 x 350pm to a maximum area of 1.4 x 1.4 mm. The collection time for a 
single image was less than 5 minutes with 256 scans. For the larger image at 64 scans, the 
mosaic was collected in 17 minutes.
FT-Raman Analysis of Breast Tissue:
FT-Raman  spectra of the  67  breast  tissue  samples  were  recorded  using  a Nicolet  910 
spectrophotometer, equipped with a Nd:YV04  near-infrared laser which eliminates the 
problems of sample fluorescence and photo-decomposition. The low power near-infrared 
laser in the FT-Raman spectrophotometer makes it possible to analyse biological tissues 
without the loss of sensitivity due to fluorescence of organics.
Prior  to  analysis  of  the  tissues,  FT-Raman  spectrophotometer  was  calibrated  using 
sulphur,  diamond  and  cyclohexane  as  standards  at 4cm'1   resolution.  Spectra of all the 
samples  analysed  were  checked  against  these  standards  to  monitor  the  accuracy  and 
precision of the technique by checking the peak positioning.
The tissue samples were analysed mounted on glass slides and attached to a metal post
(sample  holder).  Scattered  radiation  was  collected  and  collimated  by  180°  reflective 
optical  geometry.  The  spectra  were  obtained  by  using  450mW  of  laser  power,  256 
number of scans (depending upon samples) and 4cm-1  resolution.  Data processing was 
performed  using  a  680D  spectral  workstation.  Three  nuclei  were  analysed  for  each 
specimen taking fifteen spectra for each tissue.Chapter 8: Results 147
CHAPTER 8:  RESULTS:
CLINICOPATHOLOGICAL FINDINGS:
All  the  103  breast  cancer  cases  studied  were  diagnosed  at  the  Royal  Free  Hospital 
between 1985 and  1995. Two further cases were also studied, making a total of 105; one 
of these was diagnosed in  1969 and the other one in  1971. These were included for the 
purpose of comparison and both of these were low nuclear grade DCIS.  However, these 
were  not  included  in  the  final  statistical  analysis  as  the  fixatives  and  the  processing 
regimes  used  were  probably  different  three  decades  ago.  Furthermore,  there  was  no 
control over delay in fixation at the time.  It is well known that different fixatives affect 
the result of ICC (1), and also does delay in fixation (2). A short delay (up to  1   hour) in 
fixation results in significant decrease in mitotic count, with the potential for alteration of 
histological grade (2). A decrease in intensity and percent nuclear staining with p53 also 
occurs,  MIB1  labelling  or  ER  staining  are  not  profoundly  affected  (2;3).  From 
1985-1995,  duration  of  fixation  was  fairly  uniform  at  the  routine  histopathology 
laboratory.
Of the cases studied, 50/103 (49%) were pure DCIS, 53/103 (51%) were IDC including 
38/103 (37%) LN negative (non-metastatic) and 15/103 (15%) primary breast carcinomas 
with  their  metastatically  involved  lymph  nodes.  Age  at  diagnosis  ranged  from  26-88 
years,  with a median of 55  years.  The 53  IDC  patients tended to be younger than  the 
DCIS  patients,  with  an  age  range  at  diagnosis  of 26-84  and  a median  of 52  years  as 
compared with the 50 DCIS patients who had an age range at diagnosis of 33-88 with a 
median of 55 years. All except one of the patients were female, the one male had a grade 
II  IDC,  LN  negative.  This  incidence  of 1%  is  in agreement with that  in the published 
literature on male breast cancer (4-6). In a more recent study, male breast cancer has been 
shown to be  even  less  common  (7).  This case  was  not  included  in  the  final  statistical 
analysis in view of the possible differences in tumour biology in males as compared to 
females (8).
All patients were treated by mastectomy or local excision with or without radiotherapy. 
57/103 (55%) had their tumour in the left breast, 43/103 (42%) in the right breast,  1/103 
(1%)  presented  with  bilateral  breast  lumps  and  in  2/103  (2%)  cases,  the  side  was  not 
recorded.  2/103  (2%) were post-chemotherapy, but apart from that no other patient hadChapter 8: Results 148
received any prior treatment.  All cases were sporadic, except one whose twin sister also 
had breast carcinoma.
Histological grading, typing and LN status of DCIS cases:
The  50  DCIS  cases were all  pure, that  is without any prior history of breast disease  in 
either  ipsilateral  or  contralateral  breast  and  also  without  any  associated  invasive 
component, although  1/50 (2%) had a focus of micro-invasion (this was an HNG).  It is 
known that micro-invasive carcinoma (MIC) behaves clinically like DCIS rather than an 
established invasive carcinoma (8). However, since biologically it is not strictly DCIS, it 
was not included in the final statistical analysis.
Of the  DCIS  cases,  18/50 (36%)  were  LNG,  17/50 (34%) were  ING  and  15/50 (30%) 
were HNG. The distribution of DCIS in this study is unusual and suggests that the case 
mix is not typical. Histological type was recorded as: 9 comedo,  8 cribriform, 5 solid, 4 
papillary,  4  mixed  cribriform  and  papillary,  4  mixed  comedo  and  cribriform,  3  mixed 
cribriform+solid+papillary,  3  comedo+cribriform+solid,  3  mixed  comedo  and  solid,  2 
micropapillary and clinging, 2 cribriform and clinging,  1  cribriform and solid,  1  apocrine 
and  1   mixed  lobular and ductal  in  situ carcinoma.  Comedo-type necrosis was found in 
16/50  (32%)  of DCIS  and was more  frequent  in  HNG;  as  10/14  (71%)  of HNG,  5/18 
(27%) of ING and  1/17 (6%) of LNG had comedo-type necrosis.  15/50 (30%) of DCIS 
had  associated  benign  changes  including  cystic  change,  fibrosis,  apocrine  metaplasia, 
focal epithelial hyperplasia, sclerosing adenosis and a papilloma. 3/50 (6%) of DCIS had 
associated atypical ductal hyperplasia (ADH).  3/15 (20%) of HNG DCIS had associated 
Paget’s disease of the nipple.
Lymph node status was unknown in 24/50 (48%) DCIS, histologically proven LN-ive in 
25/50 (50%) DCIS and  1/50 (2%) had LN micrometastasis, this particular case was the 
one  with  microinvasion  and  was  a high  nuclear  grade.  Although occult axillary  lymph 
node metastases are considered insignificant clinically (9), this case as mentioned above, 
was excluded from the statistical analysis.
Histological grading, typing and LN status of IDC cases:
The 53  IDC cases included 38/53  (72%) LN negative (non-metastatic) and  15/53  (28%) 
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negative  and  6/38  (16%)  were  clinically  LN-ive,  without  any  documentation  of 
histological  LN  status.  During  final  statistical  analysis,  when  LN  -ive  cases  were 
compared against  LN+ive,  the analysis was carried out twice.  Firstly,  including all  LN- 
ive  cases,  and  then  only  histologically  LN-ive  cases  to  eliminate  the  factor  of  poor 
sensitivity of clinical assessment.
Within  15 metastatic IDC cases,  10/15 (67%) had between  1-3  involved LN, 2/15 (13%) 
had 4-7  and  3/15  (20%)  had  more than  7  LN  involved.  Within  the total  53  IDC,  7/53 
(13%) were G I, 26/53 (49%) were G II and 20/53 (38%) were G III. Elston and Ellis (10) 
found G I to be  19%, G II 34% and G III were 47% in a series of 1830 patients. Among 
38 LN negative patients, 6/38 (16%) were G I, 20/38 (53%) were G II and  12/38 (32%) 
were GUI. Among 15 metastatic cases, 1/15 (7%) was G I, 6/15 (40%) were G II and 8/15 
(53%) were G III. The association of a higher histological grade with positive lymph node 
status is shown in table  8.1.  Metastatic cases were most often grade III  (8/15  or 53%) 
whereas only  12/38 (32%) of non-metastatic were grade III. However, a chi-squared test 
did not show this association to be statistically significant, with a p value of 0.25.
Table 8.1; Correlation of IDC grades with lymph node status
Histological grade of IDC cases
LN status GI GH GUI Total
LN negative 6 20 12 38
LN positive 1 6 8 15
Total 7 26 20 53
Histological typing revealed that 36/38 (94%) of non-metastatic IDC were invasive 
ductal, 1/38 (3%) was lobular (G I, LN-ive) and 1/38 (3%) was mixed lobular (G II, LN- 
ive). All 15/15 (100%) of metastatic IDC were invasive ductal in type.
Some normal surrounding breast tissue was found in 30/53 (57%) of total IDC and 24/53 
(45%) had associated DCIS. All G I IDC had either LNG or ING DCIS associated with 
them, none had HNG. G II IDC had all three grades of DCIS associated with them and G 
III  had  only  HNG  associated  with  them.  This  suggests  that  perhaps  GII  is  not  a  pure 
disease, some cases are similar to LNG and GI and others may be biologically similar to 
HNG  and  GUI.  The  correlation  of IDC  grades  with  the  grades  of associated  DCIS  isChapter 8: Results 150
tabulated in table 8.2. A chi-squared test showed this association to be significant with a p 
value of <0.05.
Table 8.2; Correlation of IDC histological grades with associated
DCIS grades
Histological grades of IDC
DCIS grades GI G II GUI Total
LNG 2 3 0 5
ING 2 6 0 8
HNG 0 6 5 11
Total 4 15 5 24
NUCLEAR GRADING OF DCIS BY IMAGE ANALYSIS:
The grading of 50 DCIS cases was done with the help of an image analyser on the basis 
of mean  nuclear  area  (MNA)  and  it  correlated  well  with  the  visual  grading  by  light 
microscopy  as  shown  in  table  8.3  (p  value  <0.0001  using  a  chi-squared  test).  The 
quantitation was carried out without prior knowledge of histopathological grade.
Table 83; Correlation between light microscopy and IA for DCIS grading
Visual DCIS grading by light microscopy
Mean  nuclear area (MNA) 
measurement with range of 
MNA in brackets
LNG ING HNG Total
38 (< 40 urn2) 16 2 0 18
42 (40 - 45 nm2 ) 0 17 0 17
49(> 45 urn2) 0 1 14 15
Total 16 20 14 50
RESULTS OF IMMUNOSTAINING:
The  assessment  and  scoring  of bax,  bcl2,  cerbB-2,  p53,  ER  and  Ki67  was  done  as 
described in chapter 7. Results of the scoring are tabulated in tables 8.4-8.11. Tables 8.4-
8.6  show the immunoprofiles of LNG, ING and HNG cases respectively.  Tables  8.7-8.9 
show the immunoproflles of G I, G II and G III cases (LN negative) respectively. TableChapter 8: R o u ts 151
8.10  shows  the  immunoproflles  of  metastatic  IDC  and  table  8.11  shows  the 
immunostaining results of their corresponding lymph nodes. The empty boxes under the 
bax column indicate cases that were not immunostained with this particular marker. Note 
some immunoproflles in each group suggest mixed profiles.
Table 8.4; Immunoproflles of LNG cases
No. Histology Bax Be  12 Ki67 ER p53 cerbB-2
1 LNG 2 1 63 0 1
2 LNG 2 2 2 96 0 1
3 LNG 2 3 15 20 1
4 LNG 2 2 51 0 2
5 LNG 2 3 8 70 0 2
6 LNG 3 0 5 0 0 0
7 LNG 0 0 8 17 0 2
8 LNG 1 0 7 97 0 0
9 LNG 2 2 8 94 0 0
10 LNG 2 5 49 0 1
11 LNG 3 2 5 52 0 0
12 LNG 2 0 22 0 0 0
13 LNG 2 0 4 30 0 0
14 LNG 0 0 2 13 0 0
15 LNG 2 8 54 0 1
16 LNG 1 6 48 0 1
17 LNG 3 2 1 26 0 1
18 LNG 2 2 12 53 0 2
Table 8.5; Immunoproflles of ING cases
No. Histology Bax Be  12 Ki67 ER p53 cerbB-2
1 ING 1 2 50 0 0
2 ING 0 3 1 1 0
3 ING 0 6 0 0 2
4 ING 0 1 10 75 1 1
5 ING 2 4 89 0 1
6 ING 2 3 8 78 0 0
7 ING 0 1 8 24 0 0
8 ING 1 1 14 46 0 1
Continued on next pageChapterS: Results 152
Table 8.5; Immunoproflles of ING cases
No. Histology Bax Be 12 Ki67 ER p53 cerbB-2
9 ING 2 0 13 0 6 2
10 ING 1 1 9 86 0 1
11 ING 2 2 6 91 10 0
12 ING 2 9 50 0 1
13 ING 2 2 7 63 0 2
14 ING 1 5 40 0 0
15 ING 2 32 75 10 2
16 ING 2 3 9 85 0 2
17 ING 0 1 4 83 0 1
Table 8.6; Immunoproflles of HNG cases
No. Histology Bax Be  12 KJ67 ER p53 cerbB-2
1 HNG 2 0 17 0 80 3
2 HNG 2 2 11 38 5 3
3 HNG 0 0 31 0 80 3
4 HNG 2 12 76 11 3
5 HNG 1 21 24 46 3
6 HNG 3 1 31 15 79 3
7 HNG 1 7 0 12 2
8 HNG 2 0 14 0 10 1
9 HNG 2 0 40 0 4 3
10 HNG 3 0 28 0 77 3
11 HNG 1 0 49 0 0 2
12 HNG 3 0 5 94 0 1
13 HNG 0 1 0 0 2
14 HNG 0 14 0 0 3
15 HNG 2 2 20 20 0 1
Table 8.7; Immunoproflles of IDC GI, LN negative
No. Histology Bax Be  12 Ki67 ER p53 cerbB-2
1 GI 2 1 21 50 2 1
2 GI 2 2 5 57 0 1
3 GI 0 0 2 50 0 1
4 GI 1 0 17 11 0 2
5 GI 2 2 18 39 0 1
6 GI 2 2 15 82 0 1Chapter 8: Results 153
Table 8.8; Immunoproflles of IDC GII, LN negative
No. Histology Bax Be 12 Ki67 ER p53 cerbB-2
1 GII 2 0 24 37 0 0
2 GII 0 0 21 50 0 3
3 GII 1 1 80 45 30 2
4 GII 3 0 14 10 2 3
5 GII 2 1 16 0 60 2
6 GII 2 0 7 26 0 1
7 GII 3 3 12 80 0 1
8 GII 1 3 16 70 2 0 1
9 GII 2 1 15 50 0 1
10 GII 1 2 11 60 0 1
11 GII 2 3 9 50 1 1
12 GII 2 2 10 90 1 1
13 GII 1 0 23 0 1 1
14 GII 3 3 15 53 1 3
15 GII 1 2 12 40 0 1
16 GII 3 3 14 64 0 2
17 GII 1 2 2 30 0 1
18 GII 3 2 17 78 0 1
19 GII 2 12 37 1 2
20 GII 1 3 40 0 0 2
Table 8.9; Immunoproflles of IDC GUI, LN negative
No. Histology Bax Be  12 Ki67 ER p53 cerbB-2
1 GUI 1 0 75 0 6 2
2 g iii 0 0 26 0 0 2
3 GUI 2 0 28 0 2 2
4 GIII 2 0 39 0 2 2
5 GIII 1 0 21 0 0 2
6 GIII 1 0 25 50 0 1
7 GIII 0 0 40 0 40 2
8 GIII 0 50 0 1 1
9 GIII 2 0 35 0 25 3
10 GIII 2 3 32 81 50 0
11 GIII 1 2 30 0 30 1
12 GIII 2 1 50 0 70 1Chapter 8: Results 154
Table 8.10; Immunoproflles of IDC LN positive (metastatic)
No. Histology Bax Be 12 Ki67 ER p53 cerbB-2
1 G I 0 14 61 4 1
2 GII 2 2 15 34 0 2
3 GII 2 22 37 5 3
4 GII 2 1 9 69 15 1
5 GII 2 2 27 47 1 0
6 GII 1 1 32 72 70 2
7 GII 3 2 16 50 0 0
8 GUI 2 1 33 20 10 1
9 GIII 3 0 21 0 0 2
10 GIII 1 1 28 43 30 3
11 GIII 3 3 37 56 0 1
12 GIII 1 0 27 0 50 2
13 GIII 1 0 22 0 0 1
14 GIII 1 2 18 43 10 0
15 GIII 2 0 14 0 0 2
Table 8.11; Immunoprofiles of metastatic lymph nodes
No. Histology Bax Be  12 Ki67 ER p53 cerbB-2
1 LN 0 5 63 10 1
2 LN 1 1 25 40 0 2
3 LN 2 24 30 7 3
4 LN 2 2 3 40 25 2
5 LN 1 0 30 67 0 0
6 LN 1 0 24 53 70 2
7 LN 2 13 57 0 0
8 LN 1 0 37 20 20 1
9 LN 1 0 31 0 0 3
10 LN 1 0 36 50 40 1
11 LN 1 1 25 58 0 2
12 LN 0 38 0 50 2
13 LN 1 0 32 0 0 2
14 LN 1 2 22 53 20 0
15 LN 2 0 20 20 0 1Chapter 8: Results 155
Table 8.12 shows the immunoproflles of normal breast tissue that was near the cancerous 
tissue in 30/53 (57%) of cases.
Explanation:
N G I = normal tissue near grade I IDC, LN negative.
N G 1 1  = normal tissue near grade II IDC, LN negative.
N G 111 = normal tissue near grade III IDC, LN negative.
N GI M= normal tissue near grade I metastatic IDC.
N GII M= normal tissue near grade II metastatic IDC.
N GUI M= normal tissue near grade III metastatic IDC.
Table 8.12; Immunoproflles of normal breast tissue
No. Histology Bax Be 12 Ki67 ER p53 cerbB-2
1 N GI 2 1 5 60 0 1
2 N GI 2 0 1 57 0 1
3 N GI 0 0 1 50 0 1
4 N GI 3 0 6 48 0 2
5 N GI 2 2 4 67 0 2
6 N GI 3 1 1 30 0 1
7 N GII 3 0 10 53 0 0
8 N GII 2 0 1 55 0 2
9 N GII 2 2 4 50 0 1
10 N GII 3 2 1 51 0 1
11 N GII 2 3 1 48 0 1
12 N GII 3 0 1 0 0 0
13 N GII 0 2 1 34 0 0
14 N GII 3 1 5 30 0 0
15 N GII 1 0 1 51 0 0
16 NGIII 1 1 24 28 0 2
17 N GIII 3 0 9 33 0 2
18 NGIII 2 1 1 20 0 2
19 NGIII 1 0 3 0 0 2
20 NGIII 1 0 5 50 0 1
21 NGIII 0 1 10 24 0 1
22 NGIII 0 11 58 0 1
23 NGIII 1 3 2 50 0 1
24 NGIII 3 1 1 20 0 1
25 N GI M 2 2 53 0 1
26 N GII M 2 2 40 0 1
27 N GII M 2 2 1 70 1 1
28 N GIII M 3 1 1 2 0 0
29 N GIII M 2 1 4 50 0 1
30 N GIII M 2 1 3 20 0 0Chapter 8: Results 156
Table 8.13 shows the immunostaining results of 24/53 (45%) DCIS associated with IDC.
Explanation:
LNG Gl= lower nuclear grade associated with grade I IDC.
LNG Gll= lower nuclear grade associated with grade II IDC.
ING GI= intermediate nuclear grade associated with grade I IDC.
ING G 11= intermediate nuclear grade associated with grade II IDC.
ING GII M= intermediate nuclear grade associated with grade II metastatic IDC.
HNG Gll=high nuclear grade associated with grade II IDC.
HNG Gil M=high nuclear grade associated with grade II metastatic IDC.
HNG GIII=high nuclear grade associated with grade III IDC.
HNG Gill M=high nuclear grade associated with grade III metastatic IDC.
Table 8.13; Immunoproflles of DCIS associated with IDC
No. Histology Bax Be  12 Ki67 ER p53 cerbB-2
1 LNG GI 2 1 10 60 1 1
2 LNG GI 2 2 4 66 0 1
3 LNG GII 1 1 10 57 0 0
4 LNG GII 2 3 8 80 0 1
5 LNG GII 1 1 5 40 0 1
6 ING GI 0 0 6 48 0 2
7 ING GI 2 2 6 68 0 2
8 ING GII 2 0 13 46 0 0
9 ING GII 1 0 7 0 28 2
10 ING GII 2 0 6 26 0 1
11 ING GII 3 3 12 80 0 3
12 ING GII 1 3 16 70 16 1
13 ING GII M 2 10 40 2 2
14 HNG GII 1 0 17 50 0 3
15 HNG GII 2 1 16 0 60 2
16 HNG GII 0 2 14 0 0 1
17 HNG GII 3 3 15 58 0 3
18 HNG GIII 1 0 30 0 1 2
19 HNG GIII 2 0 35 0 35 3
20 HNG GII M 2 2 12 64 10 3
21 HNG GII M 2 1 20 50 0 0
22 HNG GIII M 2 1 25 10 10 1
23 HNG GIII M 3 1 19 1 0 2
24 HNG GIII M 1 1 24 43 27 3
5/24 (21%) were LNG,  8/24 (33%) ING and  11/24 (46%) HNG. The incidence of HNG 
was higher in this group of DCIS as compared to pure DCIS.Chapter 8: Results 157
Twenty cases were repeated for cerbB-2 without antigen retrieval and gave the following 
results shown in table 8.14.
Table 8.14; Cases stained for cerbB-2 without antigen
retrieval
Number Histology Result %  Positive 
cases
1 Normal breast Negative
2 Normal breast Negative
0/15 Normal 3 Normal breast Negative
4 Normal breast Negative
5 Normal breast Negative
6 DCIS GI Negative
7 DCIS GII Negative
2/5=40% DCIS
8 DCIS GII Negative
9 DCIS Gill Positive
10 DCIS GUI Positive
11 IDC GI Negative
12 I DC GII Negative
13 IDC GII Negative
14 IDC GII Negative
15 IDC GII Negative
3/10=30% IDC
16 IDC GII Negative
17 IDC GIII Negative
18 IDC GIII Positive
19 IDC GIII Positive
20 IDC GIII PositiveChapter 8: Results 158
The incidence of bax, bcl2, Ki67, ER, p53 and cerbB-2 expression in normal breast tissue 
adjacent to IDC and in DCIS and IDC grades, metastatic IDC and lymph nodes is shown 
in  table  8.15  and  also  in  figures  8.2,  8.4,  8.6,  8.8,  8.10,  8.12.  For  Ki67,  the  range  of 
labelled cells is recorded with medians in brackets. For other markers, the actual number 
of positive cases is recorded with percentages in brackets.
Table 8.15; Incidence of bax, bc!2, Ki67, ER, p53 and cerbB-2 in normal and
cancerous breast tissue
Bax Bcl2 Ki67 ER p53 cerbB-2
Normal 19/27 9/30 1-24 27/30 0/30 7/30
(70%) (30%) (?)__ (90%) (0%) (23%)
LNG
9/12 11/18 1-22 16/18 1/18 4/18
(75%) (61%) (5) (89%) (6%) (2 2%)
ING 5/10 7/17 2-32 14/17 2/17 5/17
(50%) (41%) (8) (82%) (12%) (29%)
HNG
8/10 3/15 1-49 6/15 8/15 12/15
(80%) (2 0%) (17) (40%) (53%) (80%)
Total 22/32 21/50 1-49 36/50 11/50 24/50
DCIS (69%) (42%) (8) (72%) (22%) (48%)
GI
4/6 3/6 2-21 6/6 0/6 1/6
(67%) (50%) (16) (100%) (0%) (17%)
GII
11/19 11/20 2-80 17/20 3/20 8/20
(58%) (55%) (16) (85%) (15%) (40%)
GIII
5/11 2/12 21-75 2/12 5/12 7/12
(45%) (17%) (34) (17%) (42%) (58%)
Total 20/36 16/38 2-80 25/38 8/38 16/38
IDC
...  . . . . . .. . . (42%) (18) (66%) (21%) (42%)
IDC
8/13 6/15 9-37 11/15 6/15 7/15
(62%) (40%) (2 2) (73%) (40%) (47%)
LN
3/13 4/15 3-38 12/15 7/15 8/15
(23%) (27%) (25) (80%) (47%) (53%)
Grand 50/81 43/103 1-80 72/103 25/103 47/103
Total* (62%) (42%) (17) (70%) ....(24%)... (46%)
Grand 53/94 47/118 1-80 84/118 32/118 55/118
Total** (56%) (40%) (15) (71%) . . . . . . . . . . . .07%) (4Z°/®>_ _
*  result of all 103 cases
**  includes all 103 cases plus 15 LN=118
Note;  this was preliminary cerbB-2 analysis as on repeat, normal cases were 
negative and IDC positivity was 30% as tabulated in Table 8.14.Chapter 8: Results 159
Bax immunostaining:
The bax staining localization was predominantly cytoplasmic but in several cases nuclear 
staining  was  also  observed  (figure  8.1a).  Figure  8.1  (a-n)  shows  cases  of bax  positive 
normal breast, LNG, ING and HNG DCIS, G I, G II and G III IDC.
Normal  breast tissue adjacent to  tumour areas  showed  positive  bax  staining in  70% of 
cases. Overall, 62% of breast carcinoma cases were positive, with 69% of DCIS, 56% of 
non-metastatic IDC and 62% of metastatic IDC showing positive bax staining as depicted 
in table 8.15. Metastatic lymph nodes showed only 23% positivity. Figure 8.2 shows bax 
incidence compared in normal breast tissue, different grades of DCIS and IDC and lymph 
node metastases with their primary tumour. Normal breast tissue was also compared with 
DCIS and IDC as whole groups to enable comparison with the results in the literature.Chapter 8: Results 160
Figure 8.1;  Photomicrographs  of bax  immunostaining showing cases of normal 
breast tissue, LNG, ING and HNG DCIS, GI, GII and GIII IDC.
Figure  8.1a;  Normal  breast  tissue  positive  for  bax  showing 
cytoplasmic and some nuclear staining at a magnification x 400
Figure 8.1b; Bax positive LNG DCIS magnification *  100Chapter 8: Results 161
Figure 8.1c; Bax positive ING DCIS magnification *  100
Figure 8.Id; Another case of Bax positive ING DCIS
magnification *  100Chapter 8: Results 162
Figure 8.1e; Bax positive HNG DCIS magnification *  100
Figure 8.1f; Another case of Bax positive HNG DCIS
magnification x 100Chapter 8: Results 163
Figure 8.1g; Bax positive grade I IDC magnification *  100
Figure 8.1 h; Same case as in figure 8.1  h at magnification x 400Chapter 8: Resubs 164
Figure 8.1 j; Bax positive grade II IDC magnification *  100
Figure 8.1k; Same case as in figure 8.1k at magnification ><400Chapter 8: Results 165
Figure 8.1m; Bax positive grade III IDC magnification xlOO
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Figure 8.1n; Same case in figure 8.In at magnification x400Chapter 8: Results 166
Figure 8.2; Bar graphs showing bax incidence in different groups of patients
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Figure 8.2a;  Bax  incidence  in normal  breast tissue,  DCIS 
and IDC sub groups, metastatic primary and lymph node
Normal DCIS
Metastatic
Figure  8.2b;  Bax  incidence  in  normal  breast  tissue  as
compared  to  DCIS  as  whole  group,  IDC  lymph  node
negative and metastatic primaryChapter 8: Results 167
The mean scores and standard deviations for bax for the different patient groups in figure 
8.2 are shown in tables 8.16 and 8.17. These were done to assess variability in different 
groups.  In this case, there was no significant difference statistically. Similar calculations, 
not shown here, were also done for the other molecular markers studied.
Table 8.16; Mean and standard deviations for bax score in 
groups of patients shown in figure 8.2a
Group Mean score Standard deviation
Normal 1.925 0.997
LNG 1.833 1.029
ING 1 .2 0 1 0.918
HNG 2 .0 0 1 0.942
GI 1.501 0.836
GII 1.789 0.917
GIII 1.272 0.786
Metastatic primary 1.846 0.801
LN metastasis 1.230 0.725
Total 1.677 0.923
Table 8.17; Mean and standard deviations for bax score in 
groups of patients shown in figure 8.2b
Group Mean score Standard deviation
Normal 1.926 0.997
DCIS 1.687 0.998
IDC, LN- 1.583 0.874
Metastatic primary 1.846 0.801
Total 1.732 0.933
Bcl2 immunostaining:
The bcl2  staining localization was predominantly cytoplasmic and in several cases also 
involved the nuclear envelope. Figure 8.3 (a-b) shows bcl2 positive cases. Normal breast 
tissue  adjacent  to  tumour  areas  showed  some  cytoplasmic  and  nuclear  envelope  bcl2  
staining in at least  19/30 (63%) cases and 8/30 (27%) of these were considered positive 
which  served  as  internal  positive  controls  in  bcl2  negative  tumours.  Overall,  42%  of 
breast carcinoma cases were positive, with 42% DCIS, 42% non-metastatic IDC and 40% 
metastatic  IDC  showing  positive  staining  as  shown  in  table  8.15  and  figure  8.4.  The 
metastatic LNs showed positivity in 27% of cases.Chapter 8: Results 168
Figure 8.3; Photomicrographs of bc!2 positive normal breast and DCIS.
V
Figure 8.3a; Normal breast tissue positive for bcl2 
magnification x 400
Figure 8.3b; A micropapillary ING DCIS showing bcl2 positivity
at a magnification of x 100Chapter 8: Results 169
Figure 8.4; Bar graphs showing bc!2 incidence in different groups of patients
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Figure  8.4b;  Bcl2  incidence  in  normal  breast  tissue  as
compared  to  DCIS  as  whole  group,  IDC  lymph  node
negative and metastatic primaryChapter 8: Results 170
Ki67 immunostaining:
Ki67 immunostaining was nuclear as shown in figure 8.5. However 4/118 cases showed 
strong membrane staining including one HNG  DCIS, one GIII  non-metastatic  IDC and 
one metastatic  IDC  with its corresponding LN.  These were repeated at least 3  times to 
confirm the results and showed the same result on repeat. The significance of this finding 
is unclear. Normal tissue adjacent to tumour had a median Ki67 labelling index (LI) of 2. 
Overall, the median LI was  17 in the  103 breast carcinoma cases, with a median of 8 in 
DCIS cases,  18 in non-metastatic IDC, 22 in metastatic IDC and 25  in metastatic LN as 
shown in table 8.15 and figure 8 .6 .
Figure 8.5; Photomicrograph of a case showing Ki67 staining
%
Figure 8.5; A case of HNG DCIS showing nuclear staining with 
MIB1 antibody for Ki67, magnification x 400.Chapter 8: Results 171
Figure 8 .6 ; Bar graphs showing median values for Ki67 labelling index in different
groups of patients.
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Figure  8 .6 a;  Ki67 incidence in normal breast tissue, DCIS 
and IDC sub groups, metastatic primary and lymph node
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Figure  8.6b;  Ki67  incidence  in  normal  breast  tissue  as
compared  to  DCIS  as  whole  group,  IDC  lymph  node
negative and metastatic primaryChapter 8: Results 172
ER immunostaining:
ER staining was nuclear as shown in  figure 8.7. There was occasional pale cytoplasmic 
staining of tumour cells in some cases. The proportion of weakly staining nuclei as well 
as moderately to darkly staining nuclei was recorded in each case.  In some cases, a few 
stromal  and  myoepithelial  cells  also  stained  positively  for  ER.  Normal  breast  tissue 
adjacent to tumour was positive in 90% of cases. Overall, 70% of breast carcinoma cases 
were ER positive, with 72% of DCIS, 6 6 % of non-metastatic IDC, 73% of metastatic IDC 
and 80% of metastatic LN showing ER positivity. This is shown in table 8.15 and figure 
8 .8 . The relatively high number of positive cases in the metastatic group could either be 
due to the  small  number of cases  in this  group or it could be that  high  grade  tumours 
which are also ER positive are particularly liable to metastasise.
Figure 8.7; Photomicrograph of an ER positive case
Figure 8.7; Normal breast tissue showing nuclear staining for ER
at a magnification of x 400.Chapter 8: Results 173
Figure 8 .8 ; Bar graphs showing ER incidence in different groups of patients
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Figure  8 .8 a;  ER  incidence  in  normal  breast  tissue,  DCIS 
and IDC sub groups, metastatic primary and lymph node
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Figure  8.8b;  ER  incidence  in  normal  breast  tissue  as
compared  to  DCIS  as  whole  group,  IDC  lymph  node
negative and metastatic primaryChapter 8: Results 174
P53 immunostaining:
P53 immunostaining was nuclear as shown in figure 8.9. In some cases, stromal cells also 
stained positively. None of the normal breast tissue exhibited positive p53 staining except 
a  very  few cells  in  some  cases,  and  even that  was restricted  to  less than one  cell  per 
thousand. Therefore, with the cut-off of 10% for p53 staining, none of the normal tissues 
was considered positive. Overall, 24% of breast carcinoma cases were p53 positive, with 
22% of DCIS, 21% of non-metastatic IDC, 40% of metastatic IDC and 47% of metastatic 
lymph nodes. This is shown in figures 8.10 and table 8.15.
Figure 8.9; Photomicrograph of a p53 positive case.
Figure 8.9; A case of HNG DCIS showing p53 nuclear staining at 
a magnification of x 400.Chapter 8: Results 175
Figure 8.10; Bar graphs showing p53 incidence in different groups of patients.
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Figure 8.10a; P53 incidence in normal breast tissue, DCIS 
and IDC sub groups, metastatic primary and lymph node
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Figure  8.10b;  P53  incidence  in  normal  breast  tissue  as
compared  to  DCIS  as  whole  group,  IDC  lymph  node
negative and metastatic primaryChapter 8: Results 176
CerbB-2 immunostaining:
CerbB-2 staining was membranous as shown in figure 8.11. In the initial analysis, 23% of 
normal breast tissues were positive. However, none of the normal tissues had a score of 3, 
all positive cases had a score of 2.  Therefore, some cases were reanalysed  for cerbB-2 
according to UK guidelines and when normal cases were repeated without microwaving, 
none was positive.  Overall,  initially 46% of breast carcinoma cases were positive, with 
48% of DCIS, 42% of non-metastatic IDC, 47% of metastatic IDC and 53% of metastatic 
LN. This is shown in table 8.15 and figure 8.12. On repeat without microwaving,  cerbB- 
2 positivity was found to be 30% (3/10) in IDC and 40% (2/5) in DCIS cases as shown in 
table 8.14.
Figure 8.11; Photomicrograph of a cerbB-2 positive case.
Figure 8.11; A case of HNG DCIS showing strong membrane 
staining for cerbB-2, magnification x 400.Chapter 8: Results 177
Figure 8.12; Bar graphs showing cerbB-2 incidence in different groups of patients
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Figure  8.12a;  cerbB-2  incidence  in  normal  breast  tissue, 
DCIS  and  IDC  sub groups,  metastatic primary  and  lymph 
node
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Figure 8.12b; cerbB-2 incidence in normal breast tissue as
compared  to  DCIS  as  whole  group,  IDC  lymph  node
negative and metastatic primaryChapter 8: Results 178
RESULTS OF STATISTICAL ANALYSIS:
CORRELATIONS OF MARKERS WITH DIFFERENT GROUPS:
The  values  of molecular markers  studied,  bax,  bcl2,  Ki67,  ER,  p53  and  cerbB-2  were 
compared in different patient groups and different samples (areas within sections from the 
tissues  of these  patients)  employing  Mann-Whitney  or  Kruskal  Wallis  tests  and  the 
following analyses were made:
Normal Tissues Compared to LNG, ING and HNG DCIS, GI, GII and GIII IDC LN 
Negative, IDC LN Positive and Lymph Node Metastases:
In the first analysis, the normal tissues (surrounds of cancerous tissues) were compared 
against the other groups and the markers which significantly differed between the groups 
are shown in table 8.18.
Table 8.18; Groups compared against each other for molecular markers
No. Group (number) Molecular markers (p values)
1 Normal (30) versus LNG (18) Ki67 (0.034)
2 Normal versus ING (17) Ki67 (0.001), p53 (0.009)
3 Normal versus HNG (14)
Ki67 (<0.0001), ER (0.002)(-), p53 
(0.0001), cerbB-2 (<0.0001)
5 Normal versus G I (6) Ki67 (0.005)
6 Normal versus G 11 (19) Bcl2 (0.047), Ki67 (<0.0001), p53 
J0.0001), cerbB-2 (0.002)
7 Normal versus G III (12) Ki67 (0.0001), ER (0.0001)(-), p53 
10.0001), cerbB-2 (0.044)
8
Normal versus Metastatic 
primary (15)
Ki67 (<0.0001), p53 (<0.0001)
9
Normal versus Metastatic 
LN (15)
Bax (0.027X-), Ki67 (<0 .0 0 0 1 ), p53 
(<0 .0 0 0 1 )
Minus sign (-) indicates a lower value in the latter group.Chapter 8: Results 179
Normal Tissues Compared to DCIS and IDC as Whole Groups:
In the next analysis, normal tissues (n=30) were compared against pure DCIS (n=49) and 
the  three markers  significantly  higher in  DCIS  were  Ki67,  p53  and  cerbB-2  (p values 
<0.0001, 0.002 and 0.003 respectively).
Normal  tissues were  also compared  against  IDC  LN  negative  (n=37)  with which they 
were associated and again the three markers which were significantly higher in the latter 
group were Ki67, p53 and cerbB-2 (p values <0.0001, <0.0001 and 0.01 respectively).
Comparison between DCIS Subgroups:
The subgroups within the pure DCIS group (n=49) were compared against each other as 
follows: LNG (n=18) versus ING (n=17) versus HNG (n=14) and the p values are shown 
in table 8.19 below:
Table 8.19; p values of molecular markers in DCIS subgroups
Markers LNG versus ING 
(p values)
ING versus HNG 
(p values)
Bax 0.159 0.134
Bcl2 0.909 0.05 (-)
Ki67 0.05 0 .0 0 1
ER 0.483 0.004 (-)
p53 0 .0 2 <0 .0 0 0 1
cerbB-2 0.732 <0 .0 0 0 1
Negative correlations with the increasing grade of DCIS are indicated by minus (-) sign. 
Except bax, the rest of the markers were  significantly related to the nuclear grades of 
DCIS.  Bcl2  and  ER  showed  a  negative  correlation  with  increasing  nuclear  grades  of 
DCIS as expected; and Ki67, p53 and cerbB- 2 showed a positive correlation.
Figures 8.13a-c show an LNG case positive for bax, bcl2 and ER respectively.  Figures 
8.14a-c show an HNG case positive for Ki67, p53 and cerbB-2 respectively and figures 
8.15a-b show another HNG case positive for cerbB-2.Chapter 8: Results 180
Figure 8.13; Photomicrographs of an LNG DCIS case positive for bax, bcL2 & ER.
Figure 8.13a; Bax positive LNG, magnification x 200
Figure 8.13b; Same LNG case as in 8.13a showing bcl2 positivity
at a magnification x 100Chapter 8: Results 181
Figure 8.13c; Same LNG case as in 8.13a showing ER positivity, 
magnification x 100
Figure 8.14; Photomicrographs of an HNG DCIS case positive for Ki67, p53 and 
cerbB-2.
Figure  8.14a;  Ki67  immunostaining  in  an  HNG  case  at  a
magnification x 100Chapter 8: Results 182
Figure 8.14b; Same HNG case as in 8.14a showing p53 positivity 
at a magnification xlOO
Figure 8.14c; Same case as in 8.14a showing cerbB-2 positivity at
a magnification x 100Chapter 8: Results 183
Figure 8.15; Photomicrographs of an HNG DCIS case positive for cerbB-2.
Figure  8.15a;  Another  HNG  case  positive  for cerbB-2  showing 
the normal looking duct near the bottom of the picture to be cerbB- 
2 negative, magnification x 50
Figure 8.15b; Same case as in 8.15a at a magnification x 400Chapter 8: Results 184
Comparison Between IDC (LN negative) Subgroups:
The subgroups within IDC  LN-ve cases (n=37) were also compared against each other: 
G I (n=6 ) versus G II (n=19) versus G III (n=12) and the p values are depicted in table 
8.20.
Table 8.20; p values of Molecular Markers in IDC subgroups
Markers GI versus GII (p values) GII versus GUI (p values)
Bax 0.642 0.363
Bcl2 0.355 0.027 (-)
Ki67 0.882 <0 .0 0 0 1
ER 0.656 0.004 (-)
p53 0.355 0 .0 2 0
cerbB-2 0.324 0.042
Negative correlations with the increasing grade of DCIS are indicated by minus (-) sign. 
Once again, all the markers correlated significantly with the histopathological grades of 
non-metastatic IDC except Bax. Figure 8.16 shows a G I IDC case positive for Bcl2 and 
figure  8.17  shows the same case staining positively for ER.  Figure  8.18  shows a G  III 
IDC case positive for Ki67 and same case is positive for p53 as shown in figure 8.19.
Comparison between Comparable Subgroups of Pure DCIS and IDC LN Negative:
The subgroups of pure DCIS and non-metastatic IDC were compared against each other 
and the markers which differed significantly between the two are shown in table 8 .2 1 .
Table 8.21; Subgroups compared against each other for molecular markers
No. Sub - group (number) Molecular markers (p value)
1 LNG (18) versus GI (5) Ki67 (0.09)
2 ING (17) versus GII (19) Ki67 (<0.0001)
3 HNG (14) versus GUI (12) Ki67 (0.003), cerbB-2 (0.021)(-)
In the above, Ki67 is higher in the latter groups, whereas cerbB-2 is significantly lower in 
GUI as compared to HNG indicated by a minus (-) sign.Chapter 8: Results 185
Figure 8.16; Photomicrograph of a G I IDC case positive for bc!2.
Figure 8.16a; G I IDC positive for bc!2, magnification x 50
Figure 8.16b; Same case as in figure 8.16a, magnification x 400Chapter 8: Results 186
Figure 8.17; Photomicrograph of a G I IDC case positive for ER.
Figure 8.17a;  Same  GI  IDC  case as  in  figure  8.16,  positive  for 
ER, magnification x 50
Figure  8.17b;  Same  case  as  in  8.16  and  8.17a,  showing  the
different  intensity  staining  of  the  nuclei  for  ER  at  a
magnification x 400Chapter 8: Results 187
Figure 8.18; Photomicrograph of a G III IDC case positive for Ki67.
Figure  8.18a;  GUI  IDC  showing  Ki67  immunostaining  at  a 
magnification of x 100
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Figure 8.18b; Same case as in 8.18a, magnification x 400Chapter 8: Results 188
Figure 8.19; Photomicrograph of a G III IDC case positive for p53
Figure 8.19a; Same case as in figure 8.18 showing p53 positivity 
at a magnification of x 2 0 0
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Figure 8.19b; Same case as in figures 8.18 and 8.19a showing p53
positivity at a magnification of x 400Chapter 8: Results 189
Comparison Between Pure DCIS and IDC LN Negative:
Ki67  was  significantly  higher  in  LN  negative  IDC  (n=37)  as  compared  to  pure  DCIS 
(n=49), the p value being <0.0001.
Comparison Between Non-Metastatic and Metastatic IDC:
IDC LN negative (n=37) and IDC LN positive (n=15) cases were compared against each 
other, but no significant difference with respect to expression of molecular markers was 
found between the two groups. The analysis was carried out twice first including all the 
lymph  node  negative  cases  and  second  excluding  the  six  cases  (16%)  which  were 
clinically lymph node negative, in view of high clinical false negative rate. This could be 
partly  due  to  the  small  number  of metastatic  cases  or  possibly  due  to  other  markers 
involved in the step from invasion to metastasis.
Comparison Between IDC (LN Positive) and Their Corresponding Lymph Nodes:
The 15 metastatic IDC were compared against their 15 involved lymph nodes and in this 
case  only  bax  expression  was  significantly  different  between  the  two,  being  much 
reduced in the lymph node metastases, with a p value of 0.045. The expression of the rest 
of the  markers  was  not  significantly  different.  Figure  8.20  illustrates  a  LN  metastasis 
showing immunostaining for various markers.Chapter 8: Results 190
Figure 8.20; Photomicrographs of a metastasis-containing lymph node positive for 
(a) bc!2, (b) ER, (c) Ki67, (d) p53, (e) cerbB-2 and (f) bax
b   ^
Figure 8.20a; Photomicrograph of a metastasis-containing lymph 
node positive for bcl2, magnification x 100
Figure 8.20b; Photomicrograph of a metastasis-containing lymph
node positive for ER, magnification x 100Chapter 8: Results 191
Figure 8.20c; Photomicrograph of a metastasis-containing lymph 
node positive for Ki67, magnification x 100
Figure 8.20(1; Photomicrograph of a metastasis-containing lymph 
node positive for p53, magnification x 100Chapter 8: Results 192
Figure 8.20e; Photomicrograph of a metastasis-containing lymph 
node positive for cerbB-2, magnification x 100
Figure 8.20f; Photomicrograph of a metastasis-containing lymph
node positive for bax, magnification x 100Chapter 8: Results 193
Comparison Between DCIS and IDC as Whole Groups:
In the next step, all DCIS (n=73) cases including pure DCIS (n=49) and DCIS associated 
with IDC (n=24) were compared against all IDC (n=52) cases including non-metastatic 
(n=37) and metastatic (n=15) and the only marker significantly different between these 
two groups was Ki67, being higher in the latter group, p value<0.0001.
Comparison Between Pure DCIS and DCIS Associated With IDC:
Pure DCIS (n=49) cases were also compared with DCIS associated with IDC (n=24) and 
in this case the only marker significantly different between the two groups was Ki67 ( p 
value = 0.024), being higher in the latter group.
Comparison between DCIS and its associated IDC:
DCIS associated with IDC (n=24) were compared against IDC (n=37) with which these 
were associated. Once again, Ki67 was the differentiating marker between the two, being 
higher in IDC (p value = 0.015).
CORRELATIONS OF MARKERS WITH COMEDO-TYPE NECROSIS:
Comedo-type  necrosis  was  significantly  related  to  high  Ki67  labelling  index  (>10% 
labelled cells) and to p53  and cerbB-2 positivity, the p values being 0.001, <0.001  and 
0 .01 respectively as shown in table 8 .2 2.
Table 8.22; Distribution of molecular markers in cases with and
without necrosis.
Molecular
markers
Cases with 
necrosis
Cases without 
necrosis p value
Ki67  high (>10%) 
Ki67 low (<10%)
11
5
5
2 0
0 .0 0 1
p53+
p53-
9
7
2
23 <0 .0 0 1
cerbB-2+ 11 8
0 .01 cerbB-2- 5 17Chapter 8: Results 194
CORRELATIONS BETWEEN MARKERS:
The correlations between  all the markers-  bax,  bcl2,  Ki67,  ER, p53  and cerbB-2  were 
studied  using  Spearman’s  rank  correlation  test,  which  is  a  non-parametric  test,  as  the 
histograms  revealed  distribution  of these  markers  was  not  normal.  These  correlations 
were studied within the following groups:
1-  All  101  patients  including  49  pure  DCIS  cases,  37  non-metastatic  IDC  and  15 
metastatic cases (table 8.23).
2-  All  170  samples  including the above  101  cases,  plus  15  metastatic  LN,  30  normal 
breast tissue areas associated with IDC and 24 DCIS associated with IDC (table 8.24).
3-  All 73 DCIS cases including 49 pure DCIS and 24 DCIS associated with IDC (table 
8.25).
4-  All 52 IDC cases including 37 non-metastatic and 15 metastatic (table 8.26).
5-  All 23  LNG DCIS  including  18  from pure  DCIS  group and 5  associated with IDC 
(table 8.27).
6-  All 25  ING  DCIS  including  17  from pure DCIS  group and  8  associated with  IDC 
(table 8.28).
7-  All 25 HNG DCIS including  14 from pure DCIS group and  11  associated with IDC 
(table 8.29).
8-  All 7 G I IDC including 6 non-metastatic and 1  metastatic (table 8.30).
9-  All 25 GII IDC including 19 non-metastatic and 6 metastatic (table 8.31).
10- All 20 G III IDC including 12 non-metastatic and 8 metastatic (table 8.32).
11 - All 15 metastatic LN ( table 8.33).
Negative correlations are indicated by a minus (-) sign. Some boxes have been left blank 
to avoid repetition of the same correlations.
Table 8.23; Nonparametric correlations-all cases (101), p values are shown
Bax Bcl2 Ki67 ER p53
Bax
Bcl2 0.010*
Ki67 0.400 0.061(-)
ER 0.261 <0.0001**
I
*
*
©
o
©
p53 0.837 0.302 <0.0001** 0.008**(-)
cerbB-2 0.911 0.165 <0.0001**
I
*
*
O
o
© <0.0001**
♦Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed).Chapter 8: Results 195
It  can  be  seen  from  the  above  table  that  significant  positive  correlations  were  found 
between  bax  and  bcl2,  bcl2  and  ER,  Ki67  and  p53,  Ki67  and  cerbB-2,  and  p53  and 
cerbB-2. Significant negative correlations were seen between ER and Ki67, ER and p53, 
and ER and cerbB-2. There was a trend towards negative correlation between bcl2 and 
Ki67.
Table 8.24;Nonparametric correlations-all samples (170), p values are shown
Bax Bcl2 K167 ER p53
Bax
Be  12 0.002**
K167 0.018*(-) 0.019*(-)
ER 0.122 <0.0001** <0.0001 *♦(-)
p53 0.208 0.364 <0.0001** 0.005**(-)
cerbB-2 0.682 0.246 <0.0001** 0.001**0 <0.0001**
* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed).
In all the 170 samples, once again there were positive correlations demonstrated between 
bax  and  bcl2,  bcl2  and  ER,  Ki67  and  p53,  Ki67  and  cerbB-2,  and  p53  and  cerbB-2. 
Significant negative correlations were observed between bax and Ki67, bcl2 and Ki67, 
Ki67 and ER, ER and p53, and ER and cerbB-2. Therefore, by increasing the number of 
samples, two additional negative correlations, that is between bax and Ki67 and between 
bcl2 and Ki67, became apparent.
Table 8.25;Nonparametric correlations-all DCIS (73), p values are shown
~3- Bax I  Bcl2 Ki67 ER
Bax  |
Bcl2  ||_ 0.066 II  ...............
Ki67 0.937 0.199  |
ER  | 0.811 J   <0.0001**  | 0.006**(-) 1   ....
P53  | 0.893 0.189 <0.0001** 0.002**0
cerbB-2  | 0.468 J   0.823 <0.0001** J   0.032*(-)  I <0.0001**
♦Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01  level (2-tailed).
Within  all  DCIS,  positive  correlations  were observed between bcl2  and  ER,  Ki67  and 
p53,  Ki67  and  cerbB-2,  and  p53  and  cerbB-2.  There  was  a  trend  towards  positive 
correlation between bax and bcl2.  There were significant negative correlations between 
Ki67 and ER, ER and p53, and ER and cerbB-2.Chapter 8: Results 196
Table 8.26; Nonparametric correlations-all IDC (52), p values are shown
Bax Bcl2 Ki67 ER p53
Bax
Bcl2 0.014*
Ki67 0.136 0.073(-)
ER 0.052 <0.0001** 0.001 **(-)
p53 0.397 0.721 0.001** 0.342
cerbB-2 L  0.735 0.132 0.324 0.029*(-) 0.369
•Correlation is significant at the.05 level (2-tailed). 
••Correlation is significant at the.01  level (2-tailed).
The significant positive correlations within IDC cases were between bax and bcl2, bcl2 
and ER, and Ki67 and p53. The significant negative correlations were between Ki67 and 
ER and cerbB-2 and ER. There was a trend toward positive correlation between ER and 
bax; and a trend toward negative correlation between Ki67 and bcl2.
Table 8.27; Nonparametric correlations LNG cases (23), p values are shown
Bax Be  12 Ki67 ER p53
Bax
Bcl2 0.099
Ki67 0.541 0.597
ER 0.811 0.012* 0.505
_p53 0.832 0.926 0.843 0.633
cerbB-2 0.814 0.014* 0.943 0.577 0.646
•Correlation is significant at the 0.05 level (2-tailed).
The two significant positive correlations in this subgroup were between bcl2 and ER and 
bcl2 and cerbB-2. There was a trend towards positive correlation between bax and bcl2.
Table 8.28; Nonparametric correlations ING cases (25), p values are shown
Bax Bcl2 Ki67 ER p53
Bax
Bcl2 0.171
Ki67 0.656 0.189
ER 0.644 <0.0001** 0.882
p53 0.652 0.967 0.115 0.525
cerbB-2 0.358 0.525 0.125 0.860 0.564
** Correlation is significant at the 0.01 level (2-tailed).
In ING cases, there was a positive correlation between bcl2 and ER.Chapter 8: Results 197
Table 8.29; Nonparametric correlations HNG cases (25), p values are shown
1 Bax Be  12 Ki67 ER p53
Bax  |  I   I
Be  12 1 0.484 1
Ki67 1 0.388 1 0.118
ER I I 0.162 1 0.004" 1 0.138 I I
p53 I I 0.935 I I 0.644 0.150 0.259
cerbB-2 1 0.864 I I 0.816 I I 0.366 1 0.690 [  0.015^
♦Correlation is significant at the 0.05 level (2-tailed). 
♦♦Correlation is significant at the 0.01  level (2-tailed).
In HNG cases, there was a positive correlation between bcl2 and ER and p53 and cerbB- 
2. It is interesting to note that in LNG cases, there was a positive correlation between bcl2 
and cerbB-2, whereas in HNG cases, there was a positive correlation between p53 and 
cerbB-2.
Table 830; Nonparametric correlations GI cases (7), p values are shown
Bax Be  12 Ki67 ER p53
Bax
Bcl2 0.022*
Ki67 0.305 0.618
ER 0.396 0.554 0.379
p53 0.550 0.394 0.631 0.525
cerbB-2 0.353 0.322 0.661 0.139 0.582
♦Correlation is significant at the  0.05 level (2-tailed).
The significant correlation in GI cases was between bax and bcl2.
Table 8.31; Nonparametric correlations GII cases (25), p values are shown
Bax Bcl2 Ki67 ER p53
Bax
Be  12 0.287
Ki67 0.271 0.402
ER 0.262 0.057 0.459
p53 0.600 0.499 0.234 0.904
cerbB-2 0.825 0.639 0.589 0.740 0.265
There was a trend toward positive correlation between bcl2 and ER in GII cases.Chapter 8: Results 198
Table 832; Nonparametric correlations GUI cases (20), p values are shown
Bax Be  12 Ki67 ER p53
Bax
Be  12 0.307
Ki67 0.628 0.618
ER 0.485 0.001 ♦♦ 0.735
p53 0.672 0.076 0.041 ♦ 0.781
cerbB-2 0.693 0.006"(-) 0.964 0.029+(-) 0.813
♦Correlation is significant at the 0.05 level (2-tailed). 
♦♦Correlation is significant at the 0.01  level (2-tailed).
The  significant positive correlations  within GUI  cases  were  between bcl2  and  ER  and 
Ki67 and p53, whereas negative correlations occurred between bcl2 and cerbB-2 and ER 
and cerbB-2.
Table 833; Nonparametric correlations-metastatic LN (15), p values are shown
Bax  Be  12 Ki67 ER P53
Bax
Bcl2 0.102
Ki67 0.001 ♦♦(-) 0.033 ♦(-)
ER 0.414 0.386 0.077(-)
p53 0.260 0.728 0.728 0.872
cerbB-2 |  0.286 0.976 0.486 0.033 ♦(-) 0.908
♦Correlation is significant at the.05 level (2-tailed).
♦♦ Correlation is significant at the .01  level (2-tailed).
Within  the  lymph  nodes  with  metastatic  tumour,  all  significant  correlations  were 
negative; between bax and Ki67, between bcl2 and Ki67 and between ER and cerbB-2. 
There was a trend towards negative correlation between ER and Ki67.Chapter 8: Results 199
RESULTS OF PCR:
Of the 32/118 (27%) samples that were positive for p53 protein by immunostaining,  18 
were amplified with the polymerase chain reaction (PCR) for exons 5-8 of the P53 gene. 
Two other cases, which had more than 5% cells labelled with p53  were also amplified, 
making a total of 20 cases. These included 10 DCIS (1  LNG, 2 ING, 7 HNG),  8 IDC LN- 
ive (0 G I, 3 G II, 5 G III),  1   IDC LN+ive and  1   LN metastasis. Figures 8.21-8.29 show 
the pictures of ethidium bromide stained gels of cases 1-20 amplified for exon 5-8, where 
L =  lOObp DNA ladder, + = positive control and  -   = negative control. All the pictures 
contain wells in which samples were loaded, at the top. The direction of the arrow along 
x-axis indicates the direction in which samples were loaded and the direction of arrow 
along y-axis shows the direction in which DNA molecules migrated. The smallest DNA 
molecules move fastest and hence  100 bp molecules within the DNA ladder migrate the 
most. The exons 5 - 8 of P53 gene were all between 100 - 300 bp.
Figure 8.21;  Amplification products of exon 5 of P53 for cases 
1  - 8, showing all cases contain DNA between 100 - 300 bpChapter 8: Results 200
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Figure 8.22; Amplification products of exon 5 for cases 9 - 13 on 
the top side of the picture and cases  14 - 20 at the bottom of the 
picture  showing  all  cases  except  no.  13  contain  DNA  between 
100 - 300 bp. The  ladder at bottom of the picture is not clearly 
visible
-  1 0   9 8 7 6 5 4 3 2 1   +   L
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4
Figure  8.23;  Amplification  products  of exon  6  for cases  1-10 
showing cases  no.  1,  2,  3,  5  7,  9  and  10  contain  DNA  between 
100-300 bpChapter 8: Results 201
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Figure  8.24;  Amplification  products  of exon  6  for  cases  11-20 
showing cases no.  11,  13,  15,  16,  18 and 20 contain  DNA  between 
100 - 300 bp, in cases  14 and  16 additional DNA fragments smaller 
than 1  OObp can be seen migrating further downwards
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Figure  8.25;  Amplification  products  of exon  7  for  cases  1   -   9 
showing all cases contain  DNA between  100 - 300 bp. The  100 bp 
DNA ladder was accidentally loaded twiceChapter 8: Results 202
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Figure  8.26;  Amplification  products  of exon  7  for  cases  10-20 
showing all cases contain DNA between 100 - 300 bp
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Figure  8.27;  Amplification  products  of exon  8  for  cases  1   -  4 
showing all cases contain DNA between  100 -  300 bp. There is some 
smudging effect seen in the case of negative control possibly due to 
primer effect.  The empty  lane between 2 and 3  indicates that it was 
not loaded with a sample as the well was brokenChapter 8: Results 203
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Figure 8.28; Amplification products of exon 8 for cases 5 -9  showing 
all cases contain DNA between 100 - 300 bp
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Figure 8.29; Amplification products of exon 8 for cases  10-20 showing 
all cases contain DNA between  100 -  300 bp. Two positive controls were 
used with these casesChapter 8: Results 204
Table 8.34 shows the results of amplification of exons 5-8 of P53 gene by PCR for the 20 
cases and the results of p53  immunostaining expressed as percent positive cells for the 
same cases.  Plus and minus signs indicate the detection or absence of a particular exon 
respectively.
Table 834;Cases positive for p53 by immunostaining and amplified for exon 5-8 of PS3
No. Histology p53 (%) Exon 5 Exon 6 Exon 7 Exon 8
1 LNG 20 + + + +
2 ING 6 + + + +
3 ING 10 + + + +
4 HNG 80 + - + +
5 HNG 5 + + + +
6 HNG 46 + - + +
7 HNG 79 + + + +
8 HNG 12 + - + +
9 HNG 10 + + + +
10 HNG 77 + + + +
11 GII 30 + + + +
12 GII 60 + - + +
13 GII 20 - + + +
14 GIII 16 + - + +
15 GIII 25 + + + +
16 GIII 50 + + + +
17 GIII 30 + - + +
18 GIII 70 + + + +
19 G III LN+ive 10 + - + +
20 Metastatic LN 20 + + + +
Cases 4, 6,  8,  12,  14,  17 and  19 did not show the presence of exon 6 and case  13  was 
negative for exon 5. This seems probably to be due to some technical problem with exon 
6 amplification, resulting in undetectable quantity of DNA. If there were true deletion of 
exon 6, then all other exons would also be absent in these cases resulting in deletion of 
whole of P53 gene. Alternatively, there could be deletion or mutation in exon 6 in these 
cases.  Case  13  probably did not have enough DNA in it to allow detection of exon 5. 
Generally, all cases positive for p53 by immunostaining had exons 5, 7 and 8 detectable 
by PCR and most cases also had exon 6. All the samples had repeat PCR performed byChapter 8: Results 205
MWG  Biotech  to  double  check  results  and  they  were  similar.  The  next  question  was 
whether these had any p53 mutation as determined by DNA sequencing.
RESULTS OF SEQUENCE ANALYSIS:
Unfortunately, the samples could not be sequenced, the probable reason being that they 
had a secondary structure which meant that the sequencing primers could not work. The 
PCR was repeated by MWG Biotech to confirm that PCR worked, which was reported 
that it did.  However, they were unable to sequence it.  It is possible that cloning of the 
PCR product in a specific vector could help to sequence these samples.
FTIR ANALYSIS OF BREAST TISSUES:
In this  study,  FTIR-Attenuated  Total  Reflectance  (ATR)  microspectroscopy  and  FTIR 
Chemical Imaging were employed to study the biochemical changes taking place within 
the breast carcinoma. FTIR spectra of the normal breast tissue were compared with the 
malignant tissue.  Different grades of DCIS (LNG, ING and HNG) and IDC (GI, GII and 
GIII) were analysed  as shown in table 8.35.
Table 835; Number of cases studied with FTIR, 
FTIR Chemical imaging and FT-Raman
No. Histology Total number of Cases
1 Normal 7
2 LNG 10
3 ING 10
4 HNG 10
5 GI 10
6 GII 10
7 GIII 10
Total Number 67
FTIR Spectroscopic Differences between Normal, DCIS and IDC:
The FTIR spectra of the normal breast tissue, a case of HNG DCIS and a case of GIII 
IDC  are  given  in  figure  8.30.  The  most  noticeable  feature  of each  spectrum  is  the 
complexity,  with prominent absorption in almost all  regions of the  spectra.  Significant 
differences exist both in the absolute and relative intensities of the absorption bands of the 
spectra. The significance is spectroscopic, not statistical as in spectroscopy, a differenceChapter 8: Results 206
of 10 wavelengths is considered significant. The reason that DCIS and IDC of same grade 
gave  different  spectra  as  opposed  to  no  difference  suggested  by  the  initial  molecular 
marker  study  could  be  that  by  immunohistochemistry  only  6  markers  were  studied, 
whereas  an  FTIR  spectrum  was  a  collective  reflection  of total  number  and  types  of 
proteins in each case, which could have been more than  100,000. Before the spectrum of 
cancer tissue is discussed in detail  it is important to characterise the positioning of the 
peaks and their assignment for the normal tissue.
The  FTIR  spectrum  of normal  tissue  has  well  defined  peaks  in the  region of 3500  to 
650cm'1   (see figure  8.30 and table  8.36).  Assignment of the peaks is attributed to the 
previous  infrared  spectroscopic  studies  on  natural  tissues  and  on  cellular  organic 
macromolecules (1 1-2 1).
A broad band centred  at  3285cm'1   indicates the  presence of amino  groups.  Secondary 
amines  and arylamines  exhibit only  a single  characteristic  infrared  band  in the N -  H 
stretching  region  (3500  -   3100cm'1 ).  A  weak  infrared  band  present  in  the  region  of 
(3050 -  3070cm'1) is characteristic of secondary amides.
The region between 3100 to 2700cm'1  is due to the presence of C -  H vibrations of lipids, 
proteins and DNA.  The peak centred at 2958cm'1   is due to CH3 antisymmetric stretch. 
Peaks  centred  at  2920  and  2850cm'1   confirm  the  presence  of CH2  antisymmetric  and 
symmetric stretches respectively.
The strong absorption band  in the region of 1700 to  1600cm'1   is arising from (C  = O) 
vibrations of the amide groups of polypeptide chains.  In the infrared spectrum, (C = O) 
bands tend to be among the strongest and this intensity of the carbonyl band makes the 
detection of this group simpler.
The peak centred at  1656cm'1   is due to bonded (C = O) and band at  1538cm'1   confirms 
the presence of C -  N -  H moieties.  Mono substitute amides usually exist with the NH 
and (C = O) bonds.  The hydrogen bonded stretch is seen near 3290cm'1   with a weaker 
band near 3070  cm' 1  is  a  Fermi  resonance enhanced overtone of 1538cm'1   band.  This 
band at  1538cm'1   involves both (C -  N)  stretch and (C -  N -  H) in-plane bend in the 
amide II band. This band is a characteristic for mono-substituted amides. Amide III bands 
absorb more weakly and are confirmed by the presence of peaks at 1310 and 1260cm'1.Wavenumbers (cm-1)
Figure 8.30; FTIR Spectra of Normal, DOS (HNG) and IDC (GUI) Breast Tissues 
Where; Blue = Normal, Red = DCIS and Black = IDCChapter 8: Results 208
Table 836; Peak assignments of the FTIR spectra of normal breast tissue and
breast carcinoma (cm'1 )
Peak Assignment Normal
DCIS
LNG
DCIS
ING
DCIS
HNG
IDC
GI
IDC
GII
IDC
GUI
N - H vibrations  3600 - 3100 cm'1
N -  H (bonded stretch, primary amines) 3290 3288 3288 3288 3286 3286 3287
N -  H (bonded stretch, secondary amines) 3086 3084 3084 3085 3083 3083 3083
C - H vibrations  3300 - 2800 cm'1
CH 3 (antisymmetric stretch) 2959 2958 2958 2957 2959 2957 2957
CH 2 (antisymmetric stretch) 2921 2920 2920 2919 2919 2918 2918
CH 2 (symmetric stretch) 2851 2851 2850 2850 2849 2849 2849
C -  O vibrations  1670 -1630 cm'1
C —  O (amide 1 symmetric stretch) 1656 1651 1651 1650 1649 1649 1649
Vibrational bands for lipids, proteins, collagen etc. cm'
C - N— H (symmetric stretch) Amide II 1538 1539 1539 1539 1539 1539 1539
CH2  (symmetric deformations) 1452 1442 1442 1441 1442 1442 1442
CH3  (symmetric deformations) 1379 1379 1379 1379 1379 1379 1379
C— N— H (symmetric stretch) Amide III 1310 1310 1309 1310 1309 1309 1309
C— N— H (symmetric stretch) Amide III 1260 1261 1261 1260 1261 1260 1260
C -  O (stretching) 1161 1161 1160 1160 1161 1161 1161
O -  P —  O (antisymmetric stretching) 1067 1068 1067 1068 1068 1068 1068
O —  P —  O (symmetric stretching) 1029 1029 1029 1029 1029 1029 1028
The band centred at  1160 cm'1   is due to C -  O stretching modes of the C -  OH of cell 
proteins and C -  O group of carbohydrates.
The broad band centred at 1029cm'1  is mainly arising from the O -  P -  O (antisymmetric 
stretching)  vibrational  modes  of phosphodiester  backbone,  and  peaks  in  the  region  of 
1100  to  900cm'1   represent  symmetrical  O  -  P -  O  stretching  vibrations.  These  bands 
appear as a well defined doublet in the normal spectrum, whereas in the spectra of IDC 
and DCIS, it is a broad band with a split doublet, possessing higher intensity.
In summary,  the  spectral  data confirm the  presence of DNA,  proteins,  lipids and  fatty 
acids. Spectral bands in the region of 1700 to 900cm'1  arise from (C = O, CH2, CH3, C -  
O  -   C  and  O  -   P  -   O)  groups  confirming  the  presence  of phospholipids,  proteins, 
carbohydrates, collagen and amino acids. A band centred at 3285cm*1  further confirms the 
presence of amino groups in the natural tissues.Chapter 8: Results 209
FTIR Spectroscopic Differences between IDC Grades (I, II, and III):
As mentioned earlier, significant spectroscopic differences between spectra of normal and 
invasive ductal carcinoma (IDC) nuclei are observed (figure 8.30). Spectra of normal and 
breast  carcinoma  nuclei  are  complex  and  posses  well-defined  and  prominent  spectral 
bands at  1700 to 900cm'1   and 3500 to 2700cm'1   region. Differences in the intensity and 
positioning of peaks in the spectra are attributed to the compositional changes between 
the normal and cancer tissue.
The increase in intensity of the C -  H peaks may be attributed to the increase in the lipids, 
proteins and DNA.  Similarly,  increase in intensity and  shifting of peaks  in the area of 
1700  to  1500cm'1   (carbonyl  stretching  and  amide-bending  vibrations  in  the  DNA) 
confirm the changes in the chemical structure of normal tissue. An overall shift of peaks 
in the fingerprint region (1700 to 800cm'1 ) is observed in the spectra.
Spectral  area  of  1250  to  960  cm'1   (peaks  assigned  toO-P-O,  P-0  and  C  -   O 
stretching  vibrations  of  the  phosphodiester  group)  shows  significant  spectroscopic 
differences between the nuclear spectra of IDC grades, as peak positioning is also shifted 
in addition to change in absorbency of the peaks. This indicates that chemical structure is 
changing with the formation of new peaks suggesting the formation of new groups, as 
two small peaks in the region of 1200 to 1000cm'1  merge together to form a broad band. 
This band could be attributed to C -  O of phospholipids and proteins and appears to be 
due to increase in these substances in the cancer cells.
A prominent difference is also observed in the bands appearing at  1080 and  1030 cm'1 . 
The grade I has a well-defined doublet, similar to the one observed in the FTIR spectrum 
of the  normal  tissue.  The  peak  centred  at  1029cm'1,  increases  in  intensity  with  the 
increasing grade (I to III), whereas the peak centred at 1068cm'1  reduces in intensity with 
the increasing grade (I to III) (figure 8.31).A
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Figure 8.31; FTIR Spectra of different IDC grades, where Red = GUI, Blue = GII, and black = GIChapter 8: Results 211
FTIR Spectroscopic Differences between DCIS Grades (LNG, ING and HNG):
FTIR  spectra  of the  DCIS  nuclei  provide  prominent  absorption  bands  to  distinguish 
between the three nuclear grades.  FTIR spectra of sections  from  LNG,  ING and HNG 
DCIS normalised with respect to maximum absorption intensity are given in figure 8.32. 
Significant  spectroscopic  differences  are  observed  in  both  the  relative  and  absolute 
intensities of absorption bands in the spectra.
The  absolute  intensity  of each  of the  C  -   H  peaks  in  the  3500  to  2700cm1   region 
increases  with  increasing  grade  (low  -   intermediate  -   high),  indicating  increasing 
concentrations of fatty acyl chains.  In addition the relative intensity of the absorption at 
around 2960 to 2922cm'1  is highest in HNG progressing to the lowest relative intensity in 
LNG. This indicates that the tissue section giving rise to spectrum from HNG nuclei is 
lipid/acylglyceride rich, the one ffom LNG nuclei is protein rich and the one from ING 
nuclei contains significant amounts of both lipids/acylglyceride and protein.
The  variation  in  intensity  of the  peaks  in the  spectral  region  of  1700  -  900cm'1   also 
confirm that the higher nuclear grade spectrum is rich in acylglyceride and low nuclear 
grade  spectrum  is  rich  in  protein  contents.  Absorption  bands  in  the  region  of 
1700 -  900cm'1  confirms the presence of C = O, CH2, CH3 and C -  O -  C vibrations of 
phospholipids. Phospholipids exhibits two intense absorption bands  1067 and  1029cm'1  
arising from vibrations of phosphodiester groups (15).
The amide I band centred at 1654cm'1   not only varies in intensity, but varies in shape as 
well, indicating that different tumour grades have varying protein contents. This is due to 
the  fact  that  the  infrared  absorption  band  for  amide  I  groups  is  sensitive  to  protein 
conformations, therefore, this band can be employed to grade the DCIS nuclei, in addition 
to relative intensities.
The presence of peaks centred at  1310,  1260,  1067 and 1029cm'1   in the  1700 -  900cm'1  
region can be attributed to type I collagen. The difference in intensity and shape of these 
peaks  indicates  the  varying  type  and  amount  of type  I  collagen  present  in  the  three 
nuclear grade tissues. Therefore, combining the three parameters of lipids/acylglyceride, 
proteins and collagen together can help in classifying three different nuclear grades (high, 
intermediate and low) more precisely and consistently.A
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Figure 8.32; FTIR Spectra of different DCIS grades, where; Red = HNG, Blue = ING, and Black = LNGChapter 8: Results 213
FTIR Chemical Imaging:
In  this  study,  a total  of 67  samples,  as described  in table  8.35  were  studied  by  FTIR 
Chemical  Imaging technique and the results obtained are extremely  interesting.  Digilab 
rapid-scan  FTIR  spectrometer  Excalibur  FTS  3000  with  the  UMA-600  infrared 
microscope  equipped  with  a  liquid  nitrogen  cooled  MCTA  detector  and  a  MCT  focal 
plane array detector was used to analyse a total of 67 samples and all the images were 
collected  at  8cm' 1  spectral  resolution.  The  samples  were  analysed  on  a  glass  slide  by 
external  reflectance  at a  spatial  resolution  of 1.4  x  1.4  mm.  The  collection time  for a 
single image was 5 minutes with 256 scans. For the larger image at 64 scans the mosaic 
was collected in 17 minutes.
A  representative of visible  image  of a sample  is given  in  figure  8.33  and the  red  line 
indicates the area imaged.
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Figure  8.33;  Visible  image  of a  breast  carcinoma 
section
A spectral region was defined and the shift of the centre of gravity of the peak centered at 
1658cm'1   relative to a baseline could be imaged. In the image shown in figure 8.34, the 
red  region  of the  image  illustrates  the  greatest  shift  and  the  blue  region  shows  the 
minimum shift.Chapter 8: Results 214
The  image  in  Figure  8.34  was  collected  using  a 64  x  64  MCT  focal  Plane  array  and 
collected at  8cm' 1  resolution.  This technique was  used  for  imaging all  the  normal  and 
cancerous tissues.
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Figure  8.34;  The  image  obtained  64  x  64  MCT  focal  Plane  array  and 
collected at  8cm' 1  resolution. A spectral region indicating the shift of the 
centre of gravity of the peak centered at 1658cm'1  relative to a baseline.
Strong  absorption  bands  in  the  region  of (1700  to  1600cm1 )  arising  from  (C  =  O) 
vibrations of the amide groups of polypeptide chain, tend to be among the strongest and 
the intensity of the carbonyl band makes the detection of this group simpler.  The Peak 
centred at (1632cm'1 ) is due to bonded (C = O) and the band at (1538cm1 ) confirms the 
presence of (C -  N -  H) moieties.
Mono substitute amides usually exist with the (-NH) and (C = O) bonds. This band at 
(1538cm'1 ) involves both (C -  N) stretch and (C -  N -  H) in-plane bend in the amide II 
band. This band is a characteristic for mono-substituted amides. Amide III bands absorb 
more weakly and are confirmed by the presence of peaks at (1310 and 1235cm'1 ). A Band 
centred at (1160 cm'1 ) is due to (C - O) stretching modes of the (C -  OH) of cell proteins 
and (C - O) group of carbohydrates.
Spectral bands in the region of (1700 to 900cm1 ) arise from (C = O, CH2, CH3, C-O-C 
and O -  P -  O) groups confirming the presence of phospholipids, proteins, carbohydrates,Chapter 8: Results 215
collagen  and  amino  acids.  As  described  earlier,  differences  between  normal  and 
cancerous  tissues'  nuclear  spectra  are  observed.  Spectra  of normal  and  breast  cancer 
tissue are complex  and possess well  defined and  prominent spectral  bands  at  (1700 to 
700cm'1 ) & (3500 to 2700cm'1 ) region.  Difference in intensity and positioning of peaks 
in the spectra are attributed to the compositional changes between the normal and cancer 
tissue.
The intensity increase of the (C -  H) peaks may be attributed to the increase in the lipids, 
proteins and DNA contents indicating the increment of fatty acids. Similarly, increase in 
intensity and shifting of peaks in the area of 1700 to  1500cm1   (carbonyl stretching and 
amide-bending vibrations in the DNA) confirm the changes in the chemical  structure of 
normal tissue.  An overall  shift of peaks in the fingerprint region (1700 to  1000cm'1 ) is 
observed  in the  spectrum  of breast cancer tissue.  Figure  8.35  shows the  shift  in these 
bands as characterised by an infrared image of the Amide I band between 1700-1600cm'1 . 
The deeper the red colour the greater the infrared shift in this spectral region.
W av en u m b er
Figure 8.35; The image above obtained by a mosaic of an area 1.4 X 1.4 mm, Band 
shift of Amide I band between 1700 -  1600 cm'1Chapter 8: Results 216
Different colours in the image represent 
the varying nature of chemical structure 
present  in  the  tissue.  The  technique 
allows the extraction of the IR spectrum 
from  the  required  area  of the  IR  image 
and  comparison  with  the  surrounding 
area,  as  illustrated  in  figures  8.35  and 
8.36.  By  employing  FTIR  chemical 
imaging useful information pertaining to 
carbonyl  stretching  and  amide-bending 
vibrations in the DNA can be extracted.
This  data  can  then  be  used  to  define 
infrared  images  that  show  the  shift  of 
amide bands between  1700 to 1500cm'1.
The images extracted show that this shift 
is significant sometimes varying by as much as 10 cm'1 with changing grades. In addition 
PCA analysis can be applied to the images to extract further data producing images based 
on the principal components. Employing an infrared chemical imaging technique, spectra 
from the required image can be obtained and more accurately analysed.
As the wavenumber positioning, intensity and shape of the peak is a critical parameter in 
differentiating between the type and grades of the cancer tissue. Therefore, it is important 
to demonstrate the accuracy and reproducibility of the FTIR chemical imaging technique. 
To demonstrate this,  15 spectra within one sample of each LNG DCIS were obtained and 
the peak positioning and its shape were monitored. The spectra were collected at a spatial 
resolution of 0.5  x 0.5 mm. spectral resolution of 8cm'1  and averaging 256 numbers of 
scans. The difference within the peak positioning of the spectra of the same tissue was 
less than ± 0.1cm1. This process was also repeated for other DCIS and IDC grades and 
similar  results  were  obtained  confirming  the  reproducibility  and  accuracy  of  this 
technique.
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Figure  8.36;  PCA  map  showing  different 
colours  based  on  varying  principal 
componentsChapter 8: Results 217
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Figure 8.37a;  FTIR spectra of DCIS LNG indicating that there were no major 
differences in shape and positioning of peaks within the fingerprint region
Once the variability within the same case was evaluated and reproducibility of the FTIR 
chemical  imaging  was  established,  it  was  important  to  establish  variability  within 
different cases of the same grade.  FTIR nuclear spectra of 10 cases of LNG DCIS are 
shown in figure 8.37a, which indicate that there is no significant peak shift or change in 
the shape of the peaks relative to each other.
The difference within the peak  positioning of the nuclear spectra of the different cases 
within same grade was less than ± 0.5cm1.  Spectra in figure 8.37b and  8.37c are from 
ING and HNG DCIS, which also demonstrate that there is very little peak shift or change 
in the shape of the peaks relative to each other confirming that nuclear spectra of the same 
grade across the different samples did not possess major variability.
This was also checked for IDC grades (GI, GII and GUI) and results obtained confirmed 
that there is no significant spectral variability within the grades. Spectra are presented in 
figure 8.38a, 8.38b and 8.38c.Chapter 8: Results 218
Figure 8.37b;  FTIR spectra of DCIS  ING  indicating that there were no major 
differences in shape and positioning of peaks
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Figure 8.37c;  FTIR spectra of DCIS  HNG  indicating that there were  no  major 
differences in shape and positioning of peaks
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Figure  8.38a;  FTIR  spectra  of IDC  Gl  indicating  that  there  were  no  major 
differences in shape and positioning of peaks
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Figure  8.38b;  FTIR  spectra  of IDC  GII  indicating that there  were  no  major 
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Figure  8.38c;  FTIR  spectra  of IDC  GIII  indicating  that  there  were  no  major 
differences in shape and positioning of peaks
FTIR Chemical Imaging of IDC Grades (I, II, and III):
As  mentioned  earlier,  significant  spectroscopic  differences  between  FTIR  spectra 
obtained  by  ATR-FTIR  micro-spectroscopy of invasive  ductal  carcinoma  (IDC) tissue 
grades Gl, GII and GIII are observed. FTIR chemical imaging spectra of grades Gl, GII 
and GIII as shown in figure  8.39, also confirmed these findings.  These  spectra of IDC 
grades have well-defined and prominent spectral bands at  1700 to 900cm'1   and 3500 to 
2700cm’1  region.
A small increase in intensity of the C -  H peaks may be attributed to the increase in the 
lipids, proteins and DNA. Similarly, increase in intensity and shifting of peaks in the area 
of 1700  to  1500cm’1   (carbonyl  stretching  and  amide-bending  vibrations  in  the  DNA) 
confirm  the  changes  in  the  chemical  structure  in  different  grades.  An  overall  shift  of 
peaks  in  the  fingerprint  region  (1700  to  1000cm'1 )  is  also  evident  in  the  spectra  of 
different IDC grades.Chapter 8: Results 221
Spectral  area of 1200  to  1000  cm'1   (peaks assigned  toO-P-O,  P-0  and C -  O 
stretching vibrations of the phosphodiester group) again shows significant spectroscopic 
difference between the nuclear spectra of IDC grades, as peak positioning is also shifted 
in addition to change in absorbency of the peaks. This indicates that chemical structure is 
changing with the  formation of new peaks suggesting the  formation of new groups, as 
two  small  peaks  in the  region  of 1200  to  1000cm'1   split  further  in to  three  peaks and 
intensity  of  band  is  also  increased.  This  band  could  be  attributed  to  C  -   O  of 
phospholipids and proteins and appears to be due to increase in these substances from Gl 
to GIII.
A prominent difference is also observed in the bands appearing at  1080 and  1030 cm'1. 
The grade Gl has a single well defined peak, which is beginning to split in to a doublet in 
grade GII and a well defined doublet is observed in the GIII spectrum. The peak centred 
at  1029cm'1 , increases in intensity with the increasing grade (I to III), whereas the peak 
centred at 1068cm*1  reduces in intensity with the increasing grade (I to III) (figure 8.38). 
A similar trend was also observed in the ATR-FTIR spectra for the IDC grades.
Gll GIII   Gl
2.8
2.4
3500 3000 2500 2000 1500 1000
Wavenumber cm'
Figure 8.39;  FTIR Spectroscopic Differences between IDC grades (Gl, GII and 
GIII)Chapter 8: Results 222
FTIR Chemical Imaging of DCIS Grades (LNG, ING and HNG):
FTIR chemical  imaging  spectra of the  DCIS  tissues provide  absorption  bands that are 
more or less similar to that obtained by FTIR ATR-micro-spectroscopy, but are slightly 
well defined due to the increased  sensitivity of the technique.  Spectra of sections from 
LNG, ING and HNG DCIS in the region of 1700 to  1300cm'1  are shown in figure 8.40. 
This region provides significant spectroscopic difference both in the relative and absolute 
intensities of absorption bands in the spectra and also shift in the positioning of the peaks.
The variation in  intensity  of the  peaks  in the  spectral  region of 1700 -  1300cm'1   also 
confirm that the higher nuclear grade spectrum is rich in acylglyceride and low nuclear 
grade  spectrum  is  rich  in  protein  contents.  Absorption  bands  in  the  region  of 
1700 - 1350cm'1   confirms the presence of C = O, CH2, CH3 and C -  O -  C vibrations. 
The  amide  I  band  present  between  1750  at  1600cm'1   not  only  varies  in  intensity,  but 
varies  in  shape  as  well,  indicating  that  different  tumour  grades  have  varying  protein 
contents.
  LNG  ING  HNG
— 1 ---------------------------------------1 -------------------------------------------1 -----------------------------------------1 —
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Figure 8.40; FTIR Spectroscopic Differences between DCIS Grades (LNG, 
ING and HNG)Chapter 8: Results 223
This amide  I  vibrational  mode  exhibits  significantly high  sensitivity to conformational 
changes in the secondary structure, as a shift in the bands (4 to  8cm'1 ) was also observed 
indicating the changing nature of chemical structure. The peaks of maximum absorption 
in the amide I stretching band region shifted to lower frequencies with increasing nuclear 
grades  indicating  stronger  hydrogen  bonding.  This  is  due  to  the  fact  that  the  infrared 
absorption band for amide I  groups is sensitive to protein conformations, therefore, this 
band can be employed to differentiate between the DCIS grades, in addition to relative 
intensities and wavenumber shift.
These  results  indicate  that  the  composition  of the  bulk  of proteins  in  breast  tissues 
undergo considerable changes during carcinogenesis, including changes in the extent of 
hydrogen bonding between the amide groups in proteins, conformational differences such 
as  increase  in  helical  and  decrease  in  turn  secondary  structure  and  differences  in  the 
relative content of collagen rich connective tissue for the different type of tissues.
FT-RAMAN ANALYSIS OF BREAST TISSUES:
In addition to the  FTIR  spectroscopic  and  imaging technique,  FT-Raman spectroscopy 
was also employed to compliment the spectral data, as it provides additional information 
regarding the polarisation of the molecules. It is important to note that the FTIR and FT- 
Raman both are vibrational spectroscopic techniques and compliment each other. Infrared 
spectroscopy  provides  information  regarding  the  change  in  the  dipole  moment  of the 
molecule,  whereas,  Raman  spectroscopy  identifies  the  change  in  the  polarisation  of 
molecules.  Hence  combining  both  techniques  together  provides  a  complete  picture  of 
chemical structural properties of molecules.
FT-Raman spectroscopy has the potential to identify markers associated with malignant 
changes.  Normal  and  neoplastic  tissues  have  distinct  biochemical  features,  which  are 
manifestations of unique biological processes. The direct detection of these biochemical 
constituents  may  provide  new  methodology  for  non-invasive  detection  of  disease 
processes,  together  with  information  for  classifying,  grading  and  evaluating  the 
progression of malignant neoplasms to provide a potential diagnostic tool.Chapter 8: Results 224
FT-Raman Spectroscopic Differences between Normal, DCIS and IDC:
FT-Raman nuclear spectra of a normal breast tissue, a case of DCIS HNG and a case of 
IDC GIII are given in figure 8.41. The most notable feature of each spectrum is the low 
fluorescence background, with well defined peaks in the regions of 1800 to 550cm'1  of the 
spectra.  Obvious  spectroscopic  differences  exist  in  both  the  absolute  and  relative 
intensities of the peaks in the spectra. Before the spectrum of cancer tissue is discussed in 
detail it is important to characterise the positions of the peaks and their assignment. These 
are  shown  in  table  8.37.  Assignment  of the  peaks  is  attributed  to  previous  Raman 
spectroscopic studies on natural tissues and on cellular organic macromolecules (15;22- 
27).
The  peak  present  at  1655cm'1   in  the  spectrum  of  normal  breast  tissue  is  due  to  a 
C = C stretch amide I band.  The intensity of bands varies with the degree of fatty acid 
unsaturation and depends on the lipid to protein ratio. The spectral bands at  1455,  1442 
and 1303cm'1  are due to CH3 and CH2 scissoring deformations. The peaks present at 970, 
876 and 720cm'1  in the spectra are due to C -  C stretch.C
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Figure 8.41; FT-Raman Spectra of normal, DCIS (HNG) and IDC (GIII) Where;
Red = Normal, Black = IDC (GIII) and Blue = DCIS (HNG)Chapter 8: Results 226
The changes in the relative intensities of the C -  H bending mode, peaks present in the 
region  of 2960  -  2700cm'1   are  due  to  the  amide  I  band  and  can  be  related  to  tissue 
pathology (Table 8.37).  The empty boxes indicate the absence of well-defined peaks in 
the last row of the table. In addition to variation in the intensity of the peaks the relative 
shift is another important parameter to  consider.  A  number of spectral  features can be 
employed to differentiate between the normal tissue and the cancerous lesions.
Table 837; Peak assignments of the FT-Raman spectra of normal breast tissue
and  breast carcinoma (cm'1 )
Peak Assignment Normal
DCIS
HNG
DCIS
ING
DCIS
LNG
IDC
Gl
IDC
GII
IDC
GIU
1  C - H vibrations  3300 - 2800 cm'1
|  CH3 (antisymmetric stretch) 2959 2958 2958 2957 2959 2957 2957
CH2  (antisymmetric stretch) 2921 2920 2920 2919 2919 2918 2918
CH2 (symmetric stretch) 2851 2851 2850 2850 2849 2849 2849
Vibrational bands for lipids, proteins, collagen etc. 1670 -  750 cm'1
C = C (symmetric stretch Amide I) 1662 1660 1658 1658 1660 1659 1658
C -  N —  H (symmetric stretch) Amide II 1538 1537 1537 1539 1539 1537 1536
CH 2  (symmetric deformations Amide II) 1442 1452 1452 1451 1452 1452 1452
CH 3  (symmetric deformations Amide II) 1379 1379 1379 1379 1379 1379 1379
C —  N —  H (symmetric stretch Amide III) 1260 1261 1261 1260 1261 1260 1260
O —  P —  O (symmetric stretching) 1096 1096 1095 1095 1095 1095 1095
C —  C (stretch Amide I, collagen) ---- 992 992 992 992 992 992
|  C —  C (stretch), polysaccharides 780 795 795 795 792 792 792
|  C —  C (stretch) 751 750
The C = C band of the lipids at  1660cm'1   which is an amide I band,  is relatively well 
defined in the cancerous tissue as compared to the band at 1660cm'1  in the normal tissue. 
The shift in this peak and variation in intensity further confirms the biochemical change 
of  the  structure.  The  shifting  of  the  prominent  1442cm'1   peak  in  normal  tissue  to 
1452cm'1   in  cancerous  tissue  is  significant  and  is  attributed  to  CH2  deformation  of 
lipids/acylglyceride  and  proteins.  In addition to  shifting of the peak,  it is well  defined 
both in the DCIS and IDC tissues. This obvious change in spectral features and intensity 
demonstrates that differences between the normal and cancerous tissues can be achieved 
using this technique. While the spectrum of normal tissue is composed of spectral bands 
relating to lipids, the spectrum of cancerous tissue possesses spectral bands corresponding 
to  proteins.  The  position  of  the  amide  I  band  and  the  presence  of  proline  and 
hydroxyproline bands at 992 and 795cm' 1  suggest that the major protein component in 
cancerous tissue is collagen, as evidenced by the histopathological examinations.Chapter 8: Results 111
The  lower  intensity  of the  lipids/acylglyceride  bands  in the  cancerous  tissue  spectrum 
implies a relative increase in the protein content.
The  spectral  differences  in  the  region  of 960  -  800cm’1   and  1400 -   1080cm'1   further 
confirm the increment of protein content and relative decrease in the lipids/acylglyceride 
content  in  the  cancerous  tissues.  The  bands  at  1655,  1442  and  1262cm’1   are  due  to 
amide I, CH2 bending and amide III vibrations of the proteins respectively. The presence 
of amide I bands further confirms the increment in protein content in the cancer tissue as 
compared to normal tissue.
FT-Raman Spectroscopic Differences between IDC Grades (I, II and III):
Figure 8.42 illustrates the differences between grades I, II and III of IDC. The FT-Raman 
spectrum of the normal tissue is weaker in intensity than that of the IDC tissue and the 
intensity of the peaks increases with increasing grades, as the grade III has the highest 
intensity, grade I possessing the minimum and grade II lying at an intermediate level.
The increase in intensity of the C -  H peaks suggests change in the lipids, proteins and 
DNA contents. The absolute intensity of each of the C -  H peaks in 3500 to 2700cm'1  
region varies with increasing grade  (I,  II  and  III),  indicating varying concentrations of 
fatty acyl chains.
Similarly,  increase  in  intensity  and  shifting  of peaks  in  the  area  of  1660  to  600cm'1  
(carbonyl stretching and amide-bending vibrations in the DNA) confirm the changes in 
the  chemical  structure  of breast  tissue  and  this  change  in  intensity  provides  useful 
information in differentiating between the IDC grades.C
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Figure 8.42; FT-Raman spectra of different IDC grades, where; Red = GIII, Blue = GII and Black = GlChapter 8: Results 229
FT-Raman Spectroscopic Difference between DCIS Grades (LNG, ING and HNG):
FT-Raman  nuclear  spectra  from  low,  intermediate  and  high  grades  of  DCIS  tissues 
normalised with respect to maximum absorption intensity are given in figure 8.43. There 
are significant spectroscopic differences observed between the three DCIS grades in both 
the relative and absolute intensities of absorption bands in the spectra.
The absolute intensity of each of the C -  H peaks, in 3500 to 2700cm'1  region, increases 
with increasing grade (low -  intermediate -  high), indicating increasing concentrations of 
fatty  acyl  chains.  In  addition,  the  intensity  of the  absorption bands  at  2958,  2920 and 
2851cm'1   is highest in  HNG progressing to  the  lowest relative  intensity  in  LNG.  This 
indicates  that  the  tissue  section  giving  rise  to  the  spectrum  from  HNG  is 
lipid/acylglyceride rich and the one giving rise to the spectrum from LNG is protein rich 
while  the  one  giving  rise  to  the  ING  spectrum  contains  significant  amounts  of both 
lipids/acylglyceride and protein. This compliments the FTIR data reported in the previous 
section.
Similarly, the variation in intensity of the peaks in the spectral region of 1660 - 700cm'1  
also confirms that the higher nuclear grade spectrum is rich in acylglyceride and the low 
nuclear grade spectrum is rich in protein contents.
The amide I band centred at 1660cm'1  not only varies in intensity, but varies in shape as 
well,  since HNG has a higher intensity as compared to  ING and LNG,  confirming the 
varying protein contents with respect to the grades.C
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Figure 8.43; FT-Raman spectra of different DCIS grades, where; Red = HNG, Blue = ING and Black = LNGChapter 9: Discussion 231
CHAPTER 9:  DISCUSSION:
This is a retrospective study in which DCIS has been studied from various aspects; DCIS 
classification according to nuclear grades was correlated to molecular marker expression 
and to  IDC  grades;  DCIS  nuclear grades were classified objectively by  image analysis 
according to mean nuclear area measurement;  DCIS  and  IDC  cases were amplified by 
PCR to determine the type and incidence of P53 mutations in these; and finally, DCIS 
and IDC  grades were studied by  FTIR and FT-Raman to detect any compositional and 
chemical structural differences with a view to explore the potential of these techniques as 
non-invasive in-vivo diagnostic tools. The overall aim of the study was not to look at a 
large  number  of cases  or  to  correlate  molecular  biology  with  outcome,  but  to  study 
carefully  selected  groups  of  well-designated  cases  for  patterns  of molecular  marker 
expression, which might correlate with biological behaviour.
CORRELATION OF IDC GRADES WITH ASSOCIATED DCIS GRADES:
This study has shown a close correlation between DCIS grade and the grade of infiltrating 
carcinoma when DCIS was present as a component of infiltrating carcinoma. All G I IDC 
had either LNG or ING DCIS  associated with them, none had HNG.  G  II IDC had all 
three grades of DCIS associated with them and G III had only HNG associated with them. 
Similarly Lampejo et al showed that well-differentiated DCIS was associated with grade I 
tumours,  intermediately  differentiated  with  grade  II  tumours  and  poorly  differentiated 
DCIS equally with grade II and grade III infiltrating tumours (1). Cadman et al (2) have 
also  shown  that  poorly  differentiated  DCIS  was  mainly  associated  with  GIII  IDC, 
intermediate differentiated DCIS with all 3  grades of IDC and well differentiated DCIS 
with Gl IDC only employing classification by Holland et al(3).
In  the  present  study,  the  incidence  of HNG  was  higher  in  DCIS  associated  with  IDC 
(46%) as compared to the incidence of HNG in pure DCIS (30%). Lampejo et al (1) have 
also shown a high incidence of HNG (69%) in DCIS cases associated with IDC whereas 
the incidence of HNG in pure DCIS cases has been shown to be lower (32%) by Faverly 
et al  (4) and  39%  by  Zafrani  et  al  (5).  However,  the present  study  has  compared  the 
incidence of HNG in both the pure DCIS and DCIS associated with IDC together for the 
first  time.  The  explanation  for  this  finding  could  be  that  HNG  has  more  chances  ofChapter 9: Discussion 232
invasive carcinoma associated with it as shown by Patchefsky (6) and consequently less 
likely to be pure DCIS.
DCIS  CLASSIFICATION  IN  RELATION  TO  MOLECULAR  MARKER 
EXPRESSION:
At present, there is insufficient evidence to show that there is any correlation between the 
DCIS classification system which is currently in use in the UK and clinical behaviour of 
DCIS,  although  prospective trials  are underway  to  determine the prognosis of patients 
with different DCIS grades. One study (7) has shown this classification based on nuclear 
grade as well as Van Nuys classification to predict recurrence in DCIS. The classification 
currently  in use  in the  UK  has  been  derived  from  the  one  by  Holland  et al,  which  is 
recommended by the European Pathologists Working Group (EPWG). The difference is 
that classification based on nuclear grade divides DCIS into LNG, ING and HNG and the 
one by Holland et al divides DCIS into well, intermediate and poorly differentiated DCIS. 
Furthermore,  the  classification  by  Holland  et  al takes  into account polarity of cells  in 
addition to  nuclear  grade.  The  advantage  of classifying  DCIS  on the  basis  of nuclear 
grade is that the cytonuclear features on which the classification is based, are much more 
consistent  throughout  a  lesion  as  compared  to  architectural  pattern.  Furthermore,  the 
criteria for the classification are well defined and therefore, should result in better inter­
observer reproducibility. In some studies (8-10), the reproducibility of this classification 
has been shown to be good.
The biological validity of the histological classification of DCIS based on nuclear grades 
was  supported  in the present  study  by  significant association of histological  grades of 
DCIS  with  bcl2,  Ki67,  ER,  p53  and  cerbB-2.  Correlation  of biological  features  with 
histological grades of DCIS employing Holland’s classfication has also been reported by 
Bobrow et al (11) and Zafrani et al (5). Bobrow et al (11) studied 105 cases of pure DCIS 
for immunohistochemical expression of cerbB-2, p53, PR and KiSl. They considered any 
amount of staining with cerbB-2, p53 and PR antibodies as positive and for KiSl, they 
used an arbitrary cut-off of 10% or more labelled cells as representing high proliferation 
rate.  They showed positivity of PR to be 45%,  cerbB-2 45%, p53  33% and cases with 
high proliferative activity (>10% labelled cells) to be 54%. The pure DCIS they studied 
was selected on the basis of absence of an associated invasive component; however, they 
did  not  exclude  cases  with  a past  history  of invasive  breast  cancer.  Zafrani  et  al  (5)Chapter 9: Discussion 233
studied 97 cases of pure DCIS for expression of ER, PR, p53, cerbB-2 and Ki67 by IHC. 
They found that 81% cases were positive for ER, 73% for PR, 40% for p53 and 57% for 
cerbB-2.  They  also  showed  that  52%  of tumours  had  a  high  proliferative  activity  as 
determined by Ki67 labelling using 10% as a cut off value. In these two studies, there was 
a significant correlation between poorly differentiated DCIS and the expression of cerbB- 
2 and p53, and a high level of proliferation.  In contrast, well differentiated DCIS had a 
low level of staining with antibodies to proliferation markers and rarely expressed cerbB- 
2  oncoprotein or p53  protein.  Biological  features of the  intermediate group showed an 
intermediate pattern or a combination of features of both of the other two types. Bobrow 
et al  (11)  noted  a significant  association between positive  expression  of PR and well- 
differentiated DCIS. In contrast, Zafrani et al (5) found no significant correlation between 
DCIS subtypes and either ER or PR expression. Inconsistencies in these two studies can 
be explained by the  use  of different  antibodies to detect the  markers and the  different 
methodology to  show them.  Bobrow et al  (11)  noted the nuclear diameter of different 
histological  grades  of  DCIS  as  follows:  poorly  differentiated  >  20pm  (3  RBCs), 
intermediate  differentiated  15-20pm  (2.5-3  RBCs)  and  well  differentiated  <  15pm  (2 
RBCs).
In  neither  of  above-mentioned  two  studies  were  the  histological  grades  of  DCIS 
compared against histological grades of IDC with respect to the expression of molecular 
markers.  Furthermore,  there  is  no  previous  study  comparing  pure  DCIS  against  DCIS 
associated with IDC in terms of molecular marker expression. Finally, bcl2 and bax were 
not  included  in  these  series  (5; 11).  A  study  by  Quinn  et  al,  which  found  that  bcl2 
correlated negatively with increasing histological  grades of DCIS  employing Holland’s 
(3)  classification,  similar to  the  present  study,  did  not  include  pure  DCIS  cases  (12). 
Furthermore, as the above mentioned two  studies  used positivity cut-off values  for the 
markers  studied,  and  much  simpler statistical  analysis,  it was  felt  necessary to  further 
confirm the biological validity of the classification by including actual score values and 
employing different statistical methods.
Radiological (3) and 3-dimensional (4;5) studies also support this classification system. 
There is evidence that mammographic appearance shows quite good correlation with this 
classification (3)  in that poorly differentiated DCIS  is generally associated with linear, 
branching or coarse-granular microcalcifications which can usually be easily recognizedChapter 9: Discussion 234
as malignant. There is also good correlation between the extent of microcalcifications and 
the extent of poorly differentiated DCIS within the breast. Well differentiated DCIS with 
a non-solid growth pattern is  usually  associated  with multiple clusters of fine-granular 
(sand-like) microcalcifications on mammography.  Microcalcification is less common in 
the intermediate category of DCIS, but, when present, may produce either coarse-granular 
or fine-granular appearances on mammography.
Three  dimensional  studies  (4)  using  a  stereomicroscopic  technique  have  shown 
correlation between types of DCIS and the pattern of growth within the mammary tree. It 
was  shown  by  Faverly  et  al  that  practically  all  DCIS  was  segmental  (unicentric),  not 
multicentric  and  17/19  (90%)  of the  poorly  differentiated  DCIS  showed  continuous 
growth  whereas  19/27  (70%)  of  the  well  differentiated  DCIS  was  discontinuous 
(multifocal) within a segment. Irrespective of the histologic grade, only 5/60 (8%) of total 
DCIS had a multifocal distribution.
A  study  by  Gupta  et  al  has  compared  three  different  classifications  of pure  DCIS 
(Holland,  Van Nuys  and  Cardiff)  in  102  cases  in  relation  to  expression  of biological 
markers  including  p53,  E-cadherin  and  MIB1  (13).  All  these  classification  systems 
showed  good  correlations  with  the  markers  studied,  with  well  differentiated  lesions 
expressing high E-cadherin,  low p53  and low MIB1  labelling and poorly differentiated 
lesions  showing  the  reverse.  The  authors  concluded  that  of  the  three  classification 
systems, the Cardiff classification correlated the best with the markers.
Scott et al (14) have suggested a different classification with which over 90% of DCIS 
can be easily classified into the following five categories: high grade (HG), intermediate 
grade (IG), low grade (LG), pure micropapillary (M), and pure apocrine (A). Mack et al 
(15)  investigated  whether  there  is  a  relationship  between  lesion  size  and  the 
immunohistochemical expression of p53, cerbB-2, bcl2, and Ki67 with this categorization 
of DCIS. They studied 70 cases of DCIS with IHC.  Of the 70 DCIS cases,  17 (24.3%) 
were HG, 23 (32.9%) were IG, 21 (30%) were LG, seven (10%) were pure micropapillary 
cases,  and two (2.9%) were pure apocrine DCIS.  The mean size of the DCIS  for each 
subcategory  was  statistically  significantly  different  (p=0.008).  In  particular,  the 
micropapillary  DCIS  cases  were  largest  (mean  size,  17  mm).  The  mean 
immunohistochemical  scores  for  cerbB-2  for  each  category  were  also  statistically 
different (p=0.007), whereas the mean scores for p53 and Ki67 for each category showedChapter 9: Discussion 235
a trend toward significance (p=0.073, p=0.062, respectively).  There were no significant 
differences  between  bcl2  mean  scores  and  each  subcategory.  Because  this  combined 
histological  cytological  classification  system  was  predictive  of  size  and  cerbB-2 
positivity,  they  supported the  clinical  relevance  of this particular classification  system. 
However, apocrine DCIS can easily be assigned to one of the three categories based on 
the nuclear grade (16), therefore obviating the need for a time-cosuming exercise.
Ringberg et al investigated cell biological  factors in  187 cases of DCIS  employing the 
Van Nuys classification and showed that ER and PR negativity, cerbB-2 overexpression, 
low bcl2 expression, p53 accumulation, DNA non-diploidy and high Ki67 were strongly 
associated with high grade DCIS and comedo-type necrosis (17). They therefore proposed 
a summary cell  biological  index  (CBI-7)  based  on a combination of these  factors and 
found this index was a strong predictor for ipsilateral recurrence by univariate analysis 
after a median follow-up of 62 months and hence had prognostic value, whereas none of 
these markers had any individual prognostic significance. The antibodies to ER, p53, bcl2 
and Ki67 that they used were same as in this study, however their anti-cerbB-2 antibody 
was different. They used a cut-off of 10% labelled cells to define a positive case for ER, 
PR, cerbB-2, bcl2, p53 and Ki67. The incidence of positive cases was 60% for ER, 43% 
for PR, 54% for cerbB-2, 56% for bcl2, 26% for p53, 42% for high Ki67 (>10% cells) 
and 60% for DNA non-diploidy.
In  a recent  trial  by  EORTC  (protocol  10853)  (18),  the  risk  of distant  metastases  was 
significantly higher in poorly differentiated DCIS as compared to well differentiated. On 
the  basis  of the  results  of EORTC  trial  and  the  present  study,  classification  based on 
nuclear  grades  is  strongly  recommended.  The  present  study  proves  that  there  is  a 
biological  basis  of  DCIS  classification  based  on  nuclear  grades  and  supports  the 
hypothesis of different biological routes for different grades of DCIS. However, as there 
was insignificant difference in molecular marker expression between LNG versus ING as 
compared to ING versus HNG, this suggests that biologically LNG and ING may behave 
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Bax and Bcl2 in Breast Carcinoma:
There is scanty data available in the literature on bax incidence in DCIS, its relation to 
DCIS grades and the role of bax in the pathogenesis of breast carcinoma. In the present 
study,  bax  positivity  was  observed  to  be  62%  in  breast  carcinoma cases  with 69%  of 
DCIS,  56% of LN  negative  IDC  and 62% of LN  positive  IDC  being positive.  Lymph 
node  metastases  showed  23%  positivity.  It  did  not  correlate  to  the  histopathological 
grades of DCIS or IDC. However, bax protein expression was significantly lower in the 
metastatic lymph nodes, this novel observation suggests that reduced levels of bax protein 
may contribute to lymph node metastases. This is supported by the study by Krajewski et 
al (19) who found that reduced expression of bax is associated with poor response rates to 
chemotherapy and shorter survival in patients with metastatic breast cancer. Bax did not 
correlate to ER, p53 or cerbB-2. Lack of correlation with ER suggests that unlike bcl2, it 
is not hormonally regulated. It correlated positively with bcl2 in all cases and especially 
in  well  differentiated  grades  of DCIS  and  IDC.  Bax  correlated  negatively  with  Ki67, 
especially in metastatic lymph nodes.
A retrospective study by Dimitrakakis et al (2) has looked at the expression of p53, bcl-2, 
bax  and  cerbB-2  genes  in  breast  cancer  patients  to  investigate  their  prognostic 
significance.  Archival  tissues  from  121  patients  treated  between  1986-1992  were 
analysed and incidence of percent positive cases was 24%, 15%, 59% and 53% for cerbB- 
2,  p53,  bcl-2  and  bax  respectively.  They  found  a  significant  correlation  between  bax 
expression and age >60 years (p=0.04) and also between bax expression and tumour size 
(p=0.02)  as  well  as  stage  (p=0.001).  Fifteen  percent  of patients  with  stage  I  cancers 
expressed the bax gene, compared with 58% and 65% with stage II and III respectively. 
There were no other correlations with clinical or histological parameters. None of the four 
markers proved to be independent predictors of five-year survival, in either univariate or 
multivariate analysis.
Rochaix et al studied bax expression in 110 IDC and found it to be expressed in 75% of 
cases (20). It did not correlate to tumour grade, ER or p53 expression, a finding similar to 
that of the present study. Lack of correlation with p53 could be explained by the mutation 
or  inactivation of p53,  the  latter being unable to  promote  BAX gene  expression.  They 
found  that  bcl-X  correlated  positively  with  ER  and  concluded  that  bcl2  and  bak  are 
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Rochaix et al, the present study showed a positive correlation between the expression of 
bax  and  bcl2,  which  was more  pronounced  in  well  differentiated  grades  of DCIS  and 
IDC. Similarly, positive correlation between bcl2 and bax has been reported by Krajewski 
etalin IDC (19).
Kapucuoglu et al  (21) reported on  bax  protein expression in DCIS  and  its histological 
grades,  which  showed  bax  expression  to  be  67%  in  DCIS,  similar  to  these  results. 
However, in contrast to Kapucuoglu et al, this study did not show significant correlation 
of bax with poorly differentiated DCIS.  They also found a positive correlation between 
bcl2 and bax in IDC, similar to the present findings and the findings of Krajewski et al 
(19), but their finding of a negative correlation between bcl2  and bax  in DCIS  was in 
contrast to the present findings.
Sturm et al (22) investigated the BAX gene in 68 breast cancer specimens for the presence 
of mutations  in  the  coding  sequence  by  SSCP-PCR  and  direct  sequencing,  and  bax 
protein expression by IHC. They also screened for mutations in the exons 5-8 of the P53 
gene  by  SSCP-PCR.  They  found  differential  expression  of bax  in  the  breast  cancer 
samples, but there was no mutation in the coding sequence of the BAX gene besides a 
polymorphism in exon 6. In contrast, they identified 23.5% tumours bearing mutations in 
the P53 gene. Thus, there seem to be other not yet identified regulators apart from p53, 
involved in the regulation of bax protein expression. Similarly, the present study did not 
show any correlation between bax and p53 protein expression.
Bcl2  positivity  in  this  study  was  42%  and  bcl2  correlated  significantly  with  well 
differentiated  DCIS  and  IDC  and also  with bax and  ER.  The correlation with ER was 
particularly strong. This correlation has been reported previously (23;24). Bcl2 correlated 
negatively  with  Ki67  in  all  cases  and  especially  in  lymph  node  metastases.  The 
correlation  of bcl2  with  well  differentiated  IDC  is  similar to  the  findings  reported  in 
literature  (23;25;26).  The  relationship  between  bcl2  and  differentiation  grade  has  also 
been reported in DCIS (12;27). The finding of positive correlation between bcl2 and ER 
in both DCIS and IDC in this study relates well with the studies reported by Yang et al 
(23). They looked at bax, bcl2, p53, MIB1 and ER in 177 cases of IDC. They did not find 
any correlation between bax and ER in IDC, similarly the present study did not show any 
correlation between bax and ER in either DCIS or IDC. The fact that bcl2, but not bax, is 
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observed that oestradiol  had an anti-apoptotic effect in normal breast and breast cancer 
cells,  whereas  antioestrogens  and  progestins  had  a  proapoptotic  effect.  Employing 
quantitative  RT-PCR,  they  showed  that  oestradiol  increased  bcl2  mRNA  levels  at  48 
hours  of  treatment  via  a  transcriptional  mechanism,  whereas  none  of  the  hormone 
treatments  altered  the  pro-apoptotic  protein  levels,  bax  and  bak.  Furthermore,  bcl2 
displayed a strong cyclical variation in normal breast with the menstrual cycle and was 
considered the most hormone dependent member of the family.
Bcl2 in the present study did not correlate significantly to p53 or cerbB-2, which has also 
been  reported  by  Quinn  et  al  (12).  However,  in  subgroup  analysis,  bcl2  correlated 
positively to cerbB-2  in  LNG  cases (n=23),  and negatively  in GUI  cases  (n=20).  This 
seems to  be  a very  interesting  finding.  A  strong  inverse  correlation  between bcl2  and 
proliferative activity as measured by MIB1  has been reported in breast cancer (23). The 
present  data  have  confirmed  this  relationship  as  mentioned  above.  This  supports  the 
suggestion that apoptosis and proliferation are mechanistically linked (23).
P53 transactivates p21  and mdm2, and influences bcl-2 expression (29;30). In addition it 
has been shown that activation of the wild-type p53 direct signalling pathway leads to bax 
up-regulation and bcl-2 down-regulation, resulting in rapid apoptosis (31;32). Mutant p53 
down-regulates  bcl-2  expression  in  a  mammary  epithelial  cell  line  (33).  An  inverse 
correlation  between  bcl-2  and  p53  has  been  demonstrated  in  breast  carcinoma  (25), 
pancreatic cancer (34), thyroid cancer (35) and non-Hodgkin’s lymphoma (36). However, 
bcl-2/bax regulated apoptosis can occur in a p53-independent manner (37).  The lack of 
significant  association  between  p53  and  bcl-2  and  also  between  p53  and  bax  in  the 
present study could be due to p53-independent apoptotic pathways.
Wild-type  p53  transactivates  the  WAF1/CIP1/SDI1  gene  in response  to  DNA  damage. 
The  WAF1  gene encodes the p21  nuclear protein, a potent inhibitor of cyclin-dependent 
kinase (CDK) activity.  P21  interacts with proliferating cell nuclear antigen  (PCNA) to 
block  PCNA-dependent  DNA  replication,  leading  to  Gi  cell-cycle  arrest  (38;39).  In 
normal  cells,  the  transcription  of mdm2  is  dependent  on  p53  and  the  mdm2  protein 
regulates p53 by a negative feedback loop (30).
Bcl-2  expression  was  found  to  be  inversely  proportional  to  mitotic  index  and  to  be 
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be explained by the finding that bcl-2 can inhibit the transition of cells from resting (Go) 
to a cycling phase and hence reduce their proliferation and turnover, possibly due to the 
presence of an anti-proliferative domain in bcl-2 (41-43).
Apoptosis  is  important  for  both  tissue  development  and  differentiation  and  its 
deregulation  may  contribute  to  tumourigenesis.  The  BCL-2  family  of genes  has  been 
shown to encode proteins,  which can either suppress  or accelerate  apoptosis  (44).  The 
bcl-2 apoptotic pathway is involved in morphogenesis and differentiation. In human fetal 
tissues, bcl-2 protein has been demonstrated in most developing epithelia and is expressed 
in cells at different stages of differentiation (45). In normal adult tissues, bcl-2 protein is 
regularly present in ductal epithelial cells of all exocrine glands.  Immunohistochemical 
studies have detected bcl-2  overexpression  in hypertrophic,  hyperplastic  and dysplastic 
lesions  from  skin  (46),  uterine  cervix  (47)  gastrointestinal  (48)  and  breast  (27;49) 
epithelia.
Overexpression  of bcl-2  gives  cells  a  survival  advantage  and  this,  together  with  the 
alterations of other oncoproteins, may lead to rapid and uncontrolled cell growth, which 
characterizes the development of cancer. Enhanced expression of bcl-2 has been reported 
in several lymphoid and non-lymphoid tumours (45).  Complex and not well understood 
interactions exist between the proteins involved in apoptosis regulation.  Bcl-2  and Bax 
seem to form homo- and hetero-dimers and the ratio between the two proteins determines 
cell death or survival (50).
Proliferative Activity in Breast Carcinoma:
The relationship  of proliferative  activity to  prognosis  in  invasive  breast  cancer is  well 
established  (51;52).  Proliferative  activity  in  DCIS  has also been reported  (53;54).  The 
evaluation of proliferation in tissue sections has been facilitated by the development of 
antibodies to proliferation antigens that can easily be used on archival material (55;56). 
Some groups (5;11) have used arbitrary cut off values of 10% to categorize high and low 
proliferative  activity  with  immunostaining  of antibodies  against  proliferation  antigens 
(Ki67, KiSl) and found good correlation of proliferative activity with DCIS grades. Some 
researchers have used a cut off value for Ki67 in breast carcinomas as well (57;58).
In this study, proliferative activity as measured by Ki67 labelling index (LI) significantly 
correlated  to  DCIS  and  IDC  grades  and  it  is  shown  for the  first  time  that  of all  theChapter 9: Discussion 240
markers studied,  was the best discriminant between normal,  DCIS,  IDC  (LN negative) 
and IDC (LN positive or metastatic). Ki67 correlated positively to p53 and cerbB-2, and 
negatively to ER and bcl2.
Hoshi et al (58) have studied Ki67 in ADH versus DCIS and they showed that the MIB1 
labeling index of ADH was very low (0 -  2.3%) and was the best parameter to distinguish 
it from DCIS (p < 0.01).  Therefore, they suggested that the lower level of proliferative 
activity is one of the most distinctive features of ADH.
ER Status in Breast Carcinoma:
Oestrogen receptor (ER) expression has been intensively investigated in invasive breast 
cancers by both radioligand binding assays and immunohistochemistry and expression is 
reported  to  be  present  in  about  60%  of cases  overall,  but  data  on  incidence  of ER 
positivity in DCIS is controversial. In this study, overall 70% of breast carcinoma cases 
were ER positive with 72% of DCIS, 66% of LN negative IDC, 73% of LN positive IDC 
and  80%  of  LN  metastases  being  positive.  ER  expression  correlated  negatively  to 
increasing grades of DCIS and IDC. However, there was no significant difference in ER 
expression between DCIS and IDC. Normal tissues were significantly more positive than 
DCIS and IDC (LN negative) but not more than metastatic cases. ER correlated positively 
to bcl2 as discussed already, and negatively to Ki67, p53  and cerbB-2.  ER positivity is 
known to correlate with low histological grade of IDC.  In 70% of positive cases, ER is 
functional, which has implications for therapy and prognosis (59).
There  have  been  some  studies  looking  at  hormone  receptors  in  DCIS.  Burr et  al  (60) 
included only 38 cases of pure DCIS in their study and found a correlation between large 
cell size and absence of ER. They found ER expression in 91% of non-comedo and 57% 
of comedo  DCIS.  Giri  et  al  (61)  studied  48  cases  of pure  DCIS  using  three  different 
antibodies and showed ER positivity to be 42-45% overall. They found that less than one 
fifth of comedo carcinomas expressed ER, whereas more than half the cribriform, solid 
and micropapillary categories showed ER expression. Poller et al (62) looked at 151 cases 
of pure DCIS and found that 32% expressed ER and that ER expression was significantly 
associated with small cell size, higher S phase fraction and absence of cerbB2 expression. 
The association between high S-phase fraction and ER status in Poller et al’s (62) study is 
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labelling index as shown in table  8.21.  Similar to the present study,  Bobrow et al (11) 
found a correlation between PR expression and low proliferation rate. They showed PR 
positivity in 45% of 105 cases.
Two studies have looked at both ER and PR together in DCIS cases. Pallis et al (63) using 
a  quantitative  immunoassay  on  57  cases  of in  situ  carcinomas,  some  of which  were 
lobular in type, showed that 54% were ER positive and 30% were PR positive.  Wilbur 
and  Barrows  (64)  showed  ER  and  PR expression  to  be  75%  and  65%  respectively  in 
lobular and ductal  in situ cases studied with immunohistochemistry.  It has been shown 
that there is a significant reduction in ER positivity from the periphery of the tumours 
towards the centre (65), which was a phenomenon inconsistently observed in this study. 
This is thought to be a biological phenomenon within the tumour and not due to delays in 
fixation at the centre of excised tumours.  In fact,  in one study (66),  it was  shown that 
none of the fixation or processing regimes had any deleterious effect on the sensitivity of 
the ER assessment performed by IHC.
Some researchers (67) have quantified immunohistochemically stained hormone receptor 
expression  by  computer-assisted  image  analysis  and  found  good  correlation  between 
semi-quantitative  and  quantitative  methods.  Nevertheless,  there  remains  the  need  for 
quality assurance (68) for immunohistochemical assays for the determination of hormone 
receptor status.
One recent study (69) has reported on the incidence of androgen receptor in DCIS, and its 
relation to the expression of ER and PR in DCIS. The study was done by Selim et al and 
showed positive AR expression by IHC in  19/57 (33%) of cases. AR expression did not 
correlate to degree of differentiation of DCIS unlike ER and PR, neither did it correlate to 
ER  or  PR  expression.  There  was  a  suggestion  that  AR  expression  may  be  related  to 
apocrine differentiation of DCIS.
P53 Expression in Breast Carcinoma:
In this study, p53  expression was seen in 24% of breast carcinoma cases with 22% of 
DCIS, 21% of LN negative IDC, 40% of LN positive IDC and 47% of LN metastases 
being positive.  P53  expression  correlated positively to  increasing  grades  of DCIS  and 
IDC, although it did not significantly differ between the two. However, it was increased 
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statistically  significant.  P53  correlated  negatively  to  ER  as  mentioned  above,  and 
positively to Ki67 and cerbB-2.
Walker et  al  (70),  in a study  of  10  cases  of DCIS,  showed  p53  expression  in  5  cases 
(50%), 4 of which were comedo in type. Poller et al (71) have shown p53 expression in 
25%  of DCIS  cases  overall,  similar  to  the  present  results.  They  noted  a  significant 
association between p53 and cell size but in contrast to the present results, they found no 
significant  association  between  p53  protein  expression  and  cerbB-2  expression  or  ER 
expression.  However,  Bobrow  et  al  (11)  found  positive  correlations  between  p53  and 
cerbB-2, as well as between p53 and KiSl and negative correlations between p53 and PR 
as well as between cerbB-2 and PR, in DCIS, which is similar to findings in this study.
The expression of p53  protein, detected by IHC, has been shown to be associated with 
high histologic grade of IDC and poor outcome (72). In a study of 297 LN negative IDC 
by  Ferrero  et  al,  p53  status  determined  by  immunoluminometric  assay  correlated 
positively  to  high histopathological  grade  and  negatively to  positive  ER  status  (73),  a 
finding similar to that of our study. Goel et al (74) have also found positive correlation 
between  p53  and  PCNA  expression  (determined  immunohistochemically)  and 
histopathological grade of 35 IDC cases.
CerbB-2 Expression in Breast Carcinoma:
CerbB-2 expression was (initially with microwaving for antigen retrieval) found in 46% 
of breast carcinoma cases,  with 48% of DCIS,  42% of LN negative IDC,  47% of LN 
positive  IDC and 53% of LN metastases being positive.  CerbB-2 expression correlated 
positively  to  increasing  grades  of DCIS  and  IDC,  but  was  not  significantly  different 
between these two, except in HNG as compared to GUI, where it was significantly lower 
in the latter.. The finding of 48% of DCIS cases positive for cerbB2 is in accordance with 
the  literature  (75)  but  42%  positivity  in  case  of IDC  is  slightly  higher  than  reported 
studies (15-30%). This finding could be explained partly by the small number of cases 
(n=38), especially of grade  I  IDC  (n=6) as these are more often cerbB-2 negative;  and 
partly due to improved antigen retrieval by the microwave method employed. When cases 
were repeated without antigen retrieval, the positivity was observed to be 30% in IDC and 
nil  in normal breast tissue.  Thus there  is a need to  standardise protocol  across various 
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CerbB-2  expression in  DCIS  has been studied by several  groups (75;76) and it is well 
established that although it is expressed in only  15-30% of IDC, in DCIS it is expressed 
in 40-70% of cases predominantly in comedo-type and is associated with large cell size 
(75).
An  inverse  relationship  between  cerbB-2  expression  and  hormone  receptor  status  has 
been  reported  in  IDC  and  DCIS  (62)  and  the  present  results  have  confirmed  this 
relationship.
Molecular Marker Expression in the Pathogenesis of Breast Carcinoma:
Although the markers  studied have previously been  looked at in breast carcinoma,  but 
their role in the pathogenesis of breast carcinoma is not entirely clear. Therefore, in the 
present study, these markers were studied in various different groups of breast carcinoma 
simultaneously,  in  order  to  better  clarify  their  role.  Normal  breast  tissue  showed 
significantly lower expression of Ki67, p53 and cerbB-2 (poor prognostic markers) when 
compared against DCIS and IDC. Ki67 and p53 were also lower in normal breast tissue as 
compared  to  LN  positive  IDC  and  LN  metastases.  In  contrast,  bcl2  and  ER  (good 
prognostic markers) and bax (unknown value as a prognostic marker) did not significantly 
differ between normal  breast tissue  and  other  groups.  When normal  breast  tissue  was 
compared  against  individual  grades  of  DCIS  and  IDC,  Ki67  was  the  only  marker 
significantly higher in well differentiated grades of DCIS and IDC. However, in addition 
to higher Ki67 values, p53 and cerB-2 expression was also higher and ER expression was 
lower in poorly differentiated grades of DCIS and IDC when compared to normal breast 
tissue.
Comparing DCIS with invasive  lesions of the same differentiation grade,  it was found 
that_proliferation was  elevated  in the  invasive  lesions.  Altered expression of the  other 
proteins  was  in  general  only  slightly  different  in  the  invasive  lesions  compared  with 
DCIS, except cerbB-2, which was significantly higher in HNG DCIS compared to GUI 
IDC.  The number of proteins with altered expression per lesion was highest in poorly 
differentiated  lesions  and  was  comparable  between  DCIS  and  IDC  of  the  same 
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Proliferation  was  found  to  be  significantly  higher  in  DCIS  associated  with  IDC  as 
compared to pure DCIS, and in LN negative IDC as compared to both pure DCIS and 
DCIS associated with IDC. Hence proliferation increased in the following order:
Pure DCIS  1   »  DCIS associated with IDC    ■ —» ^   LN negative IDC
However,  none  of  the  markers  differed  significantly  between  LN  negative  and  LN 
positive IDC, suggesting that these markers are probably not involved in the critical step 
of invasion to metastasis.  However, as  16% of cases were clinically node negative, the 
analysis  was  repeated  after  excluding  them  and  again  no  significant  differences  were 
detected  between  LN  +ive  and  LN  -ive  IDC.  This  could  be  attributable  to  a  smaller 
number  of  histologically  LN-ive  cases.  The  only  marker  significantly  reduced  in 
metastatic LNs as compared to their primaries was bax.
In conclusion, proliferation seems to be the main differentiating factor in transition from 
normal breast to DCIS to IDC without lymph node involvement and bax is much reduced 
in LN  metastases as compared to primaries.  Other proteins (ER,  cerbB-2  and p53) are 
mainly related to differentiation of DCIS and IDC but probably play a minor role in the 
transition from DCIS to an invasive breast lesion of the same differentiation grade. Well- 
differentiated  in  situ  and  invasive  breast  lesions  share  many  of  the  aberrations  in 
expression  of these  proteins,  as  do  poorly  differentiated  in  situ  and  invasive  lesions. 
However, there are many differences between the well and poorly-differentiated lesions. 
This further supports the existence of different biological progression routes leading to 
breast cancer. None of the proteins studied seems to be involved in the development of 
metastasis.
The findings of the present study have been supported recently by a similar study done by 
Mommers et al (77), who have looked at alterations in the expression of proteins involved 
in proliferation and  apoptosis  in non-invasive  and  invasive ductal  breast  lesions.  They 
performed IHC on 106 usual ductal hyperplasias (UDH), 61 DCIS lesions and 53 invasive 
ductal  breast  carcinomas.  Increased  proliferation  (Ki67),  overexpression  of cyclin  Dl, 
cerbB-2, p21  and p53, and decreased expression of bcl-2 and p27 could already be found 
in UDH. Significant differences between UDH and DCIS lesions were found for only one 
protein when UDH was compared with well-differentiated DCIS (p27), for three proteins 
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all  proteins  when  compared  with  poorly-differentiated  DCIS.  Similar  to  the  present 
results,  comparing  DCIS  with  invasive  lesions  of  the  same  differentiation  grade, 
proliferation  was  elevated  in  the  invasive  lesions.  They  concluded  that  the  biggest 
changes in expression of these proliferation and apoptosis related proteins occured during 
the  transition  from  hyperplasia  to  DCIS;  they  probably  played  a  minor  role  in  the 
transition from DCIS to an invasive breast lesion of the same differentiation grade.
Similar results  have  also  been  found  by  Wamberg  et  al  (78)  in  a recent  study.  They 
studied p53, cerbB-2, Ki67, ER, PR and bcl2 in pure DCIS, small invasive lesions and 
mixed  lesions  with  both  invasive  and  in  situ  components  and  showed  that  all  these 
markers correlated with grade rather than invasiveness. Therefore they concluded that the 
step  between  in  situ  and  invasive  cancer  seems  to  occur  independently  of the  grade. 
However, metastatic lymph nodes were not included the above mentioned two studies.
NUCLEAR GRADING OF DCIS BY IMAGE ANALYSIS:
Evaluation  of  the  nuclear  grade  is  the  least  satisfactory  of  the  three  elements  of 
histological  grading  system  in  IDC  due  to  lack  of  interobserver  reproducibility  and 
therefore  contributes  to  differences  in  allocating  overall  grade  (79).  However, 
determination of nuclear grade is important both in DCIS and IDC as it has been found to 
predict recurrence in the case of DCIS (80) and is an important component of the grading 
system  for  IDC  (81).  The  best  way  in  which  differences  in  nuclear  features  can  be 
assessed  with  accuracy  is  by  the  use  of morphometry  or  image  analysis,  which  are 
expensive and time-consuming processes, not always practical in a routine laboratory.
In this study, by employing image analysis,  it was  shown that DCIS  grading by mean 
nuclear area measurement correlated well with the visual grading by light microscopy and 
thus provides a quantitative, objective and reproducible means of classifying DCIS into 
three grades. This information was not available from published literature at the time.
It is known that mean nuclear area in DCIS is slightly higher than that in invasive breast 
cancer  (82).  It  has  also  been  shown  that  DCIS  has  a  higher  mean  nuclear  area  as 
compared to benign lesions and ADH (58;83-85). One recent study by Tan et al (86) has 
reported on a significant correlation between nuclear grade assessed histologically  and 
nuclear area similar to the present study. They reported nuclear area to be 44pm in LNG, 
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P53 MUTATION:
P53 mutations could not be detected in this study in spite of successful amplification of 
P53 exons  5  -   8  by  PCR.  This  information would have been useful to  confirm a P53 
mutation in cases immunopositive for p53 and furthermore to characterize incidence and 
type  of  mutation  in  different  DCIS  grades  as  published  literature  lacks  enough 
information in this respect. If a mutant allele has been cloned, then the sequence can be 
determined easily using synthetic oligonucleotide primers, basing the sequence of these 
primers on the known sequence of the wild-type gene. If the mutant allele has not already 
been  cloned,  or  where  the  mutation  cannot  be  predicted  (as  in  the  case  of P53),  the 
quickest method  is to  amplify  the  region  of interest by  PCR or  RT-PCR  and then to 
sequence the PCR reaction product.  In either case, the wild type sequence needs to be 
known for comparison with the mutants, and as the basis for primer design.
Mutations  in  P53  are  scattered  throughout  the  P53  coding  sequence  but  tend  to  be 
clustered in exons 5-8.  Studies have been published in which each individual exon has 
been  amplified  and  subsequently  sequenced  but  this  is  an  extremely  labour-intensive 
approach  and  is  not  suitable  for  analysis  of a  large  number  of specimens.  However, 
samples can be pre-screened for mutations in specific exons using a modification of the 
PCR. This technique is called single-strand conformation polymorphism (SSCP) analysis 
and can detect nucleotide substitutions, insertions and deletions in PCR-amplified DNA 
fragments.  SSCP relies  on  the  sequence  specific  migration of single-stranded  DNA  in 
non-denaturing  polyacrylamide  gels.  PCR  products  are  radioactively  labelled  during 
amplification, run out on non-denaturing polyacrylamide gels alongside controls of wild- 
type DNA amplified with the same primers, and visualization is by autoradiography.  In 
this  way,  the  individual  DNA  strands  of the  amplified product  are  observed  and  size 
differences between wild-type DNA and sample DNA are an indication of polymorphism. 
The exons identified to contain mutations by SSCP are then sequenced.
Southern  blotting  and  hybridization  to  detect  RFLPs  can  detect  large-scale  DNA 
rearrangements,  insertions and repeat expansions,  but point mutations generally cannot. 
Other molecular techniques such as SSCP and DDGE can help to locate a point mutation, 
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P53  mutation  is a common  event  in  sporadic  breast cancer being  found  in  15-50% of 
invasive carcinomas. Although many studies have been published about P53 alterations in 
breast  cancer,  there  are  limited  data  on  the  molecular  biological  detection  of  P53 
mutations in in situ lesions and the implications for breast carcinogenesis are unclear. P53 
immunoreactivity correlates well with mutations of the corresponding gene, although this 
correlation  is  not  absolute,  since  non-sense  mutations  and  deletions  can  result  in  the 
absence of positive p53 immunostaining.
In one study (87), P53 mutations were studied in 30 breast cancers using PCR and manual 
sequencing  methods  and  5/30  (17%)  cases  had  P53  mutations.  All  mutations  were 
detected in ductal carcinomas NOS type.  All the 4 lobular and 2 mucinous carcinomas 
showed wild-type P53 sequence only. In another study (88), P53 mutations in exons 5-8 
were  detected  by  DGGE  and  confirmed  by  sequencing  in  14/82  (17%)  of  breast 
carcinomas.
Done et al (89) showed that a P53 mutation present in invasive breast cancer was found in 
all surrounding areas of ductal carcinoma in situ (DCIS) but not in areas of hyperplasia or 
normal breast epithelium. In another study, Done et al (57) studied patients with DCIS, 
but  without  invasive breast  cancer,  to  determine  the  spectrum  of DCIS  types that can 
harbour a P53 mutation.  Formalin-fixed, paraffin wax-embedded tissues from 94 patients 
with  DCIS  were  stained  immunohistochemically  with  an  anti-p53  antibody.  Positively 
stained tissue areas were analyzed for the presence of P53 mutations by SSCP and direct 
sequencing.  DCIS  from  10  of 94  (11%)  patients were  found  to  contain P53  missense 
mutations.  All  10  were  of  a  solid  or  a  comedo  histologic  pattern  and  were  either 
intermediate  or  high  nuclear  grade.  The  frequency  of P53  missense  mutations  was 
statistically  significantly  different  among the  three  overall  histologic  grade  categories, 
0/49 (0%) of low-grade DCIS,  1/23 (4%) of intermediate-grade DCIS, and 9/22 (41%) of 
high-grade DCIS had a P53 mutation. This finding that P53 mutations can occur before 
the development of invasive breast cancer, particularly in DCIS of high histologic grade, 
has potentially important implications for prevention and treatment.
Ho  et  al  (90)  evaluated  a  series  of microdissected,  pure  DCIS  lesions  comprising  a 
spectrum  of morphologic  subtypes  (comedo,  micropapillary,  papillary,  cribriform,  and 
solid) and their corresponding normal breast tissue for genetic aberrations in HER-2/neu 
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chain  reaction,  and  P53  mutations  were  identified  by  SSCP  analysis.  HER-2/neu 
amplification was identified in  12 of 30 DCIS samples (40%), and P53 mutations were 
identified in 6 of 30 DCIS samples (20%). The genetic alterations were not present in any 
of the normal breast tissue samples. HER-2/neu amplification occurred predominantly in 
the comedo subtype (69% vs.  18% of the noncomedo subtype; p = 0.008) and in lesions 
of high nuclear grade (63% vs.  14% of low grade; p = 0.01). These workers did not find 
any difference  in the  frequency of P53  mutations among the  subtypes or between low 
grade  and  high  grade  lesions  neither  did  they  observe  any  correlation  between  the 
presence of the two genetic alterations. They concluded that the presence of HER-2/neu 
amplification,  but  not  P53  mutations,  correlates  with  histologic  subtype  and  nuclear 
grade. The relatively frequent occurrence of HER-2/neu amplification and P53 mutations 
in  DCIS  tissue  and  their  absence  in  normal  breast  tissue  suggests  that  these  genetic 
aberrations are important early events in breast duct carcinogenesis.
Lisboa et al (91) studied tissue samples from 83 patients with different stages of breast 
cancer and from 13 patients with benign breast lesions screening for P53 gene mutations 
by polymerase chain reaction (PCR) followed by temperature-gradient gel electrophoresis 
(TGGE).  P53  protein  accumulation  was  analysed  by  immunohistochemistry  (IHC). 
Additionally,  23  pairs  of  primary  tumours  and  corresponding  lymph  nodes  were 
examined. P53 gene aberrations were found in 55.7% of the infiltrating carcinomas,  in 
31.5% of the ductal carcinomas in situ (DCIS) and in one atypical ductal hyperplasia. A 
positive  correlation  was  seen  with  high-grade  tumours  and  with  comedo  DCIS. 
Concordance  between  TGGE  and  IHC  was  seen  in  only  63%  of the  cases  analysed. 
Among  8  pairs  of primary  tumours  and  their  corresponding  lymph  node  metastases 
showing P53 mutation, only 3 harboured identical P53 mutations in the same exon, while 
in 5 cases with mutant P53 in the primaries, no mutation was seen in the lymph node. 
They  concluded  that  P53  mutations  are  frequent  in  breast  tumours  associated  with 
unfavourable  prognosis,  including  high-grade  or  the  comedo-type  and  that  P53  gene 
alterations occur early in breast carcinogenesis, as mutations were detected not only in in 
situ carcinomas but also in atypical ductal hyperplasia.
Munn et al  (92)  studied  36  cases  of pre-invasive  breast lesions,  including  35  cases of 
ductal carcinoma in situ (DCIS) for mutation of P53 and allelic imbalance on 17pl3. P53 
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those  with  associated  invasive  carcinoma  and,  furthermore,  were  identified  in  well- 
differentiated lesions as well as poorly differentiated ones.
O’Malley et al (93) performed p53  immunostaining using p53  antibody D07 and direct 
sequencing  following  PCR amplification of exons  5,6  and  7  in 27  noncomedo  and  12 
comedo  DCIS  (a  total  of  39  DCIS).  Four  comedo  DCIS  cases  that  were  p53 
immunopositive were further screened for P53 mutations by PCR/SSCP in exons 8 and 9 
of the P53 gene. Immunostaining with D07 was positive in 4 of 12 comedo DCIS lesions 
(33%) while all noncomedo  lesions were negative.  Direct sequencing of PCR products 
confirmed wild-type DNA in exons  5  and 6 in all noninvasive papillary carcinomas,  3 
noncomedo DCIS  lesions,  and 4  p53  antibody-positive comedo DCIS  lesions.  In these 
latter 4 cases, wild-type DNA sequences were preserved in exon 7 for all cases. A single 
case (1/4 or 25%) had a conformational shift in exon 8 within the four cases screened in 
exons  8  and 9.  Direct DNA sequencing of this exon revealed a G to A point mutation 
resulting  in  an  arginine-to-histidine  substitution  at  codon  273  of  the  protein.  They 
concluded  that  mutant  p53  protein  accumulation  in  pre-invasive  lesions  is  limited  to 
comedo  (high grade)  DCIS  and that p53  positivity by  immunohistochemistry does not 
correlate  in  all  cases  with  specific  P53  mutations  in  exons  5  to  9,  the  most  highly 
conserved regions of this gene.
Most  of the  afore-mentioned  studies  have  used  SSCP  or  TGGE  for  detection  of p53 
mutation  followed  in  some  cases  by  direct  sequencing  employing  manual  technique. 
Some of the studies (Done et al, O’Malley et al) found P53 mutation confined to comedo- 
type whereas others disagree (Ho et al, Munn et al) and therefore there remains the need 
for clarification of relation of P53 mutations to histological grade of DCIS.
In this study, an attempt was made to detect p53 mutations in DCIS by employing semi­
automated sequencer.  Unfortunately, the  samples could not be sequenced, the probable 
reason being that they had a secondary structure which meant that the sequencing primers 
could not work. The PCR was repeated by MWG Biotech to confirm that PCR worked, 
which was reported that it did. However, they were unable to sequence it. It is possible 
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FTIR  AND  FT-RAMAN  AS  POTENTIAL  DIAGNOSTIC  TECHNIQUES  IN 
BREAST CARCINOMA:
Fourier Transform Infrared (FTIR) absorption spectra are well known for their sensitivity 
to  composition  and  three-dimensional  structure  of  biomolecules.  The  biochemical 
changes in the sub-cellular levels developing in abnormal cells, including a majority of 
cancers, manifest themselves in different optical signatures, which can be detected by IR 
spectroscopy. It is known that FTIR spectra of human tissues have specificity which can 
be used to discriminate between various disease states. This technique was employed to 
investigate  whether  morphological  changes  in  DCIS  and  IDC  grades  translate  into 
compositional differences.
The results obtained  in this preliminary study have shown that it is possible to identify 
differences between the  normal  and the cancerous  tissue,  and may also  be  possible to 
differentiate between the different nuclear grades of DCIS and IDC. Although the results 
reported here are from the tissues obtained from paraffin wax-embedded sections,  it is 
possible to obtain information on fresh tissues as well. It would be useful to compare the 
spectral data both from fresh and embedded tissues because comparable results in both 
these type of cases would mean that prospective studies could be carried out.
The differences in the intensity and positioning of peaks in the spectra are attributed to 
the compositional changes between the different tumours.  The variation in intensity of 
these peaks is due to the variation in the amount of lipids, proteins and DNA contents 
present  in  the  breast  carcinoma.  As  the  disease  progresses,  changes  take  place  in  the 
chromosomal structure and there is increase in the DNA content. These variations in the 
chromosomal structure and increase in the lipids/acylglyceride, proteins and collagens are 
well  observed  in  the  infrared  spectra,  which  collectively  help  in  classification  of the 
grades.
The FTIR spectrum of normal breast tissue showed well defined peaks in the region of 
3500 to 650 cm'1 . Spectra of normal and breast carcinoma cases showed well defined and 
prominent  spectral  bands  at  3500-2700  cm'1   and  1700-900  cm'1   with  differences  in 
intensity and positioning of the peaks, which helped to differentiate between the healthy 
and  diseased  tissue.  Dukor  et  al  (94)  employed  exactly  the  same  technique  (fourier 
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reported on the analysis of cells: benign, atypical hyperplasia and malignant tissues. Their 
study  demonstrated  that  benign  vs.  malignant  cells  were  discriminated  with  100% 
accuracy,  benign  vs.  atypical  hyperplasia  were  discriminated  with  100%  accuracy  and 
malignant  vs.  atypical  hyperplasia  were  discriminated  with  an  accuracy  of 90%  and 
higher.
Weng et al (95) have done preliminary investigation showing that FTIR spectroscopy in 
conjunction  with  fibre-optics  can  reflect  differences  between  normal  and  malignant 
tissues  and  they  stated  that  it  may  be  possible  to  determine  the  applicability  of the 
technique to cancer diagnosis. Grading of NHLs has been looked at with FTIR (96) with 
significant  differences  in  spectra  between  different  grades.  Infrared  microspectroscopy 
has been applied in combination with bivariate statistics for the detection of cell changes 
in oral/oropharyngeal squamous cell (97), lung (98) and prostate carcinoma (99) with a 
view to providing a potential diagnostic tool.
These findings reported in the literature encouraged the use of both FTIR and FT-Raman 
spectroscopic techniques for discriminating between the different nuclear grades of DCIS 
and  IDC.  Spectral  area  of 3500  -   2700  cm'1   and  1250-960  cm'1   showed  significant 
spectroscopic differences between IDC grades.  Spectral bands in the region of  1700 -  
900 cm'1   showed  significant spectroscopic differences between DCIS  grades indicating 
HNG  is  lipid/acylglyceride  rich,  LNG  is  protein  rich  and  ING  contains  both 
lipids/acylglyceride and protein.
A  number  of other  investigators  have  reported  spectroscopic  differences  between  the 
normal and cancerous tissues (100-106). However, only one study reported by Jackson et 
al (107) has looked at IDC grades with FTIR and none has yet been reported in literature 
on  the  analysis  of DCIS  grades.  Findings  in  the  present  study  agree  with  the  results 
reported by Jackson et al (107), who have also shown that higher nuclear grade tissues are 
rich  in  lipids  and  acylglyceride,  intermediate  nuclear  grade  contain  both 
lipids/acylglyceride  and  proteins  and  low  nuclear  grade  tissues  are  more  protein  rich. 
However, the FTIR technique used in the present study was more refined with the use of 
an ATR (attenuated total reflectance) objective equipped with a diamond crystal, which 
allows viewing of the specimen as well.  It is also important to note that in this study it 
was  the  first  time  diamond  crystal  ATR  was  used  for  cancer  tissue  analysis.  All  the 
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and  germanium  crystals.  Use  of  diamond  ATR  further  enhances  this  technique  by 
allowing the viewing of the sample area more clearly as compared to other crystals.
It  may  be  possible  to  relate  the  spectral  variation  of breast  tumour  grades  to  normal 
variations  in  histology.  However,  this  raises  the  question  of whether  it  is  possible  to 
detect the much less pronounced changes in the spectrum expected as a consequence of 
the progression of the  disease?  Many  spectral  changes  expected to  accompany disease 
progression may be masked by variations in acylglyceride and/or collagen content.  For 
example, progression to high grade tumour is accompanied by the appearance of nuclear 
abnormalities (e.g., altered chromosomal structure, increased DNA content). The infrared 
absorption bands most useful  in studies of DNA arise from the stretching vibrations of 
phosphodiester  groups  in  the  region  of  1082  -   1244cm'1.  Since  this  region  of  the 
spectrum is dominated by absorptions from both collagen and acylglyceride, the changes 
in  cellular  DNA  that  accompany  disease  progression  may  be  masked  by  the  large 
alterations  in  collagen  and  acylglyceride  contents  that  are  possible  between  different 
tumour types. Similarly, changes in protein expression accompanying the disease process 
are also expected to manifest changes in the amide I absorption that may also be masked 
by differences in collagen content. In addition, the changes in cell membrane properties 
would be evident by the C -  H absorption bands indicating differences in acylglyceride 
contents.
Andrus et al (108) reported on 39 freeze-dried tissue samples from 17 lymphoid tumours 
(nine malignant non-Hodgkin's lymphomas) using FTIR spectroscopy. They reported on 
the cellular RNA/DNA  ratio of overlapping absorbances,  if present, due to collagen or 
glycogen. Absorbance attributable to collagen increased with lymphoma grade and was 
greater in benign inflammatory tumours than in low-grade lymphomas. They claimed that 
the  trend  observed  in  their  study  may  form  the  basis  of a  universal  cancer-grading 
parameter to assist with cancer treatment decisions and may also be useful in the analysis 
of cellular growth perturbation induced by drugs or other therapies.  They also claimed 
that their findings may potentially be applied to cell clusters and discrete areas of tumor 
tissue sections using the FTIR microscope, allowing correlation with morphology and a 
high degree of spatial resolution.
Ramesh  et  al  (109)  reported  on  the  IR  absorption  spectra  of monolayers  of cultured 
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(micro-FTIR)  technique.  They  observed  an  increase  in  the  RNA/DNA  ratio  for  H-ras 
transfected  fibroblasts,  which  correlates  with  the  increased  transcriptional  activity 
expected for the cancerous cells and concluded that the variation in absorbance between 
normal and ras transfected fibroblasts may be due to changes in the cell dimensions.
Schultz  et  al  (97)  employed  FTIR  spectroscopy  to  observe  the  changes  in  tissue 
biochemistry induced by well-differentiated and poorly differentiated oral/oropharyngeal 
squamous  cell  carcinoma.  The  biopsies  analyzed  were  each  proven  SCC  positive  and 
compared with tissue taken from the contralateral normal site. Individual infrared spectra, 
recorded  from  specific  tissue  areas,  were  correlated  with  histopathological  structures 
normally  found  in  the  oral  mucosa.  Infrared  mapping  of  these  areas  allowed  the 
generation  of biochemical  images  of molecular  structures  such  as  lipids,  sugars,  and 
proteins.  The  visualization  of  DNA  and  tissue  structures  containing  keratin  (well 
expressed in all epithelia) revealed distinct differences between normal and SCC-positive 
biopsies.  Bivariate  histogram  analysis  of  cell  components  (e.g.,  DNA  and  keratin) 
indicated that  cancer cells produced  relatively homogeneous  and clearly  abnormal  cell 
biochemistry,  whereas  differentiated  epithelial  cells  presented  a  very  heterogeneous 
distribution  of cellular  components.  They  concluded  that  using  these  features,  tissue 
containing abnormal or cancer cells can easily be distinguished  from normal  epithelial 
structures. The abnormal keratin distribution in poorly differentiated SCC and in keratin 
pearls  (present  only  in  well-differentiated  SCC)  offered  insight  into  the  process  of 
malignant tissue transformation in squamous epithelium.
Sukuta et al (110) reported on the Fourier transform infrared fiberoptic evanescent wave 
(FTIR-FEW) spectra, in the middle infrared (MIR) region, of human normal skin tissue 
and cancer tumors by identifying protein peptide bond and lipid carbonyl vibrations. Most 
importantly,  the  study  demonstrated  that  the  FTIR-FEW  technique  has  potential  as  a 
clinical diagnostic tool.
Further studies have also been reported on the FTIR analysis of normal and neoplastic 
colon (111),  breast tissue (107;112;113),  skin (114; 115) and bladder (116)  in terms of 
such  differences  in  DNA  hydrogen  bonding  interactions  and  membrane  and  protein 
structural  properties.  Some  questions  have  been  raised  but  many  answers  have  been 
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Given the number of potential confounding variables associated with cancer cytology, a 
multivariate statistical or neural network analysis would appear to be necessary before the 
implementation  of FTIR  technology  in  clinical  laboratories.  To  address  some  of the 
question highlighted in the reported studies, it will be highly recommendable to create a 
comprehensive  spectral  database  of  cancerous  tissue  and  standardisation  of  the 
classification of breast cancer tissues especially in consultation with the pathologists.
A standardised method of analysis using FTIR spectroscopy could only be achieved by 
consensus  of pathologists  and  spectroscopists.  A  combination  of both  would  further 
enhance  the  diagnosis  by  removing  some  of the  inter-observer  variation of individual 
pathologists. Although the technique is quite specialized, with a comprehensive computer 
database, minimal training and expertise will be required.
It is important to note that FTIR spectroscopy can merely act as an alternative, but will be 
an excellent complementary tool  to histopathological  discrimination among tumours of 
different grades, and it can assess variations in many variables simultaneously. In the case 
of  the  spectra,  these  variables  may  include  the  absolute  intensity  of  one  or  more 
absorption bands, the position of one or more absorptions, the relative intensities of two 
absorptions, the width of one or more absorptions, the relative width of two absorptions 
and so on.
FTIR-microspectroscopy used in this study was applied to the tissue samples mounted on 
a glass slide and spectra obtained in reflectance mode. It may also be possible to mount 
samples on infrared transparent windows,  such as calcium  fluoride, potasium bromide, 
sodium chloride and obtain spectra in the transmission mode. The spectra obtained in the 
transmission mode would provide more detailed and precise information as compared to 
that obtained  in  reflectance  mode.  Samples mounted on any  of these  windows  can be 
stored after analysis for further investigations, as this is a non-destructive technique and 
samples  are  not  altered  in  any  way  by  exposure  to  the  infrared  beam.  The  FTIR 
spectroscopic  technique  may  be  extremely  valuable  in  the  further  study  of archived 
samples in later years, as the sections stored on glass slides or in paraffin wax-embedded 
blocks can easily be analysed by FTIR.  FTIR microspectroscopy combined with ATR 
sampling may also be a valuable clinical evaluation system for regular monitoring of the 
effects of therapy (chemo- and radio-therapy) and in predicting the type and progression 
of disease.Chapter 9: Discussion 255
FTIR chemical imaging employed in this study was used for the first time for analysis of 
cancerous tissues, which illustrated the immense potential of this technique to analyse a 
large number of samples within a short period of time. Only recently, a couple of studies 
have  been  reported  on  the  analysis  of cancerous  and  normal  tissues  employing  FTIR 
imaging techniques and coupling it with artificial neural network.
An  interesting  study  by  Zhang  et  al  (117)  reported  on  the  classification  of  Fourier 
transform infrared microscopic imaging data of human breast cells by cluster analysis and 
artificial neural networks. They employed cluster analysis and artificial neural networks 
(ANNs)  to  the  automated  assessment  of  disease  state  in  Fourier  transform  infrared 
microscopic  imaging  measurements of normal  and carcinomatous  immortalized  human 
breast  cell  lines.  Cell  pixels  were  subsequently  classified  into  carcinoma  and  normal 
categories through the use of a feed-forward ANN computed with the Broyden-Fletcher- 
Goldfarb-Shanno training algorithm. Inputs to the ANN consisted of principal component 
scores  computed  from  Fourier  filtered  absorbance  data.  A  grid  search  optimization 
procedure  was  used  to  identify  the  optimal  network  architecture  and  filter  frequency 
response. Data from three images corresponding to normal cells, carcinoma cells, and a 
mixture  of normal  and  carcinoma  cells  were  used  to  build  and  test  the  classification 
methodology.  They  claimed  the  development  of  a  successful  classifier,  although 
differences  in  the  spectral  backgrounds  between  the  three  images  were  observed  to 
complicate the classification problem. They claimed the robustness of the final classifier 
through the  use of a rejection threshold procedure to prevent classification  of outlying 
pixels.
Sheng  et  al.  (118)  reported  on  the  FTIR  microspectroscopic  analysis  of  colorectal 
carcinoma  and  found  substantial  differences  in  the  spectral  bands  of cancer  and  non- 
cancerous cells.  A  shift  of phosphodiester  groups  was  noted  in the  cancerous  cells  as 
compared to the non-cancerous one, with a sensitivity of 90.91%.
FT-Raman  is  a technique which provides  complementary  information to  FTIR.  It also 
showed differences between normal and breast carcinoma tissue, between IDC grades and 
between DCIS grades.  Most of the  studies (95) on Raman analysis of cancerous tissue 
reported to date have utilized the intensity of the  1660 and  1442cm'1  band to distinguish 
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Frank  et  al  (119)  reported  on the  Raman  spectroscopy  of normal  and  diseased  human 
breast tissues. In their study Raman spectra of histologically normal human breast biopsy 
samples  were  compared  to  those  exhibiting  infiltrating  ductal  carcinoma  (IDC)  or 
fibrocystic change. They reported that sample to sample and patient to patient variation 
for normal specimens were less than 5% for the ratios of major Raman bands. The Raman 
spectra The spectrum of infiltrating ductal carcinoma samples is similar to that of human 
collagen.  Differences  between  benign  (fibrocystic)  and  malignant  (IDC)  lesions  were 
smaller than those between normal and IDC specimens, but were still reproducible.
Similar findings were observed in this study, the increase in intensity of the C -  H peaks 
suggesting the change in the lipids, proteins and DNA contents. The absolute intensity of 
each of the peaks in 3500 to 2700cm'1  and 1660 to 1450cm'1  region varies with increasing 
grade  (I,  II  and  III),  indicating  varying  concentrations  of  fatty  acyl  chains.  Results 
obtained on IDC different nuclear grades showed an increase in intensity and shifting of 
peaks in the area of 1660 to 600cm'1  (carbonyl stretching and amide-bending vibrations in 
the DNA) confirm the changes in the chemical structure of breast tissue and this change 
in intensity provides useful information in differentiating between the  IDC grades, The 
results were reproducible and variation in spectral resolution was less than ± 0.1cm'1. The 
sensitivity and reproducibility of the technique has also been investigated by a number of 
investigators (120-126) and reported that the resultant sensitivity of cancer prediction is 
very good. One of the author reported as high as 91%, with 97% specificity and an error 
margin of p<0.0001.
Raman studies on DCIS grades have not been reported in literature to date. The results 
obtained  in  this  study  suggest  that  the  higher  nuclear  grade  spectrum  is  rich  in 
acylglyceride and the low nuclear grade spectrum is rich in protein contents. The intensity 
of the absorption bands at 2958, 2920 and 2851cm'1  was highest in HNG progressing to 
the lowest relative intensity in LNG, which indicated that the tissue section giving rise to 
the spectrum from HNG is lipid/acylglyceride rich and the one giving rise to the spectrum 
from  LNG  is  protein  rich  while  the  one  giving  rise  to  the  ING  spectrum  contains 
significant  amounts  of  both  lipids/acylglyceride  and  protein.  These  findings  nicely 
compliment the FTIR studies.
Raman  spectroscopy  is  not very  sensitive to hydroxyl  bands  (water contents),  but this 
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in  water content,  can  be  easily  analysed  by  Raman  without  getting  interference  from 
water content.
Currently a number of clinical diagnostic techniques,  such as imaging by CT and  MRI 
scans  are  widely  used.  As  both these  are  visual  tools  and  do not  add  to  the  chemical 
structural confirmation of the cancer tissue, it is extremely difficult to diagnose type and 
grade  of cancer  without  taking biopsies  and  conducting  histopathological  evaluations. 
There is a need to develop a clinical diagnostic technique that can offer chemical analysis 
of the tissues helping the clinicians not only in detecting the cancer but, also potentially 
determining its type and further classification of nuclear grades in vivo. The potential of 
Raman  spectroscopy  to  do  this  opens  the  possibility  of using  this  technique  with  a 
minimally  invasive  needle  probe  for  diagnosing  lesions,  which  are  detected 
mammographically.  At  present  attempts  are  being  made  to  develop  such  a  probe  to 
analyse the tissues in vivo, which is in its final stages of development.
The  detection  of in-situ  and  early  malignancy  is  important  because  of the  improved 
survival  rate  associated  with  early  treatment  of cancer.  As  mentioned  earlier,  Raman 
spectroscopy  is  sensitive  to  the  changes  in  molecular  composition  and  molecular 
conformation that occur in tissue during carcinogenesis, and recent developments in fibre- 
optic  probe  technology  enable  its  application  as  an  in  vivo  technique  (127).  Raman 
spectroscopy may become a useful adjunct to pathological diagnosis allowing directed or 
guided  biopsies.  Manoharan  et  al  (100)  have  reported  on  developing  optical  methods 
based  on  near  infrared  Raman  spectroscopy  and  fluorescence  photon  migration  for 
diagnosis and localization of breast cancer. They have demonstrated the ability of Raman 
spectroscopy to  classify  accurately normal,  benign and  malignant breast tissues,  which 
may prove an important step in developing Raman spectroscopic needle probes as a tool 
for improving the accuracy of needle biopsy. Raman spectroscopy is considered to have 
the potential for diagnosis of arterial disease, and cancer of gynaecological tissues, soft 
tissues, breast, colon, bladder and brain (101; 128).
Mammography  is  the  only  diagnostic  tool  at  present  by  which  breast  cancer  can  be 
detected  in  its  pre-invasive  (in  situ)  stage  although  MRI  is  showing  some  promise. 
Around 95% of cases of DCIS are now detected by mammography in their preclinical, 
asymptomatic  phase  (129).  Detection  is  based  on  the  presence  of mammographically 
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differentiated  DCIS  is  more  likely  to  be  missed  mammographically  than  poorly 
differentiated  DCIS.  In  one  series  alone  (3),  7/59  (12%)  of  DCIS  were 
mammographically occult and six out of these were well differentiated DCIS.  The main 
disadvantage  of mammography  is  that  it  usually  underestimates  the  size  of DCIS  as 
compared to histological examination, especially in the case of standard mammographic 
views (oblique and cranio-caudal). If magnification views are used then the discrepancy 
in mammographic and histological size assessment of DCIS is less than 2 cm in 80-85% 
of the cases (3). Furthermore, mammogram does not reliably distinguish between DCIS 
grades.
SUMMARY AND CONCLUSIONS:
This study has looked at DCIS  grades  in relation to each other and  in relation to  IDC 
grades by employing various techniques. The immunohistochemistry suggested that DCIS 
grades are distinct in terms of molecular marker expression although LNG and ING seem 
to  be  more  similar.  The  IDC  grades  were  also  distinct.  DCIS  grades  correspond  to 
respective IDC grades and the main differentiating factor seems to be proliferation in this 
study.
However, the immunohistochemical analysis in this study has highlighted many of the 
problems  of  small  ‘molecular  marker’  studies  including  the  use  of  a  clinically 
heterogeneous  group  of  tumours,  the  reliability  of  the  information  obtained  by  the 
antibody staining, need for standardisation of staining and interpretation, small number of 
cases  available  for  subgroup analyses  and  lack  of strong  association of many markers 
with prognosis resulting in limited validity of such data. This is now understandable in 
the  light  of recent  data  on  molecular  profiling  of breast  cancer  (130)  which  helps  to 
categorise patients into high risk and low risk groups in order to decide on better use of 
adjuvant chemotherapy, especially in node-negative patients. It has been recognised that 
there are at least 70 different gene alterations in breast cancer and hence the limited value 
of small marker studies, for instance 6 in this study is a rather small number.
Breast  cancer 'gene  expression profiles'  have  been  identified  through  DNA-microarray 
technology and seem to be better predictors of clinical  outcome  in young women (less 
than 55 years old) with stage I or II breast cancer, when compared to the currently used 
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prognostic profile of breast cancer does not depend on lymph node status and that it  is 
possible to identify a group of node-positive breast cancer patients with an unexpectedly 
good prognosis.  Prospective and independent confirmation is needed, but these data are 
fascinating and carry the hope that chemotherapy decision-making in breast cancer will 
be greatly facilitated in the future (130).
The  image analysis  in  this  study although provided  a means of objectively  classifying 
DCIS  grades,  but  the  problem  of selection  bias  remains  as  the  study  is  retrospective, 
therefore, there remains a need for prospective validation before it can be recommended 
for routine use. Furthermore, with current technology, its rather time consuming and new 
technological advances in software development may render it more practical to use.
The  p53  mutation  analysis  was  disappointing  and  needs  to  be  repeated  in  future.  It 
highlights the fact that in spite of repeated attempts, sometime a technique may not work 
due to complex interplay of various factors involved.
The spectral database developed in this study on the other hand suggests an enormous 
potential to offer pre-operative diagnosis of DCIS, IDC, their grades and extent as well as 
the  nodal  status  in  order  to  offer  better  management  to  patients  resulting  in  better 
outcome. It may be possible in future to assess the extent of DCIS and IDC in vivo and to 
assess nodal status preoperatively to help in better management and outcome.
There are, I believe, the following reasons for distinct FTIR spectra for DCIS and IDC 
grades:
1)  Minimal  heterogeneity  the  spectra  were  taken  only  from  nuclei  of each  case. 
Surrounding stroma was not included as it is likely that areas of stroma, collagen, 
calcification,  necrosis,  mucin,  milk  etc  will  have  their  own  distinct  spectra. 
Therefore, rare subtypes of DCIS  like apocrine, clear cell, papillary,  signet ring 
were not included. All IDC were not otherwise specified. The purpose of the study 
was to establish a database of nuclei of DCIS and IDC first as no such database 
exists.  Once that  is done,  then  in  future,  variations  in normal  histology  can  be 
looked at and compared against the baseline.  This fact has been highlighted by 
Jackson  et  al  who  in  the  study  of IDC  noted  that  if consistent  points  are  not 
compared  with  each other,  tissue heterogeneity  can pose  considerable problem.Chapter 9: Discussion 260
Therefore, the results of FTIR study basically mean that type and content of DNA 
is different in the three DCIS and IDC grades.
2)  Selection bias in this retrospective  study there  is a clear selection bias as  LNG 
cases  that  were  selected  had  morphologically  small  nuclei  and  HNG  had  big 
nuclei,  this  was confirmed on automated  image analysis.  In  addition,  the  lower 
grades were ER and BCL2 positive and higher grades were HER-2, p53 positive 
and  had  a  very  high  proliferative  activity  on  immunohistochemical  analysis. 
Therefore,  basically  it  is  a  feasibility  and  reproducibility  study  demonstrating 
“proof of principle” that is morphological  difference in nuclei  due to  increased 
DNA  content  and  increased  proliferation  proteins  is  reflected  in  chemical 
structural  analysis.  This  can  be  particularly  useful  in  proteomics  research.  The 
selection bias was introduced on purpose as mentioned above to establish baseline 
databases.
3)  Non-emplovment  of  statistics:  no  attempt  was  made  to  analyse  the  spectra 
statistically  because  the  statistical  analysis  involving  spectra  are  quite  complex 
and as yet there is no consensus in the literature which one to use. Furthermore, it 
was  considered  important  validating  the  findings  prospectively  on  unselected 
cases  before  trying  to  establish  parameters  like  sensitivity,  specificity,  positive 
predictive value and negative predictive value of the technique.
It seems that the initial  part of the study employing immunohistochemical  detection of 
molecular  markers  did  not  suggest  LNG  and  ING  DCIS  as  distinct  entities,  but 
spectroscopy did. This may be due to the reason that in this study immunohistochemistry 
looked  at  only  6  molecular  markers  which  may  not  have  been  significantly  different 
between the 2 groups, whereas spectra in each case were a collective reflection of all the 
proteins present in a particular case; and there can be a lot of proteins at one point from 
where a spectrum is obtained. Therefore, spectroscopy probably provides a more accurate 
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CHAPTER 10:  FUTURE WORK:
A considerable amount of study has been carried out on breast carcinoma as evidenced by 
the huge number of publications on this topic. However, particularly in the area of DCIS 
there is a need to do more research work. In this study, classification of DCIS according 
to nuclear grades appears to be clinically valid as indirectly evidenced by the statistically 
significant correlation of high nuclear grade with markers of poor prognosis (Ki67, p53 
and  cerbB-2).  In  contrast,  low  nuclear  grades  correlated  with  markers  of favourable 
prognosis (ER, Bcl2). It would be useful to determine the prognostic significance of these 
molecular  markers  prospectively  in  DCIS  studied  as  there  are  only  a  few  studies 
evaluating this (1-3). In one study, Ringberg et al (4) have evaluated the prognostic value 
of ER, PR, cerbB-2, bcl2, p53, DNA non-diploidy and Ki67 in a study of 187 cases of 
DCIS. It is likely that the combination of molecular markers studied will prove to be of 
prognostic  significance  in  DCIS  in  a  manner similar to  that  in  IDC  and  that  it  helps 
augment the information provided by the histological classification alone.  In this study, 
bax was also studied in DCIS and its prognostic value for this stage of the disease still 
needs to be evaluated. After appropriate follow-up, this could be done on these cases but 
in  order to  do  this,  the  patients  would  now need  to  be  contacted  in person  and  their 
informed consent obtained.
Other molecular markers may also be of importance in DCIS and pathogenesis of breast 
carcinoma,  for  instance  TGFp, cyclins,  pS2,  cadherins,  VEGF  (5-10)  and  a  better 
clarification of their role in prognostication of DCIS is desirable.
In addition to a possible role in prognosis of DCIS, the molecular markers studied may 
also be useful for treatment prediction in this stage as well  as in invasive disease.  For 
example,  ER determination may  guide the use of adjuvant anti-oestrogen treatment.  A 
beneficial  effect  of adjuvant  tamoxifen  for  patients  with  DCIS  operated  upon  with  a 
lumpectomy and postoperative RT has been reported both with regard to ipsilateral and 
contralateral recurrences (11). Therapies based on monoclonal antibodies directed against 
cerbB-2 may also be a treatment alternative in the future, since a high proportion of DCIS 
overexpresses  cerbB-2.  It  would  also  be  desirable  to  find  markers  for  sensitivity  or 
resistance  to  RT  in  DCIS,  as  in  IDC, p53  mutations  have  been  suggested  to  predict 
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It would be desirable to include ADH as part of the spectrum of the disease and compare 
molecular marker expression in normal,  and  UDH as well as ADH,  DCIS  and  IDC  to 
better understand the pathogenesis of breast carcinoma. There is some evidence from the 
work of Hoshi et al (13) that proliferative activity is a good discriminant between ADH 
and DCIS and it was found to be a good discriminant between normal, DCIS and IDC in 
this study as well. It is known that cerbB-2 appears earlier in breast carcinogenesis, at the 
level of atypical hyperplasia, whereas p53 overexpression is confined to carcinomas (14). 
However,  in  one  study  of  44  normal  and  benign  breast  tissues  (15),  Kandel  et  al 
demonstrated P53 gene mutations (all missense) in 10/44 (23%) of cases employing PCR- 
SSCP analysis for exons (4-10), the significance of which is yet unclear.  In this study, 
p53  positivity  was  not  seen  in  normal  tissues.  Therefore,  a  study  of normal  tissues, 
perhaps obtained as a part of reduction mammoplasty or biopsied for other reasons but 
subsequently  demonstrated  to  be  normal,  is  desirable  for  clarification;  as  the  normal 
tissues in this study came from cancerous breasts (surrounds) rather than from completely 
normal breasts.
In this study, the main differentiating factor between normal tissues, DCIS  and IDC as 
well as between the comparable subgroups of DCIS and IDC was proliferative activity, 
whereas the principal difference between IDC LN positive and its metastatic lymph nodes 
was  bax  protein  expression.  It  is  quite  possible  that  during  early  stages  of  breast 
carcinogenesis,  when  DCIS  develops  from  normal  tissue  and  IDC,  the  increase  in 
proliferation  of epithelial  cells  is  the  predominant  process,  while  the  development  of 
metastasis probably requires marked decrease in apoptosis in addition. To confirm this, a 
larger number of metastatic cases would need to be studied, looking at bax expression at 
molecular level, for instance to do RT -  PCR for bax mRNA detection. This would aid in 
understanding the development of metastasis with a view to prevent it and/or treat it.
Topoisomerase Ila is another proliferation marker, which can be looked at in DCIS and 
IDC. It is expressed in Gi, S and G2 phases  of the cell cycle. In a multivariate analysis of 
prognostic factors in 863 breast cancers, topoisomerase Ila expression was found to have 
the greatest prognostic value with regards to overall survival (OS), second only to nodal 
status (16)
For  the  cases  studied  by  PCR  amplification,  repeat  PCR  followed  by  cloning  and 
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The results of cases studied by FTIR and FT-Raman are quite interesting. This study was 
carried out on paraffin-wax embedded sections, it would be extremely useful to analyse 
fresh tissue by both  IR and  Raman spectroscopic techniques.  Furthermore, as the  fibre 
optic probe for in vivo use is in its final stages of development, it would be possible to 
employ  both  IR  and  Raman  techniques  to  investigate  patients  in  future.  As  the 
development  of  the  new  FTIR  chemical  imaging  system  has  provided  detailed 
information at a very short interval  of time, this will allow building up a spectral data 
base  of cancerous  tissues  at  a very  rapid  pace,  which  is  a missing  link  at  present,  as 
limited amount of such information are available in literature. In addition there is a need 
to develop a statistical model for both IR and Reiman spectroscopic studies on biological 
tissues.
The successful demonstration that IR and Raman spectroscopy of in vitro samples can 
distinguish  normal  from  abnormal  samples  suggests  the  possibility  that  the  same 
techniques may prove very useful in an in vivo analysis.
An  extremely  important  aspect  of  the  future  study  shall  be  to  carry  out  a  joint 
investigation with spectroscopists and pathologists, which should address the following 
issues in detail:
•  What is there, i.e., the detection with confidence
•  How far along is the disease process
•  Assurance  of precisely  and  accurately  distinguishing  between  the  diseased  and 
healthy tissue
•  Grading of cancerous tissue both by spectroscopic and pathological means.
•  Predicting an accurate statistical model
With the blending of ideas from diverse fields, a new set of perspectives may be arrived 
which will ultimately improve the health of individuals.References Chapter 1:  The breast -  embryology, anatomy and physiology 264
Reference List Chapter 1:
1.  Hamilton WJ, Boyd JD, Mossman HW. Human embryology.4th edition. Cambridge:Heffer;  1972.
2.  Salazar H, Tobon H, Josimovich HB. Developmental,gestational and postgestational modifications 
of the human breast. Clinical Obstetrics and Gynecology 1975;  18:  113-37.
3.  Gusterson B, Laurence D, Anbazhagan R, et aL The breast myoepithelial cell and its significance 
in physiology and pathology. Current Diagnostic in Pathology 1994; 1: 203-11.
4.  Parks AG. The micro-anatomy of the breast. Annals of the Royal College of  Surgeons of England 
1959;25:235-51.
5.  Osborne MP. Breast development and anatomy. In: Harris JR HSHIKD, ed. Breast diseases . 2nd 
edn. Philadelphia:Lippincott;  1991:  1-13.
6.  Ellis IO, Elston CW. The Breast. 3rd edn. Churchill Livingstone; 1997.
7.  Bocker W, Bier B, Freytag G, et aL An immunohistochemical study of the breast using antibodies 
to basal and luminal keratins,alpha-smooth muscle actin,vimentin,collagen IV and luminin.Part 
Lnormal breast and benign epithelial proliferative lesions. Virchows Archiv A-Pathological Anatomy 
and Histopathology 1992; 421: 315-22.
8.  Haagensen CD. Anatomy of the mammary glands. In: Haagensen CD, ed. Diseases of the breast.
3rd edn. Philadelphia:Saunders;  1986: 1-46.
9.  Hultborn KA, Larsson LG, Ragnhult I. The lymph drainage from the breast to the axillary and 
parasternal lymph nodes studied with the aid of colloidal AU198. Acta Radiologica 1995; 43: 52-64.
10.  Jadusingh IH. Intramammary lymph nodes. JOURNAL OF CLINICAL PA THOLOGY 1992; 45: 
1023-6.
11.  Frantz AG, Wilson JD. Endocrine disorders of the breast. In: Wilson JD FD, ed. Williams' Textbook 
of  Endocrinology. 8th edn. Philadelphia.Saunders;  1992: 975.
12.  Vogel PM, Georgiade NG, Fetter BF, et al. The correlation of histologic changes in the human 
breast with the menstrual cycle. American Journal of  Pathology 1981; 104: 23-34.
13.  Potten CS, Watson RJ, Williams GT, et al. The effect of age and menstraual cycle upon 
proliferative activity of the normal human breast. British Journal of Cancer 1988; 58:  163-8.
14.  Anderson TJ, Raab GM., Ferguson DJP. Cell turnover in the 'resting' human breast.Influence of 
parity,contraceptive pill,age and laterality. British Journal of Cancer 1982; 46: 376-82.
15.  Page DL, AndersonTJ. Stages of breast development. In: Page DL AT, ed. Diagnostic 
histopathology of  the breast. Edinburgh:Churchill Livingstone; 1987:  11-29.
16.  Hutson SW, Cowen PN, Bird CC. Morphometric studies of age related changes in normal human 
breast and their significance for evolution of mammary cancer. JOURNAL OF CLINICAL 
PATHOLOGY 1985; 38: 281-7.
17.  Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with 
special reference to possible precancerous lesions. Journal of  National Cancer Institute 1975; 55: 
231-73.
18.  Foote FW, Stewart FW. Comparative studies of cancerous versus non-cancerous breasts. Annals of 
Surgery 1945; 121: 574-85.References Chapter 1:  The breast -  embryology, anatomy and physiology 265
19.  Tavassoli FA. classification of metaplastic carcinomas of the breast. Pathology Annual 1992; 27: 89-
119.
20.  Tavassoli FA, Yeh IT. Lactational and clear cell changes of the breast in non-lactating, non­
pregnant women. American Journal of Clinical Pathology 1987; 87: 23-9.References Chapter 2: Breast cancer 266
Reference List Chapter 2:
1.  Various Contributors. The Health of the Nation. Report 1993.
2.  Eles RA, Ponder BAJ. Familial breast cancer, RSM current medical literature. Breast and 
Prostate Cancer 1992; 5: 67-70.
3.  Chen Y, Thompson W, Semenciw R, et al. Epidemiology of contralateral breast cancer. Cancer 
Epidemiology Biomarkers & Prevention 1999; 8: 855-61.
4.  Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age at first birth 
and a family history of breast cancer. American Journal of Epidemiology 1987; 125: 769-79.
5.  Kelsey JL, Berkowitz GS. Breast cancer epidemiology. Cancer Research 1988; 48: 5615-23.
6.  Kalache A, Maguire A, Thompson SG. Age at last full term pregnancy and risk of breast cancer. 
Lancet 1993; -33.
7.  McPherson K, Vessey N, Neil A, et al. Early oral contraceptive use and breast cancer: results of 
another case control study. British Journal of Cancer 1987; 56: 653-60.
8.  Van Leeuwen FE, Rookus MA. The role of exogenous hormones in the epidemiology of breast, 
ovarian and endometinal cancer. European Journal of Cancer and Clinical Oncology 1989; 25: 
1961-72.
9.  Steinberg KK, Thacker SB, et al. Meta analysis of the effect of oestrogen replacement therapy 
on the risk of breast cancer. Journal of  the American Medical Association 1991; 265:  1985-90.
10.  Kushi LH, Sellars TA, Potters JD, et aL Dietary fat and post-menopausal breast cancer. Journal 
of the National Cancer Institute 1992; 84: 1092-9.
11.  Key TJ, Verkasalo PK, Banks E.  Epidemiology of breast cancer. The Lancet Oncology 2001; 2: 
133-40.
12.  Evans JS, Wennberg JE, McNeil BJ. The influence of diagnostic radiography on the incidence 
of breast cancer and leukaemia. New England Journal of  Medicine 1986; 315: 810-5.
13.  Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. Journal of Clinical 
Oncology 1998; 16: 338-47.
14.  Cerhan JR, Kushi LH, Olson JE, et al. Twinship and risk of postmenopausal breast cancer. 
Journal of the National Cancer Institute 2000; 92: 261-5.
15.  Murphy MF, Broeders MJ, Carpenter LM, et al. Breast cancer risk in mothers of twins. British 
Journal of Cancer 1997; 75:  1066-8.
16.  Lambe M, Hsieh C, Tsaih S, et al. Maternal risk of breast cancer following multiple births: a 
nationwide study in Sweden. Cancer Causes & Control: CCC 1996; 7: 533-8.
17.  McKinna JA, Davey JB, Walsh GA, et al. The early diagnosis of breast cancer - a 20 year 
experience at the Royal Marsden Hospital. European Journal of  Cancer 1992; 28A: 911-6.
18.  Tobar L, Duffy SW, Krusemo UB.  Detection method, tumour size and node metastasis in breast 
cancers diagnosed during a trial of breast cancer screening. European Journal of Clinical 
Oncology 1987; 23: 959-62.
19.  Bassett LW, Liu TH, Giuliano AE, Gold RH. The prevalence of carcinoma in palpable versus 
impalpable mammographically detected lesions. American Journal of  Roentgenology 1991; 157: 
21-4.References Chapter 2: Breast cancer 267
20.  Carter CL, Allen C, Henson DE.  Relation of tumour size, lymph node status and survival in 
24,740 breast cancer cases. Cancer 1989; 63: 181-7.
21.  Day NE. Screening for breast cancer. British Medical Bulletin 1991; 47: 400-15.
22.  Shapiro S, Venet W, Strax P, et al. Periodic screening for breast cancer: The Health Insurance 
Plan Project and its sequelae, 1963-1986. Baltimore MD: The John Hopkins University Press 
1988.
23.  Nystrom L, Rutqvist LE, Wall S, et aL Breast cancer screening with mammography: overview of 
Swedish randomized trials. Lancet 1993; 341: 973-8.
24.  Orel SG. MR imaging of the breast. Radiologic Clinics of North America. 2000; 38: 899-913.
25.  Azzopardi JG, Chepick OF, Hartmann WH, et aL The World Health Organization histological 
typing of breast tumors.2nd ed. American Journal Of  Clinical Pathology 1982; 78: 806-16.
26.  World Health Organization. International histological classification of tumours. Histologic types 
of breast tumours. Geneva: World Health Organization.  1981.
27.  Page DL, Anderson TJ. Diagnostic histopathology of the breast. Edinburgh: Churchill 
Livingstone 1987.
28.  Tavassoli FA. Pathology of the breast. Norwalk: Appleton and Lange 1992.
29.  Rosen PP, Oberman HA. Tumours of the mammary gland. Atlas of tumour pathology.
Washington: Armed Forces Institute of  Pathology. Third series, fascicle7 1993.
30.  Elston CW, Ellis IO. Classification of malignant breast disease. In: Symmers W, ed. The Breast.
13 edn.  1997: 243.
31.  Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with 
special reference to possible precancerous lesions. Journal of the National Cancer Institute 1975; 
55:231-73.
32.  Scarff RW, Torloni H. Histological typing of breast tumours(Intemational histological 
classification of tumours, no.2). Geneva: World Health Organization.  1968.
33.  Fisher ER, Gregorio RM, Fisher B. The pathology of invasive breast cancer. A syllabus derived 
from findings of the National Surgical Adjuvant Breast Cancer Project(protocol no. 4). Cancer 
1975; 36:  144-56.
34.  Page DL, Anderson TJ, Sakamoto G. Infiltrating carcinoma: major histological types.In Page 
DL, Anderson TJ, eds. Diagnostic histopathology of the breast. London: WB Saunders 1987;  193- 
235.
35.  Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological 
grade in breast cancer: experience from a large study with long term follow-up. Histopathology 
1991; 19: 403-10.
36.  Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. A study of 
1409 cases of which 359 have been followed for 15 years. British Journal of Cancer 1957; 11: 
359-77.
37.  Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. 
American Journal Of  Clinical Pathology 1994; 102(Suppl 1): 3-8.
38.  Verhoeven D, Bourgeois N, Derde MP, et al. Comparison of cell growth in different parts of 
breast cancers. Histopathology 1990; 17: 505-9.References Chapter 2: Breast cancer 268
39.  Connor AJM, Pinder SE, Elston CW, et al. Intratumoural heterogeneity of proliferation in 
invasive breast carcinoma evaluated with MIB1 antibody. The Breast 1997.
40.  Galea M, Blarney RW, Elston CW, et al. The Nottingham Prognostic Index in primary breast 
cancer. Breast Cancer Research and Treatment 1992; 22:  187-91.
41.  Dalton LW, Page DL, Dupont WD.  Histologic grading of breast carcinoma: a reproducibility 
study.  Cancer 1994; 73: 2765-70.
42.  Frierson HF, Wolber RA, Berean KW, et aL Interobserver reproducibility of the Nottingham 
modification of the Bloom and Richardson histological grading sheme for infiltrating ductal 
carcinoma. American Journal Of Clinical Pathology 1995; 105:  195-9.
43.  Robbins P, Pinder S, de Klerk N, et aL Histological grading of breast carcinomas. A study of 
interobserver agreement. Human Pathology 1995; 26: 873-9.
44.  Pereira H, Pinder SE, Sibbering DM, et aL Pathological prognostic factors in breast cancer.IV: 
should you be a typer or grader? A comparative study of two histological prognostic features in 
operable breast carcinoma. Histopathology 1995; 27: 219-26.
45.  Gilchrist KW, Kalish L, Gould VE, et al. Interobserver reproducibility of histopathological 
features in stage II breast cancer. Breast Cancer Research and Treatment  1985; 14: 91-9.
46.  Sloane JP. National Coordinating Group for Breast Screening Pathology.Consistency of 
histopathological reporting of breast lesions detected by screening: findings of the UK National 
External Quality Assessment(EQA) Sheme. European Journal of  Cancer 1994; 30A:  1414-9.
47.  Foote FW Jr, Stewart FW. Lobular carcinoma in situ. A rare form of mammary cancer.
American Journal of  Pathology 1941; 7: 491-6.
48.  Foote FW Jr, Stewart FW. A histologic classification of carcinoma in the breast. Surgery 1946; 
19: 74-99.
49.  Ellis IO, Galea M, Broughton, et aL Pathological prognostic factors in breast 
cancer.II.Histological type.Relationship with survival in a large study with long-term follow-up. 
Histopathology 1992; 20: 479-89.
50.  Anderson TJ, Lamb J, Donnan P, et aL Comparative pathology of breast cancer in a randomized 
trial of screening. British Journal of  Cancer 1991; 64: 108-13.
51.  Ellis IO, Galea M, Locker A, et al. Early experience in breast cancer screening: Emphasis on 
development of protocols for triple assessment. Breast 1993; 2:  148-53.
52.  Rajakariar R, Walker RA. Pathological and biological features of mammographically detected 
invasive breast carcinomas. British Journal of Cancer 1995; 71:  150-4.
53.  Rosen PP, Senie RT, Farr GH, et al. Epidemiology of breast carcinoma: age, menstrual status 
and exogenous hormone usage in patients with lobular carcinoma in situ. Surgery 1979; 85: 219-
24.
54.  Schnitt SJ, Connolly JL, Harris JR, et al. Pathologic predictors of early local recurrence in stage 
I and II breast cancer treated by primary radiation therapy. Cancer 1984; 53:  1049-57.
55.  Recht A, Connolly JL, Schnitt SJ, et al. The effect of young age on tumor recurrence in the 
treated breast after conservative surgery and radiotherapy. International Journal of  Radiation 
Oncology Biology Physics 1988; 14: 3-10.References Chapter 2: Breast cancer 269
56.  Lindley R, Bulman A, Parsons P, et al. Histologic features predictive of an increased risk of 
early local recurrence after treatment of breast cancer by local tumour excision and radical 
radiotherapy. Surgery 1989;  105:  13-20.
57.  Bartelink H, Borger JH, van Dongen JA, et al. The impact of tumour size and histology on local 
control after breast-conserving therapy. Radiotherapy Oncolgy 1988; 11: 297-303.
58.  Henderson IC. The treatment of metastatic breast carcinoma with adjuvant systemic therapy. 
Annals of Oncology 1990; 1:9-11.
59.  Murray KL, Lambah PA, Dixon JM, et al. Occult lymph node metastases in 'node negative' 
breast carcinoma. Meeting of  the Pathological Society of  Great Britain and Ireland 2001; 117.
60.  Millis RR, Springall R, Lee AHS, et aL Occult axillary lymph node metastases are of no 
prognostic significance in breast cancer. Meeting of the Pathological Society of Great Britain and 
Ireland 2001; 6A.
61.  Haagensen CD, Bodian C. Personal experience with Halsted's radical mastectomy. Annals of 
Surgery 1984; 199: 443-50.
62.  Cascinelli N, Greco M, Bufalino R, et aL Prognosis of breast cancer with axillary node 
metastasis after surgical treatment only. European Journal of Cancer and Clinical Oncology 1987; 
23: 795-9.
63.  Locker A, Ellis IO, Morgan DAL, et aL Factors influencing local recurrence after excision and 
radiotherapy for primary breast cancer. British Journal of  Surgery 1989; 76: 890-4.
64.  Cox DR. Regression models and life-tables. Journal of  Royal Statistical society(B) 1972; 34: 187- 
220.
65.  Haybittle JL, Blarney RW, Elston CW, et at A prognostic index in primary breast cancer.
British Journal of Cancer 1982; 45: 361-6.
66.  Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast 
cancer. British Journal of Cancer 1987; 56: 489-92.
67.  Galea MH, Blarney RW, Elston CW, et al. The Nottingham Prognostic Index in primary breast 
cancer. Breast Cancer Research and Treatment 1992; 22:  187-91.
68.  Brown JM, Benson EA, Jones M. Confirmation of a long-term prognostic index in breast cancer. 
The Breast 1993; 2:  144-7.
69.  Fitzgibbons PL, Page DL, Weaver D, et aL Prognostic factors in breast cancer.College of 
American Pathologists Consensus statement 1999. Archives of  Pathology and Laboratory 
Medicine. 2000; 124: 966-78.
70.  Borresen AL, Anderson TI, Garber J, et al. Screening for germline TP53 mutations in breast 
cancer patients. Cancer Research 1992; 52: 3234-56.
71.  Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 mutations in breast cancer. Cancer 
Research 1992; 52: 2984-6.
72.  Wooster R, Mangion J, Eeles R, et al. A germline mutation in the androgen receptor in two 
brothers with breast cancer and Reifenstein Syndrome. Nature Genetics 1992; 2: 132-4.
73.  Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia- 
telangiectasia. New England Journal of  Medicine 1987; 316:  1289-94.
74.  Gowing NFC. A Colour Atlas of Tumour Histopathology 1993.References Chapter 2: Breast cancer 270
75.  Birch JM. Familial cancer syndromes and clusters. British Medical Bulletin Series.Genetics of 
malignant disease by BAJ Ponder.  1994.
76.  Tavassoli FA. Male breast lesions. In:Tavassoli FA, ed. Pathology of the breast. Book, Monograph 
1992; 637-59.
77.  Ribiero G. Male breast carcinoma-a review of 301 cases from the Christie Hospital and Holt 
Radium Institute, Manchester. British Journal of  Cancer 1985; 51:  115-9.
78.  Gough DB, Donohue JH, Evans MM, et aL A 50-year experience of male breast cancer: is 
outcome changing? Surgical Oncology 1993; 2: 325-33.
79.  Borgen PI, Wong GY, Vlamis V, et aL Current management of male breast cancer. A review of 
104 cases. Annals of  Surgery 1992; 215: 451-7.
80.  Sasco AJ, Lowenfels AB, Pasker-De Jong P. Epidemiology of male breast cancer. A meta­
analysis of published case-control studies and discussion of selected aetiological factors. 
International Journal of  Cancer 1993; 53: 538-49.
81.  Spence RAJ, Mackenzie G, Anderson JR, et aL Long-term survival following cancer of the 
male breast in Northern Ireland. Cancer 1985; 55: 648-52.
82.  Willsher PC, Leach IH, Ellis IO. Male breast cancer: A comparison of outcome with breast 
cancer in females. American Journal of  Surgery 1997; 173: 185-8.
83.  McDivitt RW, Stewart FW. Breast carcinoma in children. Journal of the American Medical 
Association 1966; 195: 388-90.
84.  Hartmann AW, Magrish P. Carcinoma of the breast in children: case report: six year old boy 
with adenocarcinoma. Annals of  Surgery 1955; 141: 792-7.
85.  Oberman HA, Stephens PJ. Carcinoma of the breast in chidhood. Cancer 1972; 30: 470-4.
86.  Sullivan JJ, Magee HR, Donald KJ. Secretory (juvenile) carcinoma of the breast. Pathology 
1977; 9: 341-6.
87.  Karl SR, Ballantine TVN, Zaino R. Juvenile secretory carcinoma of the breast. Journal of 
Paediatric Surgery 1985; 20: 368-71.
88.  Bryne MP, Fahey MM, Gooselaw JG. Breast cancer with axillary metastases in an eight and 
one-half year old  girl. Cancer 1973; 31: 726-8.
89.  Rosen PP, Oberman HA. Tumours of the mammary gland. Atlas of Tumour Pathology 1990.
90.  Garcia SB, Novelli M, Wright NA. The clonal origin and clonal evolution of epithelial tumours. 
International Journal of  Experimental Pathology 2000; 81: 89-116.
91.  Diallo R, Schaefer KL, Poremba C, et al. Monoclonality in normal epithelium and in 
hyperplastic and neoplastic lesions of the breast. Journal of  Pathology 2001; 193: 27-32.
92.  Going JJ, El-Monem HM, Craft JA. Clonal origins of human breast cancer. Journal of 
Pathology 2001; 194: 406-12.
93.  Sacks NPM, Baum M. Primary management of carcinoma of the breast. Lancet 1993; 342:  1402- 
8.
94.  Greening WP, Montgomery AW, Gordon AB, et al. Quadratic excision and axillary node 
dissection without radiotherapy: the long term results of a selective policy in the treatment of stage 
I breast cancer. European Journal of  Surgical Oncology 1988; 14: 221-5.References Chapter 2: Breast cancer 271
95.  Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the 
prognosis of patients with primary breast cancer. Cancer 1983; 52:  1551-7.
96.  Ranger GS, Mokbel K. The evolving role of sentinel lymph node biopsy for breast cancer. 
European Journal of  Surgical Oncology 2003; 29: 423-5.
97.  The Early Breast Triallists1  Collaborative Group. Systemic treatment of early breast cancer by 
hormonal, cytotoxic or immune therapy. Lancet 1992; 339:  1-15-71-85.
98.  Litherland S, Jackson IM. Antioestrogens in the management of hormone-dependent cancer. 
Cancer Treatment Reports 1988;  15:  183-94.
99.  Peters WP, Shpall EJ, Jones RB, et aL High dose combination cyclophosphamide, cisplatin and 
carmustine with bone marrow support as initial treatment for metastatic breast cancer. Journal of 
Clinical Oncology 1986; 6:  1368-76.
100.  Jones AL, Smith IE. Navelbine and the anthrapyrazoles. Clinics in Haematology and Oncology 
1993.
101.  Holmes FA, Wathers RS, Theriault RL, et aL Phase II trial of taxol, an active drug in the 
treatment of metastatic breast cancer. Journal of  the National Cancer Institute 1991; 83: 1797-805.
102.  Alberg AJ, Lam AP, Helzlsouer KJ. Epidemiology, prevention, and early detection of breast 
cancer. Current Opinion in Oncology 1999; 11: 435-41.References Chapter 3: Molecular biology of breast cancer 111
Reference List Chapter 3:
1.  White JA, McAlpine PJ, Antonarakis S, et al. Guidelines for human gene nomenclature.
Genomics 1997; 45:468-71.
2.  Lyon MF. Further data on the genetic-basis of segregation distortion and sterility caused by mouse t- 
haplotypes. Genetical Research 1984; 43: 205-6.
3.  Hesketh R. The oncogene and tumour suppressor gene factsbook. 2nd edn. Academic Press;  1997.
4.  Bishop JM. Cancer - the rise of the genetic paradigm. Genes Development 1995; 9:  1309-15.
5.  Mehle C, Piatyszek MA LBea. Telomerase activity in human renal cell carcinoma. Oncogene 1996; 
13:  161-6.
6.  Zhu X, Kumar R, Mandal M, et al. Cell cycle-dependent modulation of telomerase activity in 
tumor cells. Proceedings of  National Academy of  Sciences USA  1996; 93: 6091-5.
7.  Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their 
receptors in human malignancies. Critical Reviews in Oncology and Haematology 1995; 19:  183- 
232.
8.  Normanno N, Ciardiello F, Brandt R, et al. Epidermal growth factor-related peptides in the 
pathogenesis of human breast cancer. Breast Cancer Research and Treatment 1994; 29: 11-27.
9.  Todaro GJ, Fryling C, Delarco JE. Transforming growth factors produced by certain tumour cell 
lines:polypeptides that interact with epidermal growth factor receptors. Proceedings of  National 
Academy of  Sciences USA  1980; 77: 5258-61.
10.  Roberts AB, Frolick CA, Anzano MA, et al. Transforming growth factors from neoplastic and 
non-neoplastic tissues. Federal Proceedings 1983; 42: 2621-5.
11.  Levine AL, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
12.  Silberstein GB, Daniel CW. Reversible inhibition of mammary gland growth by transforming 
growth factor-beta. Science 1987; 237: 291-3.
13.  Rajkumar T, Gullick WJ. The type I growth factor receptors in human breast cancer. Breast 
Cancer Research and Treatment 1994; 29: 3-9.
14.  Almendral JM, Sommer D, Macdonaldbravo H, et al. Complexity of the early genetic response to 
growth-factors in mouse fibroblasts. Molecular Cell Biology 1988; 8: 2140-8.
15.  Zipfel PF, Irving SG, Kelly K, et al. Complexity of the primary genetic response to mitogenic 
activation of human t-cells. Molecular and Cellular Biology 1989; 9:  1041-8.
16.  Crews CM, Alessandrini A, Erikson RL. The primary structure of mek, a protein-kinase that 
phosphorylates the erk gene-product. Science 1992; 258: 478-80.
17.  Ihle JN. Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic 
cells. Advance Cancer Research 1996; 68: 23-65.
18.  Weinberg RA. The action of oncogenes in the cytoplasm and nucleus. Science 1985; 230: 770-4.
19.  Slamon DJ, de Kerion JB, Verma IM, et al. Expression of cellular oncogenes in human 
malignancies. Science 1984; 224: 256-62.
20.  Trepicchio WL, Krontiris TG. members of the rel/nf-kappa-b-family of transcriptional regulatory 
proteins bind the hrasl minisatellite dna-sequence. Nucleic Acids Research 1992; 20: 2427-34.References Chapter 3: Molecular biology of breast cancer 273
21.  Krontiris TG, Devlin B, Karp DD, et al. An association between the risk of cancer and mutations 
in the HRAS1 minisatellite locus. New England Journal of  Medicine 1993; 329: 517-23.
22.  Walker RA, Wilkinson N. p21   ras protein expression in benign and malignant human breast. 
Journal of Pathology 1988; 156:  147-53.
23.  Agnantis NJ, Petraki C, Markoulatos P, et al Immunohistochemical study of the ras oncogene 
expression in human breast lesions. Anti Cancer Research 1986; 6:  1157-60.
24.  Honran Hand P, Thor A, Wunderlich D, et al. Monoclonal antibodies of predefined specificity 
detect activated ras gene expression in human mammary and colon carcinomas. Proceedings of 
National Academy of  Sciences USA  1984; 81: 5227-31.
25.  Ohuchi N, Thor A, Page DL, et al. Expression of the 21000 molecular weight ras protein in a 
spectrum of benign and malignant human mammary tissues. Cancer Research 1986; 46: 2511-9.
26.  Candlish W, Kerr IB, Simpson HW. Immunocytochemical detection and significance of p21  ras 
family oncogene product in benign and malignant breast disease. Journal of  Pathology 1986; 150: 
163-7.
27.  Ghosh AK, Moore M, Harris M. Immunohistochemical detection of ras oncogene p21 product in 
benign and malignant mammary tissue in man. Journal of Clinical Pathology 1986; 39: 428-34.
28.  Wu JX, Carpenter PM, Gresens C, et al. The protooncogene c-fos is over-expressed in the 
majority of human osteosarcomas. Oncogene 1990; 5: 989-1000.
29.  Schutte J, Krischke W, Niederle N, et aL is there any clinical relevance of serial determinations of 
serum carcinoembryonic antigen in small cell lung-cancer patients. Cancer 1988; 62:  1348-54.
30.  Szabo E, Riffe ME, Steinberg SM, et al Altered cJUN expression: An early event in human lung 
carcinogenesis. Cancer Research 1996; 56: 305-15.
31.  Guerin M, Sheng ZM, Andrieu N, et al. Strong association between c-myb and estrogen-receptor 
expression in human breast-cancer. Oncogene 1990; 5:  131-5.
32.  Barletta C, Bartolazzi A, Reale GC, et al. Cytogenetic, molecular and phenotypic characterization 
of the newly established renal carcinoma cell line KJ29. Evidence of translocations for chromosomes 
1  and 3. Anti Cancer Research 1995; 15: 2129-36.
33.  Nurnberg W, Artuc M, Nawrath M, et al. Human c-myb is expressed in cervical carcinomas and 
transactivates the hpv-16 promoter. Cancer Research 1995; 55: 4437.
34.  Gazdar AF, Carney DN, Nau MM, et al. Characterization of variant subclasses of cell-lines 
derived from small cell lung-cancer having distinctive biochemical, morphological, and growth- 
properties. Cancer Research 1985; 45: 2924-30.
35.  Guerin M, Barrois M, Terrier MJ, et al. overexpression of either c-myc or c-erbb-2/neu proto­
oncogenes in human-breast carcinomas - correlation with poor prognosis. Oncogene Research 1988; 
3:21-31.
36.  Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast-cancer 
patients and amplification of 2 putative oncogene-coamplification units - hst-l/int-2 and c-erbb- 
2/ear-l. Cancer Research 1989; 49: 3104-8.
37.  Mariani-Costantini R, Ottini L, Falchetti M, et al. Mutations at coding mononucleotide repeats in 
gastric cancer with the microsatellite mutator phenotype. Cancer Research 1988; 16: 2161-12.References Chapter 3: Molecular biology of breast cancer 274
38.  Futreal PA, Cochran C, Marks JR, et al. mutation analysis of the thral gene in breast-cancer - 
deletion fusion of the gene to a novel sequence on 17q in the bt474 cell-line. Cancer Research 1994; 
54:  1791-4.
39.  Theillet C, Adnane J, Szepetowski P, et aL bcl-1 participates in the 1  lq 13 amplification found in 
breast-cancer. Oncogene 1990; 5:  147-9.
40.  Knudson AG. Antioncogenes and human cancer. Proceedings of  National Academy of  Sciences 
USA  1993; 90:  10914-21.
41.  Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proceedings of National 
Academy of  Sciences USA  1971; 68: 820-3.
42.  Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast 
cancer:a meta-analysis. British Journal of Cancer 1999; 80:  1968-73.
43.  Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma 
antioncogene is restricted to a subset of human tumor-cells. Proceedings of  National Academy of 
Sciences USA  1990; 87: 2775-9.
44.  Friend SH, Horowitz JM, Gerber MR, et al. deletions of a dna-sequence in retinoblastomas and 
mesenchymal tumors - organization of the sequence and its encoded protein. Proceedings of 
National Academy of  Sciences USA  1987; 84: 9059-63.
45.  Weichselbaum RR, Beckett M, Diamond A. some retinoblastomas, osteosarcomas, and soft-tissue 
sarcomas may share a common etiology. Proceedings of  National Academy of  Sciences USA  1988; 
85: 2106-9.
46.  Ruggeri B, Zhang SY, Caamano J. Human pancreatic carcinomas and cell-lines reveal frequent 
and multiple alterations in the p53 and rb-1 tumor-suppressor genes. Oncogene 1992; 7:  1503-11.
47.  Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-6.
48.  Graeber TG, Osmanian C, Jacks T, et aL Hypoxia-mediated selection of cells with diminished 
apoptotic potential in solid tumours. Nature 1995; 379: 88-91.
49.  Hassapoglidou S, Diamandis EP, Sutherland DJA. Quantification of p53 protein in tumor-cell 
lines, breast-tissue extracts and serum with time-resolved immunofluorometry. Oncogene 1993; 8: 
1501-9.
50.  Biggs PJ, Warren W, Venitt S, et al. Does a genotoxic carcinogen contribute to human breast 
cancer?The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis 1993; 8: 
275-83.
51.  Donehower LA, Bradley A. the tumor-suppressor p53. Biochemical and Biophysical Research 
Communications 1993; 1155:  181-205.
52.  Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-6.
53.  Hainaut P, Soussi T, Shomer B, et al. Database of p53 gene somatic mutations in human tumors 
and cell lines: Updated compilation and future prospects. Nucleic Acids Research 1997; 25:  151-7.
54.  Milner J. Flexibility - the key to p53 function. Trends in Biochemical Sciences 1995; 20: 49-51.
55.  Milner J, Medcalf EA, Cook AC.  Tumor suppressor p53 - analysis of wild-type and mutant p53 
complexes. Molecular Cell Biology 1991; 11:  12-9.
56.  Halazonetis T, Davis LJ, Kandil AN. Wild-type p53 adopts a mutant-like conformation when 
bound to DNA. EMBO 1993; 12:  1021-8.References Chapter 3: Molecular biology of breast cancer 275
57.  Saitoh S, Cunningham J, Devries EMG, et al. p53 gene-mutations in breast cancers in midwestem 
us women - null as well as missense-type mutations are associated with poor-prognosis. Oncogene 
1994; 9: 2869-75.
58.  Kovach JS, Hartmann A, Blaszyk H, et al. Mutation detection by highly sensitive methods 
indicates that p53 gene mutations in breast cancer can have important prognostic value.  Proceedings 
of  National Academy of  Sciences USA  1996; 93:  1093-6.
59.  Sun XF, Johannsson O, Hakansson S, et al. A novel p53 germline alteration identified in a late 
onset breast cancer kindred. Oncogene 1996; 13: 407-11.
60.  Blaszyk H, Hartmann A, Tamura Y, et al Molecular epidemiology of breast cancers in northern 
and southern Japan: The frequency, clustering, and patterns of p53 gene mutations differ among 
these two low-risk populations. Oncogene 1996; 13: 2159-66.
61.  Jolly KW, Malkin D, Douglass EC, et aL Splice-site mutation of the p53 gene in a family with 
hereditary breast-ovarian cancer. Oncogene 1994; 9: 97-102.
62.  Mazoyer S, Lalle P, Moyretlalle C, et al. 2 germ-line mutations affecting the same nucleotide at 
codon-257 of p53 gene, a rare site for mutations. Oncogene 1994; 9:  1237-9.
63.  Srivastava S, Zou ZQ, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer- 
prone family with li-fraumeni syndrome. Nature 1990; 348: 747-9.
64.  Scully R, Ganesan S, Brown M, et al. Location of BRCA1  in human breast and ovarian cancer 
cells[letter comment]. Science 1996; 272: 123-5.
65.  Miki Y, Swensen J, Shattuck-Eidens D, et aL A strong candidate for the breast and ovarian cancer 
susceptibility gene BRCA1. Science 1994; 266: 66-71.
66.  Hall JM, Lee MK, Newman B, et aL Linkage of early onset familial breast cancer to chromosome 
17q21. Science 1990; 250:  1684-9.
67.  Narod SA, Feunteun J, Lynch H.  A female breast-ovarian cancer focus on chromosome 17q21-23. 
Lancet 1991; 338: 82-3.
68.  Easton DF, Bishop DT, Ford D, et aL Genetic linkage analysis in familial breast and ovarian cancer 
results from 214 families. American Journal of  Human Genetics  1993; 52: 678-701.
69.  Ford D, Easton DF, Bishop DT, et aL The risks of cancer in BRCA1   mutation carriers. American 
Journal of  Human Genetics 1993; 53: A298.
70.  Anderson DE, Baelzioch MD. Breast cancer risks in relatives of male breast cancer patients.
Journal of  National Cancer Institute 1992; 84:  1114-7.
71.  Neugut Al, Murray T, Lee WC, et al. The association of breast cancer and colorectal cancer in 
men. Cancer 1991; 68: 2069-73.
72.  Wooster R, Bignell G, Lancaster J, et aL Identification of the breast cancer susceptibility gene 
BRCA2. Nature 1995; 378: 789-92.
73.  Sherr CJ, Roberts JM. Inhibitors of mammalian g(l) cyclin-dependent kinases. Genes 
Development 1995; 9:  1149-63.
74.  Galaktionov K, Lee AK, Eckstein J, et al. Cdc25 phosphatases as potential human oncogenes. 
Science 1995; 269:  1575-7.
75.  Meyer JS, Freidman E, McCrate MM, et al. Prediction of early course of breast carcinoma by 
thymidine labeling. Cancer 1983; 51: 1879-86.References Chapter 3: Molecular biology of breast cancer 276
76.  Tubiana M, Pejovic MJ, Renaud A, et al. Kinetic parameters and the course of the disease in 
breast cancer. Cancer 1981; 47: 937-43.
77.  Bonadonna G, Valagussa P, Tancini G, et al. Current status of Milan adjuvant chemotherapy trials 
for node-positive and node-negative breast cancer. National Cancer Institute Monograph 1986; 1: 
45-9.
78.  Remvikos Y, Beuzebocp P, Zajdela A. Correlation of proliferative activity of breast cancer with 
response to cytotoxic chemotherapy. Journal of  National Cancer Institute 1989; 81:  1383-7.
79.  Wright NA, Hall PA. Cell proliferation in pathology. Journal of Pathology 1993;  170: 327-30.
80.  Wright NA. Cell proliferation in health and disease.In:Anthony PP, MacSween RNM, eds.Recent 
Advances in Histopathology. Edinburgh: Churchill Livingstone 1984; 17-34.
81.  Uyterlinde AM, Schipper NW, Baak JPA. Comparison of extent of disease and morphometric and 
DNA flow cytometric prognostic factors in invasive ductal breast cancer. Journal of Clinical 
Pathology 1987; 40:  1432-6.
82.  Crocker J, Burnett D, Lowe D, et al. MThe clinical promise of molecular pathology. British 
Medical Journal 1994; 309: 624.
83.  Gerdes J, Schwab U, Lemke H, et al. The production of a mouse monoclonal antibody reactive 
with a human nuclear antigen associated with cell proliferation. International Journal of Cancer 
1983; 31:  13-20.
84.  Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGFR, cerbB2 protein 
expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of 
Cancer 1993; 29A:  1018-23.
85.  Bouzubar N, Walker KJ, Griffiths K, et al. Ki67 immunostaining in primary breast 
cancer:pathological and clinical associations. British Journal of  Cancer 1989; 59: 943-7.
86.  Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1  in 
breast carcinoma using image analysis; associations with other prognostic factors and survival. 
British Journal of Cancer 1995; 71:  146-9.
87.  Locker AP, Birrell K, Bell JA, et al Ki67 immunoreactivity in breast carcinoma:relationship to 
prognostic variables and short term survival. European Journal of  Surgical Oncology 1992;  18: 224-
9.
88.  Reed JC. Bcl2 and the regulation of programmed cell death. Journal of  Cell Biology 1994; 124:  1-6.
89.  Hockenberg DM. Bcl2 in cancer development and apoptosis. Journal of  Cell Science 1994;  18:51-
5.
90.  Kerr JF, Winterford CM, Harmon BV, et al. Apoptosis-its significance in cancer and cancer 
therapy. Cancer 1994; 73: 2013-26.
91.  White E. Life, death and the pursuit of apoptosis. A review. Genes Development 1996;  19:  1-15.
92.  Yang E, Korsmeyer SK. Molecular thanatopsis: a discourse on the Bcl2 family and cell death.
Blood 1996; 88: 386-401.
93.  Thompson CB. Apoptosis in the pathogenesis and the treatment of disease. Science (Washington 
DC) 1995; 267:  1456-62.
94.  Ferguson DJP, Anderson TJ. Morphologic evaluation of cell turnover in relation to the menstrual 
cycle in "resting" human breast. British Journal of Cancer 1981; 44:  177-81.References Chapter 3: Molecular biology of breast cancer 277
95.  Vaux DL, Strasser A. The molecular biology of apoptosis. Proceedings of National Academy of 
Sciences USA  1996; 93: 2239-44.
96.  Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the BCL2 gene in human follicular 
lymphoma. Science 1985; 228:  1440-3.
97.  Broise LH, Gottschalk AR, Quinfans J, et al. BCL2 and BCL2 related proteins in apoptosis 
regulation. Current Topics in Microbiological Immunology 1995; 200:  107-21.
98.  Craig RW. The BCL2 gene family. Seminars in Cancer Biology 1995; 6: 35-43.
99.  Hockenberg DM, Zutter M, Hickey W, et aL BCL2 protein is topographically restricted in tissues 
characterized by apoptotic cell death. Proceedings of  National Academy of  Sciences USA  1991; 88: 
6961-5.
100.  Nathan B, Anbazhagan R, Dyer M, et at Expression of BCL2 like immunoreactivity in the normal 
breast and in breast cancer. The Breast 1993; 2:  134-7.
101.  Doglioni C, Dei Tos AP, Laurino L, et aL The prevalance of BCL2 immunoreactivity in breast 
carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor 
status.  Virchows Archives 1994; 424: 47-51.
102.  Gee JM, Robertson JF, Ellis IO. Immunocytochemical localization of BCL2 protein in human 
breast cancers  and its relationship to a series of prognostic markers and response to endocrine 
therapy. International Journal of Cancer 1994; 59: 619-28.
103.  Silvestrini R, Veronei S, Daidone MG, et al. The BCL2 protein: A prognostic indicator strongly 
related to p53 protein in lymph node-negative breast cancer patients. Journal of Clinical Oncology 
1994; 86: 499-504.
104.  Lipponen P, Pietilainen T, Kosma VM, et al. Apoptosis suppressing protein BCL2 is expressed in 
well differentiated breast carcinomas with favourable prognosis. Journal of  Pathology 1995; 177:49-
55.
105.  Gasparini G, Barbareschi M, Doglioni C. Expression of bcl-2 protein predicts efficacy of adjuvant 
treatments in operable node-positive breast-cancer. Clinical Cancer Research 1995; 1:  189-98.
106.  Gazzaniga P, Gradilone A, Vercillo R, et al. bcl-2/bax mma expression ratio as prognostic factor 
in low-grade urinary bladder cancer. International Journal of Cancer 1996; 69:  100-4.
107.  Oltvai Z, Millman CL, Korsmeyer SJ. BCL2 heterodimerizes in vivo with a coserved homolog, 
BAX, that accelerates programmed cell death. Structure function analysis of BCL2 protein. Cell 
1993;74:609-19.
108.  Hanada M, Aime-Sempe C, Sato T, et al. Identification of conserved domains important for 
homodimerization with BCL2 and heterodimerization with BAX. Journal of Biology Chemistry 
1995; 270:  11962-9.
109.  Bargou RC, Daniel PT, Mapara MY. Expression of the BCL2 gene family in normal and 
malignant breast tissue; low bax-alpha expression in tumour cell correlates with resistance towards 
apoptosis. International Journal of  Cancer 1995; 60: 854-9.
110.  Korsmeyer SJ, Shutter JR, Vies DJ, et al. bcl-2/bax - a rheostat that regulates an antioxidant 
pathway and cell-death. Seminars in Cancer Biology 1993; 4: 327-32.
111.  Miyashita T, Reed JC. Tumour suppressor p53 is a direct transcriptional activator of the human 
BAX gene. Cell 1995; 80: 293-9.References Chapter 3: Molecular biology of breast cancer 278
112.  Krajewski S, Blomquist C, Franssila K. Reduced expression of pro-apoptotic gene BAX is 
associated with poor response rates to combination chemotherapy and shorter survival in women 
with metastatic breast adenocarcinoma. Cancer Research 1995; 55: 4471-8.
113.  Peltomaki P, delaChapelle A. Mutations predisposing to hereditary nonpolyposis colorectal cancer. 
Advance Cancer Research 1997; 71: 93-119.
114.  Yee CJ, Verrier CS, Pari FF. Microsatellite instability and loss of heterozygosity in breast cancer. 
Cancer Research 1994; 54:  1641-4.
115.  Anbazhagan R, Fujii H, abrielson E. Microsatellite instability is uncommon in breast cancer. 
Clinical Cancer Research 1999; 5: 839-44.
116.  Gasparini G, Harris A L. Clinical importance of the determination of tumour angiogenesis in breast 
carcinoma: much more than a new prognostic tool. Journal of  Clinical Oncology 1995;  13: 765-82.
117.  Folkman J. What is the evidence that tumours are angiogenesis dependent? Journal of  National 
Cancer Institute 1990; 82: 4-6.
118.  Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer 
metastasis. Cell 1994; 79:  185-8.
119.  Weidner N, Carroll RP, Flax J, et aL Tumour angiogenesis correlates with metastasis in invasive 
protate cancer. American Journal of  Pathology 1993;  143: 401-9.
120.  Macchiarini P, Fontanini G, Hardin MJ, et aL Relation of neovascularization to metastasis of 
non-small-cell lung cancer. Lancet 1992; 340:  145-6.
121.  Weidner N, Semple JP, Welch WR, et aL Tumour angiogenesis and metastasis-correlation in 
invasive breast carcinoma. New England Journal of  Medicine 1991; 324: 1-8.
122.  Toi M, Kashitani J, Tominaga T. Tumour angiogenesis is an independent prognostic indicator in 
primary breast carcinoma. International Journal of  Cancer 1993; 55: 371-4.
123.  Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion 
molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 1992; 
340:  1120-4.
124.  Bosari S, Lee AK, De Lellis RA, et aL Microvessel quantitation and prognosis in invasive breast
carcinoma. Human Pathology 1992; 23: 755-61.
125.  Hall NR, Fish DE, Hunt N, et al. Is the relationship between  angiogenesis and  metastasis in breast
cancer real? Surgical Oncology 1992; 1: 223-9.
126.  Cohen P, Guidi A, Harris J, et al Microvessel density and local recurrence in patients with early 
stage breast cancer treated by wide excision alone (WEA) (abstract). Modern Pathology 1994; 7:
14A.
127.  Sightler HE, Borrowsky AD, Dupont WD, et al. Evaluation of tumour angiogenesis as a 
prognostic marker in breast cancer(abstract). Modern Pathology 1994; 7: 22A.
128.  Goulding H, Rashid N, Robertson JF, et al. Assessment of angiogenesis in breast cancer. An 
important factor in prognosis? Human Pathology 1995; 26: 1196-200.
129.  Page DL, Jensen RA. Angiogenesis in human breast carcinoma:what is the question?Editorial. 
Human Pathology 1995; 26:  1173-4.
130.  Johnston SRD, Gore ME. Cancer Biology:clinical applications. Medicine 1999; 27: 5-10.References Chapter 3: Molecular biology of breast cancer 279
131.  Natali PG, Nicotra MR, Botti C, et al. Changes in expression of alpha-6-beta-4 integrin 
heterodimer in primary and metastatic breast-cancer. British Journal of Cancer 1992; 66: 318-22.
132.  Finn L, Dougherty G, Finley G, et al. alternative splicing of cd44 pre-messenger-ma in human 
colorectal tumors. Biochemical and Biophysical Research Communications 1994; 200:  1015-22.
133.  Duffy MJ. Proteases as prognostic markers in cancer. Clinical Cancer Research 1996; 2: 613-8.
134.  Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des. 2004; 
10: 39-49.
135.  Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase-9 
(progelatinase-b)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate 
and proteinases. Journal of Biology Chemistry 1995; 270:  18506-11.
136.  Uria J, Ferrando AA, Velasco G, et al. Structure and expression in breast-tumors of human timp-3, 
a new member of the metalloproteinase inhibitor family. Cancer Research 1994; 54: 2091-4.
137.  Rochefort H. Oestrogens, proteases and breast cancer. From cell lines to clinical applications. 
European Journal of  Cancer 1994; 10:  1583-6.
138.  Gion M, Mione R, Dittadi R, et aL Relationship between cathepsin D and other pathological and 
biological parameters in 1752 patients with primary breast cancer. European Journal of  Cancer 
1995;5:671-7.
139.  Krishnan V, Wang XH, Safe S. Estrogen receptor-spl complexes mediate estrogen-induced 
cathepsin-d gene-expression in mcf-7 human breast-cancer cells. Journal of  Biology Chemistry 1994; 
269:  15912-7.
140.  Sastre X. Current trends in histopathological assessment of breast cancer. International Journal of 
Cancer 1997; 84: 65-8.
141.  Pinkel D, Segraves R, Sudar D, et aL High resolution analysis of DNA copy no. variation using 
comparative genomic hybridization to micro-arrays. Nature Genetics 1998; 20: 207-11.
142.  Van de Vijver MJ. Genetic alterations in breast cancer. Current Diagnostic Pathology 2000; 6: 271-
81.
143.  Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 
chromosomal localisations in 1875 breast tumours:definition of phenotypic groups. Cancer Research 
1997; 57: 4360-7.
144.  Cuny M, Kramer A, Courjal F, et al. Relating genotype and phenotype in breast cancer:an analysis 
of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. 
Cancer Research 2000; 60:  1077-83.
145.  Nagasaki K, Maass N, Manabe T, et al. Identification of a novel gene,DAM 1  amplified at 
chromosome lp 13.3-21 region in human breast cancer cell lines. Cancer Letters 1999; 140: 219-26.
146.  Sainsbury JR, Farndon JR, Needham GK, et al. Epidermal-growth-factor receptor status as 
predictor of early recurrence of and death from breast cancer. Lancet 1987; 1:  1398-402.
147.  Adnane J, Gaudray P, Dionne CA, et al. BEK and FLG, two receptors to members of the FGF 
family,are amplified in subsets of human breast cancers. Oncogene 1991; 6: 659-63.
148.  Gelmann EP, Lippman ME. Understanding the role of oncogenes in human breast cancer.
In:Sluyser M,ed. Growth factors and oncogenes in breast cancer. VCH
Publishers. Weinheim, Germany.  1987.References Chapter 3: Molecular biology of breast cancer 280
149.  Walker RA, Senior PV, Jones JL, et al. An immunohistochemical and in situ hybridization study 
of c-myc and c-erbB2 expression in primary human breast carcinomas. Journal of Pathology 1989; 
158: 97-105.
150.  Escot C, Theillet C, Lidereau R, et al. Genetic alterations of the c-myc proto-oncogene (M YC) in 
human primary breast carcinomas. Proceedings of  National Academy of Sciences USA  1986; 83: 
4834-8.
151.  Locker AP, Dowle CS, Ellis IO, et at C-myc oncogene product expression  and prognosis in 
operable breast cancer. British Journal of Cancer 1989; 60: 669-72.
152.  Berns EM, Klijn JGM, van Putten WL, et al. c-myc amplification is a better prognostic factor 
than HER-2/Neu amplification in primary breast cancer. Cancer Research  1992; 52:  1107-13.
153.  Fejzo MS, Godfrey T, Chen C, et aL Molecular cytogenetic analysis of consistent abnormalities at 
8ql2-q22 in breast cancer. Genes Chromosomes Cancer 1998; 22:  105-13.
154.  Zwijsen RM, Wientjens E, Van der Klompmaker R, et al. CDK-independent activation of 
estrogen receptor by cyclin Dl. Cell 1997; 88: 405-15.
155.  Schuuring E, Verhoeven E, VanTinteren H, et al. Amplification of genes within the chromosome 
1  lql3 region is indicative of poor prognosis in patients with operable breast cancer. Cancer 
Research 1992; 52: 5229-34.
156.  Gillet C, Castronovo V vFea. Decreased expression of galectin-3 is associated with progression of 
human breast cancer. Journal of  Pathology 1996; 179: 43-8.
157.  Oyama T, Kashiwabara K, Yoshimoto K, et al. Frequent overexpression of the cyclin D1  
oncogene in invasive lobular carcinoma of the breast. Cancer Research 1998; 58: 2876-80.
158.  Courjal F, Theillet C. Comparative genomic hybridization analysis of breast tumours with 
predetermind profiles of DNA amplification. Cancer Research 1997; 57: 4368-77.
159.  Barlund M, Tirkkonen M, Forozan F, et al. Increased copy number at 17q22-24 by CGH in breast 
cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer 1997; 
20: 372-6.
160.  Couch FJ, Wang XY, Wu GJ, et al. Localisation of PS6K to chromosomal region 17q23 and 
determination of its amplification in breast cancer. Cancer Research 1999; 59:  1408-11.
161.  Brinkmann U, Gallo M, Polymeropoulos MH, et al. The human CAS(cellular apoptosis 
susceptibility) gene mapping on chromosome 20ql3 is amplified in BT474 breast cancer cells and 
part of aberrant chromosomes in breast and colon cancer cell lines. Genome Research 1996; 6:  187-
94.
162.  Anzick SL, Kononen J, Walker RL, et al. AIBI,a steroid receptor coactivator amplified in breast 
and ovarian cancer. Science 1997; 277: 965-8.
163.  Tanner MM, Trikkonen M, Kallioniemi A, et at Independent amplification and frequent 
coamplification of three nonsystemic regions on the long arm of chromosome 20 in human breast 
cancer. Cancer Research 1996; 56: 3441-5.
164.  Bautista S, Walker RL, Anzick S, et al. In breast cancer,amplification of the steroid receptor 
coactivator gene AIBI is correlated with estrogen and progesterone receptor positivity. Clinical 
Cancer Research 1998; 4: 2925-9.
165.  Tanner MM, Trikkonen M, Kallioniemi A, et al. Amplification of chromosomal region 20ql3 in 
invasive breast cancer:prognostic implications. Clinical Cancer Research  2001; 1:  1455-61.References Chapter 3: Molecular biology of breast cancer 281
166.  Kallioniemi AP, Kallioniemi O, Piper J, et al. Detection and mapping of amplified  DNA 
sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA  1994; 91: 
2156-60.
167.  Devilee P, Cornelisse CJ. Somatic genetic changes in human breast cancer. Biochimica Et 
Biophysica Acta-Reviews on Cancer 1994;  1198:  113-30.
168.  Hankins GR, DeSouza AT, Bentley RC, et aL M6P/1GF2 receptor: a candidate breast tumor 
suppressor gene. Oncogene 1996; 12: 2003-9.
169.  Berns EM KJSMea. Infrequent CDKN2(MTS1/P16) gene alterations in human primary breast 
cancer. BrJCancer 1995; 72: 964-7.
170.  Cairns P, Polascik TJ, Eby Y, et aL Sequency of homozygous deletion at pl6/CDKN2 in primary 
human tumours. Nature Genetics 1995;  11: 210-2.
171.  Freihoff D, Kempe A, Beste B, et aL Exclusion of a major role for the PTEN tumour-suppressor 
gene in breast carcinomas. British Journal of Cancer 1999; 79: 754-8.
172.  Hollenstein M, Sidransky D, Vogelstein B, et aL p53 mutations in human cancer. Science 1991; 
253: 49-53.
173.  Ozbun MA, Butel JS. Tumor suppressor p53 mutations and breast cancer: a critical analysis. 
Advance Cancer Research 1995; 66: 71-141.
174.  Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Research 
and Treatment 1994; 32: 39-47.
175.  Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumour suppressor gene protein.an 
independent marker of prognosis in breast cancers. Journal of  National Cancer Institute 1992; 84: 
845-55.
176.  Lowe SW, Ruley HE, Jacks T, et al. P53-dependent apoptosis modulates the cytotoxicity of 
anticancer agents. Cell 1993; 74: 957-67.
177.  Haider S, Negrini M, Moune M, et al. Down regulation of Bcl2 by p53 in breast cancer cells. 
Cancer Research 1994; 54: 2095-7.
178.  Kaklamanis L, Savage A, Mortensen N, et al. Early expression of Bcl2 protein in the adenoma- 
carcinoma sequence of colorectal neoplasia. Journal of  Pathology 1996;  179:  10-4.
179.  Shiina H, Igawa M, Urakami S, et al. Immunohistochemical analysis of Bcl2 expression in 
transitional cell carcinoma of the bladder. Journal of Clinical Pathology  1996; 49: 395-9.
180.  Osin P, Crook T, Kote-Jarai Z, et al. Inactivation of BRCA1 and TP53 genes is characteristic for 
medullary breast cancer phenotype. Meeting of  the Pathological Society of  Great Britain and Ireland 
2001; 21.
181.  Berx G, Cleton-Jansen AM, Nollet F, et. E-cadherin is a tumour/invasion suppressor gene mutated 
in human lobular breast cancers. EMBO 1995; 14: 6107-75.
182.  Vos CBJ, Cleton-Jansen AM, Berx G, et al. E-cadherin inactivation in lobular carcinoma in situ of 
the breast:an early event in tumorigenesis. British Journal of Cancer 1997; 76:  1131-3.
183.  Vos CBJ, TerHaar NT, Rosenberg C, et al. Genetic alterations on chromosome  16 and 17 are 
important features of ductal carcinoma in situ of the breast and are associated with histologic type. 
British Journal of Cancer 1999; 81:  1410-8.References Chapter 3: Molecular biology of breast cancer 282
184.  Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridisation  of ductal carcinoma 
in situ of breast-evidence of multiple genetic pathways. Journal of Pathology 1999; 189: 521-6.
185.  Wilson CA, Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high 
grade,non-inherited breast carcinomas. Nature Genetics 1999; 21: 236-40.
186.  Breast Cancer Linkage Consortium. Pathology of familial breast cancer:differences between 
breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349: 
1505-10.
187.  Lakhani SR, Jacquemier A, Sloane JP, et al. Multifactorial analysis of differences between 
sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. Journal of  National 
Cancer Institute 1998; 90:  1138-45.
188.  Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising  in carriers of mutations in 
BRCAlor BRCA2:are they prognostically different? Journal of Clinical Oncology 1999; 17: 3653-
63.
189.  Sorlie T, Anderson TI, Buckholm I, et al. Mutation screening of BRCA1 using PTT and LOH 
analysis at 17q21   in breast carcinomas from familial and non-familial cases. Breast Cancer Research 
and Treatment 1998; 48: 259-64.
190.  Cleton-Jansen AM, Collins N, Lakhani SR, et al. Loss of heterozygosity in sporadic breast 
tumours at the BRCA2 locus on chromosome 13ql2-ql3. British Journal of  Cancer 1995; 72: 1241-
4.
191.  Teng DH, Bogden R, Mitchell J, et aL Low incidence of BRC A2 mutations in breast carcinoma 
and other cancers. Nature Genetics 1996; 13: 241-4.
192.  Panico L, DAntonio A, Salvatore G, et al. Differential immunohistochemical detection of 
transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast 
tissues. International Journal of Cancer 1996; 65: 51-6.
193.  Radford DM, Fair KL, Phillips NJ, et al. Allelotyping of ductal carcinoma in situ of the 
breast.deletion of loci on 8p,13q,16q,17p and 17ql. Cancer Research 1995; 55: 3399-405.
194.  Noguchi S, Motomura K, Inaji H, et Clonal analysis of predominantly intraductal carcinoma and 
precancerous lesions of the breast by means of polymerase chain reaction. Cancer Research 1994;
54:  1849-53.
195.  Stratton MR, Collins N, Lakhani SR, et Loss of heterozygosity in ductal carcinoma in situ of of 
the breast. Journal of Pathology 1995; 175:  195-201.
196.  Deng D, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in normal tissue adjacent to breast 
carcinomas. Science 1996; 274: 2057-9.
197.  Lakhani SR, Chagger R, Davies S, et al. Genetic alterations in normal luminal and myoepithelial 
cells of the breast. Journal of Pathology 1999; 189: 496-503.
198.  Van de Vijver MJ. Molecular genetics in breast cancer. Advance Cancer Research 1993; 61: 25-56.
199.  isola j, de Vries S, Chu L, et al. Technical advance analysis of changes in DNA sequence copy 
number by comparative genomic hybridisation in archival paraffin-embedded tumor samples. 
American Journal of  Pathology 1994; 145:  1301-9.
200.  DeRisi J, Penland L, Brown PO, et aL Use of a cDNA microarray to analyse gene expression 
patterns in human cancer. Nature Genetics 1996; 14: 457-60.References Chapter 3: Molecular biology of breast cancer 283
201.  Schena M, Shalon D, Davis R W, et al. Quantitative monitoring of gene expression patterns with a 
complementary DNA microarray. Science 1995; 270: 467-70.
202.  Iyer VR, Eisen MB, Ross DT, et al. The Transcriptional program in the response of human 
fibroblasts to serum. Science 1999; 283: 83-7.
203.  Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma 
identified by gene expression profiling. Nature 2000; 403: 503-11.
204.  Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate 
genes uncovered by cDNA microarray screening in renal cell carcinoma. American Journal of 
Pathology 1999;  154: 981-6.
205.  Kononen J, Bubendorf L, Kallioniemi A, et aL Tissue microarrays for high-throughput molecular 
profiling of tumour specimens. Nature Medicine 1998; 4: 844-7.Reference Chapter 4: cerbB-2 in breast cancer 284
Reference List  Chapter 4:
1.  Shih C, Padhy LC, Murray M, et al. Transforming genes of carcinomas and neuroblastomas 
introduced into mouse fibroblasts. Nature 1981; 290: 261-4.
2.  Popescu NC, King CR, Kraus MH. Localization of the human cerbB2 gene on normal and 
rearranged chromosomes 17 to bonds q 12-21.32. Genomics 1989; 4: 362-6.
3.  Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to 
EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230:  1132-9.
4.  Semba K, Kamata N, Toyoshima K, et al. A v-erbB-related protooncogene,c-erbB-2,is distinct 
from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland 
adenocarcinoma. Proceedings of  the National Academy of  Sciences; USA  1985; 82: 6497-501.
5.  Yamamoto T, Ikowa S, Akiyana T, et aL Similarity of protein encoded by the human c-erbB-2 
gene to epidermal growth factor. Nature 1986; 319: 230-4.
6.  Bargmann Cl, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor 
receptor-related protein. Nature 1986; 319: 226-30.
7.  Carraway KL, Sliwkowski MX, Akita R, et aL The erbB-3 gene product is a receptor for 
heregulin.  Journal of Biological Chemistry 1994; 269:  14303-6.
8.  Plowman GD, Grenn JM, Culousco JM, et aL Heregulin induces tyrosine phosphorylation of 
HER4/pl80 cerbB-4. Nature 1993; 366: 473-5.
9.  Graus-Porta D, Beerli RR, Daly JM, et aL ErbB-2,the preferred heterodimerization partner of all 
ErbB receptors,is a mediator of lateral signalling. EMBO 1997; 16: 1647-55.
10.  Wallasch C, Weiss FU, Niederfellner G, et aL Heregulin -dependent regulation of HER2/neu 
oncogenic signaling by heterodimerazation with HER3. EMBO 1995; 14: 4267-75.
11.  Verbeek BS, Adriaansen-Slot SS, Vroom TM, et al. Overexpression of EGFR and c-erbB2 causes 
enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Letters 1998; 
425:  145-50.
12.  King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in human 
mammary carcinoma. Science 1985; 229: 974-6.
13.  Slamon DJ, Clark G, Wong SG, et al. Human breast cancer: Correlation of relapse and survival 
with amplification of the HER2/neu oncogene. Science 1987; 235:  177-82.
14.  Revillion F, Bonnatarre J, Pey JP. ErbB-2 oncogene in human breast cancer and its clinical 
significance. European Journal of Cancer 1998; 34: 791-808.
15.  Venter DJ, Kumar S, Tuzi NL, et al. Overexpression of the c-erbB-2 oncoprotein in human breast 
carcinomas: Immunohistochemical assessment correlates with gene amplification. Lancet 1987; ii: 
69-71.
16.  Yusa K, Sugimoto Y, Yamori T, et al. Low metastatic potential of clone from murine colon 
adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene. Journal of  the National 
Cancer Institute 1990; 82:  1633-6.
17.  Bouchard L, Lamarre L, Tremblay PJ, et al. Stochastic appearance of mammary tumors in 
transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989; 57: 931-6.
18.  Gusterson BA, Machin LG, Gullick WJ, et al. Immunohistochemical distribution of c-erbB-2 in 
infiltrating and in-situ breast cancer. International Journal of Cancer 1988; 42: 842-5.Reference Chapter 4: cerbB-2 in breast cancer 285
19.  van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast
cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage 
II breast cancer. New England Journal of Medicine 1988; 319:  1239-45.
20.  Allred DC, Clark GH, et al. Overexpression of HER-2/neu and its relationship with other 
prognostic factors change during the progression of in situ to invasive breast cancer. Human 
Pathology 1992; 23: 974-9.
21.  Hogue A, Snirge N, Sahin AA, et al. Assesment of HER2/neu and quantitative nuclear 
morphometry in ductal carcinoma in situ(DCIS) of the breast. Cancer Research 1994.
22.  Gusterson BA, Machin LG, Gullick WJ, et aL C-erbB-2 expression in benign and malignant breast 
disease. British Journal Of  Cancer 1988; 58: 453-7.
23.  De Potter CR, Van Dalle S, Van De Vijver, et al. The expression  of the neu oncogene product in 
breast lesions and in normal fetal and adult human tissues. Histopathology 1989;  15: 351-62.
24.  Odagiri E, Kanada N, Jibiki K, et aL Reduction of telomeric length and cerbB2 gene amplification 
in human breast cancer, fibroadenoma and gynaecomastia. relationship to histologic grade and 
clinical parameters. Cancer 1994; 73: 2978-84.
25.  Lodato RF, Maguire HC, Jr Greene MI, et al. Immunohistochemical evaluation of c-erbB-2 
oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Modern Pathology 1990; 3: 449-54.
26.  Zafrini B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in-situ carcinoma of 
the breast analysed with a new classification. Seminars in Diagnostic Pathology 1994; 11: 208-14.
27.  Leal C, Schmitt F, Bento M, et al. Ductal carcinoma in-situ of the breast.Histologic categorization 
and its relationship to ploidy and immunohistochemical expression of hormone receptors,p53 and 
cerbB-2 protein. Cancer 1995; 75: 2123-31.
28.  Inaji H, Koyama H, Motomora K, et al. Differential distribution of cerbB2 and pS2 proteins in 
ductal carcinomas in-situ of the breast. Breast Cancer Research And Treatment 1996; 37: 89-92.
29.  Bose S, Norton L, Rosen PP, et al. Immunophenotype of intraductal carcinoma. Archives of 
Pathology & Laboratory Medicine 1996;  120: 81-5.
30.  Brower F, Ahmed S, Tartter P, et al. Prognostic variables in invasive breast cancer:Contribution of 
comedo versus non-comedo in-situ component. Annals of  Surgical Oncology 1995; 2: 440-4.
31.  Moreno A, Lloveras B, Figueras A, et al. Ductal carcinoma in-situ of the breast:Correlation 
between histologic classification and biologic markers. Modern Pathology  1997;  10:  1088-92.
32.  Mack L, Kerkvliet N, Doig G, et al. Relationship of a new histological categorization of ductal 
carcinoma in-situ of the breast with size and the immunohistochemical expression of p53,c-erbB- 
2,bcl2 and ki-67. Human Pathology 1997; 28: 974-9.
33.  DePotter CR, Schelhout AM, Verbeek P, et al. Neu overexpression correlates with extent of 
disease in large cell ductal carcinoma in situ of the breast. Human Pathology 1995; 26: 601-6.
34.  Wolber R, Dupuis B, Wick M. Expression of c-erbB-2 oncoprotein in mammary and 
extramammary Paget's disease. American Journal Of  Clinical Pathology 1991; 96: 243-7.
35.  Keatings L, Sinclair J, Wright C, et al. c-erbB-2 oncoprotein expression in mammary and 
extramammary Paget's disease:An immunohistochemical study. Histopathology 1990; 17: 243-7.
36.  Ro J, El-Naggar A, Ro JY, et al. C-erbB-2 amplification in node negative human breast cancer. 
Cancer Research 1989.Reference Chapter 4: cerbB-2 in breast cancer 286
37.  Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node­
positive breast cancer. Cancer Research 1990; 50: 4332-7.
38.  Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast 
and Bowel Project:Prognostic significance of erbB-2 protein overexpression in primary breast 
cancer. Journal Of Clinical Oncology 1990; 8:  103-12.
39.  Borresen AL, Ottestad L, Gaustad A, et al. Amplification and protein overexpression of the 
neu/HER-2/c-erbB-2 proto-oncogene in human breast carcinomas: Relationship to loss of gene 
sequences on chromosome  17,family history and prognosis. British Journal Of  Cancer 1990; 62: 
585-90.
40.  O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relationship between c-erbB-2 expression,S- 
phase fraction and prognosis in breast cancer. British Journal Of Cancer 1991; 63: 444-6.
41.  McCann AH, Dervan PA, O'Regan M, et aL Prognostic significance of c-erbB-2 and estrogen 
receptor status in human breast cancer. Cancer Research 1991; 51: 3296-303.
42.  Dykins R, Corbett IP, Henry JA, et al. Long term survival in breast cancer related to 
overexpression of the c-erbB-2 oncoprotein:An immunohistochemical study using monoclonal 
antibody NCL-CB11. Journal of Pathology 1991; 163:  105-10.
43.  Paterson MC, Dietrich KD, Kanyluk J, et aL Correlation between c-erbB-2 amplification and risk 
of recurrent disease in node-negative breast cancer. Cancer Research 1991; 54: 556-67.
44.  Rilke F, Colnaghi MI, Cascinelli N, et at Prognostic significance of HER-2/neu expression in
breast cancer and its relationship to other prognostic factors. International Journal of Cancer 1991; 
49: 44-9.
45.  Kallioniemi OP, Holli K, Visakorpi T, et aL Association of c-erbB-2 protein overexpression with 
high rate of cell proliferation,increased risk of visceral metastasis and poor long term survival in 
breast cancer. International Journal of  Cancer  1991; 49: 650-5.
46.  Anbazhagan R, Gelber RD, Bettelheim R, et al. Association of c-erbB-2 expression and S-phase 
fraction in the prognosis of node-positive breast cancer. Annals of Oncology 1991; 2: 47-53.
47.  Lovekin C, Ellis IO, Locker A, et al. c-erbB-2 oncoprotein expression in primary and advanced 
breast cancer. British Journal Of  Cancer 1991; 63: 439-43.
48.  Clark GM, McGuireWL. Follow-up study of HER-2/neu amplification in primary breast cancer. 
Cancer Research 1991; 51: 944-8.
49.  Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of c-erbB-2  in
primary breast cancer. British Journal Of Cancer 1991; 63: 447-50.
50.  Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer:Prognostic 
significance of overexpression influenced by the presence of in situ carcinoma. Journal Of Clinical 
Oncology 1992; 10: 599-605.
51.  Toikkanen S, Helin H, Isola J, et aL Prognostic significance of HER-2 oncoprotein expression in 
breast cancer:A 30-year follow-up. Journal Of Clinical Oncology 1992; 10:  1044-8.
52.  Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in 
breast cancer. Journal Of Clinical Oncology 1992; 10:  1049-56.
53.  Noguchi M, Koyasaki N, Ohta N, et al. c-erbB-2 oncoprotein expression versus internal mammary 
lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive 
breast cancer. Cancer 1992; 69: 2953-60.Reference Chapter 4: cerbB-2 in breast cancer 287
54.  Press MF, Pike MC, Chazin VR, et al. HER-2/neu expression in node negative breast
cancer: Direct tissue quantitation by computerized image analysis and association of overexpression 
with increased risk of recurrent disease. Cancer Research 1993; 53: 4960-70.
55.  Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene 
amplification in primary breast cancer. Journal Of  Clinical Oncology 1993; 11:  1936-42.
56.  Marks JR, Humphrey PA, Wu K, et al. Overexpression of p53 and HER-2/neu proteins as 
prognostic markers in early stage breast cancer. Annals Of  Surgery 1994; 219: 332-41.
57.  Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB-2 overexpression in axillary 
lymph node-positive breast cancer:Results from a randomized adjuvant treatment protocol. Cancer 
1994; 74: 2956-63.
58.  Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive 
breast cancer:The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 
2359-65.
59.  Schonborn I, Zschiesche W, Spitzer E, et al c-erbB-2 overexpression in primary breast
cancer: Independent prognostic factor in patients at high risk. Breast Cancer Research And Treatment 
1994; 29: 287-95.
60.  Giai M, Roagna R, Ponzone R, et at Prognostic and predictive relevance of c-erbB-2 and ras 
expression in node-positive and negative breast cancer. Anticancer Research 1994; 14:  1441-50.
61.  Rosen PP, Lesser ML, Arroyo CD, et aL Immunohistochemical detection of HER-2/neu in patients 
with axillary lymph node-negative breast carcinoma. Cancer 1995; 75:  1320-6.
62.  Quenel N, Wafflart J, Bonichon F, et aL The prognostic value of c-erbB-2 in primary breast 
carcinomas: a study of 942 cases. Breast Cancer Research And Treatment 1995; 35: 283-91.
63.  Albanell J, Bellmunt J, Molina R, et al. Node-negative breast cancers with p53(-)/HER2-neu(-) 
status may identify women with very good prognosis. Anticancer Research 1996; 16:  1027-32.
64.  O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative 
immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer. Human 
Pathology 1996; 27: 955-63.
65.  Heiken TJ, Mehta RR, Shilkaitis A, et al. HER-2/neu and p53 expression in breast cancer:Valid 
prognostic markers when assessed by direct immunoassay, but not by immunocytochemistry 
[abstract]. Proceedings of The Annual Meeting of The American Society of Clinical Oncology 1996; 
15:  113a.
66.  Sundblad AS, Pellicer EM, Ricci L. Carcinoembryonic expression in stages I and II breast cancer:
Its relationship with clinicopathologic factors. Human Pathology 1996; 27: 297-301.
67.  Xing WR, Gilchrist KW, Harris CP, et al. FISH detection of HER-2/neu oncogene amplification 
in early onset breast cancer. Breast Cancer Research And Treatment 1996; 39: 203-12.
68.  Dittadi R, Brazzale A, Pappagalo G, et al. ErbB2 assay in breast cancer:Possibly improved clinical 
information using a quantitative method. Anticancer Research 1997; 17:  1248.
69.  Eissa S, Khalifa A, el-Gharib A, et al. Multivariate analysis of DNA ploidy, p53, c-erbB-2 protein, 
EGFR, and steroid hormone receptors for short term prognosis in breast cancer. Anticancer Research 
1997; 17: 3091-8.
70.  Fernandez-Acenero MJ, Gonzalez J, Arangoncillo Ballesteros P. Immunohistochemical 
expression of p53 and c-erbB-2 in breast carcinoma: Relation with epidemiologic factors, histologic 
features and prognosis. General Diagnostic Pathology 1997; 142: 289-96.Reference Chapter 4: cerbB-2 in breast cancer 288
71.  Press MJ, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by 
fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. Journal Of 
Clinical Oncology 1997;  15: 2894-904.
72.  Andrulis IL, Bull SB, Blackstein ME, et at neu/erbB-2 amplification identifies a poor prognosis 
group of women with node-negative breast cancer. Journal Of Clinical Oncology 1998; 16:  1340-9.
73.  Depowski P, Brien T, Sheehan C, et aL Prognostic significance of p34cdc2 cyclin-dependent 
kinase and MIB1  overexpression, and HER-2/neu gene amplification detected by fluorescence in situ 
hybridization in breast cancer. American Journal Of Clinical Pathology 1999; 112: 459-69.
74.  Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization 
for HER-2/neu in assessing the prognosis of breast cancer. Seminars in Oncology 1999; 26:  108-16.
75.  Slamon DJ, Godolphin W, Jones LA. Studies of the HER2/neu proto-oncogene in human breast 
and ovarian cancer. Science 1989; 244: 707-12.
76.  Clark G. Should selection of adjuvant chemotherapy for patients with breast cancer be based on 
erbB-2 status? Journal of the National Cancer Institute 1998; 90:  1320-1.
77.  Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue 
samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer 
Research 1994; 54: 2771-7.
78.  Rampaul RS, Pinder SE, Wencyk PM, et aL HER-2: Prognostic significance in univariate and 
multivariate analyses in lymph node negative breast cancer. Meeting of the Pathological Society of 
Great Britain and Ireland. 2001; 5 A.
79.  Ravdin PM. Should HER2 status be routinely measured for all breast cancer patients? Seminars in 
Oncology 1999; 26:  117-23.
80.  Stal O, Sullivan S, Wingreen S, et al. CerbB-2 expression and benefit from adjuvant chemotherapy 
and radiotherapy of breast cancer. European Journal of  Cancer 1995; 31:2185-90.
81.  Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in 
women with node-positive early breast cancer. New England Journal of  Medicine 1994; 330:  1260-6.
82.  Thor AD, Berry DA, Budman DR, et al. erbB-2,p53 and the efficacy of adjuvant therapy in lymph 
node-positive breast cancer. Journal of  National Cancer Institute 1998; 90:  1346-60.
83.  Paik S, Bryant J, Park C, et al. c-erbB-2 and response to doxorubicin in patients with axillary 
lymph node-positive hormone receptor negative breast cancer. Journal of the National Cancer 
Institute 1998; 90:  1361-70.
84.  Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastatic potential in 
human breast cancer cells without increasing their transformation abilities.  Cancer Research 1997; 
57:  1199-205.
85.  Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased 
resistance to Taxol via mdr-1  independent mechanisms. Oncogene 1996; 13: 1359-65.
86.  Baselga J, Seldman AD, Rosen PP, et al. HER-2 overexpression and paclitaxel sensitivity in breast 
cancer: Therapeutic implication. Oncology 1997; Supp2: 43-8.
87.  Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression 
and response to endocrine therapy in advanced breast cancer. British Journal Of Cancer 1992; 65: 
118-21.Reference Chapter 4: cerbB-2 in breast cancer 289
88.  Carlomagna C, Perrone F, Gallo C, et al. c-erbB-2 overexpression decreases the benefit of 
adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal Of 
Clinical Oncology 1996; 14: 2702-8.
89.  Newby JC, Johnston SRD, Smith IE, et al. Expression of epidermal growth factor receptor and c- 
erbB-2 during the development of tamoxifen resistance in human breast cancer. Clinical Cancer 
Research 1997; 3;  1643-51.
90.  Bianco AR, de Laurentis M, Carlomagna C, et at 20-year update of the Naples Gun Trial of 
adjuvant breast cancer therapy: Evidence of interaction between
c-erbB-2 expression and tamoxifen efficacy. Proceedings of The American Society of Clinical 
Oncology 1998; 17: 97a.
91.  Elledge R, Green S, Ciocca D, et aL HER-2 expression and response to tamoxifen in estrogen 
receptor-positive breast cancer: A SouthWest Oncology Group Study. Clinical Cancer Research 
1998; 4: 7-12.
92.  Leitzel K, Teramoto Y, Konrad K, et aL Elevated serum c-erbB-2 antigen levels and decreased 
response to hormone therapy of breast cancer. Journal Of Clinical Oncology 1995; 13:1129-35.
93.  Yamuchi H, O'Neill A, Gelman R, et aL Prediction of response to antiestrogen therapy in advanced 
breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/neu 
protein. Journal Of Clinical Oncology 1997; 15: 2518-25.
94.  Peitras RJ, Peon JC, Gallardo D, et at Monoclonal antibody to HER-2/neu receptor modulates 
repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells 
overexpressing this oncogene. Cancer Research 1999; 59:  1347-55.
95.  Haffty BJ, Brown F, Carter D, et al. Evaluation of HER-2/neu oncoprotein expression as a 
prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. 
International Journal of  Radiation Oncology Biology Physics 1996; 35: 751-7.
96.  Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program 
in HER2-overexpressing metastatic breast cancer. Seminars in Oncology  1999; 26: 71-7.
97.  Hudziak RM, Lewis G, Winget M, et al. pi 85HER2 monoclonal antibody has antiproliferative 
effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mollecular Cell 
Biology 1989; 9:  1165-72.
98.  Lewis GD, Figari I, Fendly B, et at Differential responses of human tumor cell lines to anti- 
pi 85HER2 monoclonal antibodies. Cancer Immunology Immunotherapy 1993; 37: 255-63.
99.  Carter P, Prests L, Gorman CM, et at Humanization of an anti-pl85HER2 antibody for human 
cancer therapy. Proceedings of The National Academy of  Sciences USA  1992; 89: 4285-9.
100.  Pegram MD, Slamon DJ. Combination therapy with transtuzumab(Herceptin) and cisplatin for 
chemoresistant metastatic breast cancer. Seminars in Oncology 1999; 26: 89-95.
101.  Chazin VR, Kaleko M, Miller AD, et al. Transformation mediated by the human HER-2 gene 
independent of the epidermal growth factor receptor. Oncogene 1992; 7:  1859-66.
102.  Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) 
enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing 
breast cancer xenografts. Cancer Research 1998; 58: 2825-31.
103.  Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant 
humanized anti-pl85HER2 monoclonal antibody in patients with HER2/neu overexpressing 
metastatic breast cancer. Journal Of Clinical Oncology 1996; 14: 737-44.Reference Chapter 4: cerbB-2 in breast cancer 290
104.  Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab 
(Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in 
Oncology 1999; 26: 78-83.
105.  National Institute for Clinical Excellence. Guidance on the use of trastuzumab for the treatment of 
advanced breast cancer. Technology appraisal n. 34. 2002.  http://www.nice.org.uk.
Ref Type: Report
106.  Gu XG, Schmitt M, Hiasa A, et al. A novel hydrophobized polysaccharide/oncoprotein complex 
vaccine induces in vitro and in vivo cellular and humeral immune response against HER2-expressing 
murine sarcomas. Cancer Research 1998; 58: 3385-90.
107.  Brossart P, Stuhler G, Flad T, et al. HER2/neu-derived peptides are tumor-associated antigens 
expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced 
specific cytotoxic T lymphocytes. Cancer Research 1998; 58: 732-6.
108.  Ross J, Fletcher J. The HER-2/neu oncogene:Prognostic factor, predictive factor and target for 
therapy. Seminars in Cancer Biology 1999; 9:  125-38.
109.  Hanna W, Kahn H, Trudeau M. Evaluation of HER2/neu(erbB-2) status in breast cancer: From 
bench to bedside. Modern Pathology 1999; 12: 827-34.
110.  Slamon DJ, Press MF, Godolphin W, et aL Studies of the HER-2/neu proto-oncogene in human 
breast cancer. Cancer Cells 1989;  13: 63-72.
111.  Pauletti G, Godolphin W, Press MF, et ah Detection and quantitation of HER-2/neu gene
amplification in human breast cancer archival material using fluorescence in situ hybridization. 
Oncogene 1996; 13: 72.
112.  Dowsett M, Ellis IO, Bartlett JMS, et aL Correlation between immunohistochemistry and FISH for 
HER-2 in 441 breast carcinomas from multiple hospitals. Meeting of  the Pathological Society of 
Great Britain and Ireland. 2001; 5  A.
113.  Busmanis I, Feleppa F, Jones A, et at Analysis of c-erbB-2 expression using a panel of six 
commercially available antibodies. Pathology 1994; 173: 65-75.
114.  Jacobs TW, Prioleau JE, Stillman IE, et aL Loss of tumor marker immunostaining intensity on 
stored paraffin slides  of breast cancer. Journal of  National Cancer Institute 1996; 88:  1054-9.
115.  Keshgegian AA, Cnaan A. cerbB-2 oncoprotein expression in breast carcinoma: Poor prognosis
associated with high degree of cytoplasmic positivity using CB-11  antibody. American Journal Of 
Clinical Pathology 1997; 108: 456-63.
116.  Volas GH, Leitzel K, Teramoto Y, et al. Serial c-erbB-2 levels in patients with breast carcinoma. 
Cancer 1996; 78: 267-72.
117.  Imoto S, Kitoh T, Hasebe T. Serum c-erbB-2 levels in monitorig of operable breast cancer patients. 
Japanese Journal Of  Clinical Oncology 1999; 29: 336-9.
118.  Janiska J, Wiltschke C, Brodowicz T, et aL Anti-HER-2/neu antibodies detected in sera of patients 
with breast cancer, but also in healthy females. European Journal of Cancer 1998; 34: 2135.
119.  Carney WP, Neumann R, Lipton A, et al. Potential clinical utility of serum HER-2/neu 
oncoprotein concentrations in patients with breast cancer. Clinical Chemistry 2003; 49:10:  1579-98.
120.  Sahin AA. Biologic and clinical significance of HER-2/neu(cerbB-2) in breast cancer. Advances in 
Anatomic Pathology 2000; 7:  158-66.Reference Chapter 4: cerbB-2 in breast cancer 291
121.  Grady AO, Leader M, Kay E. The use of tissue microarray technology in the assessment of HER-2 
status in breast carcinoma. Meeting of the Pathological Society of Great Britain and Ireland. 2001; 
26A.
122.  Rampaul RS, Wencyk PM, Bell JA, et al. High throughput profiling of cerbB-2: Analysis by tissue 
microarray. Meeting of the Pathological Society of Great Britain and Ireland. 2001; 26A.
123.  Ellis IO, Dowsett M, Bartlett JMS, et al. Recomendations for HER2 testing in the UK. Journal Of 
Clinical Pathology 2000; 53(12): 890-2.
124.  Lin CR, Chen WS, Kruiger W, et aL Expression cloning of human egf receptor complementary- 
dna - gene amplification and 3 related messenger-ma products in a431-cells. Science 1984; 224: 843- 
8.
125.  Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth-factor receptor cdna sequence 
and aberrant expression of the amplified gene in a431 epidermoid carcinoma-cells. Nature 1984; 
309:418-25.
126.  Carpenter G. Receptors for epidermal growth-factor and other polypeptide mitogens. Annual 
Review of Biochemistry 1987; 56: 881-914.
127.  Laurence DJR, Gusterson BA. The epidermal growth-factor - a review of structural and functional- 
relationships in the normal organism and in cancer-cells. Tumour Biology 1990; 11: 229-61.
128.  Riese DJ, Vanraaij TM, Plowman GD, et at The cellular-response to neuregulins is governed by 
complex interactions of the erbb receptor family. Mollecular Cell Biology 1995; 15: 5770-6.
129.  Horak E, Smith K, Bromley L, et al Mutant p53, egf-receptor and c-erbb-2 expression in human 
breast-cancer. Oncogene 1991; 6: 2277-84.
130.  Borg A, Baldetorp B, Ferno M, et aL erbB-2 amplification in breast-cancer with a high-rate of 
proliferation. Oncogene 1991; 6:  137-43.
131.  Benz CC, Brandt BH, Zanker KS. Gene diagnostics provide new insights into breast-cancer 
prognosis and therapy. Gene 1995; 159: 3-7.
132.  Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbb-2 amplification and risk 
of recurrent disease in node-negative breast-cancer. Cancer Research 1991; 51: 556-67.
133.  Rampaul RS, Pinder SE, Wencyk PM et aL Even with long term follow-up epidermal growth 
factor receptor (EGFR) expression is of no prognostic value in breast cancer. Meeting of  the 
Pathological Society of Great Britain and Ireland. 2001; 27A.
134.  Kraus MH, Issing W, Miki T, et aL Isolation and characterization of erbb3, a 3rd member of the 
erbB/epidermal growth-factor receptor family - evidence for overexpression in a subset of human 
mammary-tumors. Proceedings of The National Academy of  Sciences USA  1989; 86: 9193-7.
135.  Travis A, Pinder SE, Robertson JF, et al. C-erbB-3 in human breast carcinoma: expression and 
relation to prognosis and established prognostic indicators. British Journal Of Cancer 1996; 74: 229-
33.
136.  Plowman GD, Green JM, Culouscou JM, et al. Heregulin induces tyrosine phosphorylation of 
her4/pl80(erbB4). Nature 1993; 366: 473-5.References Chapter 5: Oestrogen receptors (ER) in breast cancer 292
Reference List Chapter 5:
1.  Laidlaw IJ, Clarke RB, Howell A, et al. The proliferation of normal human breast tissue implanted 
into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1995; 136: 
164-71.
2.  Moudgii VK, Dinda S, Khattree N, et al. Hormonal regulation of tumour suppressor proteins in 
breast cancer cells. Steroid Biochemistry and Molecular Biology 2001; 76: 105-17.
3.  Parker MG. Nuclear hormone receptors. London:Academic Press 1991.
4.  Beatson JT.  Treatment of inoperable cases of carcinoma of the mamma; suggestions for a new 
method of treatment with illustrative cases. Lancet 1896; 2:  104-7.
5.  Huggins C, Burgenstal BM. Inhinition of human mammary and prostatic cancer by adrenalectomy. 
Cancer Reserach 1952; 12:  134-41.
6.  Luft R, Olivecrona H. Experiences with hypophysectomy in man. Journal of  Neurosurgery  1953; 
10: 301-16.
7.  Pearson OH, Ray BS, Harrold CC, et at Hypophysectomy in the treatment of advanced cancer. 
Jouurnal of  American Medical Association 1956; 161:  17-21.
8.  Atkins H, Bulbrooke RD, Falconer MA, et aL Ten years experience of steroid assays in the 
management of breast cancer. Lancet 1968; 2:  1255-60.
9.  Glascock RF, Hoekstra WG. Selective accumulation of tritium - labelled hexoestrol by the 
reproductive organs of immature female goats and sheep. Bichemistry Journal 1959; 72: 673-82.
10.  Jensen EV, Jacobsen HI. Fate of  steroid estrogen in target tissue. Academic Press, NewYork;
1960.
11.  Folca PJ, Glascock RF, Irvine WT. Studies with tritium labelled hexoestrol in adavnced breast 
cancer; comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy 
and oophorectomy. Lancet 1961; 2: 796-8.
12.  Jensen EV, Block GE, Smith S, et at Estrogen receptors and breast cancer response to 
adrenlectomy.  1971: 55-70.
13.  Cole MP, Jones CTA, Todd EDH. A new anti-oestrogenic agent in late breast cancer; an early 
clinical appraisal of IC1 46474. British Journal of Cancer 1971; 270-5.
14.  Patterson JS, Battersby LA. Tamoxifen: An overview of recent studies in the field of oncology. 
Cancer Treatment Rep.  1980; 64: 775-8.
15.  Baum M. Controlled trial of tamoxifen as single adjuvant agent in management of early breast 
cancer: analysis at six years by the Nolvadex Adjuvant trial organisation. Lancet 1985; 1: 836-40.
16.  EBCTC group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune 
therapy:  133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 
women. Lancet 1992; 339:  1, 71-15, 85.
17.  Paech K, Webb P, Kulper GG, et al. Differential ligand activation of estrogen receptors ER alpha 
and beta at AP-1 sites. Science 1997; 277: 1508-11.
18.  Parker MG, Arbuckle N, Dauvois S, et al. Structure and function of the estrogen receptor. Ann NY 
AcadSci 1993; 684:  119-26.References Chapter 5: Oestrogen receptors (ER) in breast cancer 293
19.  Cowley SM, Hoare S, Mosselman S, et al. Estrogen receptors alpha and beta form heterodimers on 
DNA. Journal of Biology Chemistry 1997; 272:  19858-62.
20.  Tremblay GB, Tremblay A, Copeland NG et al. Cloning, chromosomal localization and functional 
analysis of the murine oestrogen receptor beta. Molecular Endocrinology  1997; 11: 353-65.
21.  Bubulya A, Wise SC, Shen XQ, et al. c-jun can mediate androgen receptor-induced transactivation. 
Journal of  Biology Chemistry 1996; 4: 24583-9.
22.  Pfahl M. Nuclear receptor/AP-1  interaction. Endocrinology Review 1993;  14: 651-8.
23.  Shemshedini L, Knauthe R, Sassone-Corsi P, et aL Cell-specific inhibitory and stimulatory effets 
of Fos and Jun on transcription activation by nuclear receptors. EMBO 1991; 10: 3839-49.
24.  Neill PO, Shabaan A, Dodson A, et aL Oestrogen receptor (ER) and heat shock protein 27 (hsp 27) 
correlates with survival in breast cancer. Meeting of  the Pathological Society of  Great Britain and 
Ireland 2001; 26A.
25.  Watanabe T, Inoue S, Ogawa S et aL Agonistic effect of tamoxifen is dependent on cell type, ERE- 
promotor context and estrogen receptor subtype functional difference between estrogen receptors 
alpha and beta. Biochem Biophys Res Commun 1997; 236: 140-5.
26.  Couse JF, Lindzey J, Grandien K, et aL Tissue distribution and quantitative analysis of estrogen 
receptor alpha and estrogen receptor beta messenger RNA in the wild type and ER alpha knockout 
mouse. Endocrinology 1997; 138: 4613-21.
27.  Katzenellenboyen BS, Korach KS. A new actor in the estrogen receptor drama-enter ER beta. 
Endocrinology 1997; 138: 861-2.
28.  Kuiper GG, Enmark E, et at Cloning of a novel estrogen receptor expressed in rat prostate and 
ovary. Proceedings of  National Academy of  Sciences USA  1996; 93: 5925-30.
29.  Carder PJ, Skliris GP, Burdall SE, et al. The cellular distribution of estrogen receptor alpha and 
beta in normal human mammary gland. Meeting of  the Pathological Society of Great Britain and 
Ireland 2001; 8A.
30.  Udokang K, Mosquera JM, Shaw JA, et al. Comparison of oestrogen receptor alpha and beta 
mRNA and protein in malignant and non-malignant breast. Meeting of  the Pathological Society of 
Great Britain and Ireland 2001; 8A.
31.  Gorski J, Toft D, Shyamala G, et al. Hormone receptors: studies on the interaction of oestrogen 
with the uterus. Recent Progress in Hormone Research 1968; 24: 45-80.
32.  Jensen EV, Smith S, DeSombre ER Hormone dependency in breast cancer. Journal of  Steroid 
Biochemistry 1976; 9: 911-7.
33.  Korenman SG, Dukes BA. Specific Oestrogen binding by the cytoplasm of human breast 
carcinoma. Journal of  Clinical Endocrinology and metabolism 1970; 30: 639-45.
34.  Jensen EV, DeSombre ER Steroid hormone binding and hormone receptors. In: Holland JF, Frie E, 
Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR, eds. Cancer Medicine . 3rd edn. Philadelphia 
: Lea and Febinger; 1993: 815-23.
35.  Greene GL, Nolan C, Engler JP, et al. Monoclonal antibodies to human estrogen receptor. 
Proceeding of  National Academy of  Sciences, USA 1980; 77: 5115-9.
36.  Jensen EV, Greene GL, DeSombre ER The estrrogen receptor immunoassay in the prognosis and 
treatment of breast cancer. Laboratory Managment 1986; 24: 25-42.References Chapter 5: Oestrogen receptors (ER) in breast cancer 294
37.  King WL, DeSombre ER, Jensen EV, et al. Comaprison of immunocytochemical and steroid 
binding assays for estrogen receptor in human breast tumours. Cancer Reserach 1985; 45: 293-304.
38.  Pusztay HM, McDonald EM. Symposium on estrogen receptor determination with monoclonal 
antibodies. Cancer Reserach (Suppliment)  1986; 46: 4231.
39.  Pertschuk LP. Immunoctyochemistry  for steroid receptors. Boca Raton. FL, CRC Press; 1990.
40.  Pertschuk LP, Kim DS, Nayer K, et al. Immunocytochemical estrogen and progestin receptor 
assays in breast cancer with monoclonal antibodies. Cancer 1990; 1663-70.
41.  Anderson J, Orntoft TF, Poulsen HS. Immunohistochemical demonstration of estrogen receptors 
(ER) in formalin-fixed paraffin-embedded human breast cancer tissue by use of a monoclonal 
antibody to ER. Journal of  Histochemistry Cytochemistry 1988; 36:  1553-60.
42.  Cheng L, Binder SW, Fu YS, et aL Demonstration of estrogen receptors by monoclonal antibody in 
formalin-fixed breast tumours. Laboratory Investigations 1988; 58: 346-53.
43.  Shintaku IP, Said JW. Detection of estrogen receptors with monoclonal antibodies in routinely 
fixed processed formalin fixed paraffin sections of breast carcinoma. American Journal of  Clinical 
Pathology 1987; 161-7.
44.  Snead DRJ, Bell JA, Dixon AR, et at Methodology of immunohistochemical detection of 
oestrogen receptor in human breast carcinoma in formalin fixed paraffin embedded tissue: a 
comparison with frozen section methodology. Histopathology 1993; 23: 233-8.
45.  Allred DC. Should immunohistochemical examination replace biochemical hormone receptor assays 
in breast cancer? American Journal of Clinical Pathology 1993; 46:  1-3.
46.  AlSaati T, Clamens S, Cohen KE, et al. Production of monoclonal antibodies to human oestrogen 
receptor protein (ER) using recombinant ER  (RER). International Journal of Cancer 1993; 55: 651-
4.
47.  Saccani JG, Johnston SRD, Salter J, et at Comparison of new immunohistochemical assay for 
oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme 
immunoassay. Journal of  Clinical Pathology 1994; 47: 900-5.
48.  Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed paraffin-embedded tissues, an 
enhancement method for immunohistochemical staining based on microwave oven heating of tissue 
sections. Journal of  Histochemistry Cytochemistry 1991; 39: 741-8.
49.  Norton AJ, Jordan S, Yeomans P. Brief high-temperature heat denaturation (pressure cooking); a 
simple and effective method of antigen retrieval for routinely processed tissues. Journal of  Pathology 
1994; 173: 371-9.
50.  Goulding H, Pinder S, Cannon P, et aL A new method for the assessment of oestrogen receptor 
status on routine formalin-fixed tissue samples. Human Pathology 1995; 26: 291-4.
51.  Jensen EV. Intracellular localisation of estrogen receptors: implications for intercation mechanism. 
Laboratory Investigations 1984; 51: 487-8.
52.  Dauvois S, White R, Parker MG.  The anti-oestrogen ICI  182 780 disrupts oestrogen receptor 
nucleocytoplasmic shuttling. Journal of Cell Science 1993; 106:  1377-88.
53.  Kinsel LB, Szabo E, Greene GL, et al. Immunocytochemical analysis of estrogen receptors as a 
predictor of prognosis in breast cancer patients : comparison with quantitative biochemical methods. 
Cancer Reserach 1989; 49:  1052-6.References Chapter 5: Oestrogen receptors (ER) in breast cancer 295
54.  Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score 
(IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. 
Pathologe 1987; 8:  138-40.
55.  Reiner A, Neumeister B, Spona J, et al. Immunocytochemical localisation of estrogen and 
progesterone receptor and prognosis in human primary breast cancer. Cancer Reserach 1990; 50: 
7057-61.
56.  National Coordinating Group for Breast Screening Pathology. Pathology reporting in breast cancer 
screening. 2, 54. 1995.  NHSBSP publications.
Ref Type: Serial (Book,Monograph)
57.  Slamon DJ, Clark GM, Wong SG, et aL Human breast cancer: correlation of relapse and survival 
with amplification of the HER-2/neu oncogene. Science 1987; 235:  177-82.
58.  Slamon DJ, Press MF, Godolphin W, et al. Studies of HER-2/neu protooncogene in human breast 
cancer. Cancer Cells 1989; 7: 371-84.
59.  Gaskell DJ, Hawkins RA, Tesdale AL, et al. The differing predictive values of oestrogen receptor 
assays for large breast cancers. Postgraduate Medical Journal 1992; 68: 900-3.
60.  Robertson JFK, Bates K, Pearson D, et aL Comparison of two oestrogen receptor assays in the 
prediction of the clinical course of patients with advanced breast cancer. British Journal of Cancer 
1992; 65: 727-30.
61.  Barnes DM, Millis. Oestrogen receptors:the history, the relevance and the methods of evaluation. 
Progress in Pathology 1995; 2: 89-114.
62.  Hayward JL, Meakin JW, Stewart HJ. Assessment of response and recurrence in breast cancer. 
Seminars in Oncology 1978; 5: 445-9.
63.  Hermanek P, Sobin L. TNM classification of  malignant tumours. 4th edn. Springer-Verlag; 1987.
64.  Bacus S, Flowers JL, Press M, et al. The evaluation of estrogen receptor in primary breast 
carcinoma by computer assisted image analysis. American Journal of Clinical Pathology 1988; 90: 
233-9.
65.  Esteban JM, Ahn C, Mehta P. Biologic significance of quantitative estrogen receptor 
immunohistochemical assay by image analysis in breast cancer. American Journal of Clinical 
Pathology 1994; 102:  158-62.
66.  Kohlberger PD, Breitenecker F, Kaider A et al. Modified true-color computer-assisted image 
analysis versus subjective scoring of estrogen receptor expression in breast cancer: A comparison. 
Anticancer Research 1999; 19: 2189-94.
67.  Rose C, Thorpe SM, Anderson KW. on behalf of the Danish Breast Cancer Cooperative group, 
Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen 
receptor values. Lancet 1985; i:  16-20.
68.  Consensus meeting. NIH consensus development conference on steroid receptors in breast cancer. 
Cancer 2001; 46: 2759-963.
69.  Skinner LG, Barnes DM, Ribeiro GG. The clinical value of multiple steroid receptor assays in 
breast cancer management. Cancer 1980; 46: 2939-45.
70.  Romain S, Chinot O, Guirou O, et al. Biological heterogeneity of ER positive breast cancers in the 
post manopausal population. International Journal of Cancer 1994; 59:  17-9.References Chapter 5: Oestrogen receptors (ER) in breast cancer 296
71.  Shoker BS, Jarvis C, Sibson DR, et al. Oestrogen receptor expression in the normal and pre- 
cancerous breast. Journal of  Pathology 1999; 188: 229-30.
72.  Simpson JF, Page DL. Status of breast cancer prognostication based on histopathologic data. 
American Journal of Clinical Pathology 1994; 102: S3-S8.
73.  Millis RR Correlation of hormone receptors with pathological features of human breast cancer. 
Cancer 1980; 46: 2869-71.
74.  Underwood JCE. Oestrogen receptors in human breast cancer; review of histopathological 
correlates and critique of histochemical methods. Diagnostic Histopathology 1983; 6:  1-22.
75.  Millis RR The relationship between the pathology of breast cancer and hormone sensitivity. Review 
Endocrinology Related Cancer (suppl 20) 1987; 13:  13-8.
76.  Furmanski P, Saunders DE, Brooks S, et al The prognostic value of estrogen receptors 
determinations in patients with primary breast cancer: an update. Cancer 1980; 46: 2794-6.
77.  Clark GM, McGuire WL. Steroid receptors and other prognostic factors in the treatment of breast 
cancer. Seminars in Oncology:  1988;  15:20-5.
78.  Howat JMT, Harris M, Swindell R, et al. The effect of oestrogen and progesterone  receptors on 
recurrence and survival in patients with carcinoma of the breast. British Journal of Cancer 1985; 51: 
263-70.
79.  Daxenbichler G, Forsthuber EP, Marth C, et al Steroid hormone receptor and prognosis in breast 
cancer. Breast Cancer Research and Treatment 1988; 12: 267-73.
80.  Poller DN, Snead DRJ, Roberts EC, et al Oestrogen receptors expression in ductal carcinoma in 
situ of the breast: relationship to flow cytometric analysis of DNA expression of cerbB2 oncoprotein. 
British Journal of Cancer 1993; 68:  156-61.
81.  Zafrani B, Leroyer A, Fourquet A, et al Mammographically detected ductal in situ carcinoma of 
the breast analysed with a new classification. A study of 127 cases : correlation with oestrogen and 
progesterone receptors, p53 and cerbB2 proteins and proliferative activity. Seminars in Diagnostic 
Pathology 1994; 11:208-14.
82.  Bur ME, Zimarowski MJ, Schnitt SJ, et al. Estrogen receptors immunohistochemistry in 
carcinoma in situ of the breast. Cancer 1992; 69:  1174-81.
83.  Giri DD, Dundas SAC, Nottingham JF, et al. Oestrogen receptors in benign epithelial lesions and 
intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989; 15: 575-84.
84.  Bobrow LG, Happerfield LC, Gregory WM, et aL The classification of ductal carcinoma in situ 
and its association with biological markers. Seminars in Diagnostic Pathology 1994; 11:  199-207.
85.  Harland RNL, Barnes DM, Howell A, et al Variation of receptor status in cancer of the breast. 
British Journal of Cancer 1983; 47: 511-5.
86.  Koendders PG, Beex LVAM, Langens R, et al. Steroid hormone receptor activity of primary 
breast cancer and pattern of the first metastases. Breast Cancer Research and Treatment 1991; 18: 
27-32.
87.  Meyer JS, Province M. Proleferative index of breast carcinoma by thymidine labelling: prognostic 
power independent of stage, estrogen and progesterone receptors. Breast Cancer Research and 
Treatment 1988;  12:  191-204.
88.  Meyer JS, Nauert J, Koehm S, et al. Cell kinetics of human tumours by in vitro 
bromodeoxyuridine labelling. Journal of Histochemistry Cytochemistry 1989; 37:  1449-54.References Chapter 5: Oestrogen receptors (ER) in breast cancer 297
89.  Camplejhon R, Ash C, Gillett C, et al. A single centre study, in a group of 881 patients, of the 
prognostic significance of DNA flow cytometry. British Journal of Cancer 1995; 71:  140-5.
90.  Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a 
human nucleasr antigen associated with cell prolioferation. International Journal of Cancer 1983;
31: 13-20.
91.  Sampson SA, Kreipe H, Gillett CE, et al. KiSl - A novel monoclonal antibody which recognises 
profilerating cells : evalution of its relationship to prognosis in mammary carcinoma. Journal of 
Pathology 1992; 168:  179-85.
92.  Gerdes J, Becker MHG, Key G, et aL Immunohistological detection of tumour growth fraction 
(Ki-67 antigen) in formalin fixed and routinely processed tissues. Journal of  Pathology 1992; 168: 
85-7.
93.  Walker KJ, Bouzubar N, Robertson J, et al. Immunocytochemical localization of estrogen 
receptor in human breast tissue. Cancer Reserach 1988; 48: 6517-22.
94.  McGuire WL, Clark GM. Prognostic factors for recurrence and survival in axillary node-negative 
breast cancer. Journal of  Steroid Biochemistry 1989; 34:  145-8.
95.  Fantl V, Richards MA, Smith R, et at Gene amplification on chromosome 11 q 13 and oestrogen 
receptor status in breast cancer. European Journal of Cancer 1990; 26: 423-9.
96.  Borg A, Tandon AK, Sigurdsson, H, et aL HER-2 /neu amplification predicts poor prognosis in 
node-positive breast cancer. Cancer Reserach 1990; 50: 4332-7.
97.  Allred DC, Clark GM, Elledge R, et at Association of p53 protein expression with tumour cell 
proliferation rate and clinical outcome of node-negative breast cancer. Journal of  National cancer 
Institute 1993; 85: 200-6.
98.  Yang Q, Sakurai T, Jing X, et at Expression of Bcl2, but not Bax, correlates with estrogen receptor 
status and tumour proliferation in invasive breast carcinoma. Journal of  Pathology 1999; 49: 775-80.
99.  Shek LL, Godolphin W. Survival with breast cancer : the importance of estrogen receptor quality. 
European Journal of Cancer Clinical Oncology 1989; 25: 243-50.
100.  Knight WA, Livingstone RB, Gregory EJ et al. Estrogen receptor as an independent prognostic 
factor for early recurrence in breast cancer. Cancer Reserach 1977; 37: 4669-71.
101.  Howell A, Barnes DM, Harland RNL, et al. Steroid hormone receptors after first relapse in breast 
cancer. Lancet 1984; 1: 588-91.
102.  Borgen PI, Wong GY, Vlamis V, et al. Current management of male breast cancer. A review of 
104 cases. Annals of  Surgery 1992; 215: 451-7.
103.  Rogers S, Day CA, Fox SB. Expression of cathepsin D and estrogen receptor in male breast 
carcinoma. Human Pathology 1993; 24:  148-51.
104.  Payne S, Bruce DM, Heys SD, et al. Prognostic parameters in male breast cancer. Journal of 
Pathology 1995; 175 (suppl): 143A.
105.  Horwitz KB, McGuire WL, Pearson OH, et al. Predicting response to endocrine therapy in human 
breast cancer: a hypothesis. Science 1975;  189: 726-7.
106.  McGuire WL, Carbonne PP, Vollmer EP. Estrogen receptors in breast cancer. Raven Press, New 
York; 1975.References Chapter 5: Oestrogen receptors (ER) in breast cancer 298
107.  McGuire WL. Hormone receptors : their role in predicting prognosis and response to endocrine 
therapy. Seminars in Oncology 1978; 5: 428-33.
108.  Snead DRJ, Goulding H, Bell JA et aL Combined progesterone and estrogen receptor status in 
predicting hormone sensitive breast cancer: better than ER alone? Meeting of  the Pathological 
Society of Great Britain and Ireland 1997.
109.  Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell 
lines. Cell 1980; 20: 352-62.
110.  Rochefort H, Capony F, Garcia M, et al. Estrogen induced lysosomal proteases secreted by breast 
cancer cells: a role in carcinogenesis? Journal of Cell Biochemistry 1987; 35:  17-29.
111.  Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. New 
England Journal of  Medicine 1990; 322: 297-302.
112.  EngTan P, Benz CC, Dollbaum C, et al. Prognostic value of cathepsin D expression in breast 
cancer immunohistochemical assessment and correlation with radiometric assay. Annals of Oncology 
1994; 5: 329-36.
113.  Masiakowski P, Breathnach R, Bloch J, et al. Cloning of cDNA sequences of hormone regulated 
genes from MCF-7 human breast cancer cell line. EMBO 1982; 10: 7895-903.
114.  Dookeran KA, Rye PP, Bearing SJ, et aL Expression of the pS2 peptide in primary breast 
carcinomas: comparison of membrane and cytoplasmic staining patterns. Journal of  Pathology 1993; 
171:  123-9.
115.  Goldstein SR. Selective oestrogen modulators: A new category of therapeutic agents for extending 
the health of post-menopausal women. American Journal of Obstetrics and Gynaecology 1998; 179: 
1479-84.
116.  Colletta AA, Wakefield LM, Howell FU, et al. Antioestrogens induce the secretion of active 
transforming growth factor beta from human fibroblasts. British Journal of Cancer 1990; 62: 405-9.
117.  Knabbe C, Lippman ME, Wakefield LM, et aL Evidence that transforming growth factor beta is a 
hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28.References Chapter 6: Ductal carcinoma in situ 299
Reference List Chapter 6:
1.  Nemoto T, Vana J, Bedwani RN, et al. Managment and survival of female breast cancer : results of 
a national survey by the American college of surgeons. Cancer 1980; 45 : 2917-24.
2.  Lagios MD. Ductal carcinoma in situ: pathology and treatment. Surgical Clinical Journal of  North 
America 1990; 70: 853-71.
3.  VanDongen JA, Holland R, Peterse JL, et al. Ducatal carcinoma in situ of the breast, second 
EORTC consensus meeting. European Journal of  Cancer 1992; 28: 626-9.
4.  Patchefeky AS, Schwartz GF, Finkelstine SD. Heterogeneity of intraductal carcinoma of the 
breast. Cancer 1989; 63: 731-41.
5.  Lennington WJ, Jensen RA, Dalton LW, et al. Ductal carcinoma in situ of the breast-heterogeneity 
of individual lesions. Cancer 1994; 73:  118-24.
6.  Lagios MD. Heterogeneity of ductal carcinoma in situ of the breast. Journal of  Cell 
Biochemistry(suppl)  1993;  17G: 49-52.
7.  Silverstein MJ. Ductal carcinoma in situ of  the breast. Williams and Wilkins, Baltimore;  1997.
8.  Schnitt SJ, Connolly J, Harris JR, et al. Pathological predictors of early local recurrence in stage I 
and II breast cancer treated by primary radiation treatment. Cancer 1984; 53:  1049-57.
9.  Evans AJ, Pinder S, Ellis IO, et al. Screen detected and symptomatic ductal carcinoma in situ : 
mamographic features with pathologic correlation. Radiology 1994; 191: 237-40.
10.  Fechner RE. One century of mammary carcinoma in situ, what have we learned? American Journal 
of  Clinical Pathology 1993;  100: 654-61.
11.  Bloodgood JC. Comedo carcinoma (or comedo adenoma) of the female breast cancer. American 
Journal of Cancer 1934; 22: 842-53.
12.  Lewis D, Geschickter CF. Comedo carcinoma of the breast. Archives of  Surgery 1938; 36: 225-44.
13.  Azzopardi JG. Underdiagnosis of malignancy. In: Azzopardi JG, ed. Problems in breast pathology. 
Philadelphia, Saunders;  1979.
14.  Page DL, Dupont WD, Rogers LW, et aL Intraductal carcinoma of the breast, follow-up after 
biopsy only. Cancer 1982; 49: 751-8.
15.  Landis SH, Murray T, Bolden S, et al. Cancer statistics, year 1998. Cancer Abstracts, Cancer 
Journal of  Clinicians 1998; 48: 6-29.
16.  Stomper PC, Connolly JL, Meyer JE, et al. Clinically occult ductal carcinoma in situ detected with 
mammography: analysis of 100 cases with radiologic-pathologic correlation. Radiology 1989; 172: 
235-41.
17.  Evans AJ, Pinder S, Wilson R, et aL Ductal carcinoma in situ of the breast: correlation between 
mammographic and pathogenic findings. American Journal of  Roentgenology 1994; 162: 1307-11.
18.  Ellis IO, Galea MH, Locker A, et al. Early experience in breast cancer screening emphasis on 
development of. The Breast 1993.
19.  Wells CA, Ellis IO, Zakhour HD, et al. RMW guidlines for cytology procedures reporting in breast 
cancer screening. Cytopathology 1994; 5: 316-34.
20.  Parker SH, Jobe WE. Percutaneous bresat biopsy. Raven Press, New York; 1993.References Chapter 6: Ductal carcinoma in situ 300
21.  Bellamy COC, McDonald C, Salter DM, et al. Non invasive ductal carcinoma of the breast: the 
relevance of histologic categorisation. Human Pathology 1993; 24: 16-23.
22.  Schwartz GF, Lagios MD, Carter D et at For the consensus conference comittee, consensus 
conference on on the classification of ductal carcinoma in situ. Cancer 1997; 80: 1798-802.
23.  Silverstein MJ, Barth A, Poller DN et aL Ten year results comparing mastectomy to excision and 
radiation therapy for ductal carcinoma in situ of the breast. European Journal of Cancer 1995; 31: 
1425-7.
24.  Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma 
in situ. Lancet 1995; 345:  1154-7.
25.  SUverstein MJ, Lagios MD, Craig PH, et aL A prognostic index for ductal carcinoma in situ of the 
breast. Cancer 1996; 77: 2267-74.
26.  Lagios MD, Margolin FR, Westdahl PR, et ah Mamographically detected ductal carcinoma in situ; 
frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local 
recurrence. Cancer 1989; 63: 619-24.
27.  Solin LJ, Yeti T, Kurtz J et at Ductal carcinoma is situ (intraductal carcinoma) of the breast treated 
with breast conserving surgery and definitive irradiation correlation of pathologic parameters with 
outcome of treatment. Cancer 1993; 71: 2532-42.
28.  Silverstein MJ. Predicting local recurrence in patients with ductal carcionoma in situ of the breast. 
In: Silverstein MJ, ed. Ductal carcinoma in situ of  the breast. Baltimore: Williams and Wilkins; 
1997:271-84.
29.  Fisher ER, Constantino J, Fisher B et aL Pathologic finding from the national surgical adjuvant 
breast project (NSABP) protocol B-17: intraductal carcionam (ductal carcioma in situ). Cancer 1995; 
75: 1310-9.
30.  PoUer DN, Galea MH, Pearson D, et al. Nuclear and flow cytometric characteristics associated 
with over expression of the cerbB2 oncoprotein in breast carcinoma. Breast Cancer Research 
Treatment 1991; 20: 3-10.
31.  Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ : a proposal for a new 
classification. Seminars in Diagnostic Pathology 1994; 11:  167-80.
32.  National Co-ordinating Group for Breast Screening Pathology. Pathology Reporting in Breast 
Cancer Screening. 2nd ed. NHBSP Publications, no 3 1995.
33.  Poller DN, Silverstein MJ, Galea MH, et al. Ductal carcinoma in situ of the breast, A proposal for 
a new simplified histological classification, association between cellular proliferation and cerbB2 
protein expression. Modern Pathology 1994; 7: 257-62.
34.  Ottesen GL, Graversen HP, Blichert-Toft M, et al. Ductal carcinoma in situ of the female breast, 
short term results of a prospective nationwide study. American Journal ofSurgicl Pathology 1992;
16:  1183-96.
35.  Logan J, Johnson R, Morgan JM, et al. Margin of excision is the most important factor in 
predicting recurrence after local excision of DCIS of the breast. Meeting of the Pathological Society 
of Great Britain and Ireland 2001; 114.
36.  Douglas Jones AG, Gupta SK, Attanoos RL, et al. A critical appraisal of six modem 
classifications of ductal carcinoma in situ of the breast (DCIS) correlation with grade of associated 
invasive disease. Histopathology 1996; 29: 397-409.
37.  Tavassoli FA. Pathology of the breast. Norwalk, Connecticut, Appleton & Lange;  1992.References Chapter 6: Ductal carcinoma in situ 301
38.  Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma : a clinicopathologic study of 37 cases. 
Modern Pathology 1994; 7: 813-8.
39.  Carter D, Orr S, Merino M. Intracystic papillary carcinoma of the breast after mastectomy, 
radiotherapy and excisional biopsy alone. Cancer 1983; 52: 14-9.
40.  Fisher ER, Brown R. Intraductal Signet ring carcinoma, A hiltrer to undescribed form of intraductal 
carcinoma of the breast. Cancer 1985; 52:  14-9.
41.  Cross AS, Azzopardi JG, Krausz T, et ah A morphological and immunocytochemical study of a 
distinctive variant of ductal carcinoma in situ of the breast. Histopathology 1985; 9: 21-37.
42.  Guerry P, Erlandson RA, Rosen PP. Cystic hypersecretory hyperplasia and cystic hypersecretory 
ductal carcinoma of the breast, pathology, therapy and follow-up of 39 patients. Cancer 1988; 61: 
1611-20.
43.  Rosenn PP, Scott M. Cystic hypersecretory duct carcinoma of the breast. American Journal of 
Surgical Pathology 1984; 8: 31-41.
44.  Camus MG, Joshi MG, Mackerem G, et aL Ductal Carcinoma in situ of the male breast. Cancer 
1994; 74:  1289-93.
45.  Tavassoli FA, Norris HJ. A comparison of the results of long term follow-up for atypical 
intraductal hyperplasia of the breast. Cancer 1990; 65: 518-29.
46.  Masood S, Sim SJ, Lu L. Immunohistochemical differentiation of atypical hyperplasia vs carcinoma 
in situ of the breast. Cancer Detection and Prevention 1992; 16: 225-35.
47.  Bocker W, Bier B, Freytag G, et at An immunohistochemical study of the breast using antibodies 
to basal and luminal keratins, alpha - smooth muscle actin, vimentin, collagen IV and laminin. Part 
II:epitheliosis and ductal carcinoma in situ.  Virchows Archive, A Pathology Anatomy Histopathology 
1992;421:323-30.
48.  Wellings SR, Jensen MH, Maraum RG. An atlas of subgross pathology of the human breast with 
special reference to possible precancerous lesions. Journal of  National Cancer Institute 1975; 55: 
231-73.
49.  Holland R, Hendriko JH, Vebeck AL, et at Extent distributions and mamographic / histological 
correlations of breast ductal carcinoma in situ. Lancet 1990; 335: 519-22.
50.  Holland R, Connolly JL, Gelman R, et aL The presence of an extensive intraductal component 
following a limited excision correlates with prominent residual disease in the remainder of the breast. 
Journal of  Clinical Oncology 1990; 8:  113-8.
51.  Faverly DRG, Burgers L, Butt P, et at Three dimension imaging of mammary ductal carcinoma in 
situ : clinical implication. Seminars in Diagnostic Pathology 1994;  11:  193-8.
52.  Rosen PP and Oberman HA. Intraepithelial (pre-invasive or in situ carcinoma),  pi 19. 1993. 
Washington DC; Armed Forces, Institute of Pathology. In : Tumours of the mammary gland.
Ref Type: Report
53.  Nielsen M, Jensen J, Andersen J. Precancerous and cancerous breast lesions during lifetime and at 
autopsy: a study of 83 women. Cancer 1984; 54: 612-5.
54.  Nielsen M, Thomsen JL, Primdahl S, et al. Breast cancer and atypia among young and middle 
aged women: a study of 110 medicolegal autopsies. British Journal of  Cancer 1987; 56: 814-9.
55.  Faverly DRG, Holland R, Burgers L. An original stereomicroscope analysis of the mammary 
glandular tree.  Virchows Archive, A Pathology Anal 1992; 421:  115-9.References Chapter 6: Ductal carcinoma in situ 302
56.  Stratton MR, Collins N, Lakhani SR, et aL Loss of heterozygosity in ductal carcinoma in situ of 
the breast. Journal of Pathology 1995;  175:  195-201.
57.  Lakhani SR, Collins N, Stratton MR, et al. Atypical ductal hyperplasia of the breast. A clonal 
proliferation exhibiting loss of heterozygosity. Journal of Clinical Pathology 1995; 48: 611-5.
58.  Radford DM, Fair K, Thompson AM, et al. Allelic loss on chromosome 17 in ductal carcinoma in 
situ of the breast. Cancer Research 1993; 53: 294-2950.
59.  Radford DM, Phillips NJ, Fair K, et al. Allelic loss and progression of breast cancer. Cancer 
Research 1995; 55: 5180-3.
60.  Fuji H, Marsh C, Cairns P, et al. Genetic divergence in the clonal evolution of breast cancer. 
Cancer Research 1996; 56:  1493-7.
61.  Nowell PC. The clonal evolution of tumour cell populations. Science 1976; 194: 23-8.
62.  Micale MA, Visscher DW, Gulino SE, et al. Chromosomal aneuploidy in proliferative breast 
disease. Human Pathology 1994; 25: 29-35.
63.  Smith HS, Lu Y, Deng G, et aL  Molecular aspects of early stages of breast cancer progression. 
Journal of Cell Biochemistry 1993; 17:  144-52.
64.  Page DL, Rogers LW. Combined histologic and cytologic criteria for the diagnosis of mammory 
atypical ductal hyperplasia. Human Pathology 1992; 23:  1095-7.
65.  Jensen RA, Dupont WD, Page DL.  Diagnostic criteria and cancer risk of proliferative breast 
lesions. Journal of Cell Biochemistry 1993; 17: 59-64.
66.  Eusebi V, Feuclale E, Foschini MP, et al. Long term follow-up of in situ carcinoma of the breast. 
Seminars in Diagnostic Pathology 1994; 11: 223-5.
67.  Farrow JH. Current concepts in the detection and treatment of the earliest of early breast cancers. 
Cancer 1970; 25: 468-77.
68.  Haagensen CD. Diseases of the breast. Philadelphia : Saunders; 1971: 586.
69.  Millis RR, Thynne GSJ. In situ ductal carcinoma of the breast: a long term follow-up study. British 
Journal of  Surgery 1975; 62: 957-62.
70.  Rosen PP, Braun DW jr, Kinne DE. The clinical significance of pre-invasive breast cancer. Cancer 
1980; 46:919-25.
71.  Wang TC, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV - 
cyclin D, transgenic mice. Nature 1994; 369: 669-71.
72.  Muller WJ, Sinn E, Pattengale PK, et al. Single step induction of mammary adenocarcinoma in 
transgenic mice bearing the activated C-neu oncogene. Cell 1988; 54: 105-15.
73.  Rodriguez E, Sreekantaiah C, Chaganti RSK. Genetic changes in epithelial solid neoplasia.
Cancer Research 1994; 54: 3398-406.
74.  Guan XY, Mettzer PS, Dalton WS, et al. Identification of cryptic sites of DNA sequence 
amplification in human breast cancer by chromosome microdissection. Nature Genetics 1994; 8: 
155-61.
75.  Leal CB, Schnitt FC, Bento MJ, et al. Ductal carcinoma in situ of the breast. Histologic 
categorization and its relationship to ploidy and immunohistochemical expression of hormone 
receptors,p53 and cerbB2 protein. Cancer 1995; 75: 2123-31.References Chapter 6: Ductal carcinoma in situ 303
76.  Futreal PA, Liu Q, Eidens DS, et aL BRCA-1 mutations in primary breast and ovarian carcinomas. 
Science 1994; 266:  120-2.
77.  Munn KE, Walker RA, Menasce L, et al. Allelic imbalance in the region of the BRCA1 gene in 
ductal carcinoma in situ of the breast. British Journal of Cancer 1996; 73: 636-9.
78.  Van de Vijrer MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer : 
association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast 
cancer. New England Journal of Medicine 1988; 319:  1239-45.
79.  Bartkova J, Barnes DM, Millis RR, et aL Immunohistochemical demonstration of cerbB2 protein 
in mammary ductal carcinoma in situ. Human Pathology 1990; 21:1164-7.
80.  Bobrow LG, Happerfield LC, Gregory WM, et aL The classification of ductal carcinoma in situ 
and its association with biological markers. Seminars in Diagnostic Pathology 1994; 11:  199-207.
81.  Gusterson BA, Machin LG, Gullick WJ, et at Immunohistochemical distribution of cerbB2 in 
infiltrating and in situ breast cancer. International Journal of Cancer 1988; 42: 842-5.
82.  Locker AP, Horrock SC, Gilmour AS, et aL Flow cytometric and histological analysis of ductal 
carcinoma in situ of the breast. British Journal of  Surgery 1990; 77: 564-7.
83.  Lodato RF, Maguire HC, Greene MI, et al. Immunohistochemical evaluation of cerbB2 oncogene 
expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Modern 
Pathology 1990; 3: 449-54.
84.  Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of cerbB2 in in situ 
breast carcinoma : a detailed morphological analysis. Journal of  Pathology 1990; 161: 7-14.
85.  Schimmelpening H, Eriksson ET, Pallis L, et aL Immunohistochemical cerbB2 protooncogene 
expression and nuclear DNA content in human mammary carcinoma in situ. American Journal of 
Clinical Pathology 1992; 97: S48-S52.
86.  Somerville JE, Clarke LA, Biggart JD. cerbB2 overexpression and histological type of in situ and 
invasive breast carcinoma. Journal of  Clinical Pathology 1992; 45:  16-20.
87.  Zafrani B, Leroyer A, Fourquet A, et at Mamographically detected ductal in situ carcinoma of the 
breast analysed with a new classification. A study of 127 cases : correlation with oestrogen and 
progeterone receptors, p53 and cerbB2 proteins and proliferative activity. Seminars in Diagnostic 
Pathology 1994; 11:208-14.
88.  Liu E, Thor A, He M, et al. The HER2 (cerbB2) oncogene is frequently amplified in in situ 
carcinomas of the breast. Oncogene 1992; 7:  1027-32.
89.  Barnes DM, Bartkova J, Cample John RS, et al. Overexpression of the cerbB2 oncoprotein:why 
does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and 
is this of prognostic significance? European Journal of  Cancer 1992; 28: 644-8.
90.  Hitchcock A, Topham S, Bell J, et al. Routine diagnosis of mammary Paget's disease, A modem 
approach. American Journal of  Surgical Pathology 1992; 16: 58-61.
91.  Keatings L, Sinclair J, Wright C, et al. cerbB2 oncoprotein expression in mammary and 
extrammary Paget's disease : an immunohistochemical study. Histopathology 1990; 17: 243-7.
92.  Lammie GA, Barnes DM, Millis RR, et al. An immunohistochemical study of the presence of 
cerbB2 protein in Paget's disease of the nipple. Histopathology 1989; 15: 505-14.References Chapter 6: Ductal carcinoma in situ 304
93.  Vielh P, Validdine P, Kheirallah S, et at Disease of the nipple without chemically and 
radiologically detectable breast tumour, histochemical and immunohistochemical study of 44 cases. 
Pathology Research Practice 1993;  189:  150-5.
94.  Maguire HC, Heilman ME, Greene MI, et al. Expression of cerbB2 in in-situ and in adjacent 
invasive ductal adenocarcinomas of the female breast. Pathobiology 1992; 6:  117-21.
95.  Bobrow LG, Millis RR, Happerfield LC, et al. cerbB-3 protein expression in ductal carcinoma in 
situ of the breast. European Journal of Cancer 1997; 33:  1846-50.
96.  Walker RA, Daering SJ. Transforming growth factor beta I in ductal carcinoma in situ and invasive 
carcinomas of the breast. European Journal of  Cancer 1992; 28: 641-4.
97.  Barteck J, Bartkova J, Vojtesek B, et aL Patterns of expression of the p53 tumour suppressor in 
human breast tissues and tumours in situ and in vitro. International Journal of Cancer 1990; 46: 839-
44.
98.  DawidofT AM, Kerns BJ, Iglehart JD, et aL Maintenance of p53 alteration throughout breast 
cancer progression. Cancer Research 1991; 51: 2605-10.
99.  O'Mally FP, Vnencak-Jones CL, Dupont WD, et al. p53 mutations are confined to the comedo 
type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data.  Laboratory 
Investigation 1994; 71: 67-72.
100.  Poller DN, Roberts EC, Bell J, et al. p53 expression in mammary ductal carcinoma in situ : 
relationship to immunohistochemical expression of estrogen receptor and cerbB2 protein. Human 
Pathology 1993; 24: 463-8.
101.  Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumour suppressor gene protein : 
an independent marker of prognosis in breast cancers. Journal of  National Cancer Institute 1992; 84: 
845-55.
102.  Walker RA, Dearing SJ, Lane DP, et aL Expression of p53 protein in infiltrating and in situ breast 
carcinomas. Journal of  Pathology 1991; 165: 203-11.
103.  Tsuda H, Iwaya K, Fukutomi T, et al. p53 mutations and cerbB2 amplification in intraductal and 
invasive breast carcinomas of high histologic grade. Japanes Journal of Cancer Research 1993; 84: 
394-401.  '
104.  Yamashita H, Kobayashi S, Iwase H, et al. Analysis of oncogenes and tumour suppressor genes in 
human breast cancer. Japanes Journal of Cancer Research 1993; 84: 871-8.
105.  Leek RD, Kaklamanis L, Pezzella F, et al. Bcl2 in normal human breast and carcinoma, association 
with oestrogen receptor positive, epidermal growth factor receptor - negative tumours and in situ 
cancer. British Journal of Cancer 1994; 69: 135-9.
106.  Quinn CM, Ostrowski JL, Harkins L, et al.  Loss of Bcl2 expression in DCIS of the breast relates 
to poor histological differentiation and to expression of p53 and cerbB2 proteins. Histopathology 
1998; 33: 531-6.
107.  Rehman S, Crow J, Revell P. BAX protein expression in DCIS of the breast in relation to invasive 
ductal carcinoma and other molecular markers. Pathology Oncology Research 2000; 6: 256-63.
108.  Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D  mRNA 
distinguishes invasive and insitu breast carcinomas from non-malignant lesions. Nat Med 1995; 1: 
1257-60.
109.  Going JJ, Andersen TJ, Wyllie AH. Ras p21 in breast tissue : associations with pathology and 
cellular localisation. British Journal of Cancer 1992; 65: 45-50.References Chapter 6: Ductal carcinoma in situ 305
110.  Poller DN, Snead DRJ, Roberts EC, et al. Oestrogen receptor expression in ductal carcinoma in 
situ of the breast: relationship to flow cytometric analysis of DNA and expression of the cerbB2 
oncoprotein. British Journal of  Cancer 1993; 68:  156-61.
111.  Barnes R, Masood S. Potential value of hormone receptor assay in carcinoma in situ of the breast. 
American Journal of Clinical Pathology 1990; 94: 533-7.
112.  Giri DD, Dundas SAC, Nottingham JF, et al. Oestrogen receptors in benign epithelial lesions and 
intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989; 15: 575-84.
113.  Malafa M, Chaudhuri B, Thomford NR, et aL Estrogen receptors in ductal carcinoma in situ of 
breast. American Journal of  Surgery 1990; 56: 436-9.
114.  Ronay G, Sponsel N, Tulusan AH. Duktales carcinoma in situ  (DCIS) steroid rezeptoven and 
proliferations kinetik. Pathologe 1990; 11: 327-31.
115.  Pallis L, Wilking N, Cedermark B, et aL Receptors for estrogen and progesterone in breast 
carcinoma in situ. Anticancer Research 1992; 12: 2113-5.
116.  Burr ME, Zimarowski MJ, Schnitt SJ, et al. Estrogen receptor immunohistochemistry in 
carcinoma in situ of the breast. Cancer 1992; 69:  1181.
117.  Murphy C, Sibbering DM, Ellis IO, et at Progesterone receptor status in DCIS. Proceedings of 
British Association of  Surgical Oncology 1994.
118.  Inaji H, Koyama H, Motomura K, et aL Immunohistochemical survey of pS2 expression in 
intraductal lesions associated with invasive ductal carcinoma of the breast. International Journal of 
Cancer 1993; 55: 883-6.
119.  Luqmani YA, Campbell T, Soomro S, et al. Immunohistochemical localisation of pS2 protein in 
ductal carcinoma in situ and benign lesions of the breast. British Journal of Cancer 1993; 67: 749-53.
120.  Haknel E, Harvey JM, Joyce R, et aL Stromolysin 3 expression in breast cancer biopsies: clinico 
pathological correlation. International Journal of  Cancer 1993; 55: 771-4.
121.  Douglas Jones AG, Schmid KW, Bier B, et al. Metallothionein (MT) expression in ductal 
carcinoma in situ (DCIS) of the breast. Human Pathology 1995; 26: 217-72.
122.  Royds JA, Stephenson TJ, Rees RC, et al. nm 23 protein expression in ductal in situ and invasive 
human breast carcinoma. Journal of  National Cancer Institute 1993; 85: 727-31.
123.  Simpson JF, O'Malley F, Dupont WD, et al. Heterogeneous expression of nm23 gene product in 
non invasive breast carcinoma. Cancer 1994; 73: 2352-8.
124.  Hanby AM, Gillett CE, Pignatelli M, et al. (31 and (34 integrin  expression  in methacam and
formalin fixed materials from in situ ductal carcinoma  of the breast. Journal of  Pathology 1993; 
171:257-62.
125.  Bacus SS, Gudkov AV, Zelnick CR, et al. Neu differentiation factor (henegulin) induces 
expression of intracellular adhesions molecules-1: implications for mammary tumours. Cancer 
Research 1993; 53: 5251-61.
126.  Bellamy CO, Harrisson DJ. Evaluation of glutathione-S-transferase PI in non invasive ductal 
carcinoma of breast. British Journal of Cancer 1994; 69:  183-5.
127.  Guidi AJ, Fischer L, Harris JR, et al. Microvessel density and  distribution  in ductal carcinoma in
situ of the breast. Journal of  National Cancer Institute 1994; 86: 614-9.References Chapter 6: Ductal carcinoma in situ 306
128.  Yassin R, Heflelfinger S, Miller MA, et al. Angiogenesis of in situ ductal carcinoma and 
proliferative ductal lesions of the breast. American Journal of Clinical Pathology 1994; 102: 529.
129.  Barnes DM, Meyer JS, Gonzalez JG, et al. Relationship between cerbB2 immunoreactivity and 
thymidine labelling index in breast carcinoma in situ. Breast Cancer Research Treatment 1991; 18: 
11-7.
130.  Killeen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast: a comparison with 
histologic features. Cancer 1991; 68: 2602-7.
131.  Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Research 
Treatment 1986; 7: 171-80.
132.  Ernster VL, Barcley J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in 
situ of the breast. Journal of  American Medical Association 1996; 275: 913-8.
133.  Baird RM, Worth A, Hislop G. Recurrence after lumpectomy for comedo type intraductal 
carcinoma of the breast. American Journal of  Surgery 1990; 159: 479-81.
134.  Swhwartz GF, Finkel GC, Gaicia JC, et al. Sub-clinical ductal carcinoma in situ of the breast: 
treated by local excision and surveillance alone. Cancer 1992; 70: 2468-74.
135.  Arnesson LG, Smedo S, Fagerberg G, et al. Follow up of two treatment modalities for ductal 
cancer in situ of the breast. British Journal of  Surgery 1989; 76: 672-5.
136.  Carpenter R, Boutter PS, Cooke T, et al. Management of screen detected ductal carcinoma in situ 
of the female breast. British Journal of  Surgery 1989; 76: 564-7.
137.  Cataliotti L, Distante V, Ciatto S, et al. Intraductal breast cancer review of 183 consecutive cases. 
European Journal of Cancer 1992; 28: 917-20.
138.  Fisher ER, Sass R, Fisher B, et aL Pathologic findings from the national surgical adjuvant breast 
project (protocol 6) I : intraductal carcinoma (DCIS). Cancer  1986; 57:  197-208.
139.  Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation 
therapy for the treatment of intraductal breast cancer. New England Journal of Medicine 1993; 328: 
1581-6.
140.  Gallagher WJ, Koerner FC, Wood WC. Treatment of intraductal carcinoma with limited surgery : 
long term follow up. Journal of  Clinical Oncology 1989; 7: 376-80.
141.  Price P, Sinnett MD, Gusterson B, et al. Ductal carcinoma in situ : predictors of local recurrence 
and progression in patients treated by surgery alone. British Journal of Cancer 1990; 61: 869-72.
142.  Bornstein BA, Recht A, Connolly JL, et al. Results of treating ductal carcinoma in situ of the 
breast with conservative surgery and radiation therapy. Cancer 1991; 67: 7-13.
143.  Haffy BG, Peschel RE, Papadopoulos D, et al. Radiation therapy for ductal carcinoma in situ of the 
breast. Conn.Medicine 1990; 54: 482-4.
144.  Kurtz JM, Jacquenmer J, Torhorst J, et al. Conservation therapy for breast cancers other than 
infiltrating ductal carcinoma. Cancer 1989; 63: 1630-5.
145.  McCormick B, Rosen PP, Kinne DE, et al. Ductal carcinoma insitu of the breast: an analysis of 
local control after conservation surgery and radiotherapy. International Journal of Radiation 
Oncology Biology Physics 1991; 21: 289-92.
146.  Recht A, Danoff BS, Solin LJ, et al. Intraductal carcinoma of the breast: results of treatment with 
excisional biopsy and irradiation. Journal of  Clinical Oncology 1985; 3:  1339-43.References Chapter 6: Ductal carcinoma in situ 307
147.  Ringberg A, Andersen I, Aspegren K, et al. Breast carcinoma in situ in 167 women - incidence, 
mode of presentation, therapy and follow-up. European Journal of  Surgical Oncology 1991; 17: 466-
76.
148.  Silverstein MJ, Cohlan BF, Gierson ED, et al. Ductal carcinoma in situ: 227 cases without micro­
invasion. European Journal of Cancer 1992; 28: 630-4.
149.  Solin LJ, Recht A, Fourquet A, et al. Ten year results of breast conserving surgery and definitive 
irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer 1991; 68: 2337-
44.
150.  Strotter AT, McNeese M, Oswald MJ, et al. The role of limited surgery with irradiation in primary 
treatment of ductal in situ breast cancer. International Journal of Radiation Oncology Biology 
Physics 1990;  18: 283-7.
151.  Zafrani B, Fourquet A, Vilcoq JR, et aL Conservative management of intraductal breast carcinoma 
with tumorectomy and radiation therapy. Cancer 1986; 57: 1299-301.
152.  Fisher B, Dignam J, Wolmark N, et aL Lumpectomy and radiation therapy for the treatment of 
intraductal breast cancer: findings from national surgical adjuvant breast and bowl project B-17. 
Journal of Clinical Oncology 1998; 16: 441-52.
153.  Lagios MD, Page DL. Radiation therapy for in situ or localised breast cancer. New England Journal 
of Medicine 1993; 21: 1577-8.
154.  Page DL, Lagios MD. Pathologic analysis of the NSA BP-B17 trial: unanswered questions 
remaining unanswered considering current concepts of ductal carcinoma in situ. Cancer 1995; 75: 
1219-22.
155.  Recht A. Side effects of radiation therapy. In: Silverstein MJ, ed. Ductal carcinoma in situ of  the 
breast. Baltimore: Williams and Watkins;  1997: 347-50.
156.  Page DL, Dupont WD, Rogers LW, et aL Continued local recurrence of carcinoma 15-25 years 
after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 
1995; 76:  1197-200.
157.  Silverstein MJ, Lagios MD, Craig PH et al. The Van Nys Prognostic Index for ductal carcinoma in 
situ. Breast Journal 1996; 2: 38-40.
158.  Schnitt SJ, Harris JR, Smith BL. Developing a prognostic index for ductal carcinoma in situ of the 
breast. Are we there yet?[Editorial]. Cancer 1996; 77: 2189-92.
159.  Hansen N, Giuiliano A. Axillary dissection for ductal carcinoma in situ. In: Silverstein MJ, ed. 
Ductal carcinoma in situ of  the breast. Baltimore: Williams and Watkins; 1997: 577-84.
160.  Silverstein MJ, Rosser RJ, Gierson ED, et al. Axillary dissection for intraductal breast carcinoma - 
is it indicated. Cancer 1987; 59:  1819-24.
161.  Giuiliano A, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel 
lymphadenectomy. Annal of  Surgery 1995; 222: 394-401.
162.  Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in th epatient 
with breast cancer. JAMA  1996; 276:  1818-22.
163.  Krag DN, Weaver DL, Alex JC, et al. Surgical resection and radio-localisation of sentinel lymp 
node in breast cancer using a gamma probe. Surgical Oncology 1993; 2: 335-40.
164.  Holland R, Faverly DRG. Whole organ studies. In: Silverstein MJ, ed. Ductal carcinoma in situ of 
the breast. Baltimore: Williams and Watkins; 2001: 233-40.References Chapter 6: Ductal carcinoma in situ 308
165.  Sibbering DM, Robertson JFR, Blarney RW, et al. With a clear margin of excision, radiotherapy 
may be unnecessary after local excision of DCIS.  1994. Proceedings of the British Association of 
Surgical Oncology.
Ref Type: Conference Proceeding
166.  Silverstein MJ, Lagios MD, Lewinsky BS, Colburn WJ, et al. Breast irradiation is unnecessary for 
widely excised ductal carcinoma in situ (DCIS) [abstract]. Breast Cancer Research Treatment 1997; 
46: 23.
167.  Silverstein MJ, Lagios MD, Waisman JR, et al. Margin width : a critical determinant of local 
control in patients with ductal carcinoma in situ (DCIS) of the breast [abstract].  17, 120A. 1998. 
Proceedings of American Society of Clinical Oncology.
Ref Type: Conference Proceeding
168.  Sibbering DM, Blamer RW. Nottingham Experience. In: Silverstein MJ, ed. Ductal carcinoma in 
situ of the breast. Baltimore: Williams and Watkins; 1997: 367-72.
169.  Recht A, Van Dongen JA, Fentiman IS, et al Third meeing of the DCIS working party of the 
EORTC (Conference report). European Journal of  Cancer 1994; 38A:  1895-901.
170.  Rubin P, Constine LS, Fajardo LF, et aL Late effects consensus conference - RTOG EORTC - 
introduction. Radiotherapy and Oncology 1995; 35: 5-7.
171.  UK Coordinating Committe on Cancer Research (UKCCCR) Ductal Carcinoma in situ (DCIS) 
Working Party on behalf of DCIS trialists in the UK.  Australia and New Zealand. Radiotherapy 
and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, 
Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362: 95-102.
172.  Bentzen SM. Randomized clinical trials in oncology: Too many or too few? European Journal of 
Cancer 1995; 31: 31.
173.  Solin LJ, Fourquet A, McCormick B, et aL Salvage treatment for local recurrence for ductal 
carcinoma in situ (intraductal carcinoma) of the breast. International Journal of  Radiation Oncology 
Biology Physics 1994; 30: 3-9.
174.  Solin LJ, Kurtz J, Fourquet A, et at Fifteen year results of breast conserving surgery and 
definitive breast irradiation for treatment of ductal carcinoma in situ of the breast. Journal of  Clinical 
Oncology 1996; 14: 754-63.
175.  Silverstein MJ, Lagios MD, Mortino S, et aL Outcome after invasive local recurrence in patients 
with ductal carcinoma in situ of the breast. Journal of Clinical Oncology 1998; 16: 1367-73.References Chapter 7: Materials and Methods 309
Reference List Chapter 7:
1.  National Co-ordinating Group for Breast Screening Pathology. Pathology Reporting in Breast 
Cancer Screening. 2nd ed. NHBSP Publications,no 3 1995.
2.  Holland R, Peterse JL, Millis RR, et aL Ductal carcinoma in situ: a proposal for a new 
classification. Seminars in Diagnostic Pathology 1994; 11:  167-80.
3.  Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological 
grade in breast cancer: experience from a large study with long-term follow-up.  Histopathology 
1991; 19: 403-10.
4.  Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a 
fluorescent group. Proceedings of  Society of Expermental and Biological Medicine.  1941; 47: 200-2.
5.  Coons AH. Fluorescent antibody methods. ln:Danielli,J.F.ed.General Cytochemical Methods. New 
York, Academic Press 1978; 399-422.
6.  Sternberger LA. Immunocytochemistry,2nd ed.New York,  Wiley,  1979.
7.  Vandesande F. A critical review of immunocytochemical methods for light microscopy. Journal of 
Neuroscience Methods 1979; 1: 3-23.
8.  Julia MP, Susan VN. Immunocytochemistry. Modern Methods and Applications. 2nd 
ed. Wright, Bristol 1986.
9.  Kohler G, Milstein C. Continuous culture of fused cells producing antibodies of predefined 
specificity. Nature 1975; 256: 495-7.
10.  Nakane PK, Pierce GB. Enzyme-labelled antibodies:preparation and isolation of antigens. Journal 
of  Histochemistry Cytochemistry 1966; 14: 929-31.
11.  Graham RC, Karnovsky MJ. The early stages of absorption of injected horseradish peroxidase in 
the proximal tubules of mouse kidney.ultrastructural cytochemistry by a new technique. Journal of 
Histochemistry Cytochemistry 1966; 14: 291-302.
12.  Sternberger LA, Hardy PHJr, Cuculis JJ, et al. The unlabelled antibody-enzyme method for 
immunohistochemistry.preparation and properties of soluble antigen-antibody complex (horseradish 
peroxidase-anti horseradish peroxidase) and its use in identification of spirochetes. Journal of 
Histochemistry Cytochemistry 1970; 18: 315-33.
13.  Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labelling of monoclonal antibodies using 
immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase(APAAP) 
complexes. Journal of  Histochemistry Cytochemistry 1984; 32: 219-29.
14.  Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex(ABC) in immunoperoxidase 
techniques: a comparison between ABC and unlabelled antibody PAP procedures. Journal of 
Histochemistry Cytochemistry 1981; 29: 577-80.
15.  Green NM. Avidin.3.The nature of the biotin-binding site. Biochemistry Journal 1963; 89: 599-609.
16.  Lohmann D, Ruhri C, Schmitt M, et al. Accumulation of p53 protein as an indicator for p53 gene 
mutation in breast cancer; occurrence of false-positives and false-negatives. Diagnostic in Molecular 
Pathology 1993; 2: 36-41.
17.  Vilain MO, Delobelle-Deroide A, Bloget F, et al. Immunohistochemical detection of oestrogen and 
progesterone receptors in formalin-fixed, paraffin-embedded tissues after microwave treatment. 
Comparison with biochemical assay in a series of 123 breast carcinomas with determination of the 
positivity cut off. Annals of Pathology 1997; 17: 82-8.References Chapter 7: Materials and Methods 310
18.  Rudas M, Neumayer R, Gnant MFX, et aL p53 protein expression, cell proliferation and steroid 
hormone receptors in ductal and lobular in situ carcinomas of the breast. European Journal of 
Cancer 1997; 33: 39-44.
19.  Quinn CM, Astrowski JL, Harkins L, et al. Loss of bcl-2 expression in ductal carcinoma in situ of 
the breast relates to poor histological differentiation and to expression of p53 and cerbB-2 proteins. 
Histopathology 1998; 33: 531-6.
20.  Bobrow LG, Happerfield LC, Gregory WM, et al. The classification of ductal carcinoma in situ 
and its association with biological markers. Seminars in Diagnostic Pathology 1994; 11:  199-207.
21.  Ringberg A, Anagnostaki L, Anderson H, et al. Cell biological factors in ductal carcinoma in situ 
(DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. 
European Journal of Cancer (Oxford, England: 1990) 2001; 37: 1514-22.
22.  Elkablawy MA, Maxwell P, Williamson K, et at Apoptosis and cell-cycle regulatory proteins in 
colorectal carcinoma: relationship to tumour stage and patient survival. Journal of  Pathology 2001; 
194: -436.
23.  Sinicrope FA, Ruan SB, Cleary KR, et al. Bcl2 and p53 oncoprotein expression during colorectal 
tumorigenesis. Cancer Research 1995; 55: 237-41.
24.  Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical determination of in vivo 
distribution of BAX, a dominant inhibitor of BCL2. American Journal of  Pathology 1994; 145: 
1323-36.
25.  Slamon DJ, Press MF, Godolphin W, et aL Studies of the HER-2/neu proto-oncogene in human 
breast cancer. Cancer Cells 1989; 13: 63-72.
26.  Lee AKC, Dugan J, Hamilton WM, et aL Quantitative DNA analysis in breast carcinomas: a 
comparison between image analysis and flow cytometry. Modern Pathology 1991; 4:  178-82.
27.  Anttila MA, Ji H, Juhola MT, et aL The prognostic significance of p53 expression quantitated by 
computerized image analysis in ep[ithelial ovarian cancer. International Journal of  Gynaecological 
Pathology 1999; 18: 42-51.
28.  Francis DVf, Adeyanju MO, George SS, et al. Manual versus image analysis estimation of PCNA 
in breast carcinoma. Analytical and Quantitative Cytology and Histology 2000; 22:  11-6.
29.  Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences 
and restriction site analysis for diagnosis of sickle cell anaemia. Science 1985; 230:  1350-4.
30.  Rolfs A, Schuller I, Finckh U, et al. PCR:clinical diagnosis and research. Heidelberg: Springer. 
1992.
31.  Going JJ, Lamb RF. Practical histological microdissection  for PCR analysis. Journal of  Pathology 
1996; 179: 121-4.
32.  Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning:a laboratory manual. Cold Spring 
Harbor:Cold Spring Harbor Laboratory Press.  1989.
33.  Maxam AM, Gilbert W. A new method for sequencing DNA. Proceedings of  National Academy of 
Sciences USA  1977; 74: 560-4.
34.  Sanger F, Nicklen S, Coulsen AR. DNA sequencing with chain terminating inhibitors. Proceedings 
of  National Academy of  Sciences USA  1977; 74: 5463-7.
35.  Alphey L. DNA sequencing. From experimental methods to Bioinformatics. Bios scientific 
publishers 1997.References Chapter 7: Materials and Methods 311
36.  Rehman I, Smith R, Hench LL, et al. Structural evaluation of human and sheep bone and 
comparison with synthetic hydroxyapatite by FT-Raman spectroscopy. Journal of Biomedical 
Materials Research 1995; 29:  1287-94.
37.  Kachi S, Hirano K, Takesue Y, et al. Unusual corneal deposit after the topical use of cyclosporine 
as eyedrops. American Journal of Opthalmology 2000;  130: 667-9.
38.  Rigas B, Wong PT. Human colon adenocarcinoma cell lines display infrared spectroscopic features 
of malignant colon tissues. Cancer Research 1992; 52: 84-8.
39.  Das RM, Ahmed MK, Mantsch HH, et al. FTIR spectroscopy of methy 1-mercury exposed mouse 
lung.  Molecular and Cellular Biochemistry 1995; 145: 75-9.
40.  Redd DCB, Feng ZC, Yue KT, et al. Raman spectroscopic characterisation of human breast tissues, 
implication for breast cancer diagnosis. Applied Spectroscopy 1993; 47: 787-91.
41.  deGroot B, Zuurbier CJ, vanBeek JH. Dynamics of tissue oxygenation in isolated rabbit heart as 
measured with near - infrared spectroscopy. The American Journal of  Physiology 1999; 276: H1616- 
H1624.
42.  Teller J, Wolf M, Keel M, et aL can near - infrared spectroscopy of the liver monitor tissue 
oxygenation. European Journal of  Pediatrics 2000; 159: 549.
43.  Jackson M, Mansfield JR, et al. Classification of breast tumours by grade and steroid receptor 
status using pattern recognition analysis of infrared spectra. Cancer Detection and Prevention 1999; 
23: 245-53.
44.  McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary - node - negative 
breast cancer. N England Journal of  Medicine 1992; 326: 1756-61.
45.  Robbins P, Pinder S, deKlerk N, et at Histological grading of breast carcinomas; A study of 
interobserver agreement. Hum Pathol 1995; 26: 873-9.References Chapter 8: Results 312
Reference List Chapter 8;
1.  Julia MP, Susan VN. Immunocytochemistry.Modern Methods and Applications.2nd 
ed. Wright, Bristol 1986.
2.  Brearley N, Kumah P, Bell JA, et al. Delay to fixation of invasive breast carcinoma: effect on 
mitotic count, MIB1, ER and p53 expression. Meeting of the Pathological Society of Great Britain 
and Ireland 200V, 6A.
3.  Lee H, Dawe E, Morgan JM, et aL Effects of fixation and processing on the sensitivity of ER 
immunocytochemistry. Meeting of the Pathological Society of Great Britain and Ireland 2001; 119.
4.  Tavassoli FA. Male breast lesions. ImTavassoli FA, ed. Pathology of the breast. Norwalk: Appleton 
and Lange; 1992: 637-59.
5.  Ribiero G. Male breast carcinoma-a review of 301 cases from the Christie Hospital and Holt 
Radium Institute, Manchester. British Journal of Cancer 1985; 51: 115-9.
6.  Gough DB, Donohue JH, Evans MM, et al. A 50-year experience of male breast cancer: is 
outcome changing? Surgical Oncology 1993; 2: 325-33.
7.  Willsher PC, Leach IH, Ellis IO, et al. Male breast cancer: a comparison of outcome with breast 
cancer in females. American Journal of  Surgery 1997; 173:  185-8.
8.  National Co-ordinating Group for Breast Screening Pathology. Pathology Reporting in Breast 
Cancer Screening. 2nd ed. NHBSP Publications,no 3 1995.
9.  Millis RR, Springall R, Lee AHS, et al. Occult axillary lymph node metastases are of no prognostic 
significance in breast cancer. Meeting of  the Pathological Society of  Great Britain and Ireland 2001; 
6A.
10.  Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological 
grade in breast cancer: experience from a large study with long term follow-up. Histopathology 
1991; 19: 403-10.
11.  Andrus PG, Strickland RD. Cancer grading by Fourier transform infrared spectroscopy. 
Biospectroscopy 1998; 4: 37-46.
12.  Schultz CP, Liu KZ, Kerr PD, et al. In situ infrared histopathology of keratinization in human 
oral/oropharyngeal squamous cell carcinoma. Oncology Research 1998; 10: 277-86.
13.  Wang HP, Wang HC, Huang YJ. Microscopic FTIR studies of lung cancer cells in pleural fluid.
The Science of the Total Environment 1997; 204: 283-7.
14.  Paluszkiewicz C, Kwiatek WM. Analysis of human cancer prostate tissues using FTIR 
microspectroscopy and SRIXE techniques. Journal of  Molecular Structure 2001; 565-566: 329-34.
15.  Jackson M, Mansfield JR, et al. Classification of breast tumours by grade and steroid receptor 
status using pattern recognition analysis of infrared spectra. Cancer Detection and Prevention 1999; 
23: 245-53.
16.  Weng SF, Ling XF, Yang LM, et al. Use of mid-infrared fiber optics to determine the extent of 
spread of gastric and colonic cancer. Gastroenterology 2000; 118 (4): 6436 Part 2.
17.  Wood BR, Quinn MA, Tait B, et al. FTIR microspectroscopic study of cell types and potential 
confounding variables in screening for cervical malignancies. Biospectroscopy 1998; 4: 75-91.References Chapter 8: Resuits 313
18.  Yang D, Castro DJ, el Sayed IH, et al. A Fourier-transform infrared spectroscopic comparison of 
cultured human fibroblast and fibrosarcoma cells: a new method for detection of malignancies. 
Journal of  Clinical Laser Medicine & Surgery 1995; 13: 55-9.
19.  Wallon J, Yan SH, Tong J, et aL Identification of breast carcinomatous tissue by near - infrared 
reflectance spectroscopy. Applied Spectroscopy 1994; 48: 190-3.
20.  Wong PTT, Goldstein SM, Grekin RC, et aL Distinct infrared spectroscopic patterns of human 
basal cell carcinoma. Cancer Research 1993; 53: 762-5.
21.  Ramesh J, Salman A, Hammody Z, et al. FTIR microscopic studies on normal and H-ras oncogene 
transfected cultured mouse fibroblasts. European Biophysics Journal: EBJ 2001; 30: 250-5.
22.  Manoharan R, Shafer K, Perelman L, et aL Raman spectroscopy and fluorescence photon 
migration for breast cancer diagnosis and imaging. Photochemistry and Photobiology 1998; 67: 15- 
22.
23.  Stone N, Stavroulaki P, Kendall C, et aL Raman spectroscopy for early detection of laryngeal 
malignancy: preliminary results. The Laryngoscope 2000; 110:  1756-63.
24.  Pappas D, Smith BW, Winefordner JD. Raman spectroscopy in bioanalysis. Talanta 2000; 51: 
131-44.
25.  Hawi SR, Campbell WB, Kajdacsy-Balla A, et at Characterization of normal and malignant 
human hepatocytes by Raman microspectroscopy. Cancer Letters 1996; 110: 35-40.
26.  Verma SP, Wallach DF, Philippot JR, et al. Abnormal Raman scattering by plasma of patients 
with cancer. Journal of the National Cancer Institute 1987; 78: 587-9.
27.  Liu CH, Das BB, Sha-Glassman WL, et aL Raman, fluorescence, and time-resolved light scattering 
as optical diagnostic techniques to separate diseased and normal biomedical media. Journal of 
Photochemistry and Photobiology.B, Biology 1992; 16:  187-209.References Chapter 9: Discussion 314
Reference List Chapter 9:
1.  Lampejo OT, Barnes DM, Smith P, et al. Evaluation of infiltrating ductal carcinomas with a DCIS 
component: Correlation of the histologic type of the in situ component with grade of the infiltrating 
component. Seminars in Diagnostic Pathology 1994; 11: 215-22.
2.  Cadman BA, Ostrowski JL, Quinn CM. Invasive ductal carcinoma accompanied by ductal 
carcinoma in situ (DCIS): Comparison of DCIS grade with grade of invasive component. Breast 
1997; 6:  132-7.
3.  Holland R, Hendricks JH. Microcalcifications associated with ductal carcinoma in 
situ:mammographic-pathologic correlation. Seminars in Diagnostic Pathology 1994; 11:  181-92.
4.  Faverly DRG, Burgers L, Bult P, et al. Three dimensional imaging of mammary ductal carcinoma 
in situxlinical implications. Seminars in Diagnostic Pathology 1994; 11:  193-7.
5.  Zafrani B, Leroyer A, Fourquet A, et aL Mammographically detected ductal carcinoma in situ  of 
the breast analyzed with a new classification. A study of 127 cases. Seminars in Diagnostic 
Pathology 1994;  11:208-13.
6.  Patchefsky AS, Schwartz GF, Finkelstine SD. Heterogeneity of intraductal carcinoma of the 
breast. Cancer 1989; 63: 731-41.
7.  Badve S, A'Hern RP, Ward AM, et aL Prediction of local recurrence of ductal carcinoma in situ of 
the breast using five histological classifications: A comparative study with long follow-up. Human 
Pathology 1998; 29: 915-23.
8.  Wells WA, Carney PA, Eliassen MS, et al Pathologists' agreement with experts and 
reproducibility of breast ductal carcinoma-in-situ classification schemes. American Journal of 
Surgical Pathology 2000; 24: 651-9.
9.  Sloane JP, Amendoeira I, Apostolikas N, et aL Consistency achieved by 23 European pathologists 
in categorizing ductal carcinoma in situ of the breast using five classifications. Human Pathology 
1998; 29:  1056-62.
10.  Bethwaite P, Smith N, Delahunt B, et ah Reproducibility of new classification schemes for the 
pathology of ductal carcinoma in situ of the breast. Journal of  Clinical Pathology 1998; 51: 450-4.
11.  Bobrow LG, Happerfield LC, Gregory WM, et al. The classification of ductal carcinoma in situ 
and its association with biological markers. Seminars in Diagnostic Pathology 1994; 11:  199-207.
12.  Quinn CM, Ostrowski JL, Harkins L, et al.  Loss of Bcl2 expression in DCIS of the breast relates 
to poor histological differentiation and to expression of p53 and cerbB2 proteins. Histopathology 
1998; 33: 531-6.
13.  Gupta SK, Douglas-Jones AG, Johnson RC, et aL Classification of DCIS of the breast in relation 
to biological markers: p53, E-cadherin and MIB1 expression. Meeting of  the Pathological Society of 
Great Britain and Ireland.  1997.
14.  Scott MA, Lagios MD, Axelsson K, et al. Ductal carcinoma in situ of the breast: Reproducibility of 
histological subtype analysis. Human Pathology 1997; 28: 967-73.
15.  Mack L, Kerkvliet N, Doig G, et al. Relationship of a new histological categorization of ductal 
carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, 
bcl-2, and ki-67. Human Pathology 1997; 28: 974-9.
16.  Leal C, Henrique R, Monteiro P, et al. Apocrine ductal carcinoma in situ of the breast: Histologic 
classification and expression of biologic markers. Human Pathology 2001; 32: 487-93.References Chapter 9: Discussion 315
17.  Ringberg A, Anagnostaki L, Anderson H, et al. Cell biological factors in ductal carcinoma in situ 
(DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. 
European Journal of Cancer (Oxford, England: 1990) 2001; 37: 1514-22.
18.  Bijker N, Peterse JL, Duchateau L, et aL Risk factors for recurrence and metastasis after breast- 
conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and 
treatment of cancer trial 10853. Journal of Clinical Oncology 2001;  19: 2263-71.
19.  Krajewski S, Blomquist C, Franssila K, et at Reduced expression of proapoptotic gene BAX is 
associated with poor response rates to combination chemotherapy and shorter survival in women 
with metastatic breast adenocarcinoma. Cancer Research 1995; 55: 4471-8.
20.  Rochaix P, Krajewski S, Reed J, et aL In vivo patterns of Bcl2 family protein expression in breast 
carcinoma in relation to apoptosis.  Journal of Pathology 1999; 187: 410-5.
21.  Kapucuoglu N, Losi L, Eusebi V. Immunohistochemical localization of bcl2 and bax proteins in in 
situ and invasive duct breast carcinomas.  Virchows Archives 1997; 430:  17-22.
22.  Sturm I, Papadopoulos S, Hillebrand T, et aL Impaired BAX protein expression in breast cancer: 
mutational analysis of the BAX and the p53 gene. International Journal of  Cancer 2000; 87: 517-21.
23.  Yang Q, Sakurai T, Jing X, et al. Expression of bcl2, but not bax, correlates with oestrogen 
receptor status and tumour proliferation in invasive breast carcinoma. Pathology International.  1999; 
49: 775-80.
24.  Gee JMW, Robertson JFR, Ellis IO, et aL Immunocytochemical localization of bcl2 protein in 
human breast cancers and its relationship to a series of prognostic markers and response to endocrine 
therapy. International Journal of  Cancer 1994; 59: 619-28.
25.  Joensuu H, Pylkkanen L, Toikkanen S. Bcl2 protein expression and long-term survival in breast 
cancer. American Journal of  Pathology 1994; 145:  1191-8.
26.  Van Slooten HJ, Clahsen PC, Van Dierendonck JH. Expression of be 12 in node-negative breast 
cancer is associated with various prognostic factors, but does not predict response to one course of 
peri-operative chemotherapy. British Journal of Cancer 1996; 74: 78-85.
27.  Siziopikou KP, Prioleau JE, Harris JR, et al. Bcl-2 expression in the spectrum of preinvasive 
breast lesions. Cancer 1996; 77: 499-506.
28.  Gompel A, Somai S, Chaouat M, et al. Hormonal regulation of apoptosis in breast cells and tissues. 
Steroids 2000; 65: 593-8.
29.  Palazzo JP, Kafka NJ, Grasso L, et al. The role of p53, p21WAF1  /CIP1 and Bcl2 in radioresistant 
colorectal carcinoma. Human Pathology 1997; 28:  1195.
30.  Wu X, Bayle JH, Olson D, Levine AT. The p53-mdm2 autoregulatory feedback loop. Genes 
Development 1993; 7:  1132.
31.  Miyashita T, Krajewska S, Krajewska M, et al. Tumour suppressor p53 is a regulator of bcl2 and 
bax gene expression in vivo. Oncogene 1994; 6:  1796-805.
32.  Miyashita T, Reed JC. Tumour suppressor p53 is a direct transcriptional activator of the human bax 
gene. Cell 1995; 80: 293-9.
33.  Haider S, Negrini M, Monne M, et al. Down-regulation of bcl2 by p53 in breast cancer cells. 
Cancer Research 1994; 54: 2095-7.
34.  Campani D, Esposito I, Boggi U, et al. Bcl-2 expression in pancreas development and pancreatic 
cancer progression. Journal of Pathology 2001; 194: 444-50.References Chapter 9: Discussion 316
35.  Pollina L, Pacini F, Fontanini G, et al. Bcl-2, p53 and proliferating cell nuclear antigen expression 
is related to the degree of differentiation in thyroid carcinomas. British Journal of  Cancer 1996; 73: 
139-43.
36.  Nakamura S, Akazawa K, Kinukawa N, et al. Inverse correlation between the expression of bcl-2 
and p53 proteins in primary gastric lymphoma. Human Pathology 1996; 3: 225-33.
37.  Butt AJ, Firth SM, King MA. Insulin-like growth factor-binding protein-3 modulates expression of 
Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer 
cells. Journal of Biology Chemistry 2000; 275: 39174-81.
38.  EL-Deiry WS, Harper JW, O'Connor PM, et al. WAFl/Cipl  is induced in p53 mediated G1 arrest 
and apoptosis. Cancer Research 1994; 54:  1169-74.
39.  Li R, Waga S, Hannon GJ, et aL Differential effects by the p21  CDK inhibitor on PCNA- 
dependent DNA replication and repair. Nature 1994; 371: 534-7.
40.  Elkablawy MA, Maxwell P, Williamson K, et al. Apoptosis and cell-cycle regulatory proteins in 
colorectal carcinoma: relationship to tumour stage and patient survival. Journal of  Pathology 2001; 
194: -436.
41.  Huang DC, O'Reilly LA, Strasser A, et aL The anti-apoptosis function of Bcl-2 can be genetically 
separated from its inhibitory effect on cell-cycle entry. EMBOJ 1997; 16: 4628-38.
42.  O'Reilly LA, Harris AW, Tarlinton DM, et aL Expression of a bcl-2 transgene reduces 
proliferation and slows turnover of developing B lymphocytes in vivo. Journal of  Immunology 1997; 
159: 2301-11.
43.  Pietenpol JA, Papadopoulos N, Markowitz S, et aL Paradoxical inhibition of solid tumour cell 
growth by bcl-2. Cancer Research 1994; 54: 3714-7.
44.  Reed JC. Bcl-2 and the regulation of programmed cell death. Journal of Cell Biology 1994; 124:  1- 
6.
45.  Lu QL, Abel P, Foster CS, et al Bcl-2: role in epithelial differentiation and oncogenesis. Human 
Pathology 1996; 27:  102-10.
46.  Nakagawa K, Yamamura K, Maeda S, et al Bcl-2 expression in epidermal keratinocytic diseases. 
Cancer 1994; 74:  1720-4.
47.  Saegusa M, Takano Y, Hashimura M, et al. The possible role of bcl-2 expression in the 
progression of tumours of the uterine cervix. Cancer 1995; 76: 2297-303.
48.  Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein 
expression in gastric epithelial dysplasia. Cancer 1994; 73: 2904.
49.  Sabourin JC, Martin A, Baruch J, et al. Bcl-2 expression in normal breast tissue during the 
menstrual cycle. International Journal of Cancer 1994; 59: 1-6.
50.  Adams JM, Cory S. The bcl-2 protein family: arbiters of cell survival. Science 1998; 281:  1322-6.
51.  Meyer JS, Hixon B. Advanced stage and early relapse of breast carcinomas associated with high 
thymidine labelling indices. Cancer Research 1979; 39: 225-35.
52.  Baak JPA, Van Dop H, Kurver PHJ, et al. The value of morphometry to classic prognosticators in 
breast cancer. Cancer 1985; 56: 374-82.
53.  Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Research 
and Treatment 1986; 7:  171-80.References Chapter 9: Discussion 317
54.  Locker AP, Horrocks C, Gilmour AS. Flow cytometric and histological analysis of ductal 
carcinoma in situ of the breast. British Journal of  Surgery 1990; 77: 564-7.
55.  Sampson SA, Kreipe H, Gillet CE, et al. Ki-S 1-A novel monoclonal antibody which recognizes 
proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma. Journal of 
Pathology 1992; 168:  179-85.
56.  Catoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the 
Ki-67 antigen (M1B1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed 
paraffin sections. Journal of  Pathology 1992; 168: 357-63.
57.  Done SJ, Eskandarian S, Bull S, et al. p53 missense mutations in microdissected high-grade ductal 
carcinoma in situ of the breast. Journal of the National Cancer Institute 2001; 93: 700-4.
58.  Hoshi K, Tokunaga M, Mochizuki M, et al. Pathological characterization of atypical ductal 
hyperplasia of the breast. Gan to Kagaku Ryoho.Cancer & Chemotherapy 1995; 22 Supplement 1: 
36-41.
59.  Benner SE, Clark GM, McGuire WL. Steroid receptors, cellular kinetics and lymph node status as 
prognostic factors in breast cancer. American Journal of  Medical Sciences 1988; 296: 59-66.
60.  Bur ME, Zimarowski MJ, Scnitt SJ, et al. Estrogen receptor immunohistochemistry in carcinoma 
in situ of the breast. Cancer 1992; 69:  1174-81.
61.  Giri DD, Dundas SAC, Nottingham JF, et al. Oestrogen receptors in benign epithelial lesions and 
intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989; 15: 575-84.
62.  Poller DN, Snead DRJ, Roberts EC, et aL Oestrogen receptor expression in ductal carcinoma in 
situ of the breast: relationship to flow cytometric analysis of DNA and expression of the cerbB2 
oncoprotein. British Journal of  Cancer 1993; 68:  156-61.
63.  Pallis L, Wilking N, Cedermark B, et al. Receptors for estrogen and progesterone in breast 
carcinoma in situ. Anticancer Research 1992; 12: 2113-6.
64.  Wilbur DC, Barrows GH. Estrogen and progesterone receptor and cerbB2 oncoprotein analysis in 
pure in situ breast carcinoma:An immunohistochemical study. Modern Pathology 1993; 6:  114-20.
65.  Collett N, Morgan JM, Douglas-Jones AG. Intratumoural distribution of ER in breast tumours: 
higher ER at the periphery. Meeting of the Pathological Society of Great Britain and Ireland 2001;
120.
66.  Lee H, Da  we E, Morgan JM, et al. Effects of fixation and processing on the sensitivity of ER 
immunocytochemistry. Meeting of  the Pathological Society of Great Britain and Ireland 2001; 119.
67.  Kohlberger PD, Breitenecker F, Kaider A, et al. Modified true-color computer-assisted image 
analysis versus subjective scoring of estrogen receptor expression in breast cancer: A comparison. 
Anticancer Research 1999; 19: 2189-93.
68.  Barnes DM, Millis RR, Beex LV, et al. Increased use of immunohistochemistry for oestrogen 
receptor measurement in mammary carcinoma: The need for quality assurance. European Journal of 
Cancer 1998; 34:  1677-82.
69.  Selim AGA, El-Ayat G, Wells CA, et al. Androgen receptor expression in ductal carcinoma in situ 
of the breast: relation to oestrogen and progesterone receptors. Journal of Clinical Pathology 2002; 
55:  14-6.
70.  Walker RA, Dearing SJ, Lane DP, et al. Expression of p53 protein in infiltrating and in situ breast 
carcinomas. Journal of Pathology 1991; 165: 203-11.References Chapter 9: Discussion 318
71.  Poller DN, Roberts EC, Bell JA, et al. p53 protein expression in mammary ductal carcinoma in 
situ: Relationship to immunohistochemical expression of estrogen receptor and cerbB2 protein. 
Human Pathology 1993; 24: 463-8.
72.  Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumour cell 
proliferation rate and clinical outcome in node-negative breast cancer. Journal of National Cancer 
Institute 1993; 85: 200-6.
73.  Ferrero JM, Ramaioli A, Formento JL, et aL p53 determination alongside classical prognostic 
factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Annals of 
Oncology 2000; 11: 393-7.
74.  Goel MM, Goel R, Mehrotra A, et al. Immunohistochemical localization and correlation of p53 
and PCNA expression in breast carcinoma. Indian Journal of  Experimental Biology 2000; 38: 225-
30.
75.  Ramachandra S, Machin L, Ashley S, et aL Immunohistochemical distribution of cerbB2 in in situ 
breast carcinoma-a detailed morphological analysis. Journal of  Pathology 1990; 161: 7-14.
76.  Lovekin C, Ellis IO, Locker A, et aL cerbB2 oncoprotein expression in primary and advanced 
breast cancer. British Journal of Cancer 1991; 63: 439-43.
77.  Mommers EC, Leonhart AM, et aL Similarity in expression of cell cycle proteins between in situ 
and invasive ductal breast lesions of same differentiation grade. The Journal of  Pathology 2001; 194: 
327-33.
78.  Warnberg F, Nordgren H, Bergkvist L, et aL Tumour markers in breast carcinoma correlate with 
grade rather than with invasiveness. British Journal of  Cancer 2001; 85: 869-74.
79.  Dunne B, Going JJ. Nuclear grading in breast cancer. Meeting of  the Pathological Society of Great 
Britain 2001; 113.
80.  Lagios MD, Margolin FR, Westdahl PR, et aL Mamographically detected ductal carcinoma in situ; 
frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local 
recurrence. Cancer 1989; 63: 619-24.
81.  Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological 
grade in breast cancer: experience from a large study with long term follow-up. Histopathology 
1991; 19: 403-10.
82.  Poller DN, Galea MH, Pearson D, et al. Nuclear and flow cytometric characteristics associated 
with over expression of the cerbB2 oncoprotein in breast carcinoma. Breast Cancer Research 
Treatment 1991; 20: 3-10.
83.  Nagashima T, Suzuki M, Yagata H, et al. Cytomorphometric differentiation of intraductal 
proliferative breast lesions. Breast Cancer (Tokyo, Japan) 2000; 7: 43-7.
84.  Ruiz A, Almenar S, Callaghan RC, et al. Benign, preinvasive and invasive ductal breast lesions. A 
comparative study with quantitative techniques: morphometry, image- and flow cytometry.
Pathology, Research and Practice 1999; 195: 741-6.
85.  Zaitoun AM, Ebbs SR. Quantitative cytological assessment of Ki67 and AgNORs using computer- 
digitized image analysis of four clinicopathological breast lesions. Cytopathology: Official Journal 
of  the British Society for Clinical Cytology 2000; 11: 243-54.
86.  Tan PH, Goh BB, Chiang G, et aL Correlation of nuclear morphometry with pathologic parameters 
in ductal carcinoma in situ of the breast. Modern Pathology 2001; 14: 937-41.References Chapter 9: Discussion 319
87.  Bacon T, Howes G, Humphreys S.  Preliminary investigation of the nature and frequency of p53 
mutations related to type and grade of breast cancer. Meeting of the Pathological Society of Great 
Britain and Ireland 2001; 126.
88.  Tawfik H, El-Monem HA, Craft JA, et al. Heterogeneity of p53 mutation in human breast cancer. 
Meeting of the Pathological Society of Great Britain and Ireland 2001; 22.
89.  Done SJ, Arneson NC, Ozcelik H, et al. p53 mutations in mammary ductal carcinoma in situ but 
not in epithelial hyperplasias. Cancer Research 1998; 58: 785-9.
90.  Ho GH, Calvano JE, Bisogna M, et al. In microdissected ductal carcinoma in situ, HER-2/neu 
amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. 
Cancer 2000; 89: 2153-60.
91.  Lisboa BW, Vogtlander S, Gilster T, et al. Molecular and immunohistochemical analysis of p53 
mutations in scrapings and tissue from preinvasive and invasive breast cancer.  Virchows Archiv: an 
International Journal of Pathology 1997; 431: 375-81.
92.  Munn KE, Walker RA, Menasce L, et al. Mutation of the TP53 gene and allelic imbalance at 
chromosome 17pl 3 in ductal carcinoma in situ. British Journal of  Cancer 1996; 74:  1578-85.
93.  O'Malley FP, Vnencak-Jones CL, Dupont WD, et al. p53 mutations are confined to the comedo 
type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.  Laboratory 
Investigation; a Journal of Technical Methods and Pathology 1994; 71: 67-72.
94.  Dukor RK, Liebman MN, Johnson BL. A new, non-destructive method for analysis of clinical 
samples with FT-IR microspectroscopy. Breast cancer tissue as an example. Cell Mol. Biol. (Noisy.-le- 
grand)  1998; 44: 211-7.
95.  Weng SF, Ling XF, Song YY, et aL FTIR fiber optics and FT-Raman spectroscopic studies for the 
diagnosis of cancer. Am Clin Lab 2000; 19: 20.
96.  Andrus PG, Strickland RD. Cancer grading by Fourier transform infrared spectroscopy. 
Biospectroscopy 1998; 4: 37-46.
97.  Schultz CP, Liu KZ, Kerr PD, et al. In situ infrared histopathology of keratinization in human 
oral/oropharyngeal squamous cell carcinoma. Oncology Research 1998; 10: 277-86.
98.  Wang HP, Wang HC, Huang YJ. Microscopic FTIR studies of lung cancer cells in pleural fluid.
The Science of  the Total Environment 1997; 204: 283-7.
99.  Paluszkiewicz C, Kwiatek WM. Analysis of human cancer prostate tissues using FTIR 
microspectroscopy and SRIXE techniques. Journal of  Molecular Structure 2001; 565-566: 329-34.
100.  Manoharan R, Shafer K, Perelman L, et aL Raman spectroscopy and fluorescence photon 
migration for breast cancer diagnosis and imaging. Photochemistry and Photobiology 1998; 67:  15- 
22.
101.  Liu CH, Das BB, Sha Glassman WL, et al. Raman, fluorescence, and time-resolved light scattering 
as optical diagnostic techniques to separate diseased and normal biomedical media. Journal of 
Photochemistry and Photobiology. B, Biology 1992; 16: 187-209.
102.  Stone N, Stavroulaki P, Kendall C, et al. Raman spectroscopy for early detection of laryngeal 
malignancy: preliminary results. The Laryngoscope 2000; 110:  1756-63.
103.  Hata TR, Scholz TA, Ermakov IV, et al. Non-invasive raman spectroscopic detection of 
carotenoids in human skin. The Journal of  Investigative Dermatology 2000; 115: 441-8.References Chapter 9: Discussion 320
104.  Pappas D, Smith BW, Winefordner JD. Raman spectroscopy in bioanalysis. Talanta 2000; 51: 
131-44.
105.  Hawi SR, Campbell WB, Kajdacsy-Balla A, et al. Characterization of normal and malignant 
human hepatocytes by Raman microspectroscopy. Cancer Letters 1996; 110: 35-40.
106.  Verma SP, Wallach DF, Philippot JR, et al. Abnormal Raman scattering by plasma of patients 
with cancer. Journal of the National Cancer Institute 1987; 78: 587-9.
107.  Jackson M, Mansfield JR, et al. Classification of breast tumours by grade and steroid receptor 
status using pattern recognition analysis of infrared spectra. Cancer Detection and Prevention 1999; 
23: 245-53.
108.  Andrus PG, Strickland RD. Cancer grading by Fourier transform infrared spectroscopy. 
Biospectroscopy 1998; 4: 37-46.
109.  Ramesh J, Salman A, Hammody Z, et aL FTIR microscopic studies on normal and H-ras oncogene 
transfected cultured mouse fibroblasts. European Biophysics Journal: EBJ 2001; 30: 250-5.
110.  Sukuta S, Bruch R. Factor analysis of cancer Fourier transform infrared evanescent wave 
fiberoptical (FTIR-FEW) spectra. Lasers in Surgery and Medicine 1999; 24: 382-8.
111.  Rigas B, Wong PT. Human colon adenocarcinoma cell lines display infrared spectroscopic features 
of malignant colon tissues. Cancer Research 1992; 52: 84-8.
112.  Wallon J, Yan SH, Tong J, et aL Identification of breast carcinomatous tissue by near - infrared 
reflectance spectroscopy. Appl.Spectroscopy 1994; 48:  190-3.
113.  Meurens M, Wallon J, Tong J, et aL Breast cancer detection by fourier transform infrared 
spectroscopy.  Vibrational Spectroscopy 1996; 10: 341-6.
114.  Codrech L, dePera M, Perez-Cullell N, et aL The effect of liposomes on skin barrier structure. Skin 
Pharm.andAppl.Skin Phsiol.  1999; 12:235-46.
115.  Wong PTT, Goldstein SM, Grekin RC, et al. Distinct infrared spectroscopic patterns of human 
basal cell carcinoma. Cancer Research 1993; 53: 762-5.
116.  Lin AY, Liang RC, Hsu HS, et al. Evidence of posible carcinogenesis during conformational 
changes in bladder mucosa induced by bladder outlet obstruction. Cancer Letters 1995; 79: 221-6.
117.  Zhang L, Small GW, Haka AS, Kidder LH, Lewis EN. Classification of Fourier transform 
infrared microscopic imaging data of human breast cells by cluster analysis and artificial neural 
networks. Appl.Spectrosc. 2003; 57:  14-22.
118.  Sheng J, Shen S, Li S, et al.  Fourier Transform Infrared spectroscopic analysis for detecting 
colorectal carcinoma. Chinese Journal of  Digestive Diseases 2001; 2:  179-83.
119.  Frank CJ, McCreery RL, Redd DC. Raman spectroscopy of normal and diseased human breast 
tissues. Anal.Chem.  1995; 67: 777-83.
120.  Dippel B, Tatsch E, Schrader B. Development of an inverted NIR-FT-Raman microscope for 
biomedical applications. Journal of  Molecular Structure 1997; 408-409: 247-51.
121.  Morjani H, Riou JF, Nabiev I, Lavelle F, Manfait M. Molecular and cellular interactions between 
intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy. 
Cancer Research 1993; 53: 4784-90.References Chapter 9: Discussion 321
122.  Nabiev IR, Morjani H, Manfait M. Selective analysis of antitumor drug interaction with living 
cancer cells as probed by surface-enhanced Raman spectroscopy. European Biophysics Journal: EBJ 
1991;  19: 311-6.
123.  Pham VH. New possibilities of Raman micro-spectroscopy.  Vibrational Spectroscopy 1996; 11:  17-
28.
124.  Stone N, Stavroulaki P, Kendall C, Birchall M, Barr H. Raman spectroscopy for early detection 
of laryngeal malignancy: preliminary results. The Laryngoscope 2000; 110:  1756-63.
125.  Verma SP, Wallach DF, Philippot JR, Zanca M, Bonnet B. Abnormal Raman scattering by 
plasma of patients with cancer. Journal of the National Cancer Institute 1987; 78: 587-9.
126.  Weng SF, Ling XF, Song YY et al. FTIR fiber optics and FT-Raman spectroscopic studies for the 
diagnosis of cancer. Am Clin Lab 2000; 19: 20.
127.  Bakker Schut TC, Witjes MJ, Sterenborg HJ, et al. In vivo detection of dysplastic tissue by 
Raman spectroscopy. Analytical Chemistry 2000; 72: 6010-8.
128.  Manoharan R, Yang W, Feld MS.  Histochemical analysis of biological tissues using Raman 
spectroscopy. Spectrochimica Acta Part A: Molecular andBiomolecular Spectroscopy 1996; 52: 
215-49.
129.  Van Dongen JA, Fentiman IS, Harris JR, et al. In situ breast cancer: The EORTC consensus 
meeting. Lancet 1989; 334: 25-7.
130.  van de Vijver MJ, He YD, van't Veer LJ, et aL A gene-expression signature as a predictor of 
survival in breast cancer. New England Journal of  Medicine 2002; 347: 1999-2009.References Chapter 10: Future work 322
Reference List Chapter 10:
1.  Penn T, Canzonieri V, Massarut S, et al. Immunohistochemical evaluation of multiple biological 
markers in ductal carcinoma in situ of the breast. European Journal of Cancer 1996; 32A:  1148-55.
2.  Rajan PB, Scott DJ, Perry RH, et al p53 protein expression in ductal carcinoma in situ (DCIS) of 
the breast. Breast Cancer Research and Treatment 1997; 42: 283-90.
3.  The Consensus Conference Committee. Consensus conference on the treatment of in situ ductal 
carcinoma of the breast, April 22-25,1999. Cancer 2000; 88: 946-54.
4.  Ringberg A, Anagnostaki L, Anderson H, et aL Cell biological factors in ductal carcinoma in situ 
(DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. 
European Journal of Cancer (Oxford, England: 1990) 2001; 37:  1514-22.
5.  Walker RA, Dealing SJ. Transforming growth factor betal  in ductal carcinoma in situ and invasive 
carcinomas of the breast. European Journal of  Cancer 1992; 28: 641-4.
6.  Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA 
distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995; 1: 
1257-60.
7.  Inaji H, Koyama H, Motomura K, et at Differential distribution of ErbB-2 and pS2 proteins in 
ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment 1996; 37: 89-92.
8.  Gupta SK, Douglas-Jones AG, Jasani B, et aL E-cadherin (E-cad) expression in duct carcinoma in 
situ (DCIS) of the breast.  Virchows Archives 1997; 430: 23-8.
9.  Guidi AJ, Schnitt SJ, Fisher L, et al. Vascular permeability factor (vascular endothelial growth 
factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 
1997; 80:  1945-53.
10.  Zaugg K, Bodis S. Is there a role for molecular prognostic factors in the clinical management of 
ductal carcinoma in situ (DCIS) of the breast? Radiotherapy Oncology 2000; 55 : 95-9.
11.  Fisher B, Dignam J, Wolmark N, et aL Tamoxifen in treatment of intraductal breast cancer: 
National surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 1999; 
353:  1993-2000.
12.  Jansson T, Inganas M, Sjogren S, et al. p53 status predicts survival in breast cancer patients treated 
with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. Journal of 
Clinical Oncology 1995;  13: 2745-51.
13.  Hoshi K, Tokunaga M, Mochizuki M, et al. Pathological characterization of atypical ductal 
hyperplasia of the breast. Gan to Kagaku Ryoho.Cancer & Chemotherapy 1995; 22 Supplement 1: 
36-41.
14.  Strickland LB, Dawson PJ. The hyperplasia-to-carcinoma sequence in the
breast.Immunohistochemical-histologic correlations. Applied Immunohistochemistry and Molecular 
Morphology. 2000; 8: 98-103.
15.  Kandel R, Li SQ, Ozcelik H, et al. p53 protein accumulation and mutations in normal and benign 
breast tissue. International Jornal of  Cancer. 2000; 87: 73-8.
16.  Rudolph P, MacGrogan G, Bonichon F, et al. Prognostic significance of Ki67 and topoisomerase 
alpha expression in infiltrating ductal carcinoma of the breast. Breast Cancer Research and 
Treatment 1999; 55: 61-71.Appendices: 323
APPENDIX I: 
PROTOCOLS FOR VARIOUS STEPS IN IMMUNOCYTOCHEMISTRY:
Preparation of paraffm-wax sections for immunocytochemistry (ICC) (1):
(a)  Sections were cut at a thickness (3 to 4 pm).
(b)  Floating of sections was done on 20% alcohol followed  by immersion in a  water
bath at 45°C.
(c)  Sections were picked on APES coated slides.
(d)  The slides were immediately placed to dry at 37°C in an oven for 48 hours.
Preparation of 3-aminopropyl-triethoxvsilane (APES) glass coated slides (1 ;2):
This was carried out to avoid section loss during microwave pre-treatment. Coated slides
can be stored at room temperature indefinitely.
(a)  Slides  were  degreased  in  hot  detergent  solution, rinsed  in  distilled  water  then
alcohol (740P) and air dried for 10 minutes.
(b)  Slides  were  immersed  in  a  freshly  prepared  2%  solution  of APES  in  acetone, 
five dips approximately (5 seconds).
(c)  Acetone was allowed to drain away.
(d)  This was followed by washing in distilled water twice.
(e)  Slides were stored air dried at 40°C overnight.
(f)  Slides were stored at room temperature in a dust free  environment.
Note 300ml. of  APES solution is sufficient  for 200 slides
Blocking Endogenous Peroxidase Activity (1 ;2):
Endogenous labels can produce a reaction product indistinguishable from specific
immunostaining, hence need to be blocked prior to staining.
(a)  Slides  were  transfered  to  a  humidity  chamber  at  room  temperature  and  the 
sections  were  covered  with  freshly prepared  0.5%  H2O2  in  water  for  10  to  15 
minutes.
(b) The solution contains 0.2ml (200pl) H2O2 (30% w/vol.) and  11.8 ml of distilled 
water.Appendices: 324
This is enough for 20 slides. 30 ml is needed for one full rack and for two racks, 60 ml is 
required (59ml of water + 1  ml of H2O2).
Antigen Retrieval bv Microwave Method (1-3):
Sections  must be mounted  on  APES  slides  for this  method to  avoid  section  loss.  The 
mechanism of action of microwave oven heating for antigen retrieval is thought to be due 
to alteration of cross-linking by formaldehyde.
(a)  Plastic jars were filled with 0.01 M citric acid buffer (pH 6.0) and the sections were 
submerged with tissue facing to the bottom of the coplin jar.
(b)  Two other plastic coplin jars were filled with cold water in the same manner. This 
helps to stop some evaporation by absorbing some of the heat.
(c)  Coplin jars were evenly spaced around the outside of the rotating plate.
(d)  Microwave was set at 700 watts for 5minute intervals, topping up solutions at the 
end  of each  interval.  Slides  must  be  covered  throughout  the  microwave  heating 
process.
(e)  Coplin  jars  were  left  to  cool  in  running  tap  water  before  placing  slides  in 
appropriate buffer for immunocytochemistry technique.
TBS buffer for immunocytochemistry (1 ;2)
Composition:-
1  -  Sodium Chloride  =  80g
2-  Tris (Tris-hydroxymethylamine)  =  6.6g
3-  Hydrochloric acid 1M  =  44ml
4-  Double distilled water  =  10 litres
(a)  Reagents were mixed  with 2  litres of distilled water on a magnetic  stirrer  with
a magnetic flea.
(b)  When  components  were  dissolved,  the  solution  was  transferred  to  a  plastic
10 litre container.
(c)  Added 8 litres of water and mixed thoroughly.
(d)  An aliquot was taken and pH adjusted to 7.6 (±0.05) using buffer solution.Appendices: 325
Developing Sections with Freshly Prepared 3.3diaminobenzidine (DAB) (1 ;2):
(a)  Buffer  solution  was  prepared  by  adding  Tris  =  121.4mg  to  12.6ml  of  double
distilled water and the pH was adjusted to 7.3 to 7.7 by adding 0.1M hydrochloric
acid (HC1). 7.6ml of HC1 was normally sufficient to obtain the required pH range.
(b)  2ml of buffer solution was added to 12 mg of 3, 3 -  diaminobenzidine tetrachloride 
(DAB)(Sigma)  stored  at  -20°C  to  the  weighing  crucible  (boat)  inside  the 
microbalance  and then remaining buffer was added to DAB in a coplin jar. This 
minimises  the  risk  of  spillage.  The  solution  was  stored  in  the  dark  at  room 
temperature.
(c)  Just prior to use,  8pl of 30% H2O2 (stored at 4°C) was added to the solution and 
this was applied directly to the slides.
(d)  The slides were  left for 2 to  10 minutes at room temperature  and then  inspected
microscopically.  The  reaction  with  TBS  was  stopped,  if  adequate  staining
developed.  At  this  stage  either  freshly  made  up  substrate  was  reapplied  if the 
reaction  was  weak,  or  0.1M  imidazole  (Sigma)  was  added  at  a concentration  of 
20pl/20ml DAB solution.
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1.  Polak JM, Van Noorden S. Modem Methods and Applications. Immunocytochemistry 1986.
2.  Elias JM. Immunohistopathology; A Practical Approach to Diagnosis. ASCP Press;  1990.
3.  Shi SR, Key ME, Kalra KL. Antigen retrieval in formali-fixed, paraffin-embedded tissues: an 
enhancement method for immunocytochemical staining based on microwave-oven heating of tissue 
sections. Journal of  Histochemistry Cytochemistry 1991; 39: 741-2.Appendices: 326
APPENDIX II:
Recommended IHC scoring method for cerbB-2 staining
Score CerbB-2
Expression
Staining Pattern
0 Negative No  staining  is  observed,  or  membrane  staining  is  less 
than 10% of tumour cells
1 Negative A  faint  membrane  staining  in  more  than  10%  tumour 
cells
2 Borderline Weak to moderate complete membrane staining in more 
than 10% tumour cells
3 Positive Strong complete membrane staining in more than 10% of 
tumour cells
Quick  Score  for  Assessment  of  ER  Immunostaining  As  Recommended  by  the 
National Coordinating Group for Breast Screening Pathology:
Score for proportion staining Score for staining intensity
0 = no nuclear staining 0 = no staining
1  = < 1% nuclear staining 1  = weak staining
2=1-10% nuclear staining 2= moderate staining
3 = 10 -  33 % nuclear staining 3 = strong staining
4 = 33 -  66 % nuclear staining
5 = 66 -  100 % nuclear staining
Adding the two scores together gives a maximum score of 8 (range from 0 -  8).
Experience suggests that if this scoring system is used the appropriate cut off values for 
treatment of advanced disease are as follows:
•  A score of 0 indicates that endocrine treatment will not work
•  A score of 2 -  3 indicates a small (20%) chance of response to endocrine therapy
•  A score of 4 -  6 indicates an even (50%) chance of response
•  A score of 7 -  8 indicates a good (75%) chance of response
Reference:
1.  NHSBSP publication no. 50, Guidelines for non-operative diagnostic procedures and reporting in 
breast cancer screening. June 2001.Appendices: 327
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Papers in Progress:
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GLOSSARY:
Allele: one of the possible different forms of a gene at a given locus.
Amplification: increase in the number of copies of a specific DNA molecule.
Anneal: the hybridization of a single-stranded DNA molecule to another single-stranded 
DNA molecule of complementary sequence.
Aneuploid: any chromosomal number that is not the exact multiple of the normal haploid 
number.
Autoradiography: the process of exposing X-ray film to a radioactive source to generate 
an image of the radioactive components of that source. The developed film showing the 
image is called an autoradiogram or autoradiograph.
Autosome:  any  chromosome  that  is  not  a  sex  chromosome  or  mitochondrial 
chromosome, there are 22 pairs of autosomes in humans.
Bacteriophage:  a  bacterial  virus.  These  are  modified  and  used  as  vectors  for  DNA 
cloning.
Base pair (bp): a pair of complementary nucleotides in double-stranded DNA.
Centromere: the point at which two chromatids of a chromosome are joined and where 
the spindle fibres become attached during mitosis and meiosis.
Chromatid: one of the two strands that make up the chromosome, held together by the 
centromere.
Chromatin:  stainable  material  of  interphase  nucleus  consisting  of  nucleic  acid  and 
associated histone protein packed into nucleosomes.
Chromosomal aberration: an abnormality in the number or structure of a chromosome.
Chromosome: a structure of DNA and associated proteins that contains the hereditary 
information of the cell in the form of a linear array of genes.Glossary: 329
Clone:  cells  having  the  same  genetic  constitution  and  derived  from  a  single  cell  by 
repeated mitosis.
Codon: three adjacent nucleotides in a nucleic acid capable of encoding a single amino 
acid.
Co-efficient of variation: the ratio of the standard deviation to the mean.
Complementary  DNA  (cDNA):  DNA  synthesized  from  an  mRNA  template  by  the 
enzyme reverse transcriptase. It does not contain introns.
Complementary sequence: sequence which will hybridize with a specified sequence.
Cosmid:  a modified  plasmid  containing  sequences  from  bacteriophage  that  allow  the 
insertion  of  large  DNA  fragments.  Cosmids  are  circular  double-stranded  molecules 
typically 45-48 kb long, including the vector sequences.
Cowden disease (CD):  It is also called multiple hamartoma syndrome and is a cancer 
associated  genodermatosis  with  an  autosomal  dominant  pattern  of inheritance.  It  was 
named after the first patient described in  1963 by Lloyd and Dennis. The main clinical 
features  are  hamartomas  of  the  skin,  breast,  thyroid,  oral  mucosa  and  intestinal 
epithelium. The gene responsible has been localized to chromosome 10q22-23 by linkage 
analysis and is probably a tumour suppressor gene.
Deletion: loss of a part of a chromosome.
Denature: to separate the two complementary strands of double-stranded DNA, usually 
done either by treatment with alkali or by use of elevated temperature.
Deoxyribonucleic  acid  (DNA):  nucleic  acid  comprising  four  different  nucleosides 
(deoxyadenosine,  deoxycytidine,  deoxyguanosine  and  deoxythymidine)  linked  by 
phosphate groups.
2’, 3’-dideoxynucleotide (ddNTP): a 2’-deoxyribonucleotide analogue which does not 
have a hydroxyl group at the 3’position.
Diploid: a cell having two chromosome sets, or an individual with two chromosome sets 
in each of its cells. Humans are diploid.Glossary: 330
DNA  cloning:  the  process  of isolating  a  particular  DNA  fragment  of interest  and  its 
insertion  into  a  vector,  so  that  it  can  be  cloned  and  prepared  in  large  quantities 
independent of other sequences.
DNA polymerase: the enzyme that replicates/synthesizes DNA.
DNA probe: a piece of single-stranded DNA which can be labelled with a radioactive 
isotope or a  fluorescent signal  and  used  to  detect  DNA  fragments  whose  sequence  is 
complementary to the sequence of the probe, by hybridization.
DNAse: an endonuclease with preference for DNA.
DNA sequence analysis: determination of the nucleotide sequence of a length of DNA 
molecule. Typically, this is performed by cloning the DNA molecule of interest, so that 
enough can be prepared to allow the sequence to be determined, usually by the Sanger 
dideoxy chain termination or Maxam Gilbert chain degradation techniques. The resulting 
reactions are then run on a large sequencing gel, capable of resolving single nucleotide 
differences in chain length. Recently PCR based methods have obviated the need to clone 
the  DNA  under  some  conditions  and  automated  DNA  sequencing  has  become  widely 
available.
Electrophoresis: a technique for separating molecules based on their differential mobility 
in an electric field.
Endonuclease: an enzyme that cleaves nucleic acids at positions within the chain. Some 
of these act on both RNA and DNA.
Exon: a segment of a gene that is represented in the final spliced mRNA product.
Exonuclease: an enzyme that degrades DNA from the end of the molecule.
Fidelity: the accuracy with which a polymerase synthesizes the strand complementary to 
the template DNA.
Fluorochrome (fluorophore):  a dye  which  absorbs  light at one  wavelength  and  then 
emits  light  at  another  (longer)  wavelength.  These  characteristic  wavelengths  are  the 
absorption and emission spectra respectively.Glossary: 331
Frameshift:  when  the  normal  protein  coding  information  changes  from  one  frame  to 
another.  This  may  be  due  to  a  mutation  or  a  sequencing  error,  or  may  be  part  of a 
regulatory mechanism.
Gene: the fundamental physical and functional unit of heredity. Genes are parts of DNA 
molecules and many of them encode proteins.
Genetic marker: a genetically controlled phenotypic feature used in inheritance studies. 
Genome: the total amount of genetic material in the cell.
Genotype: the genetic constitution of an individual.
Haploid: a cell having one chromosome set, or an individual with one chromosome set in 
each of its cells.
Hapten: a small molecule which can be detected by its high-affinity binding to a detector 
molecule, for example biotin can be detected by use of avidin, streptavidin or a specific 
antibody.
Heterogenous: composed of varied cell types.
Heterozygote: an individual possessing two different alleles at the corresponding loci on 
a pair of homologous chromosomes.
Homogenous: consisting of or composed of similar elements or ingredients, of a uniform 
quality throughout.
Homozygote: an individual possessing identical alleles at the corresponding loci on a pair 
of homologous chromosomes.
Hybridization: the process of complementary base pairing between two single strands of 
nucleic acid.
Hypothetical model of breast carcinogenesis1:  columnar cell change > columnar cell 
hyperplasia > columnar cell hyperplasia with atypia > ADH > low grade DCIS > tubular 
and grade I carcinoma
1  Schnitt SJ and Vincent-Salomon A, Columnar Cell Lesions of the Breast, Advances in Anatomic Pathology 2003; 
10(3): 113-124.Glossary: 332
Intron:  a segment of a gene not represented  in  the  final  mRNA product  because  it  is 
removed through splicing together of exons on either side of it.
Kappa:  a  measure  of  the  degree  of  non-random  agreement  between  observers  or 
measurements of the same categorical variable.
Kilobase pair (kb): a measure of the length of a nucleic acid molecule. One kb is  1000 
base pairs (bp) of nucleic acid.
Karyotype: the number, size and shape of the chromosomes in a cell.
Label:  a  detectable  entity  covalently  linked  to  a  nucleic  acid.  Typical  labels  include 
radioisotopes, fluorochromes and haptens.
Ligase:  an enzyme that joins the ends of two nucleic acid molecules to  form  a  single 
molecule.
Ligate: to covalently join two ends of nucleic acids.
Linkage: the co-segregation of two unrelated DNA sequences which are physically close 
together on the chromosome.
Linkage disequilibrium:  the  association of particular alleles  at  two  linked  loci  more 
frequently than expected by chance.
Locus: the site of a gene on a chromosome.
Mitotic index (MI): the number of mitoses expressed as a percentage of the total number 
of the tumour cells.
Mosaic: individuals with two different cell lines in their constitution.
Multicentric DCIS: two or more areas of DCIS separated by an uninvolved area of at 
least 4 cm. Typically, however, DCIS is unicentric.
Multifocal DCIS: two or more foci of DCIS separated by an uninvolved portion of duct 
of any length less than 4 cm. In most cases it is less than 1  cm.Glossary: 333
Mutation:  change  in  DNA  sequence  resulting  in  a  different  sequence  by  addition, 
subtraction or substitution of one or more bases.
Neoplasm: see ‘tumour’ below.
Northern blot: the RNA equivalent of a Southern blot.
Nucleoside: a base covalently linked to a sugar (ribose or deoxyribose). A nucleoside is a 
nucleotide without the phosphate group.
Nucleosomes:  the  repeating  structural  units  of  chromatin,  each  consisting  of 
approximately 200 base pairs of DNA wound around a protein core.
Nucleotide:  the  basic  repeat  unit  of  DNA  and  RNA  molecules,  comprising  a 
nitrogeneous base covalently  linked to a pentose sugar which  is  linked to a phosphate 
group.
Oligonucleotide:  several  nucleotides joined  together  to  form  a  short,  single-stranded 
DNA molecule.
Oligonucleotide primer: a short, synthetic DNA molecule of known sequence, typically 
18-24 bases long, which anneals to the complementary sequence on the template DNA.
Oncogenes: genes which when altered in their structure or expression, contribute to the 
abnormal  growth  of  cancer  cells.  The  mechanism  of  alteration  includes  mutation, 
amplification and translocation.
Oncogenic: an agent capable of causing or inducing the formation and development of a 
neoplasm.
Penetrance: the proportion of individuals with a particular genotype who also have the 
corresponding phenotype.
Phenotype:  the  appearance  of  an  individual,  resulting  from  the  effects  of  both 
environment and genes.
Plasmid:  an extrachromosomal,  circular DNA molecule found in some bacteria which 
can be modified and used as a vector for DNA cloning.Glossary: 334
Ploidy: a term that describes the number of chromosome sets, namely 23=haploid (1  set), 
46=diploid (2 sets).
Polymerase chain  reaction  (PCR):  a technique  for amplifying  a  specific  segment  of 
DNA.
Polymorphism: a variation in the sequence of DNA, so that two or more versions exist.
Positioned cloning: a method used to isolate gene/s whose protein product/s is/are not 
known, but whose existence can be inferred from the disease phenotype.
Primer:  an  oligonucleotide  which  anneals  to  its  complementary  sequence,  forming  a 
short  double-stranded  region.  This  is  extended  by  a  DNA  polymerase.  Primers  are 
required for the chain termination method of DNA sequencing and for PCR.
Primer walking: a strategy for sequencing in which a new sequencing primer is designed 
based  on  the  most  distant  reliable  sequence  obtained  from  the  previous  sequencing 
reaction. This primer is then used to sequence the next unknown section of the template. 
Thus the sequence is determined in a methodical, stepwise fashion.
Proofreading: the ability of a polymerase to excise incorrectly incorporated nucleotides 
and replace them with correct ones. Proofreading polymerases  have a 3’-5’exonuclease 
activity with which they remove the mismatched base.
Proteinase K: an enzyme which degrades proteins.
Pulsed field gel electrophoresis (PFGE): a technique for separation of large fragments 
of DNA. It can be used for long range mapping of the genome to detect major deletions 
and rearrangements.
Recombinant: a DNA molecule generated by ligating heterologous DNA molecules.
Restriction endonuclease (restriction enzyme):  an enzyme which recognizes a short, 
specific DNA sequence and cleaves both strands.
Restriction fragment length polymorphism  (RFLP):  DNA can be  cut  by  restriction 
endonucleases to give a set of DNA fragments and the lengths of these fragments can be 
measured by electrophoresis. A polymorphism may lead to the production of fragments ofGlossary: 335
different  sizes  from  different  versions  of the  sequence.  This  length  polymorphism  is 
called RFLP.
Reverse transcriptase: an enzyme capable of synthesizing DNA from an RNA template 
(an RNA-dependent DNA polymerase).
Ribonucleic acid (RNA): nucleic acid comprising the nucleosides adenosine, cytidine, 
guanosine and uridine.  The main difference from DNA is ribose sugar in the molecule 
instead of deoxyribose and uridine base instead of thymidine.
RNA polymerase: the enzyme that synthesizes RNA, based on a DNA template.
Southern blot: DNA that has been electrophoretically separated and immobilized on a 
solid  support  (nylon  or  nitrocellulose).  Named  after  Ed  Southern,  who  devised  this 
technique.
Splicing: removal of the introns  from an unprocessed RNA molecule.
Stop codons: codons which terminate translation. These are UAA, UGA and UAG.
Stringency: conditions that affect the specificity of hybridization between nucleic acid 
molecules. Low stringency conditions allow strands to form hybrids even when they are 
not  perfectly  complementary.  Increasing  the  temperature  and  decreasing  the  ionic 
strength increases stringency.
Template: a nucleic acid molecule used by a polymerase to direct the synthesis of a new 
nucleic acid molecule of complementary sequence.
Transcription:  the  process  by  which  an  RNA  molecule  is  synthesized  from  a  DNA 
template in the presence of RNA polymerase.
Transformation:  the  introduction  of  a  DNA  molecule  into  an  organism  (e.g.  a 
bacterium), so that the DNA molecule can be inherited by subsequent generations.
Translation:  the  process  by  which  protein  synthesis  occurs  from  the  information
encoded in mRNA molecule.
Translocation: the transfer of an area of one chromosome to another non-homologous 
chromosome.Glossary: 336
Tumour (tumor):  an abnormal  mass of tissue that results from excessive cell  division 
that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful 
body function. They may be either benign (non-cancerous) or malignant (cancerous).
Tumour suppressor genes:  genes which suppress cell  cycle  progression  and promote 
apoptosis.
Vector:  a  small,  circular  DNA  molecule  used to  clone  DNA  segments  of interest  by 
allowing their propagation in bacteria or other organisms such as yeast.
Western blot: the protein equivalent of a southern blot.
Wild -  type: the normal allele of a gene.